0001144204-14-067700.txt : 20141113 0001144204-14-067700.hdr.sgml : 20141113 20141113160049 ACCESSION NUMBER: 0001144204-14-067700 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141113 DATE AS OF CHANGE: 20141113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Celator Pharmaceuticals Inc CENTRAL INDEX KEY: 0001327467 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36179 FILM NUMBER: 141218337 BUSINESS ADDRESS: STREET 1: 303B COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 243-0123 MAIL ADDRESS: STREET 1: 303B COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 10-Q 1 v392687_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2014

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-54852

CELATOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Delaware		20-2680869
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

200 PrincetonSouth Corporate Center Suite 180 Ewing, New Jersey		08628
(Address of principal executive offices)		(Zip Code)

(609)-243-0123

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	¨		Accelerated filer	¨
Non-accelerated filer	¨	(Do not check if a smaller reporting company)	Smaller Reporting Company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of the registrant’s common stock, $0.001 par value, as of November 11, 2014 was 33,681,355.

CELATOR PHARMACEUTICALS, INC.

TABLE OF CONTENTS

		Page
Part I.	FINANCIAL INFORMATION	1

Item 1.	Financial Statements (Unaudited)	1
	Consolidated Balance Sheets as September 30, 2014 and December 31, 2013	1
	Consolidated Statements of Loss for the three and nine months ended September 30, 2014 and 2013	2
	Consolidated Statements of Stockholders’ Equity for the nine months ended September 30, 2014	3
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2014 and 2013	4
	Notes to Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20

Part II.	OTHER INFORMATION	21

Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 6.	Exhibits	21
Signature		22
Certifications

Part I. Financial Information

Item 1. Financial Statements

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Balance Sheets

(Unaudited)

	September 30, 2014			December 31, 2013
Assets
Current assets:
Cash and cash equivalents	$	20,180,490		$	23,589,516
Restricted cash		285,801			287,657
Other receivables		6,335			1,417,313
Prepaid expenses and deposits		679,681			491,465
Assets held for sale		74,086			74,086
Other current assets		541,468			468,389
Total current assets		21,767,861			26,328,426
Property and equipment, net		1,008,426			1,138,579
Other assets		612,180			5,745
Total assets	$	23,388,467		$	27,472,750

Liabilities
Current liabilities:
Accounts payable	$	183,174		$	1,193,148
Accrued liabilities		2,022,462			1,630,809
Current portion of deferred revenue		542,986			542,986
Total current liabilities		2,748,622			3,366,943
Long-term debt		10,077,056			-
Deferred revenue		180,996			588,236
Deferred rent		47,626			53,084
Total liabilities		13,054,300			4,008,263

Stockholders' equity
Preferred stock
Authorized 20,000,000 shares, par value $0.001		-			-
Common stock
Authorized 200,000,000 shares, par value $0.001
Issued and outstanding 26,078,532 and 26,035,596 shares as of September 30, 2014 and December 31, 2013, respectively		26,079			26,036
Warrants		1,083,193			1,083,193
Additional paid-in capital		157,372,043			155,953,894
Accumulated other comprehensive loss		(1,133,266	)		(1,133,266	)
Accumulated deficit		(147,013,882	)		(132,465,370	)
Total stockholders' equity		10,334,167			23,464,487
Total liabilities and stockholders' equity	$	23,388,467		$	27,472,750

See accompanying notes to consolidated financial statements.

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Statements of Loss

(Unaudited)


	Three months ended						Nine months ended
	September 30						September 30
	2014			2013			2014			2013
Expenses
Research and development	$	3,334,789		$	2,325,891		$	9,238,756		$	5,995,866
Leukemia & Lymphoma Society funding		(135,747	)		(135,746	)		(907,240	)		(425,339	)
General and administrative		1,874,412			1,434,436			5,491,779			3,922,084
(Gain) loss on disposal of property and equipment		-			(12,059	)		-			126,633
Amortization and depreciation		48,521			51,239			144,609			148,291
Operating loss		(5,121,975	)		(3,663,761	)		(13,967,904	)		(9,767,535	)
Other income (expenses)
Foreign exchange loss		(1,408	)		(16,745	)		(27,721	)		(21,229	)
Interest and miscellaneous income		2,887			3,094			7,144			6,560
Non-cash derivative instrument charge		-			-			-			(7,473,108	)
Interest expense		(359,321	)		-			(560,031	)		(147,025	)
Net loss	$	(5,479,817	)	$	(3,677,412	)	$	(14,548,512	)	$	(17,402,337	)

Net loss per share
Basic and diluted	$	(0.21	)	$	(0.14	)	$	(0.56	)	$	(0.84	)

Weighted average of common shares outstanding
Basic and diluted		26,078,532			26,026,793			26,065,006			20,641,876

See accompanying notes to consolidated financial statements.

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Statement of Stockholders’ Equity

For the Nine Months Ended September 30, 2014

(Unaudited)

							Additional		Accumulated Other
	Common Stock						Paid-In		Comprehensive			Accumulated			Stockholders’
	Number		Amount		Warrants		Capital		Loss			Deficit			Equity

Balance at December 31, 2013		26,035,596	$	26,036	$	1,083,193	$	155,953,894	$	(1,133,266	)	$	(132,465,370	)	$	23,464,487
Issued for cash on exercise of stock options		42,936		43		-		100,596		-			-			100,639
Stock based compensation		-		-		-		996,801		-			-			996,801
Warrants issued		-		-		-		320,752		-			-			320,752
Net loss for the period		-		-		-		-		-			(14,548,512	)		(14,548,512	)
Balance at September 30, 2014		26,078,532	$	26,079	$	1,083,193	$	157,372,043	$	(1,133,266	)	$	(147,013,882	)	$	10,334,167

See accompanying notes to consolidated financial statements.

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)

	Nine months ended
	September 30,
	2014			2013
Operating activities
Net loss	$	(14,548,512	)	$	(17,402,337	)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation		144,609			148,291
Non-cash stock-based compensation expense		996,801			322,069
Loss on disposal of property and equipment		-			126,633
Non-cash derivative instrument charge		-			7,473,108
Non-cash financing costs		165,232			74,751
Changes in operating assets and liabilities
Other receivables		1,407,230			1,990,932
Prepaid expenses and deposits		(189,470	)		(134,177	)
Restricted cash		(38	)		(250,037	)
Other current assets		(73,079	)		(530,391	)
Other assets		(16,568	)		-
Accounts payable		(1,007,161	)		(22,332	)
Accrued liabilities		400,843			208,124
Deferred rent		(5,458	)		23,148
Deferred revenue		(407,240	)		(425,339	)
Cash used in operating activities		(13,132,811	)		(8,397,557	)

Investing activities
Purchase of property and equipment		(14,456	)		(82,009	)
Proceeds on disposals of property and equipment		-			51,776
Cash used in investing activities		(14,456	)		(30,233	)

Financing activities
Proceeds from issuance of common stock and on options exercised		104,387			32,499,986
Payment of share issuance costs		-			(3,079,611	)
Proceeds from loans payable		9,827,216			-
Payment of debt issuance costs		(184,469	)		-
Repayments of loans payable		-			(3,000,000	)
Cash provided by financing activities		9,747,134			26,420,375

Effect of foreign exchange rate changes		(8,893	)		877

Net change in cash		(3,409,026	)		17,993,462
Cash and cash equivalents, beginning of period		23,589,516			9,648,008
Cash and cash equivalents, end of period	$	20,180,490		$	27,641,470

Supplemental disclosure of cash flow information
Interest paid		311,458			79,388

See accompanying notes to consolidated financial statements

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

Nature of Business and Liquidity

Celator Pharmaceuticals, Inc. (the “Company”), with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the Company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes.

The Company has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2014, the Company had an accumulated deficit of $147.0 million. The Company expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. At September 30, 2014, the Company had cash and cash equivalents of $20.2 million. On October 28, 2014, the Company completed a public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock. The Company received approximately $13.5 million in net proceeds from the public offering (See Note 13). Management believes that the cash and cash equivalents at September 30, 2014, cash available to the Company through the Hercules Technology Growth Capital Inc. (“Hercules”) term loan and the funds received from the October 28, 2014 public offering will be sufficient to meet estimated working capital requirements and fund planned operations into the second half of 2016.

The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. Substantial additional financing will be needed by the Company to fund its operations and to commercialize its product candidates. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

Summary of Significant Accounting Policies

The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted.

In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Basis of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.

Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.

Loss per share: The net loss per share for the nine months ended September 30, 2013 has been corrected for an immaterial error in the calculation of average weighted shares outstanding. The revision is as follows:

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

	As Reported			As Revised
Net loss	$	(17,402,337	)	$	(17,402,337	)
Net loss per share	$	(0.87	)	$	(0.84	)
Weighted average shares outstanding		19,977,071			20,641,876

The above correction has no impact on any other prior year financial statement amounts or disclosures.

New Accounting Pronouncement : In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation , which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40). The ASU provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

Fair Value Measurements

Financial instruments of the Company consist of cash deposits, money market investments, other receivables, accounts payable, certain accrued liabilities and debt. The carrying value of these financial instruments generally approximates fair value due to their short-term nature.

ASC Topic 820, Fair Value Measurements establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

ASC 820 requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.

The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:

	Fair Value		(Level 1)		(Level 2)		(Level 3)
September 30, 2014
Assets:
Money Market Fund	$	17,727,260	$	17,727,260	$	-	$	-

December 31, 2013
Assets:
Certificates of Deposit	$	15,003,472	$	15,003,472	$	-	$	-
Money Market Fund		7,597,730		7,597,730		-		-
Total	$	22,601,202	$	22,601,202	$	-	$	-

Non-cash derivative instrument charge

The Company recognized a non-cash derivative instrument charge of $7,473,108 during the nine months ended September 30, 2013. The charge related to an obligation to issue additional shares of common stock and warrants to certain existing stockholders who participated in early closings of a private placement that started in 2012 and closed on April 29, 2013. The fair value of these common shares and warrants was recognized as a derivative liability with a corresponding charge to the statement of loss. Upon the closing of the April 2013 Private Placement, the derivative liability was reclassified into stockholders’ equity as the obligation to issue additional securities no longer existed. This contractual obligation was fair valued using significant unobservable inputs (Level 3).

Other Receivables

Other receivables as of September 30, 2014 and December 31, 2013, consists of the following:

	September 30, 2014		December 31, 2013

Receivables related to the sale of New Jersey net operating losses	$	-	$	1,412,302
Other receivables		6,335		5,011
	$	6,335	$	1,417,313

Other Current Assets

Other current assets as of September 30, 2014 and December 31, 2013 consist of the following:

	September 30, 2014		December 31, 2013

Clinical trial materials	$	541,468	$	468,389

Property and Equipment

Property and equipment as of September 30, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

	September 30, 2014			December 31, 2013
Computer and equipment	$	141,998		$	136,498
Furniture and office equipment		96,457			96,457
Laboratory equipment		1,769,589			1,760,633
Capital lease equipment		155,523			155,523
Leaseholds		37,789			37,789
		2,201,356			2,186,900
Less: Accumulated depreciation		(1,192,930	)		(1,048,321	)
	$	1,008,426		$	1,138,579

	Three months ended				Nine months ended
	September 30,				September 30,
	2014		2013		2014		2013

Depreciation and amortization	$	48,521	$	51,239	$	144,609	$	148,291

In February 2012, the Company closed a laboratory in Canada and consigned certain property and equipment for sale with net book value of $507,622. At September 30, 2014 and December 31, 2013, the net book value of the remaining consigned equipment was $74,086 and consisted solely of scientific equipment, which is presented as assets held for sale on the consolidated balance sheet.

During nine months ended September 30, 2013 assets held for sale with a net book value of $177,428 were sold for proceeds of $51,776 resulting in a loss on disposal of $125,422. There were no disposals during the nine months ended September 30, 2014.

Other Assets

Other assets as of September 30, 2014 and December 31, 2013 consist of the following:

	September 30, 2014		December 31, 2013

Deferred financing costs (see Note 9)	$	589,828	$	-
Other non-current assets		22,352		5,745
	$	612,180	$	5,745

Accrued Liabilities

Accrued liabilities as of September 30, 2014 and December 31, 2013 consist of the following:

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

	September 30, 2014		December 31, 2013

Accrued bonuses	$	748,444	$	624,472
Accrued salaries and vacation		213,775		143,484
Accrued professional fees		60,000		30,911
Accrued clinical trial expenses		494,651		636,497
Accrued drug manufacturing expenses		145,565		-
Interest payable		83,339		-
Accrued trade payables other		276,688		195,445
	$	2,022,462	$	1,630,809

Loans Payable

On May 9, 2014, the Company entered into a term loan agreement for $15 million with Hercules Technology Growth Capital, Inc. (“Hercules”). The first $10 million of the term loan was funded at closing, and is repayable in installments over forty-two months including an initial interest-only period of twelve months after closing. The remaining $5 million of the term loan can be drawn down at the Company’s option at any time between December 15, 2014 and March 31, 2015. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015, contingent upon achieving full enrollment of the CPX-351 Phase 3 study by December 31, 2014. The funds will be used to provide general working capital.

On October 24, 2014, the Company achieved full enrollment of the CPX-351 Phase 3 study resulting in the interest only period extendable to December 1, 2015 and the term loan maturity date of December 1, 2017 extendable to June 1, 2018. As a result, the outstanding term loan balance has been classified as non-current at September 30, 2014.

Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase 158,006 shares of the Company’s common stock at an exercise price of $2.67 per share with a term of five years. The fair value of the warrants of $320,752 and financing costs of $357,253 incurred in connection with the term loan were recorded as debt issuance costs and will be amortized as interest expense using the effective interest method over the term of the loan. Amortization of debt issuance costs was $57,670 and $88,176 for the three and nine months ended September 30, 2014 respectively and the remaining unamortized debt issuance costs of $589,828 are included in other non-current assets.

In addition, the Company will pay an end of term charge of $592,500 on the earliest to occur of (i) the term loan maturity date, (ii) the date that the Company prepays the outstanding loan, or (iii) the date that the loan become due and payable. The end of term charge will be accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company accrued $50,396 and $77,056 of this fee during the three and nine months ended September 30, 2014 respectively.

Long-term debt as of September 30, 2014 consists of the following:

Loan payable	$	10,000,000
End of term fee		77,056
Long-term debt	$	10,077,056

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

10.

Stock-Based Compensation

The following table summarizes the activity of the Company’s stock option plans for the nine months ended September 30, 2014:

	Number of options			Exercise price

December 31, 2013		2,578,252		$	2.98
Granted		499,100			3.13
Exercised		(42,936	)		2.34
Cancelled		(14,603	)		3.17
September 30, 2014		3,019,813		$	3.01

Exercisable at September 30, 2014		1,193,556		$	2.75

The following table provides information regarding stock options activity during the periods:

	Three months ended						Nine months ended
	September 30,						September 30,
	2014			2013			2014			2013

Stock compensation expense recognized	$	354,204		$	235,289		$	996,801		$	322,069
Weighted average grant-date fair value of stock options issued (per share)	$	2.22		$	2.11		$	2.68		$	2.14
Grant-date fair value of stock options issued	$	45,732		$	59,080		$	1,337,588		$	3,314,341

Volatility		112.0	%		117.0	%		114.4	%		118.3	%
Risk-free interest rate		1.9	%		1.6	%		2.0	%		1.9	%
Dividend yield		0	%		0	%		0	%		0	%
Expected life in years		6.0			6.0			6.2			6.2
Intrinsic value of stock options exercised	$	-		$	-		$	38,892		$	-

The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.

The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At September 30, 2014, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $3,988,729 and 2.9 years, respectively.

11.

Geographic Segment Information

The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.

	Total Assets
	September 30, 2014		December 31, 2013

United States	$	22,226,025	$	26,190,516
Canada		266,844		284,563
Germany		895,598		997,671
Total Assets	$	23,388,467	$	27,472,750

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

	Net Loss
	Three months ended						Nine months
	September 30,						September 30,
	2014			2013			2014			2013

United States		(5,046,236	)		(3,274,731	)		(12,977,790	)		(15,649,089	)
Canada		(433,581	)		(402,681	)		(1,570,722	)		(1,753,248	)
Total Net Loss	$	(5,479,817	)	$	(3,677,412	)	$	(14,548,512	)	$	(17,402,337	)

12.

Commitments and Contingencies

In September 2014, the Company entered into a lease agreement for a laboratory space in Vancouver, British Columbia, which expires in September 2015. The remaining minimum lease payments as of September 30, 2014 were $35,090.

In March 2013, the Company entered into an office lease agreement for office space in Ewing, New Jersey, which commenced in June 2013 with a term of sixty months. The remaining minimum lease payments as of September 30, 2014 were $530,232. Under the Ewing, New Jersey lease agreement, the Company will be obligated to maintain a letter of credit from a bank with respect to its security deposit obligations in the amount of $200,000 during the first year of the Agreement, which amount will be reduced by $40,000 per year on each of December 1, 2014, 2015, and 2016 and by $60,000 on December 1, 2017.

In February 2013, the Company renewed its office lease agreements for office space in Vancouver, British Columbia, effective April 1, 2013, which expires in June 2016. The remaining minimum lease payments as of September 30, 2014 were $111,638.

The Company has a worldwide exclusive license agreement with Princeton University dated June 2007 that provides the Company with exclusive rights to some aspects of its nanoparticle polymer technology arising from research sponsored by the Company at Princeton University between 2003 and 2007. These inventions are generally characterized as particulate constructs for release of active agents for medical application. Of the products currently in the Company’s pipeline, only the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation is subject to this agreement. The Company is obligated to pay a royalty on net sales to Princeton University of a low single-digit percentage if any invention is sold by the Company or a company to which the product covered by the invention was licensed by the Company, which was generated under the exclusive licensing agreement. No royalty or other product/sub-license-related payments have been made to date. The Company is obligated to provide Princeton University a percentage within the range of 45% to 55% of proceeds obtained from a sub-license of the intellectual property to a third party in cases where the Company has not conducted any research or development activities and is solely licensing out the original intellectual property jointly developed by the Company and Princeton University. The Company may terminate the agreement at any time by giving 90 days written notice to Princeton University. Princeton may terminate the agreement if the Company should breach or fail to perform under the agreement, with written notice of default provided by Princeton University to the Company and only if the Company fails to cure the default within 60 days. The Company is obligated under the agreement to provide an annual progress report to Princeton University on any developments of the licensed technology as well as prosecution of the patents covering the technology and the use of commercially reasonable efforts to develop licensed products.

The Company has a collaborative research agreement dated May 2001 with the British Columbia Cancer Agency (“BCCA”) whereby in consideration for the license and conditional assignment of all Company-sponsored intellectual property to the Company by BCCA, the Company will pay to BCCA a royalty in the low single digits on net sales of royalty-bearing products in territories so long as a valid claim exists for inventions made between June 2000 and June 2005 under the agreement. All obligations relating to the conduct of the research and assignment of intellectual property have been completed. No payments of royalties have been made to date. Either party may terminate the agreement if the other party commits a material breach or default and such breach or default is not reasonably cured within 45 days.

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

In consideration of funding by the Leukemia & Lymphoma Society ® (“LLS”) and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company may be required to pay LLS a cash multiple on the LLS funding, (LLS funding is the $5 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of the Phase 2 study). Subject to exclusions under the agreement, the Company is obligated to pay LLS an amount equal to 50% of the cash payments the Company receives from out-licenses and transfers of rights to the product or other liquidity event, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding the Company receives from LLS. The total amount payable by the Company to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties (not to exceed 5% of net sales) but will not exceed the maximum amount referred to in the preceding sentence.

13.

Subsequent Events

Public Offering of Common Stock and Warrants to Purchase Common Stock

On October 28, 2014, the Company completed a public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock, including the exercise in full of the underwriters’ overallotment option to purchase up to an additional 991,673 shares of common stock. The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The Company received approximately $13.5 million in net proceeds from the public offering after payment of fees, expenses and underwriting expenses. The shares of common stock and the warrants were immediately separable and were issued separately. The warrants have an exercise price of $3.58 per share and have a term of five years. In addition, the Company issued to the underwriters, underwriter warrants to purchase 114,042 shares of common stock at an exercise price of $3.58 per share.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties that may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning. One can also identify them by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements contained in this Form 10-Q quarterly report include, among others, statements about the sufficiency of its capital to fund its activities into the second half of 2016, the expected timeline for its milestones in connection with its Phase 3 clinical study, its product pipeline, statements regarding the efficacy of the Company's CombiPlex® technology, the safety, tolerability, efficacy and therapeutic potential of CPX-351, whether clinical results for CPX-351 obtained to date will be predictive of future clinical study results, and the Company's expectations regarding the Company's development plans for CPX-351 and our drug candidates, and the Company's expectations about expanding the Company's product pipeline and advancing the Company's CombiPlex platform. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, capital market conditions, the uncertainties inherent in the conduct of future clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of the Company’s drug candidates. Forward-looking statements in this Form 10-Q quarterly report involve substantial risks and uncertainties that could cause the Company's clinical development programs, future results, performance of achievements to differ significantly from those expressed or implied in the forward-looking statements. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the SEC, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.

Highlights

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the Company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The Company’s pipeline includes two clinical stage products, CPX-351, a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia, or AML, and CPX-1, a liposomal formulation of irinotecan:floxuridine, for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571, a liposomal formulation of irinotecan:cisplatin, and CPX-8, a hydrophobic docetaxel prodrug nanoparticle, or HDPN, a formulation being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory. The Company plans to advance the CombiPlex platform and widen its application to include molecularly targeted therapies. Areas of investigation include:

Combinations targeting signaling pathways associated with major cancer indications:

Inhibitors of PI3K/AKT/mTOR pathways in combination with

Inhibitors of Ras/Raf/MEK/ERK pathways

Combinations of existing chemotherapeutics with molecularly targeted agents:

Active cytotoxics such as taxanes in combination with

Cellular response modulators that control apoptosis

Combinations of epigenetic modulators:

Histone deacetylase inhibitors in combination with

Hypomethylating agents

Overview

The Company was founded in 1999 by a team led by Dr. Lawrence Mayer (currently the Company’s President and Chief Scientific Officer) and Dr. Marcel Bally from the British Columbia Cancer Agency. The Company’s strategy evolved into developing drug combination products based on CombiPlex, the Company’s proprietary drug ratio technology platform.

Since the founding of the Company, $99.1 million has been invested in research and development with funds being used with the Company’s proprietary technologies, including CombiPlex, creating a pipeline of drugs and managing the clinical studies. The Company’s commercial success depends upon its ability, and the ability of any of its future collaborators, to develop, manufacture, market, and sell the product candidates. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which the Company is developing products. There is no guarantee that the Company will be able to market or sell any of its products.

The Company intends to use future net proceeds to fund its development activities, including clinical studies, manufacturing development (including capital expenditures), working capital and other general corporate purposes.

The Company believes that, based on its current financial resources, it will need to raise additional funding for the development and potential commercialization of CPX-351. To the extent that the costs of the planned study exceed current estimates or the survival analysis does not occur within the currently anticipated timeframe, and the Company is unable to raise sufficient additional capital to cover such additional costs, the Company will need to reduce operating expenses, enter into a collaboration or other similar arrangement with respect to development and/or commercialization rights to CPX-351, out-license intellectual property rights to CPX-351, sell assets or effect a combination of the above. No assurance can be given that the Company will be able to effect any of such transactions on acceptable terms, if at all.

The Company has spent research and development funds on clinical studies, research collaborations and intellectual property costs. For the years 2010 through June 2014, the bulk of the spending has been on clinical studies. The three major studies are:

Study 204 — Randomized Phase 2 Study of CPX-351 in Newly Diagnosed AML Patients Age 60 – 75

Study 205 — Randomized Phase 2 Study of CPX-351 in AML Patients in First Relapse, Patients Age 18 – 65

Study 301 — Randomized Phase 3 Study in Patients with sAML

Study 204 was intended to be a direct test of whether delivery of a fixed, synergistic ratio of two drugs, cytarabine and daunorubicin, (i.e., CPX-351 - which is a 90 minute infusion on days 1, 3 and 5) provided increased clinical efficacy over conventional administration of the same agents (i.e., which is a 7-day continuous infusion of cytarabine, combined with daunorubicin on days 1, 2 and 3, commonly referred to as the 7+3 regimen). This study is complete. In the overall population, in patients treated with CPX-351 the response rate increased by 30.3% (66.7% vs. 51.2%), the 60-day mortality was decreased by 67.8% (4.7% vs. 14.6%), median event-free survival increased by 225.0% (6.5 months vs. 2.0 months) and the median overall survival increased 14.0% (14.7 months vs. 12.9 months). In sAML patients (approximately 41% of the overall population), the response rate increased by 82.0% (57.5% vs. 31.6%), the 60-day mortality decreased 80.7% (6.1% vs. 31.6%), the median event-free survival increased 3.5-fold (4.5 months vs. 1.3 months) and the median overall survival increased by 98.4% (12.1 months vs. 6.1 months).

Study 205 was a randomized Phase 2 clinical study designed to be a direct test of whether CPX-351 provides increased clinical efficacy over salvage therapies in first relapse AML patients age 18 – 65. This study is complete. In the overall population, CPX-351 resulted in a 20.8% relative increase in response rate (49.4% vs. 40.9%) compared to the control arm of salvage therapies, a 6.9% decrease in the 60-day mortality (14.8% vs. 15.9%), a 34.9% increase in median overall survival (8.5 months vs. 6.3 months) and an 31.1% increase in 1-year survival rate (35.8% vs. 27.3%). For patients in the unfavorable risk category (68% of the overall population), CPX-351 resulted in a 42.4% relative increase in response rate (39.3% vs. 27.6%) compared to the control arm of salvage therapies, a 33.2% decrease in 60-day mortality (16.1% vs. 24.1%), a 57.1% increase in median overall survival (6.6 months vs. 4.2 months) and a higher 1-year survival rate of 177.7% (28.6% vs. 10.3%).

Study 301 is a randomized controlled Phase 3 study in patients with sAML, with overall survival as the primary end-point. This Phase 3 study has been undertaken to confirm the Study 204 clinical observations where CPX-351 provided the largest efficacy improvements in sAML patients and to provide the necessary data for product registration. Study 301 enrolled the first patient in December 2012, completed its third independent Data and Safety Monitoring Board review in June 2014, which review recommended that the study continue as planned without any modifications. Sites in the U.S. and Canada are participating in this study. There will be significant costs associated with this study, including site enrollment grants, patient monitoring, database maintenance, statistical monitoring, data analysis, salaries and insurance.

On October 24, 2014, the Company achieved the target enrollment, of 300 patients, in its Phase 3 study of CPX-351. This Phase 3 study is a multicenter, randomized, open-label study testing CPX-351 versus the current standard of care, conventional cytarabine and daunorubicin therapy (7+3) in patients with untreated high-risk (secondary) AML. The Company expects the following milestones related to its Phase 3 clinical study:

Q4 2014 – Data and Safety and Monitoring Board pre-planned analysis of the first 225 randomized patients with a minimum of 60 days follow-up

Q2 2015 – Analysis of the induction response rate (CR+CRi), a secondary endpoint of the study

Q1 2016 – Analysis of overall survival, the primary endpoint of the study

2H 2016 – The New Drug Application (“NDA”) is anticipated to be filed.

In June 2012, the Company entered into an agreement with LLS pursuant to which the Leukemia and Lymphoma Society (LLS) is providing $5.0 million in funding from the LLS Therapy Acceleration Program (“TAP”) program for the Phase 3 study of CPX-351. The agreement provided for LLS to make an upfront payment of $2.0 million to the Company, which was received in July 2012, and further payments totaling an additional $3.0 million on the achievement of clinical milestones; however, the amount may be refundable by the Company in the event of a material breach by the Company under the agreement. The $2.0 million upfront payment has been recorded as deferred revenue and will be recognized over the estimated performance period of the research and development services to be provided under the agreement. As of September 30, 2014, $0.7 million was deferred. Since November 2012, the Company has received a total of $1.5 million for milestones achieved under this agreement. In consideration of LLS’s funding, and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company must pay LLS a multiple on the LLS funding (LLS funding is the $5 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of the Phase 2 study during 2010 and 2011). Subject to exclusions under the agreement, the Company is obligated to pay LLS an amount equal to 50% of the cash payments the Company receives from outlicenses and transfers of rights to the product or other liquidity event, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding the Company receives from LLS. The total amount payable by the Company to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties (not to exceed 5% of net sales) but will not exceed the maximum amount referred to in the preceding sentence.

On April 29, 2013, the Company entered into a securities purchase agreement and subscription agreements with certain accredited investors for the issuance and sale in the final round of a private placement of 10,430,034 shares of common stock, which the Company sold at a price of $3.116 per share for aggregate gross proceeds of $32,499,986. Warrants to purchase 0.28 shares of common stock at $3.58 per share were issued for each share of common stock purchased. The net proceeds totaled $29,420,375 for this financing.

In connection with this final closing of the financing, 1,923,599 shares of common stock and 161,327 warrants to purchase shares of common stock at $5.21 and 1,056,898 warrants to purchase shares of common stock at $3.58 per share were issued to certain existing stockholders of the Company who participated in earlier closings of this financing. The fair value of these common shares and warrants was recognized as a derivative liability with a corresponding charge to the statement of loss. The derivative liability was fair valued at $7,473,108. Upon the closing of the April 2013 private placement, the derivative liability was reclassed into Stockholders’ equity as the obligation to issue additional securities no longer existed.

Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase 158,006 shares of the Company’s common stock at an exercise price of $2.67 per share with a term of five years. The fair value of the warrants of $320,752 and financing costs of $357,253 incurred in connection with the term loan were recorded as debt issuance costs and will be amortized as interest expense using the effective interest method over the term of the loan. As of September 30, 2014, the remaining unamortized debt issuance costs of $589,828 are included in other non-current assets.

In addition, the Company will pay an end of term charge of $592,500 on the earliest to occur of (i) the term loan maturity date, (ii) the date that the Company prepays the outstanding loan, or (iii) the date that the loan become due and payable. The end of term charge will be accrued as additional interest expense using the effective interest rate method over the term of the loan. As of September 30, 2014, the accrued fee was $77,056.

Based on current projections, the Company believes it now has sufficient capital to fund its activities into the second half of 2016.

Results of Operations

Three months ended September 30, 2014 compared to the three months ended September 30, 2013

Expenses

Research and Development: The Company charges research and development costs to operations as incurred. The Company’s research and development expenses were $3,335,000 for the three months ended September 30, 2014 compared to $2,326,000 for the three months ended September 30, 2013 reflecting an increase of $1,009,000. The increase was primarily attributable to $359,000 increase in manufacturing and drug and lipid costs, $328,000 increase in outsourced clinical trial and regulatory activities related to the Phase 3 trial of CPX-351, $199,000 increase in compensation and stock option expenses, and $79,000 increase due to a greater number of patients enrolling and materials being sent to sites and the progression of the 301 study.

LLS Funding: The LLS revenue recognized for the three months ended September 30, 2014 and 2013 was $136,000 and represents the amortization of a $2,000,000 upfront payment received during 2012 that was deferred and is being recognized over the estimated performance period of the research and development services to be provided under the agreement.

General and Administrative: General and administrative expenses consist largely of salaries and related benefits, investor relations costs, external costs for professional fees relating to legal, accounting and tax services, investor relations expenses, director and scientific advisory services as well as the lease expense for the facilities.

General and administrative expenses were $1,874,000 for the three months ended September 30, 2014 compared to $1,434,000 for the three months ended September 30, 2013, reflecting an increase of $440,000. The increase was primarily attributable to $201,000 increase in consulting associated with commercial operations and strategic planning, $151,000 increase in compensation and stock option expenses, $117,000 increase in investor relations costs, and increase in professional fees of $27,000. These increases were offset by a reduction in public company related expenses of $55,000.

Gain or loss on Disposal of Property and Equipment: The Company recorded a gain on disposal of property and equipment of $12,000 for the three months ended September 30, 2013. The gain in 2013 arose from the sale of assets that were classified as held for sale at the beginning the year.

Amortization and Depreciation: Amortization and depreciation expense was $49,000 for the three months ended September 30, 2014 and $51,000 for the three months ended September 30, 2013.

Other Income and Expenses

Interest Expense: Interest expense for the three months ended September 30, 2014 was $359,000 and related to interest on a term loan entered into with Hercules Technology Capital Growth in May 2014. Interest expense includes amortization of non-cash debt issuance costs and the accrual of the end of term charge of $108,000. There was no interest expense for the three months ended September 30, 2013

Nine months ended September 30, 2014 compared to the nine months ended September 30, 2013

Expenses

Research and Development: The Company charges research and development costs to operations as incurred. The Company’s research and development expenses were $9,239,000 for the nine months ended September 30, 2014 compared to $5,996,000 for the nine months ended September 30, 2013 reflecting an increase of $3,243,000. The increase was primarily attributable to $1,116,000 increase in manufacturing, drug and lipid costs, $778,000 increase in outsourced clinical trial and regulatory activities related to the Phase 3 trial of CPX-351, $655,000 for compensation and stock option expense increase in clinical trials and regulatory departments, $387,000 for a metabolism study for CPX-351 that began the second half of 2013, $103,000 increase in quality assurance audits and external service related to manufacturing, $107,000 due to increase in drug storage and shipping costs to sites, and $88,000 increase in intellectual property costs.

LLS Funding: The LLS funding for the nine months ended September 30, 2014 was $907,000 compared to $425,000 for the nine months ended September 30, 2013. The amount recognized during the nine months ended September 30, 2014 represents payment from LLS for achieving 50% overall enrollment milestone in January 2014 of $500,000 and amortization of an upfront payment received during 2012 of $407,000. The nine months ended September 30, 2013 amount represents amortization of an upfront payment received during 2012 of $425,000.

General and Administrative: General and administrative expenses consist of salaries and related benefits, lease expense of the facilities, investor relations costs, professional fees relating to legal, accounting, and tax services and other administrative costs.

General and administrative expenses were $5,492,000 for the nine months ended September 30, 2014 compared to $3,922,000 for the nine months ended September 30, 2013, reflecting an increase of $1,570,000. The increase was primarily attributable to $835,000 due to compensation and stock option expense increase, $507,000 increase in commercial operations and strategic planning, $222,000 increase in investor relations, $60,000 for increased board of directors’ fees, and $33,000 increase in directors and officers insurance. These increases were offset by reductions in leases and building operating costs of $54,000, public company related costs of $20,000, and recruitment expenses of $24,000.

Loss on Disposal of Property and Equipment: The Company recorded a loss on disposal of property and equipment of $127,000 for the nine months ended September 30, 2013. The loss in 2013 arose from the sale of assets that were classified as held for sale at the beginning the year.

Amortization and Depreciation: Amortization and depreciation expense was $145,000 for the nine months ended September 30, 2014 and $148,000 for the nine months ended September 30, 2013.

Other Income and Expenses

Non-cash derivative instrument charge: Non-cash derivative instrument charge was $7,473,000 for the nine months ended September 30, 2013. The charge resulted from the obligation to issue additional shares of common stock and warrants by the Company, at the April 29, 2013 closing, to certain existing stockholders who participated in early closings of this financing.

Interest Expense: Interest expense was $560,000 and $147,000 for the nine months ended September 30, 2014 and September 30, 2013 respectively. Interest expense of $560,000 for the nine months ended September 30, 2014 related to interest on a Hercules Technology Capital Growth term loan entered into in May 2014 which includes $165,000 related to non-cash amortization of deferred financing costs and the accrual of the end of term charge. Interest expense of $147,000 for the nine months ended September 30, 2013 consisted of $72,000 of interest on a bank loan and $75,000 of non-cash financing costs.

Liquidity and Capital Resources

Overview

There is considerable time and cost associated with developing a potential drug or pharmaceutical product to the point of regulatory approval and commercialization. To date, the Company has funded its operations primarily through private placements of preferred stock and common stock, convertible debt and debt financings. However, we may pursue additional financing options, including entering into agreements with collaborative partners in order to provide milestone payments, license fees and equity investments. As of September 30, 2014, the Company had cash and cash equivalents of approximately $20.2 million.

On October 28, 2014, the Company completed a public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock, including the exercise in full of the underwriters’ overallotment option to purchase up to an additional 991,673shares of common stock. The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The Company received approximately $13.5 million in net proceeds from the public offering after payment of fees, expenses and underwriting expenses. The shares of common stock and the warrants were immediately separable and were issued separately. The warrants have an exercise price of $3.58 per share and have a term of five years. In addition, the Company issued to the underwriters, underwriter warrants to purchase 114,042 shares of common stock at an exercise price of $3.58 per share.

On May 9, 2014, the Company entered into a term loan agreement for $15 million with Hercules Technology Growth Capital, Inc. The first $10 million of the term loan was funded at closing, and is repayable in installments over forty-two months including an initial interest-only period of twelve months after closing. The net proceeds from the loan were $9.6 million. The remaining $5 million of the term loan can be drawn down at the Company’s option at any time between December 15, 2014 and March 31, 2015. It is the Company’s intention to draw the remaining $5 million of the term loan on or before March 31, 2015. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015, contingent upon achieving full enrollment of the CPX-351 Phase 3 study by December 31, 2014. The funds will be used to provide general working capital. On October 24, 2014, the Company achieved full enrollment of the CPX-351 Phase 3 study resulting in the interest only period extendable to December 1, 2015 and the term loan maturity date of December 1, 2017 extendable to June 1, 2018.

In April 2013, the Company raised $29.4 million of net proceeds from the final round of a private placement. We expect to continue to incur losses as we fund our research and development activities and commercial launch activities, and we do not expect material revenues for at least the next few years.

Even though we believe we currently have access to sufficient funds to meet our financial needs into the second half of 2016, our business strategy in the future will require us to raise additional capital through licensing, debt or equity sales, other means or any combination of these options. The Company’s future capital requirements will depend on many factors, including those factors described in Item 1A. “Risk Factors” of the 2013 Form 10-K annual report as well as the Company’s ability to execute on its business and strategic plans as currently conceived.

Cash Flows

Net cash used in operating activities was $13,133,000 for the nine months ended September 30, 2014. The nine months ended September 30, 2014 amount reflected the Company’s net loss of $14,549,000, offset by $1,307,000 in net non-cash charges including non-cash charge relating to amortization and depreciation of $145,000, stock-based compensation expense of $997,000 and non-cash interest expense of $165,000 related to the deferred financing costs amortization for a term loan. In addition, the Company generated $109,000 of operating cash as a result of changes in certain of its operating assets and liabilities during the nine months ended September 30, 2014. The changes in operating assets and liabilities were a decrease in other receivables of $1,407,000, and an increase in accrued expenses of $401,000; offset by increases in prepaid expenses and deposits of $189,000, other current assets of $73,000, and other assets of $17,000 and decreases in accounts payable of $1,007,000, deferred rent of $6,000 and deferred revenue of $407,000.

Net cash used in operating activities was $8,398,000 for the nine months ended September 30, 2013. The nine months ended September 30, 2013 amount reflected the Company’s net loss of $17,402,000, offset by $8,145,000 in net non-cash charges including amortization and depreciation of $148,000, stock-based compensation expense of $322,000, loss on disposal of property and equipment of $127,000, non-cash charge relating to a derivative instrument of $7,473,000 and non-cash interest expense of $75,000 related to the deferred financing costs amortization for bank loan. In addition, the Company generated $860,000 of operating cash as a result of changes in certain of its operating assets and liabilities during the nine months ended September 30, 2013. The changes in operating assets and liabilities were a decrease in other receivables of $1,991,000, and increases in accrued liabilities of $208,000 and deferred rent liability of $23,000 offset by increases in prepaid expenses and deposits $134,000, restricted cash of $250,000, and other current assets of $530,000 and decreases in accounts payable of $22,000 and deferred revenue of $425,000.

Cash used in investing activities for the nine months ended September 30, 2014 was $14,000 for property and equipment expenditures. Cash used in investing activities was $30,000 for the nine months ended September 30, 2013, reflecting $82,000 of property and equipment expenditures offset by $52,000 of proceeds from the sale of property and equipment.

Cash provided by financing activities for the nine months ended September 30, 2014 was $9,747,000. The cash inflow was from the net proceeds on issuance of debt of $9,643,000 and from exercised stock options of $104,000. Cash provided by financing activities for the nine months ended September 30, 2013 was $26,420,000. The cash inflow was from the net proceeds of $29,420,000 from the April 2013 final round of a private placement offset by $3,000,000 for the repayment of bank debt.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, other than operating leases, that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.

Critical Accounting Policies

The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2013 included in Celator Pharmaceuticals Inc.’s Form 10-K filed. There have been no significant changes in the Company’s critical accounting policies since December 31, 2013.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We invest excess cash in investment grade, interest-bearing securities and at September 30, 2014, had approximately $17.7 million invested in money market instruments. Such investments are subject to interest rate and credit risk and are not fully insured by the federal government. We believe our policy of investing in highly rated securities, whose liquidities are, at September 30, 2014, all less than 90 days minimizes such risks. In addition, while a hypothetical one percent per annum decrease in market interest rates would have decreased our interest income for the period, it would not have resulted in a loss of the principal and the decline in interest income would have been immaterial to us.

The Company had outstanding total debt at September 30, 2014 of $10 million. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015, contingent upon achieving full enrollment of the CPX-351 Phase 3 study by December 31, 2014. On October 24, 2014, the Company achieved full enrollment of the CPX-351 Phase 3 study resulting in the interest only period extendable to December 1, 2015 and the term loan maturity date of December 1, 2017 extendable to June 1, 2018.

The majority of our business is conducted in U.S. dollars. However, we do conduct certain transactions in other currencies, including Canadian dollars. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations, and during the nine months ended September 30, 2014 and 2013, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures as of the end of the period covered by this report are effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure.

Change in Internal Control over Financial Reporting

No change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

There are no material pending legal proceedings.

Item 1A. Risk Factors

Except for the historical information in this report, the matters contained in this report include forward-looking statements that involve risks and uncertainties. Our operating results and financial condition have varied in the past and may in the future vary significantly depending on a number of factors. These factors, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this report and presented elsewhere by management from time to time. Such factors may have a material adverse effect upon our business, results of operations and financial condition.

You should consider carefully the risk factors, together with all of the other information included in our Annual Report on Form 10-K for the year ended December 31, 2013. Each of these risk factors could adversely affect our business, results of operations and financial condition, as well as adversely affect the value of an investment in our common stock. There have been no material changes to our risk factors as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no sales of equity securities during the nine months ended September 30, 2014.

Item 6. Exhibits

Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index hereto and include the following:

3.1	Third Amended and Restated Certificate of Incorporation of the Company, as amended. (Incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed on August 7, 2014.)

3.2	Amend and Restated By-laws of the Company. (Incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K current report filed on April 18, 2013.)

4.1	Warrant Agreement between Celator Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC. (Filed herewith.)

4.2	Form of Underwriter Warrant. (Incorporated by reference Exhibit 4.2 to the Company’s Form 8-K current report filed with SEC on October 23, 2014).

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

32.1	Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.

101.1	The following financial statements from Celator Pharmaceuticals Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets at September 30, 2014 and December 31, 2013, (ii) the Statements of Loss for the three and nine months ended September 30, 2014 and 2013, (iii) Statement of Shareholders’ Equity for the nine months ended September 30, 2014, (iv) the Consolidated Statements of Cash Flows for the nine months ended September 30, 2014 and 2013, and (v) Notes to Consolidated Financial Statements.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELATOR PHARMACEUTICALS, INC.

Signature	Title	Date

/s/ Scott T. Jackson Scott T. Jackson	Chief Executive Officer and a Director (principal executive officer)	November 13, 2014

/s/ Fred M. Powell Fred M. Powell	Vice President and Chief Financial Officer (principal financial and accounting officer)	November 13, 2014

EXHIBIT INDEX

Exhibit No.	Description

3.1	Third Amended and Restated Certificate of Incorporation of the Company, as amended. (Incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed on August 7, 2014.)

3.2	Amend and Restated By-laws of the Company. (Incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K current report filed on April 18, 2013.)

4.1	Warrant Agreement between Celator Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC. (Filed herewith.)

4.2	Form of Underwriter Warrant. (Incorporated by reference Exhibit 4.2 to the Company’s Form 8-K current report filed with SEC on October 23, 2014).

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

32.1	Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.

101.1	The following financial statements from Celator Pharmaceuticals Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets at September 30, 2014 and December 31, 2013, (ii) the Statements of Loss for the three and nine months ended September 30, 2014 and 2013, (iii) Statement of Shareholders’ Equity for the nine months ended September 30, 2014, (iv) the Consolidated Statements of Cash Flows for the nine months ended September 30, 2014 and 2013, and (v) Notes to Consolidated Financial Statements.

EX-4.1 2 v392687_ex4-1.htm EXHIBIT 4.1

Exhibit 4.1

CELATOR PHARMACEUTICALS, INC.

WARRANT AGREEMENT

THIS WARRANT AGREEMENT (this “Warrant Agreement”) is dated October 28, 2014, between Celator Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, acting as warrant agent (the “Warrant Agent”).

WHEREAS, the Company is engaged in a public offering (the “Offering”) of Common Stock (as defined below) and Warrants (as defined below) and, in connection therewith, has determined to issue and deliver warrants (the “Warrants”) to purchase up to 760,282 shares of Common Stock (as defined below) (the “Warrant Shares”) to the investors in the Offering, including Warrants to purchase up to 99,167 shares of Common Stock subject to an overallotment option granted to the underwriters as described in the Prospectus Supplement (as defined below), each Warrant evidencing the right of the holder thereof to purchase 0.10 of a share of the Company’s common stock, par value $.001 per share (the “Common Stock”), for $3.58 per whole share of Common Stock, as adjusted from time to time as provided in Section 9 herein (the “Exercise Price”);

WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3 (File No. 333-193720), as amended (the “Registration Statement”), for the registration under the Securities Act of 1933, as amended (the “Act”), of, among other securities, the Warrants and the Common Stock issuable upon exercise of the Warrants;

WHEREAS, the Company has filed with the Commission a prospectus supplement to the Registration Statement pursuant to Rule 424(b)(5) under the Act (the “Prospectus Supplement”) describing the terms of the Warrants and the Common Stock issuable upon exercise of the Warrants;

WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection with the issuance, registration, transfer, exercise and replacement of the Warrants and, in the Warrant Agent’s capacity as the Company’s transfer agent, the delivery of the Warrant Shares.

NOW, THEREFORE, in consideration of the foregoing and for the purpose of defining the terms and provisions of the Warrants and the respective rights and obligations thereunder of the Company, the Warrant Agent and the registered holders from time to time of the Warrants (each, a “Holder” and collectively, the “Holders”), the parties hereby agree as follows:

1. Definitions. In addition to the terms defined elsewhere in this Warrant Agreement, the following terms shall have the following meanings:

“Business Day” means any day except Saturday, Sunday and any day which shall be a federal legal holiday in the United States or a day on which banking institutions in the City of New York are authorized or required by law or other government action to close.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.

“Expiration Date” means the date five (5) years after the Initial Issuance Date.

“Initial Issuance Date” means October 28, 2014.

“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

“Trading Day” means any day on which the Common Stock are traded on the NASDAQ Stock Market, or, if the NASDAQ Stock Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock are then traded; provided that “Trading Day” shall not include any day on which the Common Stock are scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock are suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time).

2. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the terms and conditions hereof, and the Warrant Agent hereby accepts such appointment. The Company may from time to time appoint such Co-Warrant Agents as it may, in its sole discretion, deem necessary or desirable.

3. Registration.

(a) The Warrant Agent shall maintain books (“Warrant Register”), for the registration of original issuance and the registration of transfer of the Warrants. The Warrants may be represented by definitive warrant certificates in physical form (“Warrant Certificates”) or by one or more book-entry warrants (“Book-Entry Warrants”) deposited with The Depository Trust Company (the “Depository”) and registered in the name of Cede & Co., a nominee of the Depository. Ownership of beneficial interests in the Book-Entry Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depository or its nominee for each Book-Entry Warrant or (ii) institutions that have accounts with the Depository (such institution, with respect to a Warrant in its account, a “Participant”).

(b) If the Warrants are not “DTC Eligible” as of the Initial Issuance Date or the Depository subsequently ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding other arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depository to deliver to the Warrant Agent for cancellation the Book-Entry Warrants, and the Company shall instruct the Warrant Agent to deliver to each Holder a Warrant Certificate.

(c) Notwithstanding the foregoing and anything else herein to the contrary, the Warrants may be issued in uncertificated form if so specified by the Company.

4. Countersignature; Transfer of Warrants; Mutilated, Destroyed, Lost or Stolen Certificates.

(a) The Warrant Certificates shall be substantially in the form of Exhibit A hereto and executed on behalf of the Company by its Chief Executive Officer, the Vice President, the Chief Financial Officer or any Vice President, either manually or by facsimile signature. The Warrant Certificates shall be countersigned by the Warrant Agent either manually or by facsimile signature and shall not be valid for any purpose unless so countersigned. In case any officer of the Company who shall have signed any of the Warrant Certificates shall cease to be such officer of the Company before countersignature by the Warrant Agent and issuance and delivery by the Company, such Warrant Certificates nevertheless, may be countersigned by the Warrant Agent, issued and delivered with the same force and effect as though the person who signed such Warrant Certificate had not ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by any person who, at the actual date of the execution of such Warrant Certificate shall be a proper officer of the Company to sign such Warrant Certificate although at the date of the execution of this Agreement any such person was not such an officer.

(b) The Warrant Agent will create a special account for the issuance of Warrant Certificates.

(c) Subject to the last sentence of this Section 4(c) and subject to applicable law, rules or regulations, or any “stop transfer” instructions the Company may give to the Warrant Agent, at any time after the Initial Issuance Date, and at or prior to 5:00 P.M., New York City time, on the Expiration Date, upon the surrender of any Warrant Certificate, together with a Form of Assignment substantially in the form of Exhibit B, to the principal office of the Warrant Agent, the Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant into the Warrant Register and the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants. The Book-Entry Warrants may be transferred only in whole and only to the Depository, to another nominee of the Depository, to a successor depository, or to a nominee of a successor depository. Upon the registration of transfer, the Company shall execute and the Warrant Agent shall, subject to the last sentence of this Section 4(c), countersign and deliver to the Person entitled thereto a Warrant Certificate or Warrant Certificates, as the case may be, as so requested. The Company may require payment from the Holder of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any transfer of Warrant Certificates. The Company shall compensate the Warrant Agent per the fee schedule mutually agreed upon by the parties hereto and provided separately on the date hereof.

(e) Upon receipt by the Warrant Agent of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining, and, in case of loss, theft or destruction, of indemnity or security in customary form and amount which shall include a corporate bond of indemnity satisfactory to the Warrant Agent, and satisfaction of any other reasonable requirements established by Section 8-405 of the Uniform Commercial Code as in effect in the State of Delaware, and reimbursement to the Company and the Warrant Agent of all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate if mutilated, the Company will make and deliver a new Warrant Certificate of like tenor to the Warrant Agent for delivery to the Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated.

5. Exercise and Duration of Warrant.

(a) All or any part of the Warrant shall be exercisable, in whole or in part, by the registered Holder at any time and from time to time on or after the Initial Issuance Date and through and including 5:00 P.M., New York City time, on the Expiration Date. At 5:00 P.M., New York City time, on the Expiration Date, the Warrant shall be terminated and no longer outstanding; provided, however that, notwithstanding the foregoing, without any further action by or on behalf of the Holder, the Warrant shall automatically be deemed to be exercised in full pursuant to the net exercise provisions of Section 10 effective immediately prior to such termination.

(b) The Holder may exercise the Warrant by delivering, not later than 5:00 p.m., New York City time, on any Business Day prior to the Expiration Date, to the principal office of the Warrant Agent (i) an exercise notice, in the form attached as Exhibit C hereto (the “Exercise Notice”), appropriately completed and duly signed by the Holder or, in the case of a Book-Entry Warrant, properly delivered by the Participant in accordance with the Depository’s procedures and (ii) payment of the Exercise Price for the number of Warrant Shares as to which the Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the Exercise Notice pursuant to Section 10), and the date such items are delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.” If the Exercise Notice is received by the Warrant Agent after 5:00 p.m., New York City Time, on the specified Exercise Date, the Warrants will be deemed to be received and exercised on the Trading Day next succeeding the Exercise Date. The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. No ink original of any Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Exercise Notice be required. Upon receipt of payment of the Exercise Price by the Warrant Agent or one of its agents, the Warrant Agent or such agent shall promptly remit such payment to the Company at an account designated by the Company to the Warrant Agent. In the event of a “cashless exercise,” the Exercise Notice must be delivered to the Company at the address specified in Section 18 hereof.

6. Delivery of Warrant Shares.

(a) Upon exercise of the Warrant, the Warrant Agent shall promptly advise the Company and the transfer agent and registrar in respect of (i) the Warrant Shares issuable upon such exercise as to the number of Warrants exercised in accordance with the terms and conditions of this Warrant Agreement, (ii) the instructions of the Holder or Participant, as the case may be, with respect to delivery of the Warrant Shares issuable upon such exercise, and the delivery of Warrant Certificates, as appropriate, evidencing the balance, if any, of the Warrants remaining after such exercise, (iii) in case of a Book-Entry Warrant, the notation that shall be made to the records maintained by the Depository, its nominee for each Book-Entry Warrant, or a Participant, as appropriate, evidencing the balance, if any, of the Warrants remaining after such exercise and (d) such other information as the Company or such transfer agent and registrar shall reasonably require. Provided that the Warrant Agent has received funds in the amount of the Exercise Price, the Company shall promptly (but in no event later than three Trading Days after the Exercise Date) issue or cause to be issued and cause to be delivered to the Holder (or upon the written order of the Holder, in such name or names as the Holder may designate) or the Participant, as the case may be, , a certificate for the Warrant Shares issuable upon such exercise, free of restrictive legends. The Holder (or any Person permissibly so designated by the Holder to receive Warrant Shares) or the Participant, as applicable, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date. In lieu of delivering physical certificates representing the Warrant Shares issuable upon exercise, provided the Company’s transfer agent is participating in the Depository’s Fast Automated Securities Transfer program, upon the written request of the Holder or the Participant, as applicable, the Company shall use its commercially reasonable efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through The Depository Trust Company or another established clearing corporation performing similar functions, if available.

(b) If by the close of the third Trading Day after delivery of a properly completed Exercise Notice (and any other documents required pursuant to Section 6(a)), the Company fails to deliver to the Holder or the Participant, as applicable, the required number of Warrant Shares in the manner required pursuant to Section 4(a), and if on or after the Trading Day immediately following such third Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall, within three Trading Days after the Holder’s request and in the Holder’s sole discretion, either (i) pay in cash to the Holder an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate or (ii) promptly honor its obligation to deliver to the Holder Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of Warrant Shares, times (B) the Closing Sales Price (as defined below) on the date of receipt of a properly completed Exercise Notice.

(c) To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to the Holder hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

7. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of the Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring the Warrant or receiving Warrant Shares upon exercise of the Warrant.

8. Reservation of Warrant Shares. The Company covenants that it will reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of the Warrants as herein provided, one hundred percent (100%) of the number of Warrant Shares that are issuable and deliverable upon the exercise of the Warrants, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed.

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of the Warrants are subject to adjustment from time to time as set forth in this Section 9.

(a) Stock Dividends and Splits. If the Company, at any time while the Warrants are outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares, or (iii) combines its outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this Section 9(a) shall become effective immediately after the effective date of such subdivision or combination.

(b) Pro Rata Distributions. If the Company, at any time while the Warrants are outstanding, distributes to all holders of Common Stock (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other asset (in each case, “Distributed Property”), then, upon the exercise of any Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date.

(c) Fundamental Transactions. If, at any time while the Warrants are outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the survivor and the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least fifty percent (50%) of the voting securities of the surviving entity, (ii) the Company effects any sale of all or substantially all of its assets or at least a majority of its Common Stock is acquired by a third party, in each case, in one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which all or substantially all of the holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a)) (in any such case, a “Fundamental Transaction”), then the Holder shall thereafter receive, upon exercise of any Warrant, in lieu of any Warrant Shares, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of such Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”). The Company shall not affect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to purchase and/or receive (as the case may be), and the other obligations under any Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous to a Fundamental Transaction.

(d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to paragraph (a) and (e) of this Section 9, the number of Warrant Shares that may be purchased upon exercise of the Warrants shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.

(e) Calculations. All calculations under this Section 9 shall be made to the nearest cent or the nearest share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the sale or issuance of any such shares shall be considered an issue or sale of Common Stock.

(f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of the Warrants and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of the Warrants (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

(g) Notice of Corporate Events. If, while the Warrants are outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction at least five Trading Days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in order to ensure that the Holder is given the practical opportunity to exercise the Warrants prior to such time so as to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice.

10. Payment of Exercise Price. The Holder shall pay the Exercise Price in immediately available funds; provided, however, pursuant to the exercise of any Warrant in full, that the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “cashless exercise,” in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows:

X = Y [(A-B)/A]

where:

X = the number of Warrant Shares to be issued to the Holder.

Y = the total number of Warrant Shares with respect to which the Warrant is being exercised in accordance with the terms of the Warrant and this Warrant Agreement if such exercise were by means of a cash exercise rather than a cashless exercise.

A = the average of the Closing Sale Prices of the shares of Common Stock (as reported by Bloomberg Financial Markets) for the five Trading Days ending on the date immediately preceding the Exercise Date.

B = the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

For purposes of the Warrants, “Closing Sale Price” means, for any security as of any date, the last trade price for such security on the principal trading market of the security, as reported by Bloomberg Financial Markets, or, if the principal trading market of the security begins to operate on an extended hours basis and does not designate the last trade price then the last trade price of such security prior to 4:00 p.m., New York City Time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, if no closing bid price is reported for such security by Bloomberg Financial Markets, the average of the bid prices and asked prices of any market makers for such security as reported in the “pink sheets” by OTC Markets Group Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder in good faith. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Company shall, within two Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder (which approval shall not be unreasonably withheld, conditioned or delayed) or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

11. Beneficial Ownership. The Company shall not effect the exercise of any Warrant, and the Holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such Person (together with such Person’s affiliates) would beneficially own in excess of 19.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (a) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such Person and its affiliates and (b) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in the most recent of (i) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be, (ii) a more recent public announcement by the Company or (iii) any other notice by the Company or the transfer agent setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, the Company shall within two Business Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Warrant, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. Neither the Warrant Agent nor the Depository Trust Company has any responsibility for monitoring compliance with this Section 11.

12. No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of any Warrant. In lieu of any fractional shares which would, otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.

13. Concerning the Warrant Agent.

(a) The Company agrees to pay to the Warrant Agent, pursuant to the fee schedule mutually agreed upon by the parties hereto and provided separately on the date hereof, for all services rendered by it hereunder and, from time to time, its reasonable expenses and counsel fees and other disbursements actually incurred in the administration and execution of this Agreement and the exercise and performance of its duties hereunder.

(b) The Company covenants and agrees to indemnify and to hold the Warrant Agent harmless against any costs, expenses (including reasonable fees of its legal counsel), losses or damages, which may be paid, incurred or suffered by or to which it may become subject, arising from or out of, directly or indirectly, any claims or liability resulting from its actions as Warrant Agent pursuant hereto; provided, that such covenant and agreement does not extend to, and the Warrant Agent shall not be indemnified with respect to, such costs, expenses, losses and damages incurred or suffered by the Warrant Agent as a result of, or arising out of, its gross negligence, bad faith, or willful misconduct.

(c) In order that the indemnification provisions contained in this Section 13 shall apply, upon the assertion of a claim for which one party may be required to indemnify the other, the party seeking indemnification shall promptly notify the other party of such assertion, and shall keep the other party advised with respect to all developments concerning such claim. The indemnifying party shall have the option to participate with the indemnified party in the defense of such claim or to defend against said claim in its own name or the name of the indemnified party. The indemnified party shall in no case confess any claim or make any compromise in any case in which the indemnifying party may be required to indemnify it except with the indemnifying party’s prior written consent.

(d) Subject to Section 13(b) above, neither party to this Agreement shall be liable to the other party for any consequential, indirect, special or incidental damages under any provisions of this Agreement or for any consequential, indirect, penal, special or incidental damages arising out of any act or failure to act hereunder even if that party has been advised of or has foreseen the possibility of such damages.

(e) Notwithstanding anything contained herein to the contrary, the rights and obligations of the parties set forth in this Section 13 shall survive termination of this Agreement or the resignation or removal of the Warrant Agent.

14. Purchase or Consolidation or Change of Name of Warrant Agent

(a) Any corporation into which the Warrant Agent or any successor Warrant Agent may be merged or with which it may be consolidated, or any corporation resulting from any merger or consolidation to which the Warrant Agent or any successor Warrant Agent shall be party, or any corporation succeeding to the corporate trust business of the Warrant Agent or any successor Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such corporation would be eligible for appointment as a successor Warrant Agent under the provisions of Section 16. In case at the time such successor Warrant Agent shall succeed to the agency created by this Agreement any of the Warrant Certificates shall have been countersigned but not delivered, any such successor Warrant Agent may adopt the countersignature of the predecessor Warrant Agent and deliver such Warrant Certificates so countersigned; and in case at that time any of the Warrant Certificates shall not have been countersigned, any successor Warrant Agent may countersign such Warrant Certificates either in the name of the predecessor Warrant Agent or in the name of the successor Warrant Agent; and in all such cases such Warrant Certificates shall have the full force provided in the Warrant Certificates and in this Agreement.

(b) In case at any time the name of the Warrant Agent shall be changed and at such time any of the Warrant Certificates shall have been countersigned but not delivered, the Warrant Agent may adopt the countersignature under its prior name and deliver such Warrant Certificates so countersigned; and in case at that time any of the Warrant Certificates shall not have been countersigned, the Warrant Agent may countersign such Warrant Certificates either in its prior name or in its changed name; and in all such cases such Warrant Certificates shall have the full force provided in the Warrant Certificates and in this Agreement.

15. Duties of the Warrant Agent. The Warrant Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions, by all of which the Company, by its acceptance hereof, shall be bound:

(a) The Warrant Agent may consult with legal counsel reasonably acceptable to the Company (who may be legal counsel for the Company), and the opinion of such counsel shall be full and complete authorization and protection to the Warrant Agent as to any action taken or omitted by it in good faith and in accordance with such opinion.

(b) Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by the Chief Executive Officer, Chief Financial Officer or Vice President of the Company; and such certificate shall be full authentication to the Warrant Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.

(c) Subject to the limitation set forth in Section 13, the Warrant Agent shall be liable hereunder for its own gross negligence, bad faith or willful misconduct, or for a breach by it of this Agreement.

(d) The Warrant Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the Warrant Certificates (except its countersignature thereof) by the Company or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Company only.

(e) The Warrant Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant Certificate (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant Certificate; nor shall it be responsible for the adjustment of the Exercise Price or the making of any change in the number of shares of Common Stock required under the provisions of Section 9 or 12 or responsible for the manner, method or amount of any such change or the ascertaining of the existence of facts that would require any such adjustment or change (except with respect to the exercise of Warrants evidenced by Warrant Certificates after actual notice of any adjustment of the Exercise Price); nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant Certificate or as to whether any shares of Common Stock will, when issued, be duly authorized, validly issued, fully paid and nonassessable.

(f) Each party hereto agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the other party hereto for the carrying out or performing by any party of the provisions of this Agreement.

(g) The Warrant Agent is hereby authorized to accept instructions with respect to the performance of its duties hereunder from the Chief Executive Officer, Chief Financial Officer or Vice President of the Company, and to apply to such officers for advice or instructions in connection with its duties, and it shall not be liable and shall be indemnified and held harmless for any action taken or suffered to be taken by it in good faith in accordance with instructions of any such officer, provided Warrant Agent carries out such instructions without gross negligence, bad faith or willful misconduct.

(h) The Warrant Agent and any shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Agreement. Nothing herein shall preclude the Warrant Agent from acting in any other capacity for the Company or for any other legal entity.

(i) The Warrant Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, provided reasonable care was exercised in the selection and continued employment thereof.

16. Change of Warrant Agent. The Warrant Agent may resign and be discharged from its duties under this Agreement upon 30 days’ notice in writing mailed to the Company and to each transfer agent of the Common Stock by registered or certified mail, and to the holders of the Warrant Certificates by first-class mail. The Company may remove the Warrant Agent or any successor Warrant Agent upon 30 days’ notice in writing, mailed to the Warrant Agent or successor Warrant Agent, as the case may be, and to each transfer agent of the Common Stock by registered or certified mail, and to the holders of the Warrant Certificates by first-class mail. If the Warrant Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Warrant Agent or by any Holder, then any Holder may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent. Any successor Warrant Agent, whether appointed by the Company or by such a court, shall be a corporation organized and doing business under the laws of the United States or of a state thereof, in good standing, which is authorized under such laws to exercise corporate trust powers and is subject to supervision or examination by federal or state authority and which has at the time of its appointment as Warrant Agent a combined capital and surplus of at least $50,000,000. After appointment, the successor Warrant Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Warrant Agent without further act or deed; but the predecessor Warrant Agent shall deliver and transfer to the successor Warrant Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing with the predecessor Warrant Agent and each transfer agent of the Common Stock, and mail a notice thereof in writing to the Holders. However, failure to give any notice provided for in this Section 16, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Warrant Agent or the appointment of the successor Warrant Agent, as the case may be.

17. Issuance of New Warrant Certificates. Notwithstanding any of the provisions of this Agreement or of the Warrants to the contrary, the Company may, at its option, issue new Warrant Certificates evidencing Warrants in such form as may be approved by its Board of Directors to reflect any adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities or property purchasable under the Warrant Certificates made in accordance with the provisions of this Agreement.

18. Notices. Notices or demands authorized by this Agreement to be given or made (i) by the Warrant Agent or by any Holder to or on the Company, (ii) subject to the provisions of Section 16, by the Company or by any Holder to or on the Warrant Agent or (iii) by the Company or the Warrant Agent to the Holders, shall be deemed given (x) on the date delivered, if delivered personally, (y) on the first Business Day following the deposit thereof with Federal Express or another recognized overnight courier, if sent by Federal Express or another recognized overnight courier, and (z) on the fourth Business Day following the mailing thereof with postage prepaid, if mailed by registered or certified mail (return receipt requested), in each case to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):

(a) If to the Company, to:

Celator Pharmaceuticals, Inc.

200 PrincetonSouth Corporate Center

Suite 180

Ewing, New Jersey 08628

(b) If to the Warrant Agent, to:

American Stock Transfer & Trust Company, LLC

6201 15th Avenue

Brooklyn, NY 11219

Attention: Corporate Trust Department

Fax: (718) 765-8711

(c) If to the Holders, to the address of such holder as shown on the Warrant Register. Any notice required to be delivered by the Company to the Holders may be given by the Warrant Agent on behalf of the Company.

19. Miscellaneous.

(a) No Rights as a Stockholder. The Holders, solely in such Persons’ capacity as holders of the Warrants, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in the Warrants or this Warrant Agreement be construed to confer upon the Holders, solely in such Persons’ capacity holders of the Warrants, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holders which such Persons are then entitled to receive upon the due exercise of the Warrant. In addition, nothing contained in the Warrants or this Warrant Agreement shall be construed as imposing any liabilities on the Holders to purchase any securities (upon exercise of any Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 19(a), the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company, contemporaneously with the giving thereof to the stockholders.

(b) Successors and Assigns. Subject to compliance with applicable securities laws, any Warrant may be assigned by the Holder. The Warrants may not be assigned by the Company except to a successor in the event of a Fundamental Transaction. The Warrants shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in the Warrants or this Warrant Agreement shall be construed to give to any Person other than the Company and the Holders any legal or equitable right, remedy or cause of action under the Warrants. Any attempted assignment in violation of this Section 19(b) shall be null and void.

(c) Registration of Common Stock. The Company will use its reasonable best efforts to maintain the effectiveness of the Registration Statement, or a new registration statement, for the registration under the Act of the Common Stock issuable upon exercise of the Warrants and ensure that a prospectus is available for delivery to the Holders until the expiration of the Warrants in accordance with the provisions of this Warrant Agreement; provided, however, that in no event shall the Holders have the right to net settle the Warrants for cash irrespective of whether an effective registration statement is then in effect.

(d) Non-circumvention. The Company hereby covenants and agrees that the Company will not, by amendment of its corporate charter, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities or any other voluntary action, seek to avoid the observance or performance of any of the terms of the Warrants or this Warrant Agreement, and will at all times in good faith carry out all the provisions of the Warrants and this Warrant Agreement. Without limiting the generality of the foregoing, the Company shall not increase the par value of any shares of Common Stock receivable upon the exercise of the Warrants above the Warrant Price then in effect.

(c) Amendment and Waiver.

(i) The Company and the Warrant Agent may from time to time supplement or amend this Warrant Agreement without the approval of any Holders of Warrants in order to cure any ambiguity, to correct or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein, or to make any other provisions with regard to matters or questions arising hereunder which the Company and the Warrant Agent may deem necessary or desirable and which shall not adversely affect the interests of the Holders.

(ii) In addition to the foregoing, this Warrant Agreement may be amended, modified or supplemented, and waiver or consents to departures from the provisions of this Warrant Agreement may be given, if the Company and the holders of outstanding Warrants representing at least a majority of the shares of Common Stock purchasable under the outstanding Warrants consent to such amendment, modification, supplement, waiver or consent.

(d) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE state and federal courts sitting in the City of New York, Borough of Manhattan, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS WARRANT AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.

(e) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant Agreement and shall not be deemed to limit or affect any of the provisions hereof.

(f) Severability. In case any one or more of the provisions of this Warrant Agreement shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant Agreement shall not in any way be affected or impaired thereby, and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant Agreement.

(g) Force Majeure. Notwithstanding anything to the contrary contained herein, the Warrant Agent shall not be liable for any delays or failures in performance resulting from acts beyond its reasonable control including, without limitation, acts of God, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war, or civil unrest.

(Signature page follows.)

IN WITNESS WHEREOF, the Company has caused this Warrant Agreement to be duly executed by its authorized officer as of the date first indicated above.

	CELATOR PHARMACEUTICALS, INC.



	By:	/s/ Scott T. Jackson
		Name: Scott T. Jackson
		Title: Chief Executive Officer

	AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC


	By:	/s/ Paula Caroppoli
		Name: Paula Caroppoli
		Title: Senior Vice President

Exhibit A

EXERCISABLE ON OR AFTER OCTOBER __, 2014

AND ON OR BEFORE THE EXPIRATION DATE

No.

Warrant to Purchase Shares

Warrant Certificate

WARRANTS TO ACQUIRE COMMON STOCK OF CELATOR PHARMACEUTICALS, INC.

This warrant certificate (this “Warrant Certificate”) certifies that , or registered assigns, is the registered holder of a Warrant (the “Warrant”) to acquire from Celator Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the number of fully paid and non-assessable shares of Common Stock, $0.001 par value, of the Company (the “Common Stock”) specified above for consideration equal to the Exercise Price (as defined in the Warrant Agreement (as defined below)) per share of Common Stock. The Exercise Price and number of shares of Common Stock and/or type of securities or property issuable upon exercise of the Warrant are subject to adjustment upon the occurrence of certain events as set forth in the Warrant Agreement. The Warrant evidenced by this Warrant Certificate shall not be exercisable after and shall terminate and become void as of 5:00 P.M., New York time, on October __, 2019 (the “Expiration Date”).

The Warrant evidenced by this Warrant Certificate is part of a duly authorized issue of warrants expiring on the Expiration Date entitling the Holder hereof to receive shares of Common Stock, and is issued or to be issued pursuant to a Warrant Agreement dated October __, 2014 (the “Warrant Agreement”), duly executed and delivered by the Company to American Stock Transfer & Trust Company, LLC, as warrant agent (the “Warrant Agent”, which term includes any successor warrant agent under the Warrant Agreement), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the Holders (“Holders” meaning, from time to time, the registered holders of the warrants issued thereunder). To the extent any provisions of this Warrant Certificate conflicts with any provision of the Warrant Agreement, the provisions of the Warrant Agreement shall apply. A copy of the Warrant Agreement may be obtained by the Holder hereof upon written request to the Company at 200 PrincetonSouth Corporate Center, Suite 180, Ewing, New Jersey 08628, Attn: Chief Financial Officer. Capitalized terms not defined herein have the meanings ascribed thereto in the Warrant Agreement.

This Warrant may be exercised, in whole or in part, at any time on or after October __, 2014 and on or before the Expiration Date, subject to the terms of the Warrant Agreement including, but not limited to, Section 4 thereof, by surrendering this Warrant Certificate, with the Form of Election to Purchase attached hereto properly completed and executed, together with payment of the Exercise Price in accordance with Section 5 or Section 10 of the Warrant Agreement. Each exercise must be for a whole number of Warrant Shares. In the event that upon any exercise of the Warrant evidenced hereby the number of shares of Common Stock acquired shall be less than the total number of shares of Common Stock which may be purchased pursuant to this Warrant, there shall be issued to the Holder hereof or such Holder’s assignee a new Warrant Certificate evidencing the unexercised portion of this Warrant.

The Warrant Agreement provides that upon the occurrence of certain events the Exercise Price set forth in this Warrant Certificate may, subject to certain conditions, be adjusted, and that upon the occurrence of certain events the number of shares of Common Stock and/or the type of securities or other property issuable upon the exercise of this Warrant shall be adjusted. No fractions of a share of Common Stock will be issued upon the exercise of this Warrant, but the Company will pay the cash value thereof determined as provided in the Warrant Agreement.

Warrant Certificates, when surrendered at the office of the Warrant Agent by the registered Holder thereof in person or by such Holder’s legal representative or attorney duly appointed and authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing in the aggregate the right to purchase a like number of Warrant Shares.

Each taker and holder of this Warrant Certificate, by taking or holding the same, consents and agrees that the holder of this Warrant Certificate when duly endorsed in blank may be treated by the Company, the Warrant Agent and all other persons dealing with this Warrant Certificate as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented hereby or the person entitled to the transfer hereof on the register of the Company maintained by the Warrant Agent, any notice to the contrary notwithstanding, provided that until such transfer on such register, the Company and the Warrant Agent may treat the registered Holder hereof as the owner for all purposes.

This Warrant does not entitle any Holder to any of the rights of a stockholder of the Company.

This Warrant Certificate and the Warrant Agreement are subject to amendment as provided in the Warrant Agreement.

This Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the Warrant Agent.

IN WITNESS WHEREOF, the undersigned have caused this Certificate to be executed as of the date set forth below.

	CELATOR PHARMACEUTICALS, INC.

	By:
		Name:
		Title:

Dated: ___________________________

Countersigned:

AMERICAN STOCK TRANSFER &
TRUST COMPANY, LLC

By:______________________________

Name:

Title:

EXHIBIT B

Form of Assignment

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto _______________ the right represented by the foregoing Warrant to purchase ______ shares of Common Stock of Celator Pharmaceuticals, Inc. and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Dated: _______________ __, ______
Holder’s Signature:
Holder’s Address:

EXHIBIT C

Form of Exercise Notice

(To be executed by the Holder to purchase shares of Common Stock
under the foregoing Warrant)

Celator Pharmaceuticals, Inc.:

(1) Description. The undersigned is the Holder of the Warrant (the “Warrant”) issued by Celator Pharmaceuticals, Inc., a Delaware corporation (the “Company”) to purchase ____________ shares of Common Stock (“Warrant Shares”) in accordance with the terms of the Warrant and the Warrant Agreement. Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant and the Warrant Agreement.

(2) Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:

_____ a Cash Exercise ; or

_____ a Cashless Exercise under Section 10 of the Warrant Agreement, with respect to the full exercise of the Warrant.

(3) Payment of Exercise Price. In the event that the Holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the Holder shall pay the Aggregate Exercise Price, in lawful money of the United States, in cash, certified check or bank draft payable or by wire transfer to the order of the Warrant Agent (or as otherwise agreed to by the Company) delivered to the Warrant Agent, together with any applicable taxes payable by the undersigned pursuant to the Warrant.

(4) Delivery. Pursuant to this Exercise Notice, the Company shall deliver to the Holder _____________ Warrant Shares in accordance with the terms of the Warrant Agreement.

Dated:

Name of Holder:

By:

Name:

Title:

(Signature must conform in all respects to name of
Holder as specified on the face of the Warrant.)

EX-31.1 3 v392687_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Chief Executive Officer Pursuant to

Exchange Act Rules 13a-14(a) or 15d-14(a)

I, Scott T. Jackson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Celator Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 13, 2014	/s/ Scott T. Jackson
	Scott T. Jackson,
	Chief Executive Officer

EX-31.2 4 v392687_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Chief Financial Officer Pursuant to

Exchange Act Rules 13a-14(a) or 15d-14(a)

I, Fred M. Powell, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Celator Pharmaceuticals, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 13, 2014	/s/ Fred M. Powell
	Fred M. Powell, Vice President and
	Chief Financial Officer

EX-32.1 5 v392687_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350,

In connection with the quarterly report of Celator Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 13, 2014	/s/ Scott T. Jackson
	Scott T. Jackson,
	Chief Executive Officer
	(Principal executive officer)

Date: November 13, 2014	/s/ Fred M. Powell
	Fred M. Powell, Vice President and
	Chief Financial Officer
	(Principal financial and accounting officer)

EX-101.INS 6 cpxx-20140930.xml XBRL INSTANCE DOCUMENT 0001327467 2013-01-01 2013-09-30 0001327467 2014-01-01 2014-09-30 0001327467 2014-05-01 2014-05-09 0001327467 2013-07-01 2013-09-30 0001327467 2014-07-01 2014-09-30 0001327467 2014-09-30 0001327467 2014-11-11 0001327467 2013-12-31 0001327467 2012-12-31 0001327467 2013-09-30 0001327467 us-gaap:CertificatesOfDepositMember 2013-12-31 0001327467 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember 2013-12-31 0001327467 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2013-12-31 0001327467 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2013-12-31 0001327467 us-gaap:MoneyMarketFundsMember 2014-09-30 0001327467 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2014-09-30 0001327467 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2014-09-30 0001327467 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2014-09-30 0001327467 us-gaap:MoneyMarketFundsMember 2013-12-31 0001327467 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2013-12-31 0001327467 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2013-12-31 0001327467 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2013-12-31 0001327467 us-gaap:FairValueInputsLevel1Member 2013-12-31 0001327467 us-gaap:FairValueInputsLevel2Member 2013-12-31 0001327467 us-gaap:FairValueInputsLevel3Member 2013-12-31 0001327467 us-gaap:FairValueInputsLevel3Member 2013-01-01 2013-09-30 0001327467 us-gaap:ComputerEquipmentMember 2014-09-30 0001327467 us-gaap:FurnitureAndFixturesMember 2014-09-30 0001327467 cpxx:LaboratoryEquipmentMember 2014-09-30 0001327467 us-gaap:AssetsHeldUnderCapitalLeasesMember 2014-09-30 0001327467 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2014-09-30 0001327467 us-gaap:ComputerEquipmentMember 2013-12-31 0001327467 us-gaap:FurnitureAndFixturesMember 2013-12-31 0001327467 cpxx:LaboratoryEquipmentMember 2013-12-31 0001327467 us-gaap:AssetsHeldUnderCapitalLeasesMember 2013-12-31 0001327467 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2013-12-31 0001327467 us-gaap:EquipmentMember 2012-02-29 0001327467 cpxx:ScientificEquipmentMember 2014-09-30 0001327467 us-gaap:AssetsHeldForSaleMember 2013-01-01 2013-09-30 0001327467 us-gaap:AssetsHeldForSaleMember 2013-01-01 2013-12-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember us-gaap:WarrantMember 2014-01-01 2014-09-30 0001327467 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001327467 us-gaap:WarrantMember 2014-07-01 2014-09-30 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember 2014-05-09 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember us-gaap:WarrantMember 2014-09-30 0001327467 cpxx:TermLoanMember 2014-01-01 2014-09-30 0001327467 cpxx:EndOfTermFeeMember 2014-01-01 2014-09-30 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember 2014-05-01 2014-05-09 0001327467 cpxx:NonVestedAwardsMember 2014-09-30 0001327467 cpxx:NonVestedAwardsMember 2014-01-01 2014-09-30 0001327467 cpxx:UnitedStatesMember 2014-09-30 0001327467 cpxx:CanadaMember 2014-09-30 0001327467 cpxx:GermanyMember 2014-09-30 0001327467 cpxx:UnitedStatesMember 2013-12-31 0001327467 cpxx:CanadaMember 2013-12-31 0001327467 cpxx:GermanyMember 2013-12-31 0001327467 cpxx:UnitedStatesMember 2013-01-01 2013-09-30 0001327467 cpxx:CanadaMember 2013-01-01 2013-09-30 0001327467 cpxx:UnitedStatesMember 2014-01-01 2014-09-30 0001327467 cpxx:CanadaMember 2014-01-01 2014-09-30 0001327467 cpxx:UnitedStatesMember 2013-07-01 2013-09-30 0001327467 cpxx:CanadaMember 2013-07-01 2013-09-30 0001327467 cpxx:UnitedStatesMember 2014-07-01 2014-09-30 0001327467 cpxx:CanadaMember 2014-07-01 2014-09-30 0001327467 cpxx:PrincetonUniversityAgreementMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0001327467 cpxx:PrincetonUniversityAgreementMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0001327467 cpxx:LeukemiaAndLymphomaSocietyAgreementMember 2014-01-01 2014-09-30 0001327467 cpxx:PrincetonUniversityAgreementMember 2014-01-01 2014-09-30 0001327467 cpxx:BritishColumbiaCancerAgencyMember 2014-01-01 2014-09-30 0001327467 cpxx:PhaseThreeStudyMember cpxx:LeukemiaAndLymphomaSocietyAgreementMember 2014-01-01 2014-09-30 0001327467 cpxx:PhaseTwoStudyMember cpxx:LeukemiaAndLymphomaSocietyAgreementMember 2014-01-01 2014-09-30 0001327467 cpxx:LeukemiaAndLymphomaSocietyAgreementMember us-gaap:MinimumMember 2014-01-01 2014-09-30 0001327467 cpxx:LeukemiaAndLymphomaSocietyAgreementMember us-gaap:MaximumMember 2014-01-01 2014-09-30 0001327467 cpxx:ColumbiaMember 2014-09-30 0001327467 cpxx:EwingNewJerseyMember 2014-09-30 0001327467 cpxx:VancouverofficespacebritishcolumbiamemberMember 2014-09-30 0001327467 us-gaap:WarrantMember 2013-12-31 0001327467 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0001327467 us-gaap:RetainedEarningsMember 2013-12-31 0001327467 us-gaap:CommonStockMember 2013-12-31 0001327467 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001327467 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001327467 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-09-30 0001327467 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-09-30 0001327467 us-gaap:RetainedEarningsMember 2014-01-01 2014-09-30 0001327467 us-gaap:CommonStockMember 2014-09-30 0001327467 us-gaap:WarrantMember 2014-09-30 0001327467 us-gaap:AdditionalPaidInCapitalMember 2014-09-30 0001327467 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-09-30 0001327467 us-gaap:RetainedEarningsMember 2014-09-30 0001327467 us-gaap:SubsequentEventMember 2014-10-01 2014-10-28 0001327467 us-gaap:ScenarioPreviouslyReportedMember 2013-01-01 2013-09-30 0001327467 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2014-10-01 2014-10-28 0001327467 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2014-10-01 2014-10-28 0001327467 us-gaap:SubsequentEventMember cpxx:UnderWriterMember us-gaap:WarrantMember 2014-10-01 2014-10-28 0001327467 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2014-10-28 0001327467 us-gaap:SubsequentEventMember cpxx:UnderWriterMember us-gaap:WarrantMember 2014-10-28 0001327467 us-gaap:SubsequentEventMember 2014-10-28 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">4.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Other Receivables</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Other receivables as of September 30, 2014 and December 31, 2013, consists of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Receivables related to the sale of New Jersey net operating losses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,412,302</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other receivables</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,417,313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">5.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Other Current Assets</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Other current assets as of September 30, 2014 and December 31, 2013 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Clinical trial materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>541,468</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>468,389</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">8.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Accrued Liabilities</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued liabilities as of September 30, 2014 and December 31, 2013 consist of the following:                </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued bonuses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>748,444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>624,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued salaries and vacation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>213,775</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>143,484</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued clinical trial expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>494,651</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>636,497</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued drug manufacturing expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,565</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Interest payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>83,339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued trade payables other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>276,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>195,445</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,022,462</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,630,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">10.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Stock-Based Compensation</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the activity of the Company’s stock option plans for the nine months ended September 30, 2014:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,578,252</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>499,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(42,936)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(14,603)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,019,813</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Exercisable at September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,193,556</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table provides information regarding stock options activity during the periods:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>Nine months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Stock compensation expense recognized</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>354,204</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>235,289</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>996,801</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>322,069</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Weighted average grant-date fair value of stock options issued (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Grant-date fair value of stock options issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>45,732</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,080</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,337,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,314,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>112.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>117.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>114.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>118.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Expected life in years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Intrinsic value of stock options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At September 30, 2014, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,988,729</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.9</font> years, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">New Accounting Pronouncement</font></i> <font style="FONT-SIZE: 10pt">: In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, <i>Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</i> , which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2014, the FASB issued ASU No. 2014-15, <i>Presentation of Financial StatementsGoing Concern (Subtopic 205-40)</i>. The ASU provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

20180490

23589516

285801

287657

6335

1417313

679681

491465

74086

541468

468389

21767861

26328426

1008426

1138579

612180

5745

23388467

27472750

183174

1193148

2022462

1630809

542986

2748622

3366943

10077056

180996

588236

47626

53084

13054300

4008263

26079

26036

1083193

157372043

155953894

-1133266

-147013882

-132465370

10334167

23464487

23388467

27472750

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">There were no transfers between levels and the following table provides the assets carried at fair value:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Money Market Fund</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,727,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17,727,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="21%"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Certificates of Deposit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,003,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,003,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Money Market Fund</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,597,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,597,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>22,601,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>22,601,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Property and equipment as of September 30, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:             </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Computer and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>141,998</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>136,498</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Furniture and office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>96,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>96,457</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Laboratory equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,769,589</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,760,633</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Capital lease equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155,523</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155,523</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Leaseholds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,201,356</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,186,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Less: Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,192,930)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,048,321)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,008,426</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,138,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>Nine months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>48,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>51,239</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>144,609</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>148,291</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Accrued liabilities as of September 30, 2014 and December 31, 2013 consist of the following:                </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued bonuses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>748,444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>624,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued salaries and vacation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>213,775</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>143,484</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued clinical trial expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>494,651</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>636,497</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued drug manufacturing expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,565</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Interest payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>83,339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accrued trade payables other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>276,688</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>195,445</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,022,462</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,630,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes the activity of the Company’s stock option plans for the nine months ended September 30, 2014:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,578,252</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>499,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(42,936)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(14,603)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,019,813</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Exercisable at September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,193,556</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table provides information regarding stock options activity during the periods:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>Nine months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%" colspan="6"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Stock compensation expense recognized</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>354,204</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>235,289</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>996,801</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>322,069</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Weighted average grant-date fair value of stock options issued (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Grant-date fair value of stock options issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>45,732</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,080</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,337,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,314,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>112.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>117.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>114.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>118.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Expected life in years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Intrinsic value of stock options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,892</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The geographic information about total assets is based on the physical location of the assets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>Total Assets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>United States</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,226,025</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26,190,516</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Canada</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>266,844</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>284,563</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Germany</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>895,598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>997,671</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Total Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>23,388,467</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>27,472,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%" colspan="11"> <div>Net Loss</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>Nine months</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>September 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="31%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>United States</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,046,236)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,274,731)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(12,977,790)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(15,649,089)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Canada</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(433,581)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(402,681)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,570,722)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,753,248)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="31%"> <div>Total Net Loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(5,479,817)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(3,677,412)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(14,548,512)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(17,402,337)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

15003472

17727260

7597730

22601202

20000000

0.001

200000000

0.001

26078532

26035596

26078532

26035596

7473108

1412302

6335

5011

2201356

141998

96457

1769589

155523

37789

2186900

136498

96457

1760633

155523

37789

1192930

1048321

148291

144609

51239

48521

507622

74086

177428

74086

51776

-125422

748444

624472

213775

143484

60000

30911

494651 636497

276688

195445

10000000

77056

10077056

158006

88176

57670

10000000

15000000

5000000

2.67

320752

357253

592500

589828

repayable in installments over forty-two months including an initial interest-only period of twelve months after closing

any time between December 15, 2014 and March 31, 2015

Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015,

P5Y 77056 50396

2578252

499100

42936

14603

3019813

1193556

2.98

3.13

2.34

3.17

3.01

2.75

5995866

9238756

2325891

3334789

425339 907240 135746 135747

3922084

5491779

1434436

1874412

-126633

12059

148291

144609

51239

48521

-9767535

-13967904

-3663761

-5121975

-21229

-27721

-16745

-1408

6560

7144

3094

2887

7473108 0 0 0

147025

560031

359321

-17402337

-14548512

-3677412

-5479817

-0.84

-0.56

-0.14

-0.21

20641876

26065006

26026793

26078532

322069

996801

235289

354204

2.14

2.68

2.11

2.22

3314341 1337588 59080 45732

1.183

1.144

1.170

1.120

0.019

0.020

0.016

0.019

P6Y2M12D

P6Y

38892

3988729

P2Y10M24D

22226025

266844

895598

26190516

284563

997671

-15649089

-1753248

-12977790

-1570722

-3274731

-402681

-5046236

-433581

0.45 0.55 0.5 P90D P60D P45D 5000000 4100000 1.5 3.55 0.05

35090

530232

111638

200000

40000

60000

1083193

-1133266

-132465370

26036

155953894

23464487

26035596

100639

100596

42936

996801

320752

-14548512

10334167

26079

1083193

157372043

-1133266

-147013882

26078532

74751

165232

-1990932

-1407230

134177

189470

250037

530391

73079

-22332

-1007161

208124

400843

23148

-5458

-425339

-407240

-8397557

-13132811

82009

14456

51776

-30233

-14456

32499986

104387

3079611

9827216

184469

3000000

26420375

9747134

877

-8893

17993462

-3409026

9648008

27641470

79388

311458

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">1.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">Nature of Business and Liquidity</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Celator Pharmaceuticals, Inc. (the “Company”), with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the Company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2014, the Company had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">147.0</font> million. The Company expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. At September 30, 2014, the Company had cash and cash equivalents of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20.2</font> million. On October 28, 2014, the Company completed a public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,602,823</font> shares of common stock and warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 760,282</font> shares of its common stock. The Company received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.5</font> million in net proceeds from the public offering (See Note 13). Management believes that the cash and cash equivalents at September 30, 2014 cash available to the Company through the Hercules Technology Growth Capital Inc. (“Hercules”) term loan and the funds received from the October 28, 2014 public offering will be sufficient to meet estimated working capital requirements and fund planned operations into the second half of 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. Substantial additional financing will be needed by the Company to fund its operations and to commercialize its product candidates. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23.05pt; MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">2.</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Summary of Significant Accounting Policies</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of consolidation:</font></i> <font style="FONT-SIZE: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of estimates</font></i><font style="FONT-SIZE: 10pt">: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Loss per share:<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></i> <font style="FONT-SIZE: 10pt">The net loss per share for the nine months ended September 30, 2013 has been corrected for an immaterial error in the calculation of average weighted shares outstanding. The revision is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>As Reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>As Revised</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(17,402,337)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(17,402,337)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Net loss per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.87)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.84)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,977,071</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,641,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The above correction has no impact on any other prior year financial statement amounts or disclosures.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>New Accounting Pronouncement</font></i> <font style="FONT-SIZE: 10pt">: In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, <i>Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation</i> , which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2014, the FASB issued ASU No. 2014-15, <i>Presentation of Financial StatementsGoing Concern (Subtopic 205-40)</i>. The ASU provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

13500000

10-Q false 2014-09-30 2014 Q3 Celator Pharmaceuticals Inc 0001327467 --12-31 Smaller Reporting Company CPXX 33681355

145565 0

83339

16568

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></i> <font style="FONT-SIZE: 10pt">The net loss per share for the nine months ended September 30, 2013 has been corrected for an immaterial error in the calculation of average weighted shares outstanding. The revision is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>As Reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>As Revised</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(17,402,337)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(17,402,337)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Net loss per share</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.87)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.84)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,977,071</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,641,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

-17402337

-0.87

19977071

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> </div> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">7.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">Other Assets</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Other assets as of September 30, 2014 and December 31, 2013 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred financing costs (see Note 9)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>589,828</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other non-current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,352</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>612,180</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Other assets as of September 30, 2014 and December 31, 2013 consist of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>September 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Deferred financing costs (see Note 9)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>589,828</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Other non-current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22,352</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>612,180</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

22352

5745

7602823

760282

991673

114042

3.58

P5Y consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock

1.95

EX-101.SCH 7 cpxx-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Loss link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statement of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Nature of Business and Liquidity link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Other Receivables link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Other Current Assets link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Other Assets link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Loans Payable link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stock Based Compensation link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Geographic Segment Information link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Other Receivables (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Other Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Loans Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Geographic Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Nature of Business and Liquidity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Fair Value Measurements (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Other Receivables (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Other Current Assets (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Property and Equipment (Details 1) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Other Assets (Details) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Loans Payable (Details) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Loans Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - Stock Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - Stock Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - Stock Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - Geographic Segment Information (Details) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 149 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 cpxx-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cpxx-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cpxx-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Other Receivables, Net, Current [Abstract] Other Receivable [Text Block] The entire disclosure for other receivable. Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Other Current Assets [Text Block] Other Current Assets [Text Block] Property Plant And Equipment [Abstract] Property Plant And Equipment Disclosure [Text Block] Payables And Accruals [Abstract] Accounts Payable And Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure [Text Block] Accounting Policies [Abstract] Consolidation, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets Current [Abstract] Current assets: Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Restricted Cash And Cash Equivalents At Carrying Value Restricted cash Accounts And Other Receivables Net Current Other receivables Other receivables, net Prepaid Expense Current And Noncurrent Prepaid expenses and deposits Disposal Group, Including Discontinued Operation, Assets, Current Assets held for sale Materials, Supplies, and Other Other current assets Clinical trial materials Assets Current Total current assets Property Plant And Equipment Net Property and equipment, net Property and equipment, net Other Assets Noncurrent Other assets Assets, Noncurrent Assets Total assets Total Assets Liabilities [Abstract] Liabilities Liabilities Current [Abstract] Current liabilities: Accounts Payable Current Accounts payable Accrued Liabilities Current Accrued liabilities Accrued liabilities Deferred Revenue Current Current portion of deferred revenue Liabilities Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt Deferred Revenue Noncurrent Deferred revenue Deferred Rent Credit Deferred rent Liabilities Total liabilities Stockholders Equity [Abstract] Stockholders' equity Preferred Stock, Value, Issued Preferred stock Authorized 20,000,000 shares, par value $0.001 Common Stock Value Common stock Authorized 200,000,000 shares, par value $0.001 Issued and outstanding 26,078,532 and 26,035,596 shares as of September 30, 2014 and December 31, 2013, respectively Warrants And Rights Outstanding Warrants Additional Paid In Capital Additional paid-in capital Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total stockholders' equity Liabilities And Stockholders Equity Total liabilities and stockholders' equity Fair Value Disclosures [Abstract] Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule Of Other Receivables [Table Text Block] Represents the other receivables. Schedule of Other Current Assets [Table Text Block] Schedule of Other Current Assets [Table Text Block] Property, Plant and Equipment [Table Text Block] Schedule Of Depreciation And Amortisation [Table Text Block] Schedule Of Depreciation And Amortization [Table Text Block] Tabular disclosure of depreciation and amortization. Schedule Of Accrued Liabilities Table [Text Block] Schedule of Accrued Liabilities [Table Text Block] Schedule of Debt [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Segment Reporting Information By Segment [Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Nature Of Business And Liquidity [Table] Legal Entity [Axis] Entity [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Medium-term Notes [Member] Equity Components [Axis] Equity Components [Axis] Fair Value, by Balance Sheet Grouping [Table] Eligible Item or Group for Fair Value Option [Axis] Fair Value, Option, Eligible Item or Group [Domain] Certificates of Deposit [Member] Money Market Funds [Member] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Assets: Certificates of Deposit, at Carrying Value Certificates of Deposit Money Market Funds, at Carrying Value Money Market Fund Assets, Fair Value Disclosure, Total Total Preferred Stock, Shares Authorized Preferred Stock, Par or Stated Value Per Share peferred stock, par valur (in dollars per share) Common Stock Shares Authorized Common stock, authorized shares Common Stock Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock Shares Issued Common stock, issued shares Common Stock Shares Outstanding Common stock, outstanding shares Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Non-cash derivative instrument charge Non-cash derivative instrument charge Non-cash derivative instrument charge The amount of non-cash derivative charges recognized during the period. Schedule Of Other Receivables [Table] Class of Financing Receivable [Axis] Class of Financing Receivable [Domain] Other Receivables [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accounts and Notes Receivable, Net, Total Receivables related to the sale of New Jersey net operating losses Other Receivables Other receivables Schedule of Other Current Asset [Table] Other Current Assets [Line Items] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Computer Equipment [Member] Computer and equipment [Member] Furniture And Fixtures [Member] Furniture and office equipment [Member] Laboratory Equipment [Member] Laboratory equipment [Member] Laboratory Equipment [Member] Assets Held Under Capital Leases [Member] Capital lease equipment [Member] Leaseholds And Leasehold Improvements [Member] Leaseholds [Member] Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Property Plant And Equipment Gross Property and equipment, gross Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Less: Accumulated depreciation Depreciation, Depletion and Amortization Depreciation and amortization Equipment [Member] Property and Equipment [Member] Scientific Equipment [Member] Scientific Equipment [Member] Scientific Equipment [Member] Assets Held For Sale [Member] Assets Held for Sale [Member] Disposal Group, Including Discontinued Operation, Long Lived Assets, Noncurrent Assets Held For Sale Long Lived Property Plant And Equipment Disposals Assets Disposals, Written Off Net Book Value Proceeds From Sale Of Property Plant And Equipment Proceeds from sale of assets Proceeds on disposals of property and equipment Gain Loss On Sale Of Property Plant Equipment Loss on disposal of property and equipment (Gain) loss on disposal of property and equipment Schedule Of Accrued Liabilities [Table] Accrued Liabilities [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accrued Bonuses Current Accrued bonuses Accrued Salaries Current Accrued salaries and vacation Accrued Professional Fees Current Accrued professional fees Accrued Clinical Trial Expenses Accrued clinical trial expenses Accrued Clinical Trial Expenses Accrued Drug Development Costs Accrued drug manufacturing expenses Accrued Drug Development Costs Interest Payable, Current Interest payable Schedule Of Loans Payable [Table] Schedule Of Loan payable [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table Loans Payable Loan payable Accrued End Of Loan Term Fee End of term fee Amount of fees associated with end of loan term. Long-term Debt Long-term debt Hercules Technology Growth Capital [Member] Equity Component [Domain] Equity Component [Domain] Warrant [Member] Warrants [Member] Term Loan [Member] End of Term Fee [Member] Stock Issued During Period, Shares, New Issues Amortization Of Financing Costs And Discounts Non-cash financing costs Line of Credit Facility, Fair Value of Amount Outstanding Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Remaining Borrowing Capacity Class of Warrant or Right, Exercise Price of Warrants or Rights Adjustments to Additional Paid in Capital, Warrant Issued Warrants issued Debt Issuance Cost Debt Issuance Cost Deferred Finance Costs, Noncurrent, Net Deferred financing costs (see Note 9) Long-term Debt, Maturities, Repayment Terms Line of Credit Facility, Frequency of Payments Line of Credit Facility, Interest Rate Description Warrants Maturity Term The number of years at exercise price of warrants to purchase in period. End of Loan Term, Fees Amount of fees associated with end of loan term. Schedule Of Share Based Compensation Stock Options Activity [Table] Schedule Of Share Based Compensation Stock Options Activity [Line Items] Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of options, Beginning balance Number of options, Ending balance Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Number of options, Granted Stock Issued During Period Shares Stock Options Exercised Number of options, Exercised Issued for cash on exercise of stock options (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Number of options, Cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Number of options, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Exercise price, Beginning balance Exercise price, Ending balance Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercise price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercise pice, Exercised Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Exercise price, Cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Exercise price, Exercisable Income Statement [Abstract] Operating Expenses [Abstract] Expenses Research And Development Expense Research and development Research And Development Arrangement With Other Funding To Offset Costs Incurred Leukemia & Lymphoma Society funding The amount of funding recorded as an offset to costs incurred from arrangement with other organizations. General And Administrative Expense General and administrative Depreciation And Amortization Amortization and depreciation Operating Income Loss Operating loss Nonoperating Income Expense [Abstract] Other income (expenses) Foreign Currency Transaction Gain Loss Before Tax Foreign exchange loss Interest And Other Income Interest and miscellaneous income Interest Expense Interest expense Net Income Loss Net loss Total Net Loss Net loss for the period Net loss Earnings Per Share Basic And Diluted [Abstract] Net loss per share Earnings Per Share Basic And Diluted Basic and diluted (in dollars per share) Net loss per share Weighted Average Number Of Common Shares Outstanding [Abstract] Weighted average of common shares outstanding Weighted Average Number Of Common Shares Outstanding [Abstract] Weighted Average Number Of Share Outstanding Basic And Diluted Basic and diluted (in shares) Weighted average shares outstanding Equity [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] EX-101.PRE 11 cpxx-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Textual) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended	12 Months Ended
Property and Equipment (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Feb. 29, 2012 Property and Equipment [Member]	Sep. 30, 2014 Scientific Equipment [Member]	Sep. 30, 2013 Assets Held for Sale [Member]	Dec. 31, 2013 Assets Held for Sale [Member]
Property, Plant and Equipment [Line Items]
Assets Held For Sale Long Lived					$ 507,622	$ 74,086
Assets Disposals, Written Off Net Book Value							177,428	74,086
Proceeds from sale of assets			0	51,776			51,776
Loss on disposal of property and equipment	$ 0	$ (12,059)	$ 0	$ 126,633			$ 125,422

XML 13 R48.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual) (USD $)	9 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Sep. 30, 2014
Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Agreement termination notice period	90 days
Rectification of default period	60 days
Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	50.00%
Cash Payment Or Royalties on net sales	5.00%
Leukemia & Lymphoma Society Agreement [Member] \| Phase 3 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	$ 5,000,000
Leukemia & Lymphoma Society Agreement [Member] \| Phase 2 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	4,100,000
Vancouver Laboratory Space, British Columbia [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	35,090
Ewing, New Jersey [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	530,232
Letters of Credit Outstanding, Amount	200,000
Contractual Obligation of letter of credit payment as on December 1, 2014	40,000
Contractual Obligation of letter of credit payment as on December 1, 2015	40,000
Contractual Obligation of letter of credit payment as on December 1, 2016	40,000
Contractual Obligation of letter of credit payment as on December 1, 2017	60,000
Vancouver Office Space, British Columbia [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	$ 111,638
British Columbia Cancer Agency [Member]
Loss Contingencies [Line Items]
Rectification of default period	45 days
Minimum [Member] \| Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	45.00%
Minimum [Member] \| Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Number of times amount payable under research funding program	1.5
Maximum [Member] \| Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	55.00%
Maximum [Member] \| Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Number of times amount payable under research funding program	3.55

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!NR'4D#`(``#@>```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4MNVS`41><%N@>!T\*B M^6F:%I8SZ&?8!FBZ`$9ZM@1+)$$RJ;W[4G(2%('KP(B!WHD%2^2[1QR<@>[B M:COTQ3V%V#E;,5'.64&V=DUGUQ7[=?-M=LF*F(QM3.\L56Q'D5TMW[Y9W.P\ MQ2+OMK%B;4K^$^>Q;FDPL72>;'ZR;E$GYO6V>I

$LJ\I5-8UXHAF+:]13/_#%W/_2EY-8$:GZFD!O,LP/\/?L8 M1^[WKH/S,3>=@4X_A<F!SUI)&GO8AIH# MV7SJ?9=_````__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R M96QS+RYR96QS(*($`BB@``(````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````(R2ST[#,`S&[TB\ M0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50? M'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+ MBQJZE/PC8C0=3Q0+\>QRI9$P4P>J M/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"\F4]KVT`4Q.^%?@>Q]WB][ZVTD!S$7@R2\^O&8G1E)=_>_CH?B1QCCON\JXQ9+4X1N MTS?[;E>9;T^?KVY,$5/=-?6A[T)E3B&:^_7'#W=?PJ%.^4^QW0^QR*MTL3)M M2L,G:^.F#<:YW@4KR^7*CG^O8=87:Q:/367& MQ\:I*9Y.0[[UVXOWV^U^$Q[ZS?=CZ-(_[F%_]N-S;$-(>=%ZW(54F>E4M.9V=C_X.1Y<'%N$(ZLR#BR0CAZ2\;16X0CCHPC#N&H)^.H1SA>R#A>(,XU M&^<:X939">?;Z"D;8L@+OGC.^=">?Z%BV".!$V'+!:K%L8W/0>,3MO$)-#[' M-CX'92QLXQ-H?,I6LD(I*WN7*]SF?E;CF]K5J_E-IUX*EU\B'_;EG#X\W1O@ ME`B'30-A')O&01QA5W6!55W855U@55=V8BE,+,].+(\3B^TZ#KJ.8T_'P>DH M.\\5YKEGY[F'>5[.FN>QK+8GN>@YSFVYSGH><(V&8$FHW3I0.TH>ULKW->> M_3SEX?.4L/-28%[Z65WO'>7&PR<&-@V$80MGTHV]^&BZ_@T``/__`P!02P,$ M%``&``@````A`,.&SV43!```^PX```\```!X;"]W;W)K8F]O:RYX;6R4EUU/ MVS`4AN\G[3]$N=_2?-`"HB!@;$-B&UH97%HF<5N+Q,YLA])_O^-$34_B-!HW M%#?UF_/QO,?)V<5;D7NO3&DNQ=P//T]\CXE49ERLYOZ?AZ^?CGU/&RHRFDO! MYOZ6:?_B_..'LXU4+\]2OG@@(/3<7QM3G@:!3M>LH/JS+)F`*TNI"FI@J5:! M+A6CF5XS9HH\B":3:5!0+OQ&X53]CX9<+GG*OLBT*I@PC8AB.340OE[S4OOG M9TN>L\_E5)N;C!N6S?TC6,H-ZWRAJO*JXCE*R]C2UKEY@'2VZE#O:(DBJ;VE[84CYQM]'Z377IO3UQD9L"?L*$8)A)/AK=>54M!1P6!1 M`+-J9,,7(A0YS"F\:`MNPP)0P<#W!,=.LPQ"(/9"F,/(X?"`@X:V(QQ;4Y-/"$' M3.9JS#"JD8-JQVL#NS&AD4OH`<>@FBYCW%JL.@9Z!#W7YBA'!ZQ]CJ=S!QJQW5P9G$G,X=O9P&'32@@GT8.]/V@(4&=+`58P?A<9U.9;`98X?F<2$\ZV:=^C@X M=USMYI-@2\*B5]TA6P^(0&+M89@X_'9]/;`=4YLXU`YN)P_LS5040YM@:&'1 M2^70D=P@AX!+,+.P>)<.;G&".P.+=PGA%B<87ECTA,8G5D<(TYLX](X^*Q!< M(@QOXL#K/"SL;%UW#>G,.HG5[`;U$((7I)3F*;RYV0_[F%.C&>S>6\__`0`` M__\#`%!+`P04``8`"````"$`.WFF MQ$E00XB`7LZWWS$F@"=M0OO0-OCG\?QG!GOBU;?W\F"]RKHIJN/:)@O7MN0Q MKS;%<;>V__G[\2ZPK:;-CIOL4!WEVOXI&_O;_:^_K-ZJ^KG92]E:8.'8K.U] MVYZ6CM/D>UEFS:(ZR2.,;*NZS%KX6.^C?0KXUD_^M9E^]_587FQ_%44*T(4\J`T]5 M]:S0[QOU""8[%[,?NPS\65L;N#NU?U=OOLMCM6TBW!XJ4L.7F9R*;'"(* M9A;44Y;RZ@`.P&^K+%1I0$2R]^[O6[%I]VN;^0M/N(P`;CW)IGTLE$G;RE^: MMBK_TQ#I36DCM#?"P/M^G"YHX!'/_X(5WEN!=4KNGJS MH/3`\>:4J4(F2S!\#H\6,P3LLWA!H)21!V5E;0O;@E`TD.37>Y^OG%?(2]XC MT0>(9R+Q&5%94&:3\X/1+#&GI&="E0`H&F1!Q*>R/L[VV7L%*^_/ZT;Z`=@> MY%!SW?B2\'T322X19"2])"9&##E0.//E*!C*=.*]+TS?(HU`00T"<2YN$LE- M(KU&&/+`D?GR%+RV(7:#[WZ`Y&DDZ`J1,<9%$)I$/"4HHUX0HLI*ID1(62`\ ME.!T2GAAZ`6?90_>J_GR%(SD(>TT#SR*!,?3<8_023GIW7XZ M3CCW720Z-8&`3MY90UCX%6$*1L+&>'6.11KILP&>DU#@[=)`&,1<^$A^8B"$ MA;X(W;'D=%$:3"A\X;%Q)4,C@1*@9VM6%C'=?NW(MO(\EM M)+V*F"+5\3Z[1(EN!J8G`\Y3U#/G-XN[Z.B($>`+CH*0F`05`A=ZB@A"Z5C) MIC[5`^?"42,SYD`SX5H+S92Q!N'#I6,^F/'7>SY>G MNP-#WECD758B]34+ME;=AMUY7(0!06F-38;Y0ER<]HG)$.[!X8);@A1!@KN4 ML7$U4ZHZ^^=+U9T"E-BP+P:H`".B&0CVP(QA[FOT)I+14R1J@V8+U(W M#=-\!JB6(J*94/>=\'T9`3$&"'>-'\0GF%<5//U!(4PQ_UG'1E2C,)$^KV7K M9IEG9(!;G)ZYFF?=I5Q!DMM6TJN(F6?5,TS$7F_CX*H%MSL!;G=ZIC]#?%<$ M'D.!B#%#H9M!=A+,^!Y']:=KQ4-?GT/"/C!:J[W;TK44IZYV,Y>'06'GU MHNYM&)3C\'2X4WJ@ZML\>AZ1)=PQ7#Y/U!V4>NX,$^`*Z)3MY!]9O2N.C760 M6UC*70C8TFI]B:0_M-6INT-YJEJX_.G^W<-EGX3;"W&ULE)1=;YLP%(;O)^T_6+XOGX$F**1JFG:KM$G3 MM(]KQQBPBC&RG:;]]SO&@26P:=U-@LWKQ^<]'ZQO7D2#GIG27+8Y#KT`(]92 M6?"VRO'W;P]72XRT(6U!&MFR'+\RC6\V[]^MCU(]Z9HQ@X#0ZAS7QG29[VM: M,T&T)SO6PIM2*D$,+%7EZTXQ4O2'1.-'09#Z@O`6.T*FWL*09Z8$FZ%MP@JBG0W=%I>@`L><--Z\]%"-!L\>JE8KL&_#]$BX( M'=C]8H87G"JI96D\P/DNT+GGE;_R@;19%QPE:'C\H7GSB+8-D0YEL`?92/EGI8V&WX+`_._W0%^"+0@4KR:$Q7^7Q M(^-5;:#:"1BROK+B=<=$R"9/TWQ3?1=0;W!%# M-FLECPB:!N[4';$M&&9`'IRY.$:O?[,*'BWDUE)R?(T1N-!0GN=-O`C7_C/D ME)XTV[DF32XE=X/$9M!R=\/&;^Z$>C\H;/G`TN@+LG7NZ\^5&L*W8AO^<._6 M;0![]!--0ITKTO12LIM+)I#[N>(,3]W?G[)(SBU<3<^?MPL4B#B0#&T0;A+@@7R^@L`N?,39MK1L%4Q>Y8TVA$ MY<%.4@R1C;OCD-]&MD:3_6V80>?,]W?P4>CW_?$`#&5'*O:9J(JW&C6LA*L" M[QHZ7[FQ=@LCNWXT]M+`./:/-7Q]&?1DX(&XE-(,"]MYX_=\\PL``/__`P!0 M2P,$%``&``@````A`.+?>"X=!```>0\``!D```!X;"]W;W)K&ULE)=MCZHX%,??;[+?@?!^>'Z2J#>C@)+<33:;O7=?(U8E`Y10 M'&>^_9Y202B.==ZH''[]M_V?T]K.?WP4N?2.:I+A1/1.0?RS__F%]P_49."#42*)1D(9^:IO)5E:0G5"1$ MP14JX9.E-!:3G?9S`#:KM4H\-"?M7]V)/5 MY;SUYW>&+F3P6R(G?-G4V?YG5B(P&])$$[##^(VB\9Z&H+$Z:1VU"?B[EO;H MD)SSYA]\V:+L>&H@VS9,B,[+WW\&B*1@*,@HADV54IS#`.!3*C):&6!(\M%^ M7[)]M45E M%K<9"Y(F6$H[3CX29-$4X MD7!*\"(10V#B@PQ:XXXV4X;K:#LE^([B*6*X?3\C:\WO6$OAD;5\8,T'`CX0 M\H&(!<:F<#6[N<=P&=K>8VZ3;K,8/V9&QEAC8^B:-6&3?EQ[M!%PPP2;7()7 MC('/O@BXV:Z%1"`D0B$1"8F-D-@*B?@1,?(;-OKGUSB%%S)4>>^A:7E]@;>Y M7C$&^N\9WFPB?D2,3(9_V*') MSQ4U;<2;/>/,9LPCLX5$("1"(1$)B8V0V#+":1.FNZYE<)45#X%QPD9FPS_U MT.S'.P>%.9-MC3.9,8],%A)!1]#C`Z==L>*&/`@OQLAL1UW8EO\;@-7$FK!_4Z8P>S*P0ZP!:J/:(WRG$@I/M/K MA`OKHH_V-YU7DYZWN/A*]^&T.8T'N@]'RFE\9?BK>SIKPX>#Q90/#!_.%]-X M:/APS("XV@$;CY5.F>Z`=])?FY?\```#__P,`4$L#!!0`!@`(````(0!Z*M>Z M>@(``"T&```9````>&PO=V]R:W-H965T^QL[AYEBUZXMH(U94XB6*,>,=4);IMB7__NK\J,#*6=A5M5<=+_,(-OEE^ M_K38*_UH&LXM`H?.E+BQMI\38EC#)361ZGD'3VJE);6PU%MB>LUIY8MD2](X MGA!)18>#PUQ?XJ'J6C!^I]A.\LX&$\U;:H'?-*(WKVZ276(GJ7[<]5=,R1XL M-J(5]L6;8B39_&';*4TW+?3]G%Q3]NKM%V?V4C"MC*IM!'8D@)[W/",S`D[+ M126@`Q<[TKPN\6TR7^>8+!<^GS^"[\WH&IE&[;]H47T3'8>P84QN`!NE'IWT MH7*WH)B<5=_[`?S0J.(UW;7VI]I_Y6+;6)AV#@VYON;5RQTW#`(%FRCU&$RU M``"_2`JW,R`0^NS_]Z*R38FS291/XRP!.=IP8^^%L\2([8Q5\F\0)0YJ,$D/ M)AG0'YZG45KD23[YOPL)1+[!.VKI:GKHMF,S!^?V.@,)I;YW8 MEP"L@2D\+;,\69`GB(X=-*MS37JL6+^CF`X2`EP#'+0\AG.Q9S"\CR%=$>@P M&D&>(*R"YGJDR0<"W^KZ(\41([QHS/@QFQ.7&+P'MF16'+]Y%32%CSQ"IJ)ATK3+#$=#U^GD^OW](\PH+-?CF6 M$Q]C97EV@A4T(:M)DB;%6QYAC&/!.USAQ(<#T=,M_T[U5G0&M;R&"<71%.IU M..]A857O#\!&63BG_K*!SS*'TQ%'(*Z5LJ\+]T49/O3+?P```/__`P!02P,$ M%``&``@````A``$)+EH2`P``*@D``!D```!X;"]W;W)K&ULE)9=;YLP%(;O)^T_(.X;,)BO*$G54'6KM$G3M(]K!TRP"AAAIVG_ M_8YQRH=3=4DOTA`_O#SGV+&SNGVI*^N9=H+Q9FVCA6M;M,EXSIK]VO[]Z^$F MMBTA29.3BC=T;;]28=]N/G]:'7GW)$I*I04)C5C;I93MTG%$5M*:B`5O:0,C M!>]J(N&RVSNB[2C)^YOJRO%<-W1JPAI;)RR[2S)X4;",WO/L4--&ZI".5D2" MORA9*][2ZNR2N)IT3X?V)N-U"Q$[5C'YVH?:5ITM'_<-[\BN@KI?$";96W9_ M<19?LZSC@A=R`7&.%CVO.7$2!Y(VJYQ!!:KM5D>+M7V'EBER;6>SZAOTA]&C MF+RW1,F/7SJ6?V,-A6[#/*D9V''^I-#'7'T$-SMG=S_T,_"CLW):D$,E?_+C M5\KVI83I#J`B5=@R?[VG(H..0LS""U12QBL0@%>K9FII0$?(2___R')9KFT_ M6`21ZR/`K1T5\H&I2-O*#D+R^J^&T"E*AWBG$!_L3^/>PHL#%(3_3W&T45_@ M/9%DL^KXT8)5`\\4+5%K$"TA^?V*H!3%WBFXOP5D!4S#\\8/\,IYAM9E)V9[ MSGAS(GV'B`;$`:]!#DJ^7$[!T%C;FL@%0VY?P%8S>,(81/H1,7.#!UWNIN"U M#=F#F^>:C=-,W+HWK5WMI1GOA!(?!^.`>2*=`Z(*A8FVF&6V&3/;9S)J6.M8OW#`6;4HDAI1DM%?N^;XRG>OQ#I^0:)P4;3FBL53=*,]K) MB\(P-CJ93@&4!!B/G9QU"PZF*]K5TW,W;"R>[8G16X7G>AX.QZU`KZ\9@D+? MC=VQJ5I/GW;Z,&C)GGXGW9XUPJIH`;N4NXC@R]/ILTY?2-[VF_^.2SBC^K&PO=V]R:W-H965TL79CDX5K6[0M6%FUAXW]S]]/#[%M<9&W95ZSEF[L M=\KMK]O?OJQ/K'_F1TJ%!0HMW]A'(;J5X_#B2)N<+UA'6_AES_HF%W#9'QS> M]30OAT5-[7BN&SE-7K4V*JSZ.1ILOZ\*^LB*EX:V`D5Z6N<"_/-CU?$/M::8 M(]?D_?-+]U"PI@.)7557XGT0M:VF6/TXM*S/=S7$_4:"O/C0'BXNY)NJZ!EG M>[$`.0>-7L:<.(D#2MMU64$$,NU63_<;^QM999YK.]OUD*!_*WKB9]\M?F2G MW_NJ_%FU%+(-=9(5V#'V+-$?I?P7+'8N5C\-%?BSMTJZSU]J\1<[?:?5X2B@ MW"%$)`-;E>^/E!>049!9>*%4*E@-!N#3:BKY:$!&\K?A[ZDJQ7%C^]$B7+H^ M`=S:42Z>*BEI6\4+%ZSY#R$R2J&(-XKXX'[\W5MX<4C"Z+:*@XZ&`!]SD6_7 M/3M9\-3`/7F7RV>0K$!91N9#?JY'!B')-=_DHF$IT!S*\;KU?7_MO$(*BY%) M+QE/);(KQ')"'/`WF830[S=K:4D107/$=>/`TXA,(8@? MA\ODNK7H'FL2UJQ=>$,&/2G(6YT]IZA^KMKBLB7MPM_VLW3$0(+ M4Y*U$#(CHOK31LG,.N,TN%%GT\@8\VA"5)_:6+G1RS@)U'[1DI02A,8ZAV'H M:>^*F8E0W=TU4,B5B1)H[RGI"!FKC#K7$=7?_QHK!"?"C2J;QL9891.B^(3# MTAW=/-"WNGF$\'W57RXO>MD`H#<\?N'II,L/](^\/U0MMVJZAP9T%TMHVAX/ M7W@A6#><0G9,P*%I^'J$0S*%(XJ[`'C/F/BXD,>[Z=B]_04``/__`P!02P,$ M%``&``@````A`'P+8HPS`@``_`0``!D```!X;"]W;W)K&ULC)1?;]HP%,7?)^T[6'YO3!)"`9%4!<16:96F:7^>C>,0BSB.;$/@ MV^_:!D9+-?$",3[^^9Q[+YD]'62#]EP;H=H#?U*(S9YID M]^`DU=M=]\"4[`"Q%HVP1P_%2++IRZ95FJX;R'V(AY2=V7YQ@Y>":65492/` MD6#T-O.$3`B0BEDI(($K.]*\RO%S/%VDF!0S7Y_?@O?FZAF96O5?M"B_B99# ML:%-K@%KI;9.^E*ZG^`PN3F]\@WXKE')*[IK[`_5?^5B4UOH=@:!7*YI>5QR MPZ"@@(F2S)&8:L``?"(IW&1`0>C!?_>BM'6.TRQ*QEF)`1\7&ULC)1?;]L@ M%,7?)^T[(-YK&[M.TBA.U;3J5FF3IFE_G@G&,:HQ%I"F_?:[0.K:293E)3'F MW,/O'L"+VU?9H!>NC5!M@4F48,1;IDK1;@K\^]?CU0PC8VE;TD:UO,!OW.#; MY>=/BYW2SZ;FW")P:$V!:VN[>1P;5G-)3:0ZWL),I;2D%H9Z$YM.I?MYV5TS) M#BS6HA'VS9MB)-G\:=,J3=<-]/U*KBE[]_:#(WLIF%9&538"NSB`'O=\$]_$ MX+1(7B([M-:MC33I6W)]03'M)#%P]'+1\.9P30[`8#>!N M>E_?P"IHK@>:?*RX/Z<8L<%"0S9W)#(X6.<#=$4%AC5Z1C(]B&<5-#,?;W)` M-YPCUR3-DH_J$1VT.*0[3^7$8ZJ,C!=>!D(_J$12<]&ULG%?;CIM($'U?:?\!\3[<[[(=#3=OI$2*5IOD&>.VC09HB\;CF;_? M:MI@NIF`DWD8AIK3I^NFM*J57U)`"UVM95S190G6.]T5]7,O?_TN? M/%DB;5;OLQ+7:"V_(R)_VOS]U^J*FQ=R0JB5@*$F:_G4MN=`54E^0E5&%'Q& M-?SG@)LJ:^&V.:KDW*!LWRVJ2M70-$>MLJ*6&4/0/,*!#X41?O>D?CS5NLET)NM]T M*\M[[NYF0E\5>8,)/K0*T*DLT:EF7_558-JL]@4HH+9+#3JLY6<]V/JRNEEU M_OPHT)6,_I;("5^W3;'_4M0(S(8RT0+L,'ZAT,][&H+%ZF1UVA7@6R/MT2&[ ME.V_^/H/*HZG%JIM@R"J*]B_QXCD8"C0*(9-F7)<0@+P6ZH*VAE@2/;67:_% MOCVM9=-1;%N-1#<55]=\TWV< MQ+R1P+4G,13#LW7;^8U4K!L+7'N6WT\%DNY,@6M/\@>I.#<6=V`Q7$6WM`?D MJ*Q*7='CK,TVJP9?)1@DJ`,Y9W0L]0!X^VJSV@SU_U7YH>Z4Y)FRK&58#Y4E MT+*O&U/35^HK]%E^PX13C("(>@1M*DH;LP!K#1I(Q$#:+QEO;/`;;WL,[7I0 M/4B'YAI+_[C!>X443!7VN85]X+ZSL&\T13@.GUH\A1@N#TFF$%,S>4S*,*!S M9+_%8[;S&,X8&)C'C:%@SA@Q$(F!6`PD8B!E`5Z0+0B:QW""8'8?%T3!G"`Q M$(F!6`PD8B!E@7LG;_O`N&3W[N"RAX?&.'LZHB8\UN?[E2X"'-<20FN%#`.9 M#&TC>!PM(N)%1+*(2!<1VSD$YQ4\(L=>S7M$P6L9!N.N7YB:D$&\[I'VI%NN MIIN>)PXZ`\WX&/,TIF$YMNEJ?$,GBS3I(F([A^",@F?UV*C'FHHNX@TS-8]7 M$3*,TSEF:+JG6;X@-.(@KF-17WF6F(.8MN?;^GTZNI=#,H;XCN5I8BHI0\S4 M93N'X.RBAUOA-;D\@W21:)?/"PT99B;':!$1+R*2143*$*QLKJ,9GB&\9+93 MQ""%L\K_$ZOH(L$J7>B)D&'8+.J:97K"\RP:`V#&?-_WA*:)&63&[F01D8ZW MT4U;HS^#%5UOPOFK9V87R&Z'#L?[;H M\4.(AWH`!Z=I/(7/A(_BH1&$'_%$1@`OMBE/;`3P?IO&$R.`UQS$U2$A^`PX M9T?T-6N.14VD$AU`BJ;0(WO#/B3838O/W<%SAUOX`.C^/,'W'H(3GJ8`^(!Q MV]_0#88OR,W_````__\#`%!+`P04``8`"````"$`>7%DU=0#``"A#0``&0`` M`'AL+W=O M<$L+4D M,68:*-0TTL^,-6O#H-D95RE=D0;7\,V1M%7*X+(]&;1I<9IWFZK2L$S3,ZJT MJ'6AL&X?T2#'8Y'AF&27"M=,B+2X3!G$3\]%0WNU*GM$KDK;UTOSE)&J`8E# M41;LHQ/5M2I;?SO5I$T/)?A^1TZ:]=K=Q42^*K*64')D*Y`S1*!3SZ$1&J"T MW>0%..!IUUI\C/1GM$X0THWMIDO0OP6^TM%GC9[)]?>VR/\L:@S9ACKQ"AP( M>>7HMYPOP69CLONEJ\#W5LOQ,;V4[`>Y_H&+TYE!N5UPQ(VM\X\8TPPR"C(K MR^5*&2DA`/BM504_&I"1]+W[>RUR=HYTVUNYOFDCP+4#INREX)*ZEETH(]5_ M`NH<#2+63<2&Z&_?6RLK<)'K?4+%N:G`?>\J#X9B"%M=EN*4I=M-2ZX:'#T( MG#8I/\AH#<)]>H29(6&_RAX27@>O&_<)=5U%->H*?`;`T^(*4CWW]?[G[\#G,P^_ONQ,+H#WXL910 MIX3GR4@\11219$J,1"0[<'+&=GB9;'@6YFWQ3<"-7,"IE8/<"0:.UN!4+]PDAV63@2D[V`DD%":ACRG/R%[Y'CFF M]*/@L8*[GD2;ROE(%#QPAN@DT]YG3'-8-HT<)69?N#:2DWV"F)Y M?F@/T8D.HR">"Z]G&4DDQ/0<%/AW1/((#7!>4KY)]FHC)(>,*SGOL*-EBY->=&/F/"XC\3*2W)"AZP6_ M:+8P7'[&HI@GQN^4:>?I)"-]UJ/0F4'B914^&/,S)7H<"D/?-_U[&Q1'54R^ M8J:K<'O">UR65,O(A4^U-K3'8768N)\M/NHHZSNTA@%LNA[S"9VO&\,&&)"; M](3_2MM345.MQ$>XE;GRX570BA%;7##2=!/F@3`8C;N/9_A7",-H9ZX`/A+" M^@M^@^&?J^U/````__\#`%!+`P04``8`"````"$`D-<'POP$``"0&0``&0`` M`'AL+W=O!]#=\?@ M6+9'8T?9'6E'6JWV\DPPME$,;0&)DW^_U53[4L`4\)+$\4=Q^A1=!^/%UX_L MZ+PG19GJ?.F*B>\Z21[K;9KOE^X_?S]_F;E.647Y-CKJ/%FZGTGI?EW]^LOB MK(O7\I`DE0,5\G+I'JKJ-/>\,CXD651.]"G)X9V=+K*H@I?%WBM/11)MZX.R MHR=]/_"R*,U=K#`OAM30NUT:)T\Z?LN2O,(B17*,*M!?'M)3>:F6Q4/*95'Q M^G;Z$NOL!"5>TF-:?=9%72>+Y]_WN2ZBER.L^T,\1/&E=OVB53Y+XT*7>E=- MH)R'0MMK?O0>/:BT6FQ36(&QW2F2W=+])N8;%;C>:E$;]&^:G,N[OYWRH,^_ M%>GVCS1/P&WHD^G`B]:O!OV^-?^"@[W6T<]U!_XLG&VRB]Z.U5_Z_'N2[@\5 MM'L**S(+FV\_GY(R!D>AS$1.3:58'T$`_'2RU%P:X$CT4?\^I]OJL'15,)F& MOA*`.R])63VGIJ3KQ&]EI;/_$!*V%!:1MH@"]?9].9&SJ9@&_54\5%0O\"FJ MHM6BT&<'KAHX9WF*S#4HYE#9K$R!/]TK@R698[Z9@^I#@2ZA'>\K)1X6WCM8 M&%MFW68D)38=1'A%/-!W%0E+OQ?)BS,P+,)UKN)$(*YUZP6LD7FX8Z:4V'`$ MT08G&J[-P$L7:E^US1HG7B/"24-B5OLN9>`+Z=^L)=J@RG!M!J;:E&B*0X83 MQQ%$&USXP[49N*^GR'#:.()H"\9H,S#UK=531#AI2`0#>AJ.T69@JDV)@%[I M:V0X<1Q!?#-Y=S=,^'UJX+Z>(L-IXPBB[7&,-@-3WUH]1823=B',?/2OIA-1 M`D;M<,=JFLI2XC8R<;19B!/&(E1?(Q[XC@JO9;K/73N\N2)<8\V0'BX,1_J],"5FUTO&-A8A5AF'4..@S`A] MAN[;JP(A5A^'4'VCXL'=103'L)CZOGH(?Q*MHI$1`V^< MVF&AQ&.ST?UQ49]]Z79[38TC MN4RP^A`9U.A&<`QL=#M!E+R%@-W1EX2XN=VXX=H(#B%&RE%14M-].]I"W5<9 M&LDB5-^H*)$8`7RC+<3JNT0),ZLEG.5^%@[K<'U4(XQEZW.&*?VS?6H=Y!#J MH)GN@S-%8A;P6]E"K(-8IQNA^H`9H<_0U+_V5I8(=9_<^G=!N`Z/2A/S:;JA M3,E;#.#>M1"KC`L1N/P M[VDTEQ!VBW`(T6<>_0S?PC7=W,+-1EN(;31AV$:K1HH,:W1]%!6J9//^T$+= MVP&-9!%J9"-3^$8KS`"^T19B]0W.$F6F^N`LJ6GJGPA:C38E3=;106R=ZWZ3 M>@9+N]6BPCK((53?J#2!Y^9- M_SIZBQ`^<[S-8*NL^TW4A,_4\9'S*=HG/Z)BG^:E6%>69__2YE]3\```#__P,`4$L# M!!0`!@`(````(0!,8H/9_P(``)8)```9````>&PO=V]R:W-H965TOCW/.4<.RX?7(DL/(0XM^_'N_F M&$E%RH3DO*0A?J,2/ZP^?UJ>N'B6&:4*@4,I0YPI52UL6\89+8BT>$5+N)-R M41`%E^)@RTI0DM2;BMSV'&=F%X25V#@LQ"T>/$U93",>'PM:*F,B:$X4Q"\S M5LG&K8AOL2N(>#Y6=S$O*K#8LYRIM]H4HR)>/!U*+L@^!^Y7=T+BQKN^Z-D7 M+!9<\E198&>;0/O,]_:]#4ZK9<*`0*<="9J&>.TN=@&V5\LZ/W\8/5#O%/(<`X!,53'<&)(2\UM\GEJ@LQ/[,F@:.[X(< M[:E4CTQ;8A0?I>+%7R-RSU;&Q#N;P(ZSB>M9WGSJ3F?C+K:)J`:,B"*KI>`G M!$T#9\J*Z!9T%^#5KXW6]HOD-/XK-GT M-;-I5[)M)#J#VC=J%O[[NMTMNT:ARP=(+1=DZY+K_4HUX6NQ#K\Y=V,6P+OE M\;KG;ON*V15PU)=SZB@N3#H[?Q=%EFGS8@`V6W@2M=D'A>T&78V,TDPO- M=5%&%=&H8C>DZ'!"(+>738M##$ELJQ1*.*:%0!\U`'8EK__38U\\Z,@X** M`]W2/)_HI>;6^<1?P[.ZO1S"6ZW6[W0!CL2('^IV( M`RLERFD*1SE6`$TGS&`U%XI7]7#:&PO=V]R M:W-H965T^8 MJD2W*?#O7ZNG&4;&TJZBK>IX@4_LUIY3?)EJ1Q/"&2B@X'PEP_PE!U+1A?*K:3O+,! MHGE++<1O&M&;"TVR1W"2ZNVN?V)*]H!8BU;8DX=B)-G\;=,I3=":654;2/`D1#H?<[/Y)D`J[5[X!/S2J>$UWK?VI#E^Y MV#06NIU!0BZO>75:#J&Q3X%$69=-X ME(`]S9B:%J&%TY3P>NCVX1-.,K338H;IP!\[BS$Q<8V(-SFL8#-S@'S^]1V/W]D&R9#Q M1\[A-(5AZ^F&?Z=Z(SJ#6EY#*>-H"@P=SE)86-7[X5HK"V?`/S;PR>,P>7$$ MXEHI>UFXTSI\1,M_````__\#`%!+`P04``8`"````"$`/WTY'YVO9M%5]WKK^PG.=\ES4N^K\LG7__DM\6+E.V^7G77ZLS^76_5ZV M[L>GGW]Z?*N;+^VA+#L'(IS;K7OHNLMFN6R+0WG*VT5]*<_PS;YN3GD';YN7 M97MIRGS7'W0Z+@//BY>GO#J[*L*FF1.CWN^KHF1U\7HJSYT*TI3'O(/QMX?J MTEZCG8HYX4YY\^7U\J&H3Q<(\5P=J^Y[']1U3L7F\\NY;O+G(^3]S7_(BVOL M_LTD_*DJFKJM]]T"PBW50*MQ5D(&4W6G*_=;]Y&]$Z+O+I\=> MH'^J\JT=_>VTA_KMEZ;:_5:=2U`;KI.\`L]U_46BGW?R(SAX.3E:]%?@C\;9 ME?O\]=C]6;_]6E8OAPXN=P09R<0VN^^L;`M0%,(L@DA&*NHC#`!>G5,E2P,4 MR;]MW0!.7.VZP]8-XT64>*$/N/-@BA9W1/E04>)WZ,$BV`5^5%,CV6I\NIE8GF7/STV]9L#M0(U:JH_6/?I M/OA)C!+.%``G'Q(.S)$RDN!3(H[-(&**!,F`&/E"__$/(@+`0:8ZH8FQ"*4&E&J_4J0.V#40`G MSR&NA&S([Q5K*``]^WX%Y$%8@1#-",6,%0CC!Y/)I@PJ%T82G"2$C3"TD*9O MM!;:NX*$L09H]*EB3`U0^\ZF#(K"2(*3A+`1A@;K>S20,-8`KQ&*&6N`\LL4 MH6>"%ZZ10FS\?9)X$?J>DV<0-L+(WH?%8'X)]#3*WT.C2S5D$X!&&(UP&A%6 MQ!1">J;9<\%7#@N6X:'O3\V"AJQ"J#@6A-%1.(T(*V(*(>W52(AYEL%7I@Q> MWP69>`8-6;+--*+G1A(G[UV\]QW,`%8K<*%FB^7T2805,<601NM^,90],\7` MSL&W>;@^UXQ&V("8*UY_/!^^?+\HJ!4)*V)*`9=M+(5]L?`EC3H%_KV0:LA: M#RJ.!6%T%$XCPHJ80DBS-:H)0@AES8A.8?-ONA9(A,F?^:"Y12M.(\**F$)( MMS5?".7-S$F!?@ZG_M7`_;!B,QIA&M&..DJ""'DU3@<15L340?JM^3HH=V;H M@+M%(!'F*T0OK^L@\M#ZRC5A:2+"BA@Z!,A=SO,2_5%H M[4CP\JDARS@S&F$TPFE$6!%3D+M<9C#'96K(*@3M,NDHG$:$%3&%@&H?SY"9 ME2&/PI6![T0$"E(U[GOJGVD2,\U81&,TPFE$6!%3$>D'1SUCIB+*11J](T&K M71HH2"L"@B22DI^5T%&%%3$F0 M'9W92&[94FQ"`M)S9C3":(33B+`BIB#2_8VF#5$;RBM"KQOF_?363D`:RHQ& M&(UP&A%6Q!1"NK^1$#,K0WE&8XGQ)I5!>L\L(!&FD>M"M8*M`^8RQ>D@PHH8 M>L@G8??KT1^%%I@56DY3#8V;!^H+F4;4X]1@$:/^PXCO.7T*845,*9`QG5<: ML)%ALK3$V*EKR"H%;5!U%/6P,+SUE(P^C]QX(<=[>RA*#[6Q0NT8.)7-2YF5 MQV/K%/6KW#01P$.ZX=-A0\>G0#XD1Y\S?P,/YN43^.$+V&=QR5_*W_/FI3JW MSK'<0TAO(=>K1NW44&^Z^M+O4WBN.]AAT?]Y@!TU)3S:]Q8`[^NZN[Z1)QCV MZ#S]!P``__\#`%!+`P04``8`"````"$`TY:PYE\#``"5"@``&0```'AL+W=O MU`TYB%3"RG:;]]CMS@`--*O(F">3A?O>NP,A49+W>)^^?WX\W"=92F949S4;+$?6/*O5U__K0Z"OFL]HQI!R*4*G'W M6E=+WU?IGA54>:)B)?RS%;*@&B[ESE>59#2K'RIR?Q($,[^@O'0QPE*.B2&V M6YZR!Y$>"E9J#")93C7DK_:\4FVT(AT3KJ#R^5#=I**H(,2&YUR_U4%=ITB7 M3[M22+K)P?<^S'/D1:KS(.#DS9'-A_ M]_1CO0(_I9.Q+3WD^IPW!$X,L:6V=L#4RE4%,)XDSJ-5.20`'PZ M!3>M`16AK_7WD6=ZG[CAS(OF04A`[FR8TH_Z!IBJHJ8'R1(BM\XPC\[K):N0G@ER M9Z(D[MQUP(6"]7E9APNR\E^@IFFCN4<-?'8:J_`AFRXE2.,TI?-%;LE&;,BF M4B:5>[QQBIETB?0P81]CG$\OKFF+,P_!ZIV8"!=*T> MLN,!NQ'%V-M>;'/KD\V4&5UN@C.I]U+%MG.QWHT(R:%WJ=K$#)[Q9!Q3?;*= MAPT91:WGT+YT?<^#2?9QBQ$<3WVR'1,-&46=9]N#??)5$XR<&6&Q[=V&C**6 M'-B:],E733"S5P^[.[;5;,@H:JL]MY,&R7@ZP,VS8'+'OK`\5TXJ#F;G)]"8 MW=WN5'(WJ<\5W1]P**CHCOV@1L"X\&WAS0$H\5>*%%56_-&Z'A.%#_ MW,/QC\$&%W@@W@JAVPMS<.D.E.O_````__\#`%!+`P04``8`"````"$`FD54 M[[H,```Z>0``#0```'AL+W-T>6QEJWVQPYT3^'-]\+:O:[:_"M:._S37__I@7DUU;1=9_MIR M`]^>ZZ_V3O_N[M>_NMU%KZ[]X[-M1QJ0\'=S_3F*MC>]WF[U;'O6[FVPM7WX M91.$GA7!9OC4VVU#VUKO<)#G]H;]_G7/LQQ?CRG<>"L9(IX5?MYOKU:!M[4B MY]%QG>B5T=(U;W7SX??1!] M^YOXSYL_O'G3_]WF\`G@AB@)M36S6<_^.J;^!LX`XB'A]W=[G[6OE@N[!D@O%7@!J$6@95! M/K;'MSP[/F)IN!7]HJ##-KPR6Q$^ MX=/C7#=-B"&#?A_52@UV(F:S91_XG8W9]?ALDHW,D3E1*AGGBT6[(<.1J5*5 M`H;FN\G[LZE3/;,RZ9(P?*X9@!-.K18=F+H5\WMBXN<P=>X+AN5MF.QEC[P9Z[6RBR(SOT3=C0DN\/KUNH_'Q8 M#Z#[].+C!$<_A=;K8,CJ'[D!N\!UUHCB:Z7(V4TUT:,)',=%W8_PH)FK"?TME.DTBOJ$*9$9/BQQ<'_;? M3F:SV71P/9U.9\9H8!A,R8^)1SO^VGZQ<WYNLS5*LS)35QPDO+.+K\V*K1EBG M/@;A&DY7I>=@!M>P1HSWW=VZ]B:"%6GH/#WCWRC8PK^/013!R9V[V[5C/06^ MY<+77CHB_5LQ$DY_P9FNN1X].ZO/P(SKKL2ZB5F,&FB+5GKYV]5Y0NXWW4+T&-J%NQX$2'?L8D<8>\P]=#*R3FDQS!3,TL+3D` M?")U"3TTL&E.^_VX ML2C+IYH@`7[$8XZ#(&.*^A0..:)1X9BZLD)\*ZX MN$+R1&J@T#)='>A+M3!"\FV$D38(89*.$0)KYBPI^3I&E!Y3!2DI5:#R6=FN M^R/6(G_?9.4/=!3O;E\VY%H1N(`'+Z;`2U'P*[3MDZ]QJ1-O@'N5#1J6#M*L M[=9]_;3W'NW09%?U,!9L+YX>R+<6K$;+M]^YSI/OV:PGJL=DO@^#R%Y%[*HC M=MZD#,^H!,\@(22#IPU_N#3FJ!)!3]+Z:,,?>FY'^8->.N4/SB7-7Z4_X/55 MB5.#":A35^%1B0`Z*RD",$(7"/!ZL$0'X)Y=((`5:XH`'#1'`'`JO*+-/!B0 M:`8^D+,$_J=B"3$FE9)C>4(IR\(O\*^0TN3";RLUDW@+CIZK&38J`+1B619B MNPHQQ.PPTW(5P$:%"DS(NFI2WJ`LYG>F$!)T`4.N$0@#51I1YY4DY@+/'$"U M1A8*ZQ#B%!B*NH8`<#J!0`PQZ"C_#BB&CC(P]8:.4C"%P.7@,\X):@DN0W:$ M`?!T,BOR.F'`98PSJH%`Z"I"$F\8=A4B*8:N8F1NBF%7(9)`Z"I"4DMT%2(I MAJYB)#%%5R&20`"-=!(AJ26Z"I$40UY)*>,^SF:@C>9TW0'`8?P81I,5L'D+PO!Q0GMN M;=2NV@7H;,7+&_C\H>']$>A*\?4/57D,%]U*'4(82(E-AN#J2IE3M:1YO@X@ MY=HX`@A.(/>J+$*5,CI<@5;%"Y/UC(71@T(JNL[EH(6C7`AV+10?7VHYR6$#X[)<^"SH%+KPB?'*&EO* M92'2\\:N[[%2*SI9T"3SE`9Z/$'%@^8G5*,XD`0NX;1!@"H+16'JHRLK&GH` M2$69*F-&*<.U2S_5('FSU8"C;K)R`$7IIHUCU6H>R-NYL0J%?H>.GJP22^&< M1&'M/(XOQ_`D;E6HN+0"H@!79AXK$*)!>*9.<7:EM\7+I>@!9,K+<)*2.3G1RCIMR6QF,,'&U63 M3"JA*568"D#U]5/:8C@-G*SGSQX?>C$=YK:&Y"LGT9I0099O`KC4U**JI%$P MB:.=L)D$<>QXR7SYZU8^?USZNK6DX.-B8M%Q95)Y"_=HW!+BEUL-+1C52VV.G9U":I8T@`\5X@*!-X MISU9456:V@3PZ@`2I;)2#-@BJBHU&\7/Q(J-02E43*T@KOS2'NK:Q2"=U9LE MUYAP[;O26J2@K/JA0\K3BOA%]JUH01=`*U_0QG#5G8DZR)*%@'WY`O`9![:J MYCT?&QM%`>46.+<`:BN2M$AK- MP";5U'DK!;F%>#FF$W8:CV8WFI+EKQ^7R"R/"(UAQMN#=2ZO]#I[^ MMXAW)O>;5-'*>B"X7J"T(&S4I97%\B'>T49PP:7`=6EEE<0(I"6TX.%*M6EE MQ3R\0H&C!?<4U,4%0^("8<3K?BRI>^.8'=F=N41?(+(,+DHKMR/&>T(+1*Y+ M*[5U'DNKAR.P)5HB\#?JA+*[_Q0TN-C*KGMX!O1$;9?9'044\FMQGOY2-++8RJYO7C_ M-B3].Z:26PKH$8D,^$%>HLQ&(UZ[AJ1V%]8ZC;J\PV">D8$!;T!<[5UX,V6` M[[5DMXEBWYP(A`\%D*+T;*\^:TMXZE]&B)\/F$9E"-V_;%W+MZ(@?-7PUM", M'&_TL22Y/P9!IB.>PA`V90#]"=X""B\8U4`OL89X'\:RK@Z9;"[PZL'GQ-0A M`Z-C-+S_8>E;APR,CLGP017K)QDR'_SM/K,0'TLQ=(^)59Z8,MD_KS$SP:,E4BEOMD[F`- M+0/\+_N(J!%'$2+8%9,A\N!$\#3C=!)S)!"6%(D`;M?.2!Q$%$D:?[-"'V<+ M-W4/?+1$HOSF=ZC^UR_YV-M7>CA^S'N9Y__S-[ M3C@X4W+4]\Z7(&(DYGK^_2,^@!UF,2S@(-Q\W,%#O>&OM@^=N?[?^\5D]O[> M'%Y-^XOIE3&RQU>S\>+]U=A8+MZ_-V?]87_Y/U`9OE3X!MY*V^*EO>SEPG#[ M^\"XV;GP:M\P$38!_V.^;ZZ3C1@^>^HRP(8[W5(A>KOLI<=W_P<``/__`P!0 M2P,$%``&``@````A`.K_HR06,P``FZH``!0```!X;"]S:&%R9613=')I;F=S M+GAM;.2=ZVXA0_R?[^)R(RLO)25=)8G@$6=G=+E9%Q M.7$N_W.)R)_^^=/-*/F838MA/O[MO9VM[7M)-N[G@^'XZK?W/IR?;#ZYEQ2S M=#Q(1_DX^^V]NZRX]\_/_NM_^:DH9@GOCHO?WKN>S28__O!#T;_.;M)B*Y]D M8YY?OS#33HO3H\;UG/Q7#9S_-GKW(^_.;;#Q+#L>#Y'@\&\[NDE=C-P#S M_NF'V;.??E!3U_QI\B8?SZX+F@ZR0?WI63;92O:V>\GN]LZC^L.W^<>M9&>G M_6$YC37+;HK_4>_M0?V'LH?SNTE6?_A@9WOS7^H_'K+N@:W] M9)1>U9\^N$Q'1:.C;FSN[FWL[]3[\PDZ&HVR:'$'WJWS:G,/933I2@_?9))_.$+?D*+^9I.-& MR_-I*FE,SNYN+O)1?;`'1Z?_^J_U'_T,Z/`F'R=GL[S_:R\Y@X!9D;R;STR> MZ;+^VE$^+O+1<,"4!\GS=)2.^QFO(;1%LO'A[$5R_V']E1=9'V%R\M+8X4#, MM"CHXL?ZNT=I<9V@69*^_I#]>3[\F(X@?H/[WF\>IOS?`8/+F]S.D573E%FFI`(,)&D]Y)Q-JMWYQ:Y;*CV9V$/1L/T8C@: MSH99"Z_A,"7&<(T8&<^9N-Y MH]=%`BWI^W4^OMJ<9=,;NKQH$.;%BF$JS\>-E]TV1;.& M@,)>?J6%)"TYG,^N\^GP+RQ]=[N'KM$_26'BUX/&TP0^GV?)_>TM]%"#DDYH M6[I:W5?RJBBT46*G/,IYLONXMWWPI+>_MVN/]->]_=[^T\=^5DE::,>PC)BQ M"X0IF$=KCHS[7[V<]]C28I+U9\./V:A!CC^F4VGSAA0>#@:P7SY&*B2-F\,Q MTCP9(B5U$L!O\YLY:I^EY";ADR&>5%L_?*.W#>L#_LV&PC[(H= M;;"%T6&=-Y>JT%,4,+@D,POVL$NE1G8Z6U#0WR>N[F\EU?I,F9WE_F&$7+N=CV?[Z:R^S<2:$(SE/!S?#L2$HB6.] MY<9+8/9#DY@$M3P8%E@]WD3:)ZW&I][!X8W0R5]22:Z-A]W$U`[MAWKC=_`8 M#P`K;2+J3-@0[^(F2S:",6YPXTD^S8978ZQU_SH=7[6+^ZLQ!@%88%.Z`;YF M,/DXR^=%X@:H3^UM/MXTG($F!R:(5K0$5SC'@J&F5PWJE:/XR38ZS6:M*WWK M?X\R5W_S>5H,^XZ>P]%S9"E"#NVT^7X? MDE7O>!LO;&H,S=9GG[)I?U@8-Y@63_*)!+9A);_F7>/(#N9P6W>1%G`B["=8 MW:H0RDUT>K[."*6<:#$81LD+#FN]6:`2E%GJO(=V-6HN?:>=S#/\V+F3-$LSQ!=^;C/JZA0+[3R_RJ/]MFSD51F$%^ M@=.DW3V7*LVV?+.Y&\'AJ4_)V/R;K$$YY.5PC'%,!I7)HB-5I>F>!)=XW,8\] MMNYI21$;?92GXTZ'L=*S7+85'1,!<3,Q^B[MV,C*#GP<#I"3"P#2&F0[OKS$ M5]'6HV86H04REB5P!C"CH2NEG-PCL;&DLRY'-AM16P^K`8Q> MO>;$1"6_G&>?9LGS$:"B\4)'\*^GZ-]6LB&3\;>__A\9<0)G?_OK_WW82VZ' MLVOT:M_6;AKH^);I]9*W6[_?PKMA-3\C-OD<`-5+GF\=\>.052:3A0"CF34Z M)>9@Z%TK'&>W]CZ0.$LRXRK!2'FH``]6CB:?$>B6+B=T-MU22.]B>#K*/GWY MMYX9N'*J_QOA`8!/@?GIE%&F\ZM$&I\>LO[U.!_E5W?)!!]8^RB'&YA2F#>3 M)N.<*27IA`Y2?(S9-2,B$,3%+S6+FQQ_SW5F$J6^F9M:W0Y'\$PV8MI3EES< MX42CR(Q)>:MK+@09B?8 MJ7^9VMQ*#HUVS9#(PCXRN*(M6)X8L?#1!PGP_9U'!UO;R0U41Q"WDNJTY5+T MY9R6EG[%C&$NH`.&CM!1P$M2:$66*6B'KVBB.Z?)*"GF8HSA309S7R:P,+SN M^,28,[DR#Q+E5^!JP38P[`SB6:#.$X?8J%AT,$=W\GA@<>$B1#1'=]**%=<6 MBAD\JT60FN2R3="VU+6F46QW>VLW$NS=.'G7G^4*2>T^<4F9Q0YA#Y2A.43) M9'Z!!J*72U`D',`&'/0>;^_VGNSNE=Y1=)=*6WGK`U:([Y?/DX`4YA.)\\'C M[=[ND]W*ZR(+HYK'I2X6=]5%H>6?23H_#5'!A,A@A+VM_;`L$4Z`CP8.8A@O M2A3J*]@XR[+D;P]W$K>I&-*I4KK^]R@Q2FN2[@U_FE7"]4B+;GAMQ$(O0G.@^2 MVWSZJRD0[P=.%5.?^BB06$[#2ZN.Q[2N2#^JRBV_$#P?(-:C2_$/::_'2Y4/ MEJ.87_Q)^,)ZR,&8TV&!\B0<3Q#'34LF2;9$0=-A.L)=[C`V)J)2:'2J+,V, MU@[%8WPQS(@FGI)DOBVZ9*R(:4):4>>8"4UB3C`6S68]5S;X;W_%`G5U)-;4 MF@IG,(SL_3Y@X'(^\GK$:X8BJ`!17\8EOY#2A[_57)9MFETIE$L*S,D$L>]> M8NX>?"FBF*2(&7R7Y9B2,OFUY,FP+>0O1ME6"!N:B&]6.0WCQ"#;#EZ)ILH$".SL^,MVE7HKK?$X:$/Y7 M^8*VE>G_:3[&V:=UB6#66],8/6Y(93078](9(T\,MR**A^/Q'#K@"Q%OU;Z? M@/N^?*8DX`^EM;]3?EZ<03K?YV2^?`[)5\`FJ43)7@7[VTHO\WRFP1>H.99[ M(,$"\I03:MV/DMKB:C9U.C"%8JO_L'6VY;&$^N*Q4DA8/Y=1U-8#<0D48*2) MHD!>>^/EX>&I$3GN:7XSG/%F0]F^2XH8,"'2,TF@[@=-BL*C&I'?3Y#(=3L5^0N("Q#8A,5>DG&65>8*2 M*Y$=+R"@7EJ#CU8R9IBQH4UBC7.32&&*";#"][^K;WB;Y$,!R,A51A"$S$*!&GUK9R MJD(>A;UMW5%D()6O#*"%_G_*OXJ_*$=*7=#VO1^>_=3'&[+YWU"`M*-?IB<@ M8=?D')!;)&]QS=Z3.1GKZ64*XL9D6`_ZX0?KU.J5?BPF%)'\]IYMXO1C=N^9 MH?(X'RW%!146U9*7$R.C9^]R!ST#FK1)/]\2'1_=;>:W@ADRY?C.*:Y>T4-( MS1@VREF.\BEE29*0H].H@$+K#W](7L\&CC-L#_M.=>!N$H91Q$B*+DH3Z)"L MD%2HWP5H6A9(\>?9LP\N&!:PDX]^B/[?=0N>_6CD=CIE08+6V0$)-7R&JKAS MVK?4)DB#03V\WZ@>X-";]%=XU`-$)X#"1#<^-F:H*'7Q(UTFML3K!,JYH%>NH@^X%CANK$(23RC(3.B9%$$'.6>.1="F%`-F@4J M^+T8U^'4WA+YZ#@F,MDIT"8*%T;2PTKM#5IC[J:/72+5$3>#P$FHB#6%+PMY&&'9*9X)*H[*'G25F^1W5_ZJ%VZQOS_*H_K]'&92E:E# M<2>E":[,F2PT=/;\H6478*O6AA\FIF@W#L\^/"22LF5# M;.Y0_=M8\Q"@\'UPQ[-C;XZUUZB)`-3C(ATS2K>^KX0L+,P-.-?O"$PL!<:P M_0R>L+C-JU`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`\*RD1<2Q;;02@X",";+@01"(49PR'7.!-MOL.#IW^2L;,%209)0A3BH1P MV MV/$$5>$2ICAOVC;7P8!.$!XFR4\$Y*OQ#X7@!&YP'X8D@U"]5RRIL!*+P"HY$26H!K4Z0W*3NE M')ED>^Z057Y1D*8RGV0XGN"=&V.H.+W>,7L! M?-?INE"?[C6;)A4[2.**L!FN2G*.E;&Y$R*`$LE(<%]28S-W*Y>!J03!'`]6 M^W6S-87B,!2Q-63QDCK6)P1-`AGYD'WUUEA-;8Q9?/ MKVVR.TJ<4@2`G;`\+R?L9#NJ(4JIT!*1HI:EFO\\)Q.D7*OE$S$#!F")XYAF M5WUR]?<0)ED%E3 MA9NT9&V_3;Q*#^"]2ZD4/];ZURL%/*JBJ=;U"CDO4NDW+5VL()HZ"30V0(L6 MC*4,'_/1G)@B,\$WDL@A:HNQ_0T"G4B4O(URLQ[^1F_K;!Q$8P$!N*%0J8&Q*\?A/<(_XHWMW-G-UHG+H1G@.Z%5&=/*SYY6M MPT.$`A"E40%$1@Q<&6'VR2(/55V\,`T*.PC"6:<(W"AH4%:<7EWIH456-!/1 M-/`=?XV[9L40.O-?+-&"#<*?TUW(N`%;<@K8_B(UJ%28$3:$26S,H'R!_&%[ M72K$T"X_&=HV[(),W,JUP-UN=F8+=#9-ZW'A95N]F;S2SZDPD*#0$$E!344F M\TH]:L\3L,Z7SS\++=79:X\FAU=\WQG]CR/"-0X8G M\W&C)GBS/JTCP*"+G4%V*/C"':6N-VO=)Z@!?=SYQ(@WDT93T/)B^$\)<7"I:`N)02R_WX4U'H MW5P'?:FK'5+PRM#H8A<)4;4V7&-TH^;8SJ)1^#$ZHXZU+RCME.D_?1_5K9@%+V MC#KM(PJ=Q3'=Y?;UKI?6;+G&%3=0E&1'&SF]1V9=F@5(.(G.^RP5;:DC&SJG M[)3ZI>W>E\\*N-77O3""-=FK-ZE0K2KDVG_91$U?::_?8VUQ?I7*C#4YXM3F MH0]'A4!:IS'KHW+XSV6"CW3TB8UPU:8Z\-^#K^VN"6>"76^NER0&%E9NV>+X M:VQ;W_,"$B(_8*V=*Z_M"/L6I+1[VXY"83[7<:`J0_ZV$4XAN4BDQ^?6C\D< M3*3;ZG0L6Z$#X.-#%%39=@F)EKY6)?*26$S9A[2B,FXVP?7H%DONT.IR323_ MGO!V:P@F%(GV=QL`/SAWMDPVVL,_;>A2H(>SPK@IU5G7R7HRGXZM6-B:40V/ MIQ?76&_]&C0)PE1Y;DF'>IM0Y&U+Z6[V6BN50F[PPVM\EQ^5*2NO=5AVBOQ< M/O.7SZZRX,MG@H7-5/Q;:@]6-%G4,?4U@5G0=>X8NQ&J6A]2;_R*4^HA!ID%K?IABO5`P6XFB3JH24A+?2"--GNN>DV>Y.>)"!*S:A8.$XRSD?& M[O[!H][VD\=Q(84`#46\*E5&PQ96C2\\&%DC)'@QHY!9B0M>H:^JF)C?;5K: MA6(T?GG[T(6_?=KP?=S,S/%8,)5UFJ&C[*JCU_&ZI'H3#K?*XU/) MMA6=H!:XCJP;A?GJ@R+Q+\;WD(G*..L2.4PQ@'2%`-H2!V&`]Q8X(D>.I_6VK^VDM-_\ M^L,7.AZ]ECPV6BZ3PS%GQ>X2YR'ZBJI@K:2+5=KNHD_5(UH$;9P/*LU\?R>> M5S-M^;N5A\#"J5QJF$-C%?E[!]6*'.X3'O>G(0/O,1M_1LP\*X$G3,6,0)0Y MR@Y(8T>$JTWPI&Z50B(T:1FLA&(ZJEA)#-UMSFXI^745B15LIO94!<%-ECTD M/K^9CS%>/AN)#:.L9J2XJGO5U3/X";CI1S-Y/])%+Z*XXPI"#'6:WF((*/_6 M0M3$$]]R%KX2@B>J\M,93;(`KJXGF.[%$@I",Z2;_3F/?57M:`?)6LBZ>IK8 MS%5HX<9C*W'*IZ+QTZV#_7]2\);0ASM/`'TMIEA+A7PX4SB"V=A#'Z/V(U7) MQ6EM()D%O8@`Q"E;.(*J"'2+K")\EEB:A5PY1Q5E)^UH0#:>4IEIL0Y//VXP MW-S;WU%)/%&+/1S[^8#,R%WLVZ_]D6"2>3`OI$[2&"@W":93Z6<"FY:P< M+45$Y($NPCHW;XCU5=->0`7:^L!R8(/(%0A:EFC^P$' M,:K;8J4Q[KJV)X!%Q7?W'A](_EUTS!TF2!TI>'RI)(MJ;HEEG;.',=X3M%8925-G>V24 M#_9=F*X.2NSY_D%O=W\/5C`$9M%`I(3#118B-U%;W&X+0^.?<-A*VE"G+!O7 M:!B7A-..WGMQC4N6\^;-QZ@T1*S,*!NYU(G3HN4LF+;^K`V#?6JE\VV3,4^! M=3X^V+:)W7_RI+<#2I8ML5XM$2K'=1V<*V8M+Q@LQ2$J8LAK=-LW0=[[=V8&)X`7>A[%5>H5WQAL3Q._J]OJB2T3Q`AB<#<2IV MU9U51HN[J*AFV\)Q9F!6L]UY9:VI'Q8'N+?'O96:\GUW]QTXDL85`Q:H_ MY5+OW\1Q#5;XTE&D\__#[TDSS;EX(VNW]^'=C#4"P@+)@0?K&/FXPHWLW_@)F?TU7['@)C+>5;:Y>F02E#-IR,$FW@7#&C8R\2XSRV`H'A!^DJZ)< M&2"US!61<3-&9*(X21BT]CJZNA'7_.,.VM7W[/B3#O87A/#, M)-"E<)/U]7;:KHP*#?(E4" M-&ST+T98F[+EPS^6MRUB\E19M.6Z!22QQ/4*U'[9;E0;T=EY[I[$!"TLWOHZ9RP>RP:;1AG;54@8H"%#A4MRH-FO;C[+)Y+L`CB MZ%+539);N.+NA+I""FI?F8]50G)C/)VXZSA\_*"T;BE.P:"HA+YC<:NZ"K<4 M.FW0$<%W0'/F[HZO*@9=R8?2<78*%"EG3#W"+6Y2P3H>9LQ!`CG1+&P*^\'G)<404A=Q5D['G6 M.HXI%[NZCA>9VTLD`,W`L8E(3Z4L+-50-49UB0K7W^FD`5!&)7$`<72`??W` MG,O@B[HU7L4!JOVZ2C/'C3ZJ7Q]JL4%*,?T",.U;["&70C\Y?.AN5QU M3EC8B/I#MR?U7SV-ZC_;,,0]E`ZO/WN;S2BB)5W3>%!)*M:?N0YY-6E[DZWD M3),+1QK_A!B8SGK7NZHV/A2S51NO%PQ>OXLE\!+_-@*B9ORK%BAVR=\T!&\, M(BZD/.UB#;%M]7I%7;C#.80CU;=>#-.@'.%%[N4R`5R8`M%-"6IT]*U\?$Z` M6+EE.0B>QJ9TXZOE(3#C[?M\W&#[Z7:#]UBPBZ7&I*B7P61QL3JE:VGSMD7[ M1^5RP_629:%)6&0?IN!;2DZ6P_GFO7JLJ1A^0BNXR//?9_7[4&-WCZ3C!RM$ MD.PWYN@)6FYG2X#C`@SB2N58`18G7.B(/N/&/1]=YL`N$1)W)#;%>(Y_=>OS M\1N]IY-Z7*OFPY>N5##T'.J4-4=,]YR8,>KC/A^(LF]F5#!TY9"D5S"'@14# MO7T'T91Q=:'3P/TH/8;?SG#152V0ZD+!A+$EQO")"S6@0N]S$Z"^ MX\&KM5<.VABM6B^PMTA=JK:R6W$%A&GG,^>`U1EMJ5S%,(LK#RP_U>%,?$7@ M`B<^_OMPVPY?RWJ\]Z1!`\EQD"X%E(GGYM/1X%8Q>J[V'Q$A(L@*V)-12DI& M=.Q#=2"",X/6F`2P&+#+A;X'X:*`[0.,&BY=Z9R)A<)X%E&-@TP%[T"$U`PJ MY)5::-$TB+9`UYG*--O5I9-\A(H!^X5KVC#?X%C+7NB8''Q-+(]TC(HA"V[? M-`M?'9LYMRR)K0I2&("!P54L2ES-SG9""CFZGN MQW#7JLRF<]W3)X<==&A:$J8V+U14I5?W\`8YE9GV@%9C;27O7#``&NJ6S]K= MGI5%&429#"><"1]3RV29##V^OAM0QW*=7P#T!E1(Z$X4#OG1G>Z%72#LQN]> MG+Y]J'G:EUWD0@,E.-<8[T[D[R4;.-X,^\F3!56$'8"?IOF=W:5(5T)%JINQ M36XEOX@"1KFE4G-\-&763(IBL1['F%=3WF;96.E/3 M'&DJ.000B%4(4KBO53PB&\DP^TI*VBT\OK#&[HUDS79'`5Y9G+7:J0ME+`CR MN(I<5L=`:`7Z6@38#,C91UC!P*^]&?;.W;.B'1J+X1E-6U[*-%M;/1WO0SE6 M7X$Q$+NZHJ>X!3JYH:GA"',8'O%JG^.?.&D\(_OG>X^\$28F8]-&SL6-T($Q M%R.0]&OXY+#(TVWV\PY2@,-(#\I'5`8,FK6/%G]=-A:B MHL'#Y,,MB;CJ*$:(B-L]TAALD.2]PL;E?.%W78I:FQ<;S35+*6550:^;G,19 M5:P!_5T2,S@R7:161!"?%?A-3-&6DZI'JH&B/V#\15FA^L%I2P"Z:5B`B]( MR9O6T9ZKF^K;$$8_D2>7(*&YXJ6J"JY09:-X,?B!*1NE_+SB7+PFJ5\K-'MV M7N$"9^/[Y/9=%:2L>RE9D7!2+P.K3L$0[C@NT/2>USP%N>`42R:':,,^GY>A MJ.3YT=&AW1H9O%I)NDK.!_:M#*@J*ZC./!6A,A67X6B]C!]515?EA:RZ"4;[0YD@]H=MK]HNML=K\Q2+1ATBH&G0;)[5T(XAX(E5LDYME.;G%M9=VAL&9_-+PZ%(\E'M`(!X` M@F5%G_"W_38Q)4H%D>+IA\639"*U5Z5!1\<=I^M%='FX_0 M%:A5>-W+TIVN2(?'O7YYM&\JN(&/7]69EX7J:F+MNH<OSXK M;ZP-Y]:D>[0]GK^U/6;J'!+F#19[Y\A)2SV"TPR*5;@FFJN*(R8#%':[%.M% M05#7>(_5NR^$V#0JT$GW$H`!9[H35ORO:>J17SQI[\K?9'75H%)UA204?`)# M"I95Z>%BX1#/0V8Z4`'0&^X6P`K??[2U4U:A58E$\--=2]XUQ*ZK3:*D[2P" M5P_-A-U;+,4B91;L"H0OR<*HA>D'KQBD;EVPC`*G_AP!R)Q@%5U0CD+K`P]]$YEN^=X*R/; M-NG]DG"RA;5U['#QO5")V\?HY`=>[UX.;."LL@]`NHZA@QFL&BR'8F(;T\$2 M1W:%"\"3O:W]Y<.74S<*TH5')IJ67=>NNG8_:PXM9$Y`85N[L,`HZ8)2&\5# M7]IA(%OFCSFI`:N74'MF+34D.T"0_,8V*NR&=)$RHRAT]\D]1X!R[TVUZ4I3 M]6O8BEX7V8,-=49$^G)#I&`:GAH.#.UM-]>2PV_J(W4.J(FAWY MMH]ZN.IB+]*:E4K<>^R53\](<9<;I/6')RM)JBU?)"MWK"*D0&[,7F%W"0CK M:P27!/)?7_6W#(Q(-9U7^S"XQ:Z7?!3)A6)]8N1RQ%67KK5YJ+8LJ4!?1/DJ MG'0[$Q4^9JWE]T0^U736/^C$\G&N8QYT2`?91/9@*\YB)&.[7;@H_*Z7(=M M"`I@ZE@HEQ$FU8\L_F)=)DM(+!Z7$;0\JD3>\7#P'MOI/L14R4JZF3?^R]&>]0=]/D?3PXW[G4 MDIG>72;-MU8OT;USY`^.N:3RZL'@W-875X]W&F*;TJK'Y>GD+ED)S9%U.TB] M^-;JX:KD63@6>\CPA]7:[]5]N15_-8G<"PN'%%>/%0Z75<_0==&H7".[TO;> MZM%4H1K/\*TSS@O5[*_N^*RC?G4M#C,E[VM*P:Z"$%:?2+6I=?O.RL[0WH>A M+G&-"55T;[7_4^?H)(<8XT%C@)\IL'.ED6QF^8&%U:-5:EM"<4^E5F@](O@: MHUA`5.G!M%OH>?5T9!O^<=4P\8.8[9_;3#9>D%13!%OFC,C`PZX/;>\D;]SA MM>.VX_)DK+?"";+=AE_3Y^K&\'F]^L.ZC];YR>L_.G>J\[E?*BJX7*KT2_EE MT>27UZJ_>\5=,D7S.Z`*&DFO'>D/4HG$/!7V)DPQXT=_Y:1XL%%'Z@3AE8.Z M+UQ5KH,-OB2;3@1]K$6C6`?EZA)4)XJPJ(U=KX)*SIRF\"5W;..;ZH0Z&Z#+*7N'O'=M88K/[.[C>\L]?Y3L?M5=_.P`8^VO\3']Z.ZO5C3/RZ`2G<*]X%%!=*E%+G<@2.%_ MX,`(<>9EZK0)@E=*=/.5U0.XN(DY>#TY7'4MV0J/UYQ)#8TOFTS`QT:I"IQ> MI7C#>QVX>HFY"F_:B(1`W?5"/179-ZM.!=N:M_ITBM?RZWTZ7VN[YZ>S<<>% M/YWM7ZONR&[^Z6RR0)+F)B1\,&+CP]F+Y'XC%+#JS97(:'RA0L$V2WJJJ7V%AW\_J6$D)W,EBK/[A$NFN>X->LNGK,<>E2V\=8 M:42VE[+Z@B\/FCQQ5\K#1.[@H_"XCE/8W>\-TE:^D$D0]C`F`DY3J@\(W'NM M`:]Y5\!A[GI'+\+U>6YXY5SL&KW(!,+C#6-A&P(C'KF*XY.T;Z?->LF)NR^9 MZ"I/O8_:@/$/E.)VQ5%?<==&?>I^85CBJL'^R[L7?\=STQ3-![0 M>TR]Y7(;/7%MNG2!Q15*3T34ZQC)NF*,3JWR.W*-*S[LW36)[NV(<4@6"\N1 M*D[>Q>/I];EV=O1&=\R3@WRN2Z=OA71@,':]><*PLXOWY>5F:W2",G5?%A!] M>V&+P5T].4H^]B&2-IF+>J__D+MIUJ;EJW!ES/N4RL$7\<-&]1X>E"V!D&%1 M-XHLX"_B:A-S!<7\AUTN4Y_N5S`POD?02UT\?:3K3B2BH2&&]KTJ9GI).'JL MNDD**&,;VOM&#;;H#NQ]CW^ZM)<\ M+[_BY&]_J9.XY1T[*-P$'2TM`]D:`*6E;>@R+U%SK($9O!,9&#&J2([<1:NDZ68HHEA]E5N^-Z7$J$>K?^[VT46,FH M2]!Y)WL>3JWD6P&CY/F=RT9Z-O9&V@62E\*@!X_;36GXG6OR33EQ:_ZNE=G5 M-W?UTJ+[``"Q0[H$Q"S$'4,E^HSZ/8VH;\SM,\9D_.UP-K"\&[NG4 M'^QULX`C*H%]77`(368*`/@;`FJA^.\WM*!&Z_@^"ZL$JI^6*I3K$WFPZS8S MT25P+EB]^ZAUUU;E!%;IS_>ZTU]?%3`7YIB;L:8JSC^:%S,.`/'I!<5,[!(3 M\YY"O&69[[%P-+434+DSJIV/7X(>!$0[#1`AYOL$!_CQ"_7>8QG]00.>" M,$^A[+:C&U^S7^]F5;ULG''7!L#(X3P0LPA':@(.,FX2`DH=JG7Q+=2%/>BN MOJS/TY(800F^0V;LZ([HS>I5F&!'F>IO??WJ@#R+I;%=R]97'V1/)<"31AWP MWW$BOH"VDP7+(XY))5YU!NK'+C9."'2MYAU<`S.R'HM+@=]/YC.=_GBC;U'A M47C2%\F+.?W:R>[Z&IL'9KM&>VUG80TV>M>TXNP0RC56J7C@Z*ID"-,JK[\ M=]33;G)RQA?4NB*,SM;UV2RUNF4(ZEA7*#B;>YXU-J!L=LY1O[;BYH1(P#"O M3_P!QWF^;]EM?43G/YA7'1_]4!2S9_]/`````/__`P!02P,$%``&``@````A M`/LL"P*:`@``?`<``!@```!X;"]W;W)K\_HY+QC/+QYD@^ZY-D*U!4ZB&"/>,E6*=E/@W[^NSR88&4O;DC:JY05^ MY`9?+#Y_FN^4OC,UYQ:!0VL*7%O;S0@QK.:2FDAUO(692FE)+0SUAIA.8R>IOMMV M9TS)#BS6HA'VL3?%2++9S:95FJX;Z/LA.:?LX-T/CNRE8%H95=D([(@'/>YY M2J8$G!;S4D`'+G:D>57@RV2V&F.RF/?Y_!%\9UY<(U.KW5]*=U?4$R.JJ_[!?BA4"V>)$=L:J^1? M+TKV5MYDM#=)@7X_/XI&DRS)\O^[$$_4-WA%+5W,M=HAV#1P3]-1MP63&3B[ MSE+(Y_7.H"57<^F*^E)0&UB-^T4VGI-[2)#M)0T)%AZR;2' M3+Z'TZLWI`.X\A#N=G!.'4'DQDE)^$&DM?@_`'JSY>.;OAWJC>B-:CA%3R-<32&Y+4_/OW`JJX_1];* MPK'77];PEN-PR,01B"NE[&'@#NBG]^;B'P```/__`P!02P,$%``&``@````A M``',Y]%K!0``L!4``!@```!X;"]W;W)K&:8!RC,<8"R;8X0XJ'>U\/;�,FO+FV^.A[8J'/8S[ ME8JB/,4>?\S"-W79M7V['580+D*A\S&G41I!I+O;30TCT&D/NFJ[#K_0FYR3 M,+J['1/T;UV]])/O0;]K7W[KZLT?]:&";$.==`4>VO:'1K]M]+_@YFAV]_U8 M@3^[8%-MBZ?]\%?[\GM5/^X&*+>$$>F!W6S>OE9]"1F%,"LF=:2RW8,`^`R: M6D\-R$CQ.OY]J3?#;AURM9(QX13PX*'JA_M:APR#\JD?VN8_A*@)A4&8"<)! MO;G.5BR15*J?1XE0T3C`K\50W-UV[4L`LP:>V1\+/0?I#42^/"(8BF:_:'B\ M!<3V4(;G.Z9NHV?(7&F0[`+B$OD%(CXC$<@Z:X,17Z]-PY#7,+#:DG/847Z& MB)@@TB7RCPA'&CSG>FD:7H<0VTI+W0=GB"284T(3(E+B(KF#<)FDDMKD.^)@ MA->+T[`KCGM/SA!1*"Z1":&>-!>(E7RGH##9KQ>F84^8]]P,$12F./>K.;U, M!8TYY6?A3L+4$ET:]G2Q#U__[HC2_>UJTU#PYXLX>4+$90E!:3#6[GY%("K/+'KQQ&6 M+A&F84^8+0/F"Q$4QFBLXD3YI700Q5DB)I[HB*/0=ZY/VTA[\KQR989!?900 MY]E841>A/)'Q.[FCRUH!VOC4U+A=]9B],>(Z1'F*,K`UM_"Y0\A8V/R[F=.^ M?/6$H^CBCC1O0F6&,97E/$F$\N3G+A.+F,72#L`5N*@?4+1R^#PW!&Z+8G*' M##CKF;'),:7]"''E:8.^/G]HY]/\"3MN(V]J^33A-/;6=$X=@J:<"EL$5]VB MMJ#W7=ZR%=Z:S`QCJDL8$\JSZ-Q!J.(D(;8$KKQ%W8'.VX/PGIT9!N5)P=*9 M#W]$N.(6=0@Z;Q'";Q&&,;F+1:*8IS]W$,Z52B=17'F+.@6=MPKA3:O,,"@/ M+"^.B?1L,3>,&#0L!QLXEUIB[H$FW<)X=EL9AA344ZDX,06 MS:C#.$8^-#JF[+QU]2UJ%0Q;Q=2))RYE4H<,V-F[3FS"7$9<>=JS)TZLWR3A MS?4G[UT,G=YQ9.M61N:I&^C7LEG^+E]TI6G#]J3%8+8?OQ(RM/FIM$F3--*0 MP>HQ128[$%->#WAW72SJ%/JMV.L4TN\4AC&3CT`C2^W$,N(PS&7$S>"B3L'F MG4)Z3IL9QCQ;QCQF9.*U1B`&.D$RE;`_?F_Y>OWBRODW[QO22U/&D$$5GRCE MG"G/A?*/&3>7BSH'FW<.:3-@9B$R)X$B)K`;3KR,YR;2B>*P=9`\MNO)%;FH MB;!Y$Y'>GBXSC*DEX5S0V;[481@72HC$FJHC4%N+OZ9_;C?C76Y#\7ML9AAS M8G%Y`^TRES?0>.:&1U+'XK'Z7G2/]:$/]M46K)&LM`-U>.*&/X;V.!Y!/;0# MG)2-7W=P,EK!^119`;QMV^'T0Y_IG<]:[_X'``#__P,`4$L#!!0`!@`(```` M(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_ M#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM M,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(D MY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P M/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC M?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO7 M6U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C M/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=% M^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=7 M0/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1 MZ!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+F MF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;3 M0IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU M4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO= M3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+ M-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX798 M8*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35 M`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`( MH6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\ M/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L: MPV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<< MS=*MOP```/__`P!02P,$%``&``@````A`);'L^%R!```LA$``!D```!X;"]W M;W)K&ULG)A=CZ,V%(;O*_4_(.X7,!])B)*LAL^N MU$I5M=M>$^(D:`!'F$QF_GV/,1#L9(&=N1C"R>.730-"IRW32,A5XD6:ER MA74U1X,"US67*3">5)#_O2<76BG5J1SY(JD>KU>OJ2DN(#$/LNS M^J,1594B77\[E:1*]CG4_8[L).VTFYL'^2)+*T+)L=9`3N>)/M;LZJX.2KO- M(8,*F.U*A8];]06M8V2J^F[3&/1OAF]T\%FA9W*+J^SP9U9B2]^9ZRP[U>:M:"\U9&A8"7-EC6D<9DU25]$IK4OS' M(=1*<1&S%;$@^_9[4S-7#G(6OZ!BMRIP;57,I89LXUF'+A^OIQ%*P+7 M3R>R;#7@VB6"M)7CV(O5[345N"DPDZ`9Z2=BT1&M0[CJ; M=TW?_3_K?>AV)O+"5+8JM(>.I3!DWW:VM=KH;S#,TI;Q'ADD$GY'L#'%9(,N M<)>U#%-L%'9,URB2`_$@H$/5?>DPQH:E/Q_?784,9A5VC_&ZP#TW*3/_D5@L MQ.0#CD""O6^688M,.(.)9C#Q.",X`[-NOC,,%IR1`[X<"'A`+-N1RI[!1#.8 M>)P1RH9E8G[9#!;*E@.^'`AX@"]T;'R'76#8_=(0B1X9VW)%K^(GC&WTC%`C MK!3S:V2P4*,<\.5`P`.#&N5`U`5&BHX[!F:;D#VLG_.S9S"\?`:3R[:E)6.-MBHL$;T/EB&- M,H\S8UY-$@$G%LTK8KDPS)5I]>.T6?/#1T($HB&`X&5N2^MN/`1<%RV6]T<( M1K$-J_3JFS:*-9*,0O>IUI3@<6;5%(D,>!,NQ1+\(6"9MNNZ*VG:!T,$68[! M_D25D",C_1%-$O$8(9CE?L8LUD@R:R55X7%FI`I_D@@FB9`3;M,EEN9(>Y-H M_.MX3%]P"<%$&XZI\4G7T*(_MCR:O18:,V@:"::1\`EBR1N6Z`DD+9CQ*"*Z MQ79FT@RT8>F?<(WOYX9KE6W?ISB?@HA#HZY-(L&T2O@$L6UI"Q<]@1Y<&\M& M=(UMY`:N3;C%MWVB6]+#/3A.LHDZZM8D$K0J?)(AS96>$DX_)9I&V-'WY[ER MH_C1EA]S"ER=L(_SG"HIN;)CJP.+0!_MC]0OS5%6BGMH#8<2V(1(\8`=P9_$ M/7/M/=/QS37LE-AFIA>"$_,E.>&_DNJ4E53)\1%2,S1VDJOXF9O?U.32'-+V MI(:S36-C>R#8$OGUG=A9? M)G:\@0<@\-^Y[V_CS>K[>YXY;[*L4E6L73'S74<6B=JFQ7[M_O/WT[=;UZGJ MN-C&F2KDVOV0E?M]\_-/JY,J7ZJ#E+4#%HIJ[1[J^KCTO"HYR#RN9NHH"_C/ M3I5Y7,/+'J>%2Q:6I8T-M=NEB7Q4R6LNBYJ,E#*+ M:XB_.J3'ZM-:GMB8R^/RY?7X+5'Y$4P\IUE:?VBCKI,GRQ_[0I7QK\[E0'=?JU3+>_IX6$:D.?L`//2KV@],<6_P2+O;/53[H#?Y;. M5N[BUZS^2YU^D^G^4$.[YY`1)K;V&B]G\Q@\%R)UG6=5/*9ITG>2UJE7^'XD$!M48"8P1^&F,B/DL M"N8WMQ96/(I()_@8U_%F5:J3`U,#/JMCC#,HEF#Y,S.*H\EU+%4(#XW^,ZD$4%_7G;1/[=RGN#FB9&\T`:^-YH1*/P()HF)`BC&])PD3\]HQ@]8Z4P ME`?Z0]=-,.PF[+O!S$.8C,ON<-':!1]-$I'P&_L4`6FBCF;>*'J)@L0^411# MA!VKD6@+2)Y)8^$9IL[>,XIYSFU-R3-INIXC$0YGO;C&-XJY[ZBQ2[Y)T_<] M4G&8T&[>=CW'13R&!8N!--T81B+`(Z&SWRY/&XJG>DX:"\]W?<^8.S!S8MYQ M$<_]AN5.FEM?[WM_-I*X@+UEG[E6<\>WS+$1-9[],=>(GD[1[5(7!*S^7C^# M&HDLRB\03)T@+G=>JZ=:;T0VSAGL)IP/4"[@E!,D6NBNSWW]U?2GASD!`78S MMRP_KF(3$'#@:=,PQQTJCLW`5?A)1^>$,PJ^1 M\G\)>F*`>@&GOA'95.`J[@D;\!F1C?,!]$T?]6*`?4%[IM'98T34AG#NWXTT M(;B*?EK-9Y\?>T9DD7_`^'=Y]VOU%'J,R,8YXY[=F1O@*EX!7GPC,@@*_2!L M![1'H.`J_&DU]]UBA1IO1.0;'L=&MU\`->+TFQX^O8K'P-]T&)%AP(40&/LL M6T`,[)U_`3_[\?D%^C0=`B.@90A#).3O`H(>"2]4X4L<#(8XR-\%&!%587$A M!$9!RRH0#7N-"%O.F'DDDQ? M'!J1C7-&06S!]!!&1,->"\[V@1$U^V!NGE'Q=,:O=FA[6(@8&BTC&D!DR'>F M-FWUL!I!Z;J`G.@)JB=[0B*;GC`PVFT+[-H9G?FV,"+:%N%LWOZ?>D`7\'0_ MG&ULE)A=CZ,V%(;O*_4_(.XG8+Z)DJR&`.U*6ZFJNMMK M0IP$#>`(R&3FW_<8\V63Q=FYR`3G\6N?U^9P\.;+1Y$K[[BJ,U)N5;325067 M*3EFY7FK?O\W?O%4I6Z2\ICDI,1;]1/7ZI?=[[]M[J1ZJR\8-PHHE/56O33- M=:UI=7K!15*OR!67\,N)5$72P&5UUNIKA9-CVZG(-4/7':U(LE)E"NOJ&0UR M.F4I#DEZ*W#9,)$*YTD#\Z\OV;7NU8KT&;DBJ=YNUY>4%%>0.&1YUGRVHJI2 MI.NOYY)4R2&'N#^0E:2]=GLQDR^RM"(U.34KD-/81.Z`@="WBCZ]4B; MH+,VZQVW*_!WI1SQ*;GES3_D_B?.SI<&EMN&B&A@Z^-GB.L4'`69E6%3I93D M,`'X5(J,;@UP)/EH_]^S8W/9JJ:SLEW=1(`K!UPW<48E526]U0TI_F,0ZJ28 MB-&).##[[G=C97@VLAVYBL9FU`88)DVRVU3DKL"N@3'K:T+W(%J#I;M@WC+J( M[Q+U1-\E9@VM=1K$.`0*]DT#?;QT?3P4IO'TJ@%K`.TA0(.?R'Y..`Z/A'-$ M$(GFA"@2SQ'#'<;A(C;YB.G2FK#UER.GG8";!&KIPC(%C+$FC$#LI40H)2(I M$2\1G!,PU>?7GL);%6P>E]HV!X?;?1DPQFMWNF&:GF'%MES?0Z()'&(ZKFLA M8>PWYP-DN>=]H##O@Z6+/C#F$C@'($]/'7@N,=!.LL3`F"4GI$0H)2(I$2\1G!.T0)L\_993(X7Y MO6#,$@-CV#UAP)^C&$MOV?(@DFA7"22BL2*>,9V+%_W_"']M4S, MF,=^#@^OQM:FG?"TH6D%'30X\%9;I`CH1R)Y$B\B/!&T!IJ:E0P=\1BSZPD7XN$LE%8GXFGF4[8[7#NT#KK>==8-49[X*0!@+$H"Y56*9I M>T(:V`N(;C@B$O((@A>#)5L&)-DBJ6*KK.$"D2TM=T\'[!UDB. MQ(L(;PBMPB:&2%(%J]GXFV2\_=HH`SC9H"&PMPW/MVU?V#O[CE@(,I2*1'(1 M>L8RSL3W7<<=[U;F`CM"82<,!:[.>(_SO%92'J(UO/-#NS9T@).6:W+&?R75.2MK)<&UL MG%7+;MLP$+P7Z#\0O$?4RT]8#I(&:0,T0%'T<:8I2B(BB@))Q\G?=RG:M!(G MA=N+)$JSL[.S2VIU^21;],BU$:HKX:E/H=#595@_$:QK>2=]22:M]2"?M.(WAS8)#N'3E+] ML.TOF)(]4&Q$*^SS0(J19,N[NE.:;EJH^RG)*3MP#XL3>BF85D95-@(ZXH6> MUKP@"P),ZU4IH`)G.]*\*O!5LKR>8K)>#?[\$GQG1L_(-&KW68ORJ^@XF`UM M<@W8*/7@H'>E>P7!Y"3Z=FC`-XU*7M%M:[^KW1RL<)49L:ZR2 MOSTHV5-YDG1/`O<]29I'>3J9S<]@(5[14.`-M72]TFJ'8&@@I^FI&\%D"^5"C4ZDBO'4N`91A!NH#V/ZVRQ6)%'\)3M,=<>`]>`20*"@)H@ M"62,);UM\B&S`[O,SG0GY=J_&*=)WTZ3_4L:!RXP<`?Q>1P'7I_98_(19A(0 M+PH$R+A`YWG^[C0="G5!T)L1>[:8!GZOP&/.4`#97BN80M?_;K4+>NW!L85> M@)$U`?WH;SY2H=CHCP`?9W3VM^3W4M.H-:7D%H',W``>U/"+^PJA]V MV499V-G#8P,'.8=9C2,`5TK9P\*=0>'7L/X#``#__P,`4$L#!!0`!@`(```` M(0`H/G6Z^@,``(\-```9````>&PO=V]R:W-H965TW`P$HB2C)M`S(^U*J]5>G@DX"6K`"#N=[K^?,@[$-M/I M]/*0@.OXN$Y581>KKZ]-;;S@GE:D79NNY9@&;@M25NUA;?[S]]-#9!J4Y6V9 MUZ3%:_,-4_/KYK:8SNV@6FS*BM0P,-N]'B_-A_=9>:ZIKU9#0'ZM\)G*MT; M]$C.W_JJ_+UJ,40;\L0SL"/DF4-_E'P()MNSV4]#!O[LC1+O\U/-_B+G[[@Z M'!FD.P!%7-BR?$LQ+2"B0&-Y`67^R>Y46!&X2?8/$O++#NA<5# MEN\%B^@.7VRA:PA3FK-\L^K)V8#:`\]IE_-*=I?`/,9'J)DB]E[`(%*,A7DY$(3"1J,_`]1P-L98"'`B^*5894!L1Q&#EZ*&50-$+> M/J^13](U:IE*!"8>-,(&`T>-=&FUMU7!KB8F5TN0HL@T@7*"(1<'_G7""D:8=.3LWF[ M4CE8U[90?4L$)G(&<:[EJFF\>C'LD%L=K;&ENMU'L7RI:VXG`7-1IQNTM8WK+F+UC5+2XL)7>GZH!K:O1ZB^Y@&#OFS9?%&M% MN+T'E/X2I+^6'X!4M;PWD`J3'YH?'R;0C^&^?HZM5`F^ES1P#6X/^`MKFMJ%.3$>U@$6\8T.O77CQ[O:[3QQ%U"MS4? M3WD_SL?M:0*TPUU^P'_D_:%JJ5'C/2SE6`LX`GK14(L'1KJAG=P1!HWP<'N$ M#Q\,?9QC`7A/"!L?^`+3I]3F)P```/__`P!02P,$%``&``@````A`.I!4U:( M`P``4@P``!@```!X;"]W;W)KWMV20!M69BR7)8_)"]?D_?+M MF\5!JD>]X]P$H%#JF.R,J>9AJ-,=+Y@>R(J7\&0C5<$,7*IMJ"O%65:_5.1A M-!Q.PX*)DEB%N>JC(3<;D?)[F>X+7AHKHGC.#/C7.U'IDUJ1]I$KF'K<5^]2 M650@L1:Y,"^U*`F*=/YI6TK%UCF,^YF.67K2KB\Z\H5(E=1R8P8@%UJCW3'/ MPED(2LM%)F`$F/9`\4U,[N@\H6,2+A=U@GX)?M"M\T#OY.&#$MEG47+(-LR3 M8>OO/.>IX1G,'`EP1M92/N*KG^#6$(+H&L`@^L\IS%V$4<(F3/O\%/*AGK:O M*LCXANUS\TT>/G*QW1F(-($T8#;FV!DB1(]]K(XK>%Z%'*BD1'$3@>[//H]2*C MHP@AL96^TXT9> MW"XQ:@C'"&2AOQ&$846TQCMN5*TS2XQ;Q,0EDG\1CC,0Z>\,X9C`J)N9F+IQ M5Y9H.[MQB:1+G+T[SJ`2^CM#V'5VZ\9=6:+M;.8229>XXFSZ&F<(N\ZHO\`M M,JD7_YC.J+_,[/.V]2O&H(KZIPQASYA75RN+M`-WO'61*][P@]E[4T#8\W:N M+%L#%G&\>662=)$KWF:O\8:PY^TL:[U9Q/'F%4K21^Z\ M"EP=&<>>5RW)!>::/]Q\>T\LM5MU>PNA7AVNCDS;7^253'*!N>8/-^G^_NR6 MWO87^55!+>/X\TOV`G/-'V[5_?W9C=WQYU<&[6[^D5\:%YAK_F"<;7_8ZXQ@ M3?[GJXYON>LP.@>P50)M'3+M/'H(=GZ(3.NM<32:WM+1Y,S8.K$=FVU`"JZV M/.%YKH-4[K$#H_!J<[=I*8^]7O,`FK.*;?D7IK:BU$'.-_#J<'`#GP1EVSM[ M8615MS=K::`MJT]WT+MS:!>&`X`W4IK3!38CS;^!Y5\```#__P,`4$L#!!0` M!@`(````(0"M^C8PTP@``/4F```9````>&PO=V]R:W-H965T#K]7E87J[9=E\[G8Y#4-IG?^@/ M0>GA;I]##UC8>]?LZ;[_U9AL3*L_?+BK`_17GKV6K;][Y:%XC:_Y?IF?,X@V MC!,;@<>B^,9,TSU#X#PDWE$]`K]?>_OL:?MRK/XH7I,L?SY4,-P.](AU;++_ M&63E#B(*,@/384J[X@@-@/][IYRE!D1D^Z/^?,WWU>&^;[D#QQM9!ICW'K.R MBG(FV>_M7LJJ./W-C0PAQ45,(0*?0L0P!^;8,1SW`RJV4(%/H6+*EMRX.[2S M[@)\RKM[QLBW/$`W'#WA")\?NB',G?J&\"EO*+M[XXX&C"\/-QMH$Q#A(=I#J8ZV"A@Z4.5CI8 MZV#3`DIT88I]1G29#*S1[72V736<4VYC0$N:G'=4DUECTH2EH0S9#*[_)_@!1V]&P-<=0 M6-6QA4(=_KDC4ZM=(I22ZC&BF^J)INX:_L@QM.(I1:E:78T>*YS;,^6-Z/$Z M&VH%S+4BA!Q(5\WW,];?!214@-%:M-?SU4HL*58SIE MU2C-*FT,9V@E'0.!;"C:FLG<,2>YO,W6.YB3EC4>VZZG#D1$U>-WJ2=H)=0] MVS,]?3U)%74UJ*S@O!74/XL+K&"=VW=K!6=/+O0$%*A5&Z&51`%%(44113%% M"44I17.*%A0M*5I1M*9HHR`UU*P*O17J=U5*[$F.'FF!6KLE6DD4"*162XZV MY(72"A?=B**8HH2BE*(Y10N*EA2M*%I3M!&HHR`!I`;_C;U'E+MRLD]KA?N^ M*U?^F4#\=N*Q%G?TVLNN,=:>EX7"$:QDE!M'1#&U2BA*!8(/=)Q+*[DNF8Y6 M!BRD%3HN*5I1M*9H(Q!\@)::]:QN_O6L%]5W>SS:!7D=_)E!4""0DO50MJBK M;RBM,!0113%%"46I0#P4=;OFTDJ.!VG$0EIA(Y84K2A:4[01J&L\(#,_83R8 MBE;9"B3S<&80%`@$1Y9Z,QP99`'B/F"`48BH3$QDM-TZD08HDU*9N;3J;LU" M&J#,DLJLI)60T5JSE@8HLU%DU!G#CA_M&?/&4B5.*^VIP9&R5+7/-&*IXJA] M@#((B@1JI7-,K1**4NHXIU8+BI;4<46MUA1M%$_[8T$]K5#U&OYOJ"5H)=E MZG/TNZF^0"NA;MB.#>\0:/)+*K]"QYOR:[1"><\>P6E6B\U&D5=3XJT#_/O. MFO`V",D)<<26U2=_WX/_'G[*KL_9+#L>R]ZN>&'OC&Z#^8LF4V<"OQ/` M_JQS=P(/OSNX84_8:8]>"0Q_$L)F1*_`UCEA>R6]`GOCA&V&]`IL?A.VV]$K M\&K,U_HTHK<87IFI'[KHW(17:3ITIM8$?O?KT+=!O^O"%'K>W7$7NM<5+#B2 M0">ZKD"%#C[U0URMN5`V@T_7%:@B(<#U6J7Y0&$(:EU7H-:#`'==@?(-[M-U M)8"F==X?;M]E'\/-NW@`^=`U@#%D0Q>'LSJTJ$[&8=-!>.GHLGW.5MOK\?L"1)Y5/_,<.6O+?$OE7A@\UA4\+I1_>SF`*^79?`@;S2`)P5/15'A%QCS M8?/"VL,_````__\#`%!+`P04``8`"````"$`Y#/17-0#``"$#```&0```'AL M+W=OIYY,X]#CB:KKZ]5Z;T0 M+BBKURB@2`E+\K<#$1GL*-!,HE@Q9:R$ M!.#;JZ@Z&K`C^+5=;S27Q1I-I\@[$2%3JJB0EUV%9-6_^L?04&CGR#C#:IS# M^4,'H&ZCP=HYA)-X$4Q#2.Y1I)EQA-4X1I/H*0[C^?\X`FT;$58;\6$D$-`Z MP&H='J7HZPUMZW/`$F]6G-T\./2P=:+!Z@J%"9!UA=';:4OULTI!B13)5K&L MT0)Y4`P!Q^ME$RVG*_\%CD1F;'9CF]"UV'<6JOZ*]C`$CD,@[0$^*+*RH-:? M($NQ*%E=0KL.Z.D<:.@L.I?#$#@.@;0'.!K@^'V"!L4"UZ5?FC!RD]YIFQ`2 ML?6+79.]-;'"1LAQA*1]Q-$&-^03M"D6.+@0Q>8=+6=NYCMC]$B<-;'B1LAQ MA*1]Q!$'M[@O[GZ3ZZZ.,FXU=+%W!H'E756X=%7MK5'G=A@AQQ&2]A$G9;CZ M'T]9&;LI&T2W;G5U]R/D,$*.(R3M(TY^T%H^GI\R=O,S"(P3[UL:!8,M-49+ M>]T/=]S"V<#MJ(V@P:NV%P;ZXU*G?6I'EQIP1NUWLH`ZR8)FSSL&^4*/NW.$ MIA!/-U_%X&34RAZG%>HW+:(S"KHSWU/:I';4P.SVLXP_6_*R. M[<$Q;U'%X@INB==HIDJB(^H92[_#*$O9$_*4G@9NZKYZ0G2MZB=[;:1\A_@ M.S7SW<.C!%Y)=^RG"?3S,;Z=)5L].PX#S!+HD6.'79Q`([J#SQ-H`(#[E@AF MP`9?R!^87V@MO)*<06/0W@^NITC](,W^GIB$*;#=Z@*F?0*=*)C`93HS)KL' M%<#^_[#Y#P``__\#`%!+`P04``8`"````"$`#5S:Z+$$``"N$```&0```'AL M+W=O]`>!\0`2]$G8C( M)=E--IN9W6?$4DD#90#;[F^_IR@**8[#N)M]Z6I_GO.GSJ4NN/KZD6?*.RFK ME!9KU=`FJD**A![3XKQ6OW_SORQ4I:KCXAAGM"!K]9-4ZM?-K[^L[K1\JRZ$ MU`HH%-5:O=3UU='U*KF0/*XT>B4%?'.B91[7\+$\Z]6U)/&Q<(:YE]=TFLEU/+D%;D\+M]NUR$S:\@ M<4BSM/YL1%4E3YSH7-`R/F00]X=AQ8G0;CX@^3Q-2EK14ZV!G,XGBF->ZDL= ME#:K8PH1L+0K)3FMU:WA1,94U3>K)D%_I>1>]?Y7J@N]!V5Z_"TM"&0;ZL0J M<*#TC9E&1X;`64?>?E.!/TKE2$[Q+:O_I/>0I.=+#>6V(2(6F'/\]$B50$9! M1IO:3"FA&4P`_BIYREH#,A)_-.,]/=:7M6K.-'L^,0TP5PZDJOV42:I*`1VJF@["%A7#QAF`_!/X0!$,0#D'4 M`U+8L!R'89NP(SW?2T2]F1/L&E*]+3DLE]O`/OB(W)9-=IU)%SHB>T1\1`)$ M0D2B/I$2`+O*,`%L,_V7*X"IP!J"I_26P"!>MS4:2TEGTJ4$D3TB/B(!(B$B M49](*8'P^RD9[P5FW$0N9NRVQ&@V@D$.=MV7_40]]@II'K`-OSX/9BS/@Q.; MGUML0]DAXB&R1\1')$`D1"3J$RDJV"9?CXH9RU&U!/+8Z[398&5U1J(H'B)[ M1'Q$`D1"1*(^D0)E]\W>V3+>1LQ8#K0E_`;3E`\1#Y$](CXB`2(A(E&?2%'! M*=F/BI^8&CNOZTN:O+F47YV>1&O"@N#G)=.0@VW)K#LX=HAXG-BP;'N5G\B5 MWW=&HO(^$@HZF[Z0(0N%G9$0BOI"4DH,.##Z.7D2.USQ1/"-M1Q]B^SFTMRD M:(>1)Y#9)6F/D2_00RL0Z.$88A0)U#C*\;$[0Z^3_U/-#7[Q@"-")-1MT;1_ M(!CSN5R(G;!Z.'HMLJ5-P!JV@K":\8W8,JS90M;VL78@O$:U0V'%M4'87"QE M[4C2EO/)+B,C^?Q&K]`?/[N$L*O%8!6UR&(IYD_D+U'\RIN3\DQV),LJ):$W M]H($4]RL.LS?WMR%`XL?!`;<6SJPN#`/E@ZL%&PO=V]R M:W-H965T,FRLD4*Q^*^_5*6KZ-NM]B^9(=-TN\7K*=L\ M5DZ'?=?N];SN8;,[MKG"Z'2-1O[TM-MF0;Y].V3'DHN..9L#"WCIE3_?M[]9H;?OM[OBN"M!_ M=]E'T?A_JWC)/^+3[G&Q.V84;5HGM@(/>?Z#F::/#)%S%[RC:@7^=6H]9D^; MMWWY[_PCR7;/+R4MMTLS8A,;/?X*LF)+$269CNTRI6V^IP'0OZW#CJ4&163S ML_K\V#V6+_=MQ^NX@YYCD7GK(2O*:,)UPRJM-6)R<@/SA*JW]-_M:-K*3.4[D[EO4XK1 M9BVH#+V/K8%_UWVGTK$5-I,S-KK%5%JP.L%D`Q.$)HA,$)L@,4%J@ID)YB98 MF&!I@I4)U@W0I5C7`:<<^R<"SF18P&6H)A*H%;"-Z$H+Z1*8(#1!9(+8!(D) M4A/,3#`WP<($2Q.L3+!N`"VZM`LAN@[5DO//(YF]S(N>/%KV#O7H3;@-*Q%U MBKNZR;0VJ2,,)`02`8F!)$!2(#,@W(DPNA3_VJ2./Y`02`0D!I(`28',@,R!+(`L@:R`K)M$BS^% M6HO_Y2QGUE6897@FG-AU$9D*DUY5P3U]!0)QD0J;6J9&D==&1FW*#2-CUOK( M!.FKH0$)@(1`(B`QD`1("F0&9`YD`60)9`5DW21:".EA>D,(F;4>0D%HU=1R M^9:^IM/:2.9$`"0$$@&)@21`4B`S(',@"R!+("L@ZR;1HLH.GLU^Y_*68=9Z M5#GQ/)680`(@(9`(2`PD`9("F0&9`UD`60)9`5DWB19":NNU$/*6L:MAXYUBA?OR/9.<]('(DH M8556^(Y1Z:15,W)"J_I^I$K+4%A52_4^'GI]=Z#K1*@32Z1TDD]U4NE4C4>/ M"&MN;X@(,S=RB2-;2PF_K\]DRGI9P+"#.!.#(2R&@(I\)1 M2R#NZ*H9AL+*'5:5QQD,,'W$W=1:Q=))Z202_:U.JHU'3Q[6NS8#]4EY%JVN M&M"$'6MX\L@Y;C&H&,4"D6J*&42"24+-\; M]HPRGVI*>@A8H]D,P==R1;2KSO[CFT\X5--2@\7ZR#__W")/E3->F()I#)[*E$SD;B5 M1VV%>J;A0UU8\8RP>CV_;T-NB?LI\5C<[[)X(JV$N.7X[L`H_*DVJQ6>[Q&:CQ+M0*H%RVTU8_68[D?:5"HT+#[?:2CH&RE&B$%&$*$:4 M($H1S1#-$2T0+1&M$*TUI$>?-:K-Z']2[T1?VXPR1YYZ?D^M9O8C1#&B!%$J$&U(EHA6B-8"\4%H M@:=ZK0?^2U6V4M%;.HG4O*>(`H'T`]+0**"ALI*AB!#%B!)$J4#-]5!6C?4P M!S%75G(0"T1+1"M$:X'.K8=YNOC:>N"APQ:HN1Z``F'EL9/?^YB>_4:9"I6! MC$*$RK&R$C)&KYDH`RF3HLQ,69T?S5P92)D%RBR5U?G1K)2!E%EK,OJ.84>. MZTL5:S.,9E4@3U6OJ4"NJEZ!1,HJ1!1)I!QCB91C@BB52#G.)%*.4'1QO"*DX9ZJJ/[$% MTA/7Z%VFRDIV"P&B$%&$*$:4($H1S1#-$2T0+1&M$*TUI$?9/"=_DKAX'J;7 M^U@N5X%3%QGEFX M,J`KU7LFYA5R.>M!#F?M_1']ID1K;.I8=(&.LF>NV'VZ=S4QT\=VZ4JU+XTK MU'*/6%>-:M1%CUBCC%>H,1ZQWA>O4*\[8NTL7J$7*[]7G9=Q_PF]<'G.?F+3 M@,_H3)P1O5]Q1K]/^F>#0C$Y%Y)@.*)?OE`H'H[HARSD@447Z""+5^A`/6*G M7KQ"YTL*8?7EIC'M&5UA)S/RZ=:7Z$7/U\USMMRM4/A2?^ MJBC_HQ1?!3WD);WB67TK]$*O]&;45_38(_0ISTOY![M!_9+P^'\```#__P,` M4$L#!!0`!@`(````(0!I67""(04``*(2```9````>&PO=V]R:W-H965T&ZR4FUT9$QTS5<9>20 M5Z>-_OU;^&6E:TV;5H>T(!7>Z!^XT;]N?_]M?27U2W/&N-5`H6HV^KEM+YYI M-MD9EVECD`NNX)';E!9F-9LMC#+-*]TIN#5CVB0XS'/ M<$"RUQ)7+1.I<9&V,/_FG%\:KE9FC\B5:?WR>OF2D?("$L]YD;K\\$=>88@VY(EFX)F0%VJ:'"B"P:8R M.NPR\%>M'?`Q?2W:O\DUQOGIW$*Z'?"(.N8=/@+<9!!1D#$LARIEI(`)P%^M MS.G2@(BD[]WUFA_:\T:?+PQG.9LC,->><=.&.974M>RU:4GY#S-"O103L7H1 MN'(1<.3!P?-^,%S[P0@9MN4L5Y^9@MVKP)5/P;!6#G(6U(\[ MW+@S8-D/@&L_P#:0/?NOYT#!=<^!*W_.S%BBF3M?WIR@R1+5Y3U(VW2[KLE5 M@V*"5#27E)8F\EQ=XPEG,QZ6P,]6`*2>BCQ1E8T./D!R&UBV;UODVFOS#99: MUMOX-VQ$BQVWH.N*R@8RV,L@E$$D@U@&R028$(0A$I"G_R$25(5&@OO@.ZP*"23W6`RN*Z0O4)"A40*B1623(D0`*AQ.0!TR_MD!5`5J"%XRN`MR$93(:0*&2OD%`AD4)BA213(H0$W)^&Y/Y:H,:=YWS&?D]0MQ$LQ1CL MAA^G@1KW"F$>B\_,@QJ+\V#$8:<+W5!V"@D4LE=(J)!((;%"DBD1O()M\O'H M4F/1JYY`'"?`)I@3/FAK=S*`AV M7E(-T=F>+(:#8Z>0@!$'RG;,_'(FUM=^,.*9#Q6A:+"9"B%1*!Z,N%`R%1)" M@N#`F,;DAN_0-W'G.VO1^QXYUNB^B@*.YH/57D4A1Z-6Q-$X,%91PE$W4/2/ M]@P/KV3$.@PX"WCD_!Y9TYT?N2LQXCMN-0X,.!(&VG+.>RM[UNVXSLI=69)V MR(5&[8BCN]HQMQ)6W6(N3CWA5IV\&#N0G\;NE^J%=A%2P7`$=3I6@^N*\]IQ M*W?(1=`C>SP6]AQ97?PL:^Y(/5JHZD1\T*@3<\1TG*4M-3R)(".&B?8GDR7V M:V'JFYPQR3[M2"!RL/+X8MQQ-%H%/;*%)*O+C&G9M)3?M@MDH96T$D-5.WI( M.^963/M6Z'I';JPPVL?<"=TW#G5?E\.;_U.50TO'I M%X$;]K[E0$_T_J45XU6X",$"UY7X&PO=V]R:W-H965TU_N?/^-M"U[H^/^_R4W,NU_I'V>G?-[_^ MLKHV[4MW+,M>`X9SM]:/?7_Q#:,KCF6==[/F4I[A+_NFK?,>?K8'H[NT9;X; MDNJ389FF9]1Y==8)@]\^PM'L]U51ADWQ6I?GGI"TY2GO8?S=L;ITC*TN'J&K M\_;E]?*M:.H+4#Q7IZK_&$AUK2[\['!NVOSY!'6_(R>VX?VO=L;DF M;;7[49U+4!OF"<_`<].\X-!LAR%(-I3L>)B!WUMM5^[SUU/_1W--R^IP[&&Z M7:@(%^;O/L*R*T!1H)E9+F8JFA,,`/ZOU16V!BB2OP_/:[7KCVO=]F;NW+01 MA&O/9=?'%:;4M>*UZYOZ;Q*$*!4AL2@)/!D)FB'']#[!85,.>%(.Y'V6PZ$< M\*0HLA?ZAJ;>#+6T0K_Y@2P`"9YPBQK M'48/D]R!?=\VL(!7QAM8KJ`Q@1J#Q(@MB\#^PK2A#$0R$,M`(@.I#&0<8(`( MHQ)@NR]0`K-@)5@-`0,X::2R601+"64@DH%8!A(92&4@XP"A;%@I7U`V9H%% M+QA`FMZ`Q"`8R.@25Y)B#!FU4)!(06(%210D59",1P1%8-U_@2*8!185O&6L MUC(ML=Z`!MV39`P9)5&02$%B!4D4)%60C$<$26!'XR6Y?2RPS0`'#Y6S$0<4 M,8>=82%JL*5_A&7)"35M'L(XO,^,`P>+XZ"(,Z[.K8*$"A(I2*P@B8*D"I+Q MB%`5[)N/JXN#Q:HH`CIR`MJ2RF,0FY1002(%B14D49!403(>$0K%[2)WV-RW M$0X6"Z4(:4#P`;%5D%!!(@6)%211D%1!,AX1JH)CDZ^*'*$SW"OTQZIX"1J8 M%G#WC6IM6!#D`,4<8K$4\2:O*DA($`N,-")!$@0=**_)C=JAJ6/%#]%B]11RK:E\%0H99(]1D0K%#)JX$@9- MB:D*90P:$L7Z&`^Q/"X6C)&!2"U3AZ MWC+E/@(W&3AQ^&2BO>28R"8AHE&#$Z%C1?9\+A'%*E'"H,4XFZE(A!P;!!=G M)&-9PXA$27`C\KB7:-LR35N`>PPH5O*2)PY@RZ*FQ)!!T\*(*$2-XYGPG\@3 MLZ2))V'0Q).*/+:Y1-)NDK&D&Q[!;F0N%K)E4;Q'QL3) M(P2B'G&6CN=*E<0J4<(@WB,"D6=[SE(:4<:R;G@$-TF/2T);*EX2`DD>D5LQ M_,F/G30EA@R:YC:B$/4(EP5 MVG]-Q06(0J)1EK)1:!1OE#%Q,@J!J%$6MFU+/#%[V\23,(CW">&QX6R])PH_ M)G$[P=T7)\I_:D<0;>%XK0@D.@A)N\.6)@H.(HGN5&-$H]PEN2J8>]Y"LF*L M$B4L:R)*&42(T-)U',F*F4`D*H4[NO^M%":1CB@*3>/<(@I-4Q]2R(-.:9IG M]2`GB1XB2IF6Y7C2:1NKY,E#Y"F+(N2P\LR%*9DV$\A%^7#W=T>^G\T%=+G9 M]_*]'^TA>:<1:/A*(V\D]Y;DWJHNVT.Y+4^G3BN:5WPG"=W&9C7"Y,(T6/C0 ML,/BE/!PZ4-#K.+)TH?^5L7AXO5IV/HDG@!?R-Z(#RP?;EI4GL#VX<)!Q9\< M_XET*?(+'!\^Q]6$P//A0_(&/O?ANPMP8R2""]I+?BA_R]M#=>ZT4[D'LLOG^45?:&VJ[$C=;W5J8NH::`A_+ MYKS5__X9?UOI6M?GS3&O<(.V^B?J].^[WW_;O./VI;L@U&N@T'1;_=+WU\`P MNN*"ZKQ;X"MJX)L3;NN\AX_MV>BN+.J]7%(W)UWKZ\7K\5N+Z"Q'-9E?WG(*IK=1%D MYP:W^7,%?G]8;EYP[>&#(E^718L[?.H7(&?0A:H^KXVU`4J[S;$$#TC8M1:= MMOJ3%626JQN[S1"@?TKTWLW^U[H+?D_:\OBC;!!$&_)$,O",\0LQS8X$P6!# M&1T/&?BSU8[HE+]6_5_X/47E^=)#NCWPB#@6'#\CU!4049!9V!Y1*G`%"X"_ M6EV2K0$1R3^VN@T3E\?^LM4=?^$M3<<"<^T9=7U<$DE=*UZ['M?_4B.+25$1 MAXG`DXE8WL*UO>7J*RHN4X$G4W$7EFOZ9"%W)H=O!P_@R2>W'AFW9./@R<;9 MBY7GN?YJ>7]"*)UA0GCR"2%ZZ@H-&NHAY[M-B]\U*`<(9G?-27%9P5K7 M>,JHPIC$7^40DD=$GHC*5H?50WHZV'AO.\OW-\8;;):"V80W;$2+/;<@.X/( M1C(XR""602*#5`;9#!@0A#$2$+?_(1)$A42"^Q!R,(7&EMSF%GQ()(.##&(9 M)#)(99#-@.`VU(GLM@.5?[MF>;[)(*A.(=]+T:V0VE@P[[@I/-%D/YJ,KBOD MH)!8(8E"4H5DDOM[@1@/GO,5AXR8PT'@BC'8LR^A"F>!FLX*81W^ M5]9!C,5U,#+<>,.!LE=(I)"#0F*%)`I)%9+-B>`5')./1Y<8BUXQ`G&(9%"#@J) M%9(H)%5(-B>"5W!+SKVB-^:"W-/]I2Q>0@QI@=U]PUL'"H+>ET1#=)81?[PX M]@J)*/&@;*?,+TTQ\X?1B&<^5H22T68N9(E"Z6C$A;*YD!`2"RZ,>4QN^`Z- M$W=^L!:]9\BS)_=5%''DC%8'%<4<35H)1]/`5$491\-`T3_2,\QV,LFY[9,F M]E::YZ[29@.N!1[$T*+(GE\"UE+N";C5-##B2!CHRNGG5L(F\1TQMS&WFN03 MCN[*I\S*I6>[Y5JV8TIKS[C2("[&$<3E.$)W_K7:(1V%5#P<0%(^WG/ MC=9C+B*&7/H&08Z8`T?V<'GYCB/U++$JD_`QDTS*$97Q3$M:32;(B$$BG8JT MV;X>)-;N3`D.26\"<8.-Q_?BGJ/)*F+(%?:/NLNHEDN*^FUW*TILLDDY>4@Y MY594&3;8TK&DW9L)RQ9C1UJ:.['[B:^_.ISG54M4I`.*HJ&5H#/2MV#Z+E6C M]HSVJ*HZK<"OY`T7:F"W&3%]_0Y7`=PJ$'R)1^L`3FV5)^L`#F&5PVO\TY!$ M22P`V@9U0'A'X`W#LK]IGK:[E_NA__YR_]C,1P<3^O]T_JMVI?W MPQ_EE^.1L?-:[E;'V^J]W)/+<_5 M8;<^T9^'E]'Q_5"NGVJGW=O('H]GH]UZNQ\V$9:'2V)4S\_;3>E6FZ^[^[LU66\X=OT'A-]M-X?J6#V?;BCV((CW@;=?]\"_#H.G\GG]]>WT[^HC++2/C5ZU)*SD0#X@/)``2`HF` MQ$`2("F0#$@.I.@237Z:QWZ'_"(,34ATF59::S(W])=&Y_1O35K]@7A`?"`! MD!!(!"0&D@!)@61`DIW M]!YPV\9N-RU:(^W.:+]RQ9T):_W.&C)M-GQB;5@!<8%X0'P@`9`02`0D!I(` M28%D0'(@19=H$M+J>H6$PEJ74!+JM0B\A#YB`)$ M(:((48PH090BRA#EB`H-Z9**_?KE\X"H-(U49:3GJF7DJK)JDQ61A\A'%"`* M$46(8D0)HA11ABA'5&A(5UGLVZ]0N=GFTT:0Q7H4^VTA?#=Q`;EHY2'R$06( M0D01HAA1@BA%E"'*$14:TB45F_&NI+\\^XK]MIG3$NDY;1:6[*CZQ$7D(?(1 M!8A"1!&B&%&"*$64(NSDMD=)O)4Z$]#1W$7F( M?$0!HA!1A"A&E"!*$66(8A\1`&B$%&$*$:4($H198AR1(6&=)5%Y7&%RK)0Z:KZ6-TTM;`%R$7F( M?$0!HA!1A"A&E"!*$66(0 MAU8^H@!1B"A"%"-*$*6(,D0YHD)#FLKV=:5<;:XO=8PZNP=$+B(/D8\H0!0B MBA#%B!)$*:(,48ZHT)`NJ5G*-=]IW8AO5D^OV\V7QXH.*,BH9Z/FT$%G\XV6 MC14>HUF[`JX0N1+9M,2I<[:I<7KM*2O.>A]C!TLKLJ-XX3A3QIU4$^.@823>N?G\AL;V)U M4(2.,89/$*7HF*%5CJC0''65S7+PUV8?K!)MB6A3TA$?4EQ:*:5=Z>B0;LIQ M8@Q6CZTF]>BQYG-[;ILCVN=[4-$#]CL;/62K<]$CC!ZSW]GH"5MI=,K91CSD@Y%IJC M+K4H+"_?M(I%VI2T00ZO(C/'6")7TDE3N''J](/'5I.V'WQ&JFL"1JH#0T;* M,6*D'&-&RC%AI!Q31LHQ8Z0<([ON M__GT=CYWC"V%CY$"=E.10D9G(D48*68W%2EAI*WFN`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``/__`P!02P,$%``&``@````A`$:B MC#M?!P``'R$``!@```!X;"]W;W)K4)5O2[TW306_& MDT\D+9*B3,N]^_K]=.Q]2XLRR\_W?6?G^_[??P5?%OU>627G M77+,S^E]_T=:]K\^_/K+W5M>O)2'-*UZ9.%DG*07](S MC>SSXI14]+-X'I:7(DUV0NET'+JCT6QX2K)SO[:P*FZQD>_WV3;U\NWK*3U7 MM9$B/285S;\\9)=263MM;S%W2HJ7U\N7;7ZZD(FG[)A5/X31?N^T7<7/Y[Q( MGH[D]W=GDFR5;?$#S)^R;9&7^;X:D+EA/5'T>3E<#LG2P]TN(P\X[+TBW=_W M'YU5[,[[PX<[$:!_LO2MU/[?*P_Y6UADN]^RE.'`74VK-.+,!G-G MM!S/K]]])A7IVBI.W.E$:)V9=YSJ4E7->_;'*9Z%7.E:WO+6^:ZE(IT;16O MS758KQ"QX+RD2A[NBORM1U5,:Z"$+PG."NRIE9:[6VS]OYOZ=&:8R./;.6^ M3_[3JBJI7KX].&/G;OB-UOA6RJP[9$R)C9+@!5A%+Q;.#;(+!!:(/(!K$&#+>I2C_!;;9" MNXR^`-R9Z>>ZEG%H(LTJF9HBFT:DB040'T@`)`02`8EU8D2$MI]/B`A;H:*B MNS3>.F,K]6LI="TDC4@3$B`^D`!(""0"$NO$"`GMG'I(NI]#:C-@8>&YFO&Z M)FY3%!LI,A);A1443PY2G6J1:W<38V*T6=\^,18V)R;)I)T9$`^(#R0`$@*) M@,0Z,;RBC53WBC?E*87C@YLR6S'=E80"K$5V;-5@(Z32YP'Q@01`0B`1D%@G M1@2XD]4>2]<7'`N;CDI2]T;\*-D`\8#X0`(@(9`(2*P3PRMZP.I><5['"V[A M/II:-F1Z+(F9VHF5VD:H22T0'T@`)`02`8EU8@3!H798C\+UW`IITU6%M.PB M\A#YB`)$(:((46P@TS]N,+2URUEVIX./)]FI.Q5ZA*ATK26B=P^]@NVG:"NE M%#U$/J(`48@H0A0;R(P&]QU:--[)=MVE&"Y+I&<;D,==!5=$*^4C"A"%B")$ ML8%,_[B-T/SC;,_&@_9=X_8>6C8D>KIK9*7;ZJLVW&.0[R35IAN0CU(!HA!1 MA"@VD!D.;B&T<+R3;MEPZ"Y+U"9RXP#R$/F(`D0AH@A1;"#3/RICW;^?+VXV M9.UK-;*R/;?V<#X'L+,-R$>I`%&(*$(4&\B,!G?+\9A:6_EN+)L4^W4:_5"W,]^*V4JOX`;86ME&YK:=J*6BEE*S9LF<'A-D<+SCNE M+ILB/0H2T:7Q;VY-:>-(H643*D\BE_J(1L^9C$Q??"7EB'>,+\Y\,G+'8ZN: M`C0?*L6KYB,E==5\;)@WH\?]T>W1D]V4'KT:N?3@:Z*PL(*P<:10J^O1JA`] M*)MB<2;6P<.FE5+;GX?(1Q0@"A%%B&(#F2YS!W>[RW6_1WV9FOG:E4A/*2`/ MI7Q$`:(0480H-I#IG]4HBD?KB#+WP4,.%UM(B(A]1@"A$ M%"&*#60&@QNXVY-=MWM&LB72DPW(XX,&+HQ6RD<4(`H118AB`YG^<0.G^Z$[,)N6D.]L*T'RD8IMHY[B'Q$`:(0480H-I`9"ZNG?&>OQN:1US5% M09Q9UI;K[XCU9YU36CRGF_1X+'O;_)6_$5):'NX:7'_`7+L3^H(I3,#(E$9$ MH&!D1B.B9;5''+)&[TQ42#!"UNKU!B-DC3KO#AV7OZZ*;Y&VCNO2B#A&AI$Q MC8C=SQY9K.@\KN,NRQ4=475P9T3S$I]G;4L.S8L..KIT:%YT1-`U0O.J"]6R M1MW]BGMWU*%>?<6=.([09^?'[KO033KDUQRN+DZ3ZHK5XX3L=]UX3?GM3"_E ML#.%\Q4=[9(#P\9K^CQ]29[3WY/B.3N7O6.ZIZ4Y$J]21?V!N_Y1Y1?Q2O64 M5_1A6OSW0'^(D-(9[HC/T/9Y7JD??(/F3QL>_@,``/__`P!02P,$%``&``@` M```A`%$-K^++GHB(* M7L4AE(V@I-!)51DF430-*\)JWS"DXB,62,M M6Y5_A*XBXNG4W.6\:H#BD95,O6I2WZOR]/NAYH(\EC#OEWA,!4`7&J&7:XD3=J\^!I1P_&R60V MCW'P&XGC-A&>-G$:3&;1Z)W$T$Q;NY@11=9+P<\>E";,2S8$"SU.@'7M[\M5PS6 M^BSOUB#ZG-*EMVM#(E/,KO2L_0CE>;7>'6'3SPC#8%=8BXR[*MU=(%D?<<:& M#=DW16_N"`S_Y.Y&&E=5BX`//0/FKDN[+LBZG/411RC>QKU3Z/;J8;`KIT7, M^8XGQ^X"R?J(,_;"'1M-2B*HLT^:A#2NJA9Q35H,3.J".I/ZB",TALOQXR[I M:%>0A7H^74*9`[D"\#SN+9.NIV06P`P_:59L3G8X(>RTMQ9R[!I%`[O>HFQB MYD"N7CR=>WIOEQ4>H8,5;"&]^0RSZ4/,#5I1<:`[6I;2R_D)>PR(7R\[V#1` MVSB"#D@W,1=?L#?2C<3@"S1-&WT6#?`M)J!E0SQ)X2:Z@H_23%L\B-^,TPUH MO9(P3C,]VT'"=IK"*7,E?I;"IKZ"SU/8<%?P19HM$`^[`:`9:\B!_B#BP&KI ME70/1D;!#.I`F';.O"C>@,'0D7$%79C^>X2VF\)NC[`"]YPK^X(#=(W\^C<` M``#__P,`4$L#!!0`!@`(````(0`7;GZX:@8```4;```8````>&PO=V]R:W-H M965T&ULG%G;;J-($'U?:?\!\>ZX;]RB.*.!T>R.M"NM5GMY M)AC;:(RQ@$QF_GZKJ3;0A4W,YB&)S:$X?:JZ3C?]].%[>72^Y7535*>-RQ^8 MZ^2GK-H6I_W&_?NOSZO0=9HV/6W38W7*-^Z/O'$_//_\T]-;57]M#GG>.A#A MU&S<0]N>']?K)COD9=H\5.?\!%=V55VF+7RL]^OF7.?IMKNI/*X%8_ZZ3(N3 MBQ$>ZWMB5+M=D>6?JNRUS$\M!JGS8]H"_^90G)M+M#*[)UR9UE]?SZNL*L\0 MXJ4X%NV/+JCKE-GCE_VIJM.7(XS[.U=I=HG=?9B$+XNLKIIJUSY`N#42G8XY M6D=KB/3\M"U@!%IVI\YW&_W/VYR\`?M;/-=^GKL?VS>OLU+_:'%M+MP8CT MP!ZW/S[E30:*0I@'X>E(674$`O#;*0M=&J!(^KW[^U9LV\/&E?Z#%S#)`>Z\ MY$W[N=`A72=[;=JJ_!=!W(3"(,($D<#>7!?W!EDCH6Y\G](V?7ZJJS<'B@8> MV9Q378+\$0)?!H8T^J'>&BD,40?YJ*-LW,!U8!`-I.?;,V?L:?T-),T,)KZ" ML1')!:$S`?1ZCC#P,IPJ9V,"Q82401_'H@=U/J:G"TW"/)Q/IKZ)2D@XQ(@!)OU0J(1S"(NC;W.< MYZ;!1$)*#2$^3@BE?$8T3FQ`***A/BQB,+.6BZ=OL@ER)OOD8/TA!AE&D1_2 M`DW&`"D$\X=5@FU0PE#2JAI#KG/`:<@I4(#D+^Q%9I#A4_UBR>58=VJ;%&2GTV(",(+XG M)*G(Q$(`/>]&P7'=BQ?GL[N+SM>AE:)X!C0W868HR&B@5"TK+C%B2*6#32V::GN_?]]+#76_1(`F..&*2WXF&D@@D]&R(5 M'Q6P34_W[_OI8;>WZ)%GQQPQ.#56/]$.$;3KV`DE M1O'.=)@ZA)HD=&P`*UC5!=PG4R;A%D;`&F"H6IL><8EWZ$WM09%'QWQL`8JQ M4`T68$INC!`LY&(H#)O<(I?@4YM0DTXW]H*5I[Q)2L<`(;D:`!8UL<@J.K1= M;HHZA<&8R:"[',U\0B#"D_*&]PMB%O-I[=`V/8>8>@?GDPX]]H8H%('@@RY&.X10]A8SO0F[O_%U:-*;Z6-C`[I, MC1`VMD/?0&8&,L]LD6M(C:;,2#'%!D0?:SAAA'Z^,OUS?<;*16[1H2DUZA8& MA$^/8.?%)2G&Q(((7PE8'`]586=UD5W(*W;!2&M+ M(8E5S*\%.C213@Q)P4EJ0)?$*18Q0:>"A>%!%$GEWUB$2F(6][6[[B[*E"Q( M8@-"ID)Z8>31V9-8F,A7(2Q:;U0A\8T[B6+?'V^%N!BD,)(BR!!E/&0J(K(G MTL($ON+CK:9=CO_+022V?BC._LT=%Z3J8@.:<[I9B,USD8/`@<*DY8PV#T9) M!.%K4@D.,UGDFS"(""(9TG3CJ0.^E2_S>I\G^?'8.%GUJD\4!+SYZK_M3SL^ M"OV"FWP?PRE(=V2P[B_`(<0YW>>_I_6^.#7.,=]!2/80P!RH\1@#/[35N3L+ M>*E:.'[H_CW`<5,.+]#9`X!W5=5>/NC7\_T!UO-_````__\#`%!+`P04``8` M"````"$`-]^7$`\$``"3#P``&````'AL+W=OMG3Q]:T\:J^D9@6MECJ:F;I&JHSF1;5?ZK]_Q4^^KK$F MK?+T2"NRU-\)T[^N_OJR.-/ZF1T(:310J-A2/S3-:6X8+#N0,F4S>B(51':T M+M,&'NN]P4XU2?,VJ3P:EFFZ1ID6E2X4YO4]&G2W*S(2T>RE)%4C1&IR3!OH M/SL4)W91*[-[Y,JT?GXY/66T/('$MC@6S7LKJFME-O^^KVB=;H\P[C=DI]E% MNWVXD2^+K*:,[IH9R!FBH[=C#HS``*75(B]@!-QVK2:[I?X-S1-DZL9JT1KT M7T'.K/==8P=Z3NHB_Z>H"+@-\\1G8$OI,T>_Y_PG2#9NLN-V!G[46DYVZV/1=Y M7_`D*=E!"Q.A%H.Q&$'A;!G0BTG8AE MSY!MN@]TQ.XTH+UT)+A[%##>U@IHNV0,.G=:X';)T%Z2'_?1ZT2@O5@PV7U# M3&A;'U':I*M%3<\:+#J8,G9*^1)&C&P&$%]&X@$DD)'D%@G,*V*`5U?#H'K[ MAHT;Q>&E#I]7HP)TE6V]#`7BMRY:V'9MVU>&N)80U\2J2_TX,GV,`BS_R48B M'"=PL!\H,Q;WF2>$,+9A*$*YP$FV""0Y&8Y)CL"N^K@C/$EQ1"GN4"#"$=L* MU"6TGHA'(@X#^*SZ-I-$/$DD8X1D$YP??9O&-R$.*_8H2R<4B+`G"%S?5':I MM0!$P2@U$8W$-E/"\4AR,AR3C(`CZWXC.*P8H6P0H4"$$=@R/4?9AM8" B M)+:9$HY'DI/AF&0$?U/OG>/C%<%AQ0CES`D%(HQX0K9C^PY2O1#,L!,:FG%*6688<>,;)7K#A$3 MR:WR'?S1O_:@B:9E-M-(/(WP:Q>?_>'^"J_$M4J\-I_2/?DWK?=%Q;0CV<%Q M8,X\V+=K<:D2#PT]M:_'6]K`9:C]>H#++X%W9W,&\([2YO+`KVW7Z_3J#P`` M`/__`P!02P,$%``&``@````A`,3APZ&H#```7SL``!D```!X;"]W;W)K&ULK)M;<^)*#H#?MVK_`\7[`+:Y5Y)3P7?NN,[N/C/$ M2:@)<0J8V[]?M=VRW!+CA.R>AT/FLRYN22UW-_CFKU^'E\:/]'C:9Z^W3:O5 M:3;2UUWVL']]NFW^Z^_@R[#9.)VWKP_;E^PUO6W^3D_-O^[^^8^;G]GQV^DY M3<\-L/!ZNFT^G\]OXW;[M'M.#]M3*WM+7^'*8W8\;,_PS^-3^_1V3+/V,@>'_>[U,MVWP_IZ[DPX_]/S_NV$U@Z[ MCY@[;(_?OK]]V66'-S#Q=?^R/__.C38;A]TX?GK-CMNO+S#N7U9WNT/;^3^$ M^<-^=\Q.V>.Y!>;:Q8W*,8_:HS98NKMYV,,(5-@;Q_3QMGEOC1/':;;O;O(` M_7N?_CQ5_FZ%0+DMM(,\`^MCXR%] MW'Y_.2?9SRC=/SV?(=T]&)$:V/CAMY>>=A!1,-.R>\K2+GN!&X#_-PY[51H0 MD>VOVZ8-CO'_Q1"EC95&.EJ M(_"IC=BM8:_7[0\'8*1&$:[FWN%3*UIVRQ[VK%Y?N:_1[&M-^"Q=7GO;`VT# M/K4-YV/.8?+DMPV?6G'0&EB=D?/.<$=:#SZUWO6QMJ!$F][WM[='+.?#>BD,`]/;UO5EZVQ,HS3O9@I90/XT_R' MB:^LW"LSMTT8'TSM$S2M'W?VJ'?3_@&-9J=E)E+&,B5([9@!GQ0RJIF6$XE-([<4*9,BB"](($@H2"1(+,A4D)D@ M"&[*A-BC/LN:%JK+6BE2 M9DT07Y!`D%"02)!8D*D@,T'F@BP$60JR$F0MR$:0I$J,K$&"C*S5SR@EG2<' M@SK1!#XH739+EUL*H9HGB"](($@H2"1(+,A4D)D@IR[@GB"^(($@H2"1(+$@DP%F0DR%V0AR%*0E2!K M03:")%5B!!Z644;@BS592^T%SL_[W;=)!L4-BX4+D\.!M5>Q(E-&S'QHTB\7 M`*XFM"3P"C*`6ZO,GX'9[OQ2".=/($R'!;%-0T/34%0*H:&X:LB("2Q-C9A< M&#ML\'#P2MH$$^3?'.=!]$7)!!:H9")!(FK6L:P8.-VQ;"4M#FL M@O2'^9*[:_6=D1EBMQ"P:=R>)I51%J3;*=;MO<'0[MFFF4`HA:5AJA2KVS'5 M(BW4+2RW1JP`XJI9(RYJ+WI%8')Q,S*((/254N;A(2DL00_1J"P57Z.\P'[< M=4$2'7X'W=0.JPKQX89,U!JD?R_!THOM:D*)FI9#+$KV\_( M8GW#U1+5_J/1(#^&+-JL1EW5P&%L'6LTY#,C0$OD/D0U6$V64USV()3JZ\!U M6")CP[(9.+5.K0O']*M M3]0Y)`0TCX'I4JV;I,NK=[OJA++(&,7&'K%.,T$I:&UE!%EX7)*A%&KC5+J^ ME`HD"B6*)(HEFDHTDV@NT4*BI40KB=82;21*#&0F4JT4JXE\YRE?+"RA@V&4 M)^H05Z6P6MZVPYXY+DFAHB>1+U$@42A1)%$LT52BF41SB182+25:2;26:"-1 M8B`S/6K!>D5ZBO6MD1Z-*KMB2R!/(E^B0*)0HDBB6**I1#.)YA(M)%I*M))H M+=%&HL1`1B[LZ[8(N;BY1="H3PW)12G:)'LH!8_4LMM90[:3\4D*)U0@42A1 M)%$LT50C>`"@^9E$ZE&@ET5JBC42)1I<2J38UU3;XN43J#53EX:76A>KA1:%P)?(T&@SR%;W= ML=B>T2YY)M&<%+5E=L\+$D#+ M2XTJ][R2:$V*E^]Y0P)H.='H4FKY7K%^`6++3:%&1E?54I163TMUZ>S1ERA` M\Z082A1)Q5BBJ52<2327B@N)EE)Q)=%:*FXD2@Q%LU^J75QUFKV3"[VGK,XG MC;[FRG M9P_9LVU*AM#=#!&YFR.J=;V^^HG6I>^)J@<3BB)8LN'0YAHI)I$N>*!:)L;8!>E MJ-P\1%7%"U53>(3!Y`VK!2.M_L<.`P(RBC<8(B+7$:):US%*H6N+G05-48"6 MA#-$Y&R.J-;9`J7069^M&98DF6T-\*$?E;(ZKU MMS'].8[5=;IL$B1D"?R9I<+/F=XIE?(X"6]\8A<(>@LB%Q'5O(>(I'Q$=``8 M("*I$!'9BA"15(R(;$T1D=0,$=F:(R*I!2*RM41$4BM$9&N-B*0VB,A6@BB7 M,G,!B39:_CNY4.)L_ZM1M6)LAYWVN;:6HE+S$-%1M:^1_F;+XE\$!*12?::P MCABB%/F*$)&OF/MB=SPEE1I?,Y0B7W-$Y&O!?75;;(6S)*4:;RN4(F]K1.1M MP[T-6^S@+B&ER][,$KGNN,J6QU4:L:4`6Y>X*$75[2&BZO81%8\HJ\6L!'B] M^J"S'5$BQ4W"JAD;2$2*B&)$Z(M]+S#%Z[6^9BA%ON:(:%P+1/K1:RZ3EGBU MUM,*I)JA%'F:(R)/BUI/2U*H M\;1"*?*T1D2>-K6>$E*X[,DL"WY(5_]8<>1IG$9FS^"+#!>EJ.(]1%3Q/J*B MXMDL#O`J*82(R&R$B*1B1!?-3O$J*<,TL5^)LEFMDSG(V--?14E2G'J*JHES<:RF8^%2< M\#LFLXL&9`M;?(B(/$:(:CW&'_(X)5OH<8:(/,X1U7I<:"F]I7"&PQ$+WY+L MH+<5(O*V1E3K;:.EZB.:D"WP:)9,]0@0TOI.`Y`G@/!ZFBJB?!5;6"[>-BM> M/#FDQZ?435]>3HU=]EV]20;[C;N;$N-K;H/Q??&>&[L"7S^/U3>H<-OBRA"N MY&U17!G!E3R2[`J\3G>?SQK&)_":7?ZS"\[M<7)1WH'7\B[&PO=V]R:W-H965TF%5G?-R8WL3U[98F?%#7IXV]E_?DR\+VZJ;M#RD%UZRC?W.:OOK]N>?UJ^\ M>JK/C#461"CKC7UNFNO*<>KLS(JTGO`K*V'DR*LB;>!G=7+J:\72@W`J+H[O MNJ%3I'EIRPBKZIX8_'C,,Q;Q[+E@92.#5.R2-L"_/N?7NHU69/>$*]+JZ?GZ M)>/%%4(\YI>\>1=!;:O(5M].):_2QPOH?O-F:=;&%C^,\$6>5;SFQV8"X1Q) MU-2\=)8.1-JN#SDHP+1;%3MN[`=OE?BN[6S7(D%_Y^RUUOYOU6?^^DN5'W[+ M2P;9ACIA!1XY?T+3;P>$P-DQO!-1@3\JZ\".Z?.E^9.__LKRT[F!<@>@"(6M M#N\1JS/(*(29^`%&RO@%",!?J\AQ:D!&TC?Q?,T/S7EC^^'$7P1>$(*]]^^ MX393;O#\V/N`C9`+3^4(<`H&WMN6U":&F;=R];WO+7S`C,E M4S8[TV9@L6\M<%I@V&@(Q$,@T0`'%'6RH/*?(`NCH*R6T*X%-)U4Y;ZU:%VB M(1`/@40#B`:8A)^@`:-L;/BKE<:GI'?2Q@,BG5%`3?:=22?,0&(#272$:(.5 M\@G:,`I,7'A+Q]OWII3Y3AG=$M>9=.(,)#:01$>(.%BYNKCQO:]=.F@L-+3O MWDG$[V;=7IEX8F$MJ;RH&]1ST*\L0@P6^/W$T)@2DTC8KX>]@40&$AM(HB.$ M'VP@.C_P.)#"0VD$1'"+\EY8?I]H,)I.B#NS_&H=050K,]W%(Z MHR[;!A(;2*(C1(T'AY7[TRVL*>D6TA)N0I$)Q2:4$(C2Q):ES0K,>@#8!W/N MRU^;O5T+T:R'@SG>6[6.D0G%)I00B$K"#J9)NCW1L^`'F:#U8L`JBS`<- M&@J"#]%W3=X=30UDMNZTH\D8O8"<5QHSGGVM.,(C'ZZ3.&-ZLM%=4==M81\_<3H^_V12CCN/675.T8* M"A9=(N(66@J)\[D;#/;CA,2A^K#5_6]]JE_V-'>>@D!`5]79\"C4&NE%E7XA M]-G.;Z2HRDJ>5J&HHZ(5!;.H<#EQ4_1W?OU14<4\DE454>AFH:`9UD:F65YB MR*_A@E4GMF>72VUE_!DO*&#>;=<=+&]/=EZXPO4&(8P1%T;$W8@Q`E=\PV<*(Z)DQL@,1H0(8R2`$;&A#$;@SN=A_"W@,,8+:(W:`ZDQ3@\S MB#\J';B.4H4LCB9QOH+#]$BB%BLXQ([@RQ43V7P`` M`/__`P!02P,$%``&``@````A`+B%O2Q+"0``\"D``!D```!X;"]W;W)K&ULK)K;#>@,Y`V)YHT)'CQL;,[C4& MV58T(`>2V]UO/UE2I4J5J2'PC&^:]J?,G])?IRRA^]]^GHZ]'^FER/+S0]\8 MC/J]]+S/#]GYY:'_Q^_AW;C?*\K=^;`[YN?TH?\K+?J_/?[[7_5[\9JF M90\4SL5#_[4LWZ;#8;%_34^[8I"_I6>X\IQ?3KL2_KR\#(NW2[H[5$FGX]`< MC=SA:9>=^[7"]'*+1O[\G.U3/]^_G])S68M9$_ MEP.0&]8-Y?<\&4Z&H/1X?\C@#H3MO4OZ_-#_9DRWIM,?/MY7!OTO2S^*UO][ MQ6O^$5VRPRH[I^`V])/H@:<\_RY"DX-`D#QDV6'5`_^Y]`[I\^[]6/XW_XC3 M[.6UA.YVX([$C4T/O_RTV(.C(#.HF['/C]``^+=WRL30`$=V/ZO/C^Q0OC[T M+7?@>"/+@/#>4UJ4828D^[W]>U'FI__7089H5"-B2A'X1)&1$KF2:,E$^,3$ MUK=?2;1E(GS*1/NF+X1[JFX7/F6>:0P\8S2Q/$!7OM"5B?")B>9-B9Y,A,]/ MM10F:-52^,0OO*VE$YD(GYAX6TL-&'SU6!"CL.[GVUPUFE$$_\$OM0:&/7+% M*+IBJX%#1_P',V]L+@X>0XV>&YN+H\=0P\>\K;DX?L04NZFYPWJ^5=/7WY6[ MQ_M+_M&#-1&<*MYV8H4UID(-)VYM5C.5_VHFP^P3*M^$S$,?!A=,T@*6GQ^/ MINW<#W_`DK&7,3,>8^@1RFFH5B:S:=`?3")S=G(:2[*PE(M2;86)]@\R8(AX?/2,!(R$C$ M2,Q(PLB"D24C*T;6C&P8V;:)9K@XC+9KH>NS1T3KKDI2';.J^F7.B,](P$C( M2,1(S$C"R(*1)2,K1M:,;!C9MHEF(53[FH5U.3D0IYKR-=M_G^4PX*`TZK#6 M@D6G+B:%B.ZL)*Y:#1CQ:V+"=&J-Z8D^IH,F",=TR$C$2,Q(4A.C:I!F@#B] M_','*A7=`D0M#SCR)7+;,]OP1L0%%=78()%5'?.K;HA4E'+4\,BF$*LHU$HD MZG)'5,6W3S%QH",C`5';!AFED"^C;%4?!QR%7"OB43%'B9:H=[\H3#]Q@W4= M"Y4.FC<3!:6X9YAB:AP[I`?GI$GU$[40X^M*NK^7A/%P=TDS3=$>FVL.K MG@]12JE'B*ZJQS(*U5UC,G(,4C@G*%6IZ^Z)PO(3[LDZM.U>C4RXRY9[9,S. M164)'ILJT4=D-H8&$MFCVBK7'=NV[F:(64HH0J2$8B(TMAW7TH42S*J$=$]$ ML=?VY&\MJ>(1`YU)$K5[U'1,O6%S3%1#P9?(KA^^B7-Z@,BLK!I/'&="JHF0 M"T68I81B1+709.*Y=,%)-"'=*ECUOL`JH4+6WAJ1447Z<"X>G]!152,;K&Z& M8\>&R[Y+@35N3M4=\NTJM5:&XPY$NDC7HH6_1M,%!1:$7(4<11S%$BD=8?=;NN M-V+)M58&D M*^HC4WNIPBC5.[Y$[5,41R%/C'A4S%'"$Q<\:LG1BB>N>=2&HZV6J%LJCD7M M1>CZZB\J0;+Z(VJOZR:ML^88U2JG$:EU/9!('J/NG)'MFA8Y1H68IZ0B1$HJ M)E*6"?6?18IJ04B);4D4H8Y\3R/KI0K3%1::T1*:T.U'->>C,;D:9ZG!OM6G5+(]\_@+;&N^)D);X]UZ,RL M*?P6W*%O@WYUAJ=?8$_AQTN>`*>BJ3BZ\"MP5)F*\P2_`I4[Y%33EWS+`JZ( MFK\A#?MH'"$MX+@SE_@'W,BP>5?S M\4\```#__P,`4$L#!!0`!@`(````(0#YS01]:00``"X/```9````>&PO=V]R M:W-H965TYYI;Z2L4EJL M=-NP=(T4"3VFQ7FE__W5_S37M:J.BV.5P9]$H*_'*B91[7^"S/9G4M27QLG/+,'%G6U,SCM-`Y M@UL^PT%/IS0A'DU>H:@-T)E^HJGEA+DPPK9?' M%`I8V+62G%;ZQG8CV]+-];()T+>4W*K>_UIUH;>@3(]?TH(@VL@3R\"!TA=F M&AT9!&=3\?:;#/Q9:D=RBE^S^B]Z"TEZOM1(MP-%3)A[_/!(E2"BH#%&#F-* M:(8%X*^6IZPT$)'XO1EOZ;&^K/3QU'!FUMB&N78@5>VGC%+7DM>JIOEW;F2W M5)QDU))@;$E&EC&SK<5X!I('CN/6$6/K:%O&W'$FT_DO/">M)T:Q;F,T=VQG MRM;]8$K\V@C&**;$LA\X3%L'C,+AR37.6D^,W1KMB?6K%6)K-BO$*":TGXKF MHG7$*!P?K]3DQ=#4EA?7\7I9TINMT5]>8;7_;!9LH*AZEKLQ^5F4H+T:R M82PK'>I10!6VQMMZ-)\LS3>4<]+:;%4;6[;8"0M6NXS6&P+[(>`/@6`(A$,@ MZ@$F@M!%`K7Q/T2"L;!("`U;`?1",Y`M+(2+-P3V0\`?`L$0"(=`U`,DV=B0 M0]EC]*;[747DFSFA?_3R;<^&^>8V-N;MBL(9*.],.ND*LE<07T$"!0D5).HC M4@#05X8!8&WU7^X`QH(]A%DZM6A2LMYM:_0H))U)%Q(%V2N(KR"!@H0*$O41 M*220WP_)XUI@QHURL>)MBV#H8F'/IG(L=IV1C#?56\IQOLF*TO:?*R MI4@+NN"=M([1NWE'9QRRV!:9=JUMIR`>1QP45B_SEISY?6X=DXS(AM#-C63M'G-$/[0KBMPG)1GLB-95FD)?647=]BOEQW,7Q7>S,6&`<$`#V8NZE_% M\0K9-&4ZL-^RU\D=^^W(Q=5`Y=F.71R9*KZ9N!NL4_UA.W%QH-S!'1?]]PX^ M=='!@)O=2O%:N<9G\D=^FN_P$``/__`P!02P,$%``&``@````A`+.\9.1V"``` M\"0``!D```!X;"]W;W)K&ULK)IMH0SK_GY ML"[AS_-;MSB=T_6V[[%2@VF%SB]QA??[\?OJTR0\GD'C)]EGYK1)MMPX;/WD[YN?URQ[F M_97UUQO4KOX@\H=L<\Z+_+7L@%Q7#)3.>=@==D'IZ6&;P0QXV%OG]/6Q_<9F^[$I;;@1GQB?G;;T%:;""B(-.Q'*ZTR?>DF+,LRX9+NU>2_*_/"/,&)22HA8 M4@2.4L0:*)$KCK9TA*-T''8&K#>T!W#Q*WY]Z0='O.!-UP/5:K9PE'[,NNF" MKG2$XUT#'4@_.-XU4+@]JX'"40W4\ASFN'Q=KH1F*#WA>-=(&:2>R`2>@W*5 M.Y[C]%WO!ZO!ZB2"7Z0K3/C*(!EF#/_EOF%BRC"5,^S&86+6,)4V/Q@FY@N_ MHVX99E?<7=7-&JS+]=/#.?]H006$P!2G-:^GS.=B>)N*&-4W[O?N6[AAN\'SI9&];##4 MHS<2-KPLU"GNZ";CVJ2.,"$30D)"(D)B0A)"IH3,")D3LB!D29%Y,[BP66@_L!EZM!:WD`/[D@:78M_;5+'GY`)(2$A$2$Q(0DA4T)FA,P) M61"R)&35)%K$=1:_*]G.;>NPHSA&4D"ASKPS#.+54%@J.KQ=*W?9YO,HAX2#)^2%A+6A>Q`]!1?1 M(RM)([*$!()8,#25TX.>7DPFM1'F=$B$HMJF*63<''%MA$))4TB+"=_8-CNM M"W.'#AHGSZWUR0MB0]34Q#Q+G]A8&%G#.O<"Z=:LFZQOQD,8.8.JJYM+$^";M68]*CP_OKV MVXGO!(W\0*0GB-G3H54C0Q!YC:@(>9DCS'$X9J@$,A+(V-^-I:-XJ2032#@Z:H83:>4,JP2R!P.:/O)J M*A$C=%(Z,:+OZB3:>/1`\8[VCN21#;`:T(@WJSQ(:D!C1&J!`XFLZDU9%9$) M(E9-W[)ZS':,0(94*4(WI10CDDK,`MY4-D/P<[DB6]-F9`0R M8>^0$)W.A-/%6\5K\_LQ/<#M=[`@;71$3'2>D-3Z01A+U M.=&7C'=B]))W[TZ9[.CT[:G1'XW0"FI7O4+D62*5U$,P4&XXH0E%(44113%% M"453BF84S2E:4+2D:*4A?3UXI]=<4+2A:4K222`Q"#SQO M+9N!_[E2+QO4YJTGD9KWF!$42*3OR(9&%9\H*PQ%2%%$44Q1(I&V'F)$W?8\9&8*(,ZJ6@ M,I&RDC)&PQLK`Y1)J,Q465T>S4P9H,R71+)4!RJPT&>V.L>[;7%3F MQE*(#8&K[I:QM')4]0H0*:L)12$BY1@A4HXQ10DBY3A%I!QG%,T1*<<%(N6X MI&B%J'+40\J;^O]Q-)-+[S:'1V8W12@T_D,B!AD@])TA/A59N=;?T M/<=L&D,J':'35>D8K82TPRS;>#XD5'J*3E>E9V@EI%F_[_8,[3G57J#75>TE M6J&V9YG17FG:>AJ8.R_S671;'PC[!I('`C7Z0/%I@OAOYR$]OZ7C=+\O6IO\ MG7]V`'?_TT.-Q3<1(\>'U$0($SN^O"ND_)G-O"?Q1[&](`SO!>B/E!_?5YB MZ1DHJ3ZOFO0,5$F?%T)Z!@J?SVL;/0/?=SQ7MR$9&0SL@OW(@N]!+G';AW\` M7=#O^\_BX69>H._#?RRH0S#PX;TKY='`A]>HE$,CY_-NBYZ![LKG+1`]`\T& M^%3;#V-44SC#']/@TZU/P?HU]5E\L2+^*.7F MY"4OX4N3:I^R@R^+4O@7=:\#=\MKGI?X![]`_:W2T[\```#__P,`4$L#!!0` M!@`(````(0!-\4MHPP0``-(0```9````>&PO=V]R:W-H965T?$5LE%V@#>+WWWV\U M32/=Y;KN9%XNU^.I0]>IKOYP\?6CR+5W4M49+9>Z.1KK&BE3>LC*TU+_\WOP M9:YK=9.4AR2G)5GJGZ36OZY^_65QH]5;?2:DT4"AK)?ZN6DNGF'4Z9D423VB M%U+"-T=:%4D#'ZN345\JDAS:H"(WK/%X:A1)5NIT:#'8Y82GZ;7@I0- M%ZE(GC0P_OJ<76JA5J2OR!5)]7:]?$EI<0&)?99GS6\ M/TP[285V^P')%UE:T9H>FQ'(&7R@.&?7<`U06BT.&63`;-U(W0<8D=2V]U@TM_N8DLY/B(E8G`D\A`HF\&&QW MP?`4P2-K[IC.E(W@R5OAVW;H\.P"P>AG`;,N`)Y=@#TR[?%_O0=:I7T//,5[ MQJ.9.78GLX<#-+C%;<7\I$E6BXK>-&@#,+&^)*RI3,_5-5$JGF)?O'^K'12- MB:R9RE*''*`L-4RX]Y4U=Q?&.TR2M.-L,,>4&5O!8#."R?HJL%.!0`5"%8A4 M(!X`!IC0.P%U^@E.,!7FA,AA(X"!-4K:@B%"?!78J4"@`J$*1"H0#P`I[0E. M>P*-\KA71;U9$'3EH-ZFZ\AI;3B'3?]^4BB4;4_I4T?(#B$!0D*$1`B)AXAD M`/3X3Z@[4X$>@K?TV5KN6+&D(SVSI*?TEB!DAY``(2%"(H3$0T2R!):0H27/ MYP(CMYF+$6\Z!!Z]%Z8[D[W8]B01YB-DAY``(2%"(H3$0T1*=/I_$F5D.=$. MX7L86[&V"/$1LD-(@)`0(1%"XB$B907K\+!\?$T?L8VA.6?IVX9"66`5?%#6 M":S=?$5G&G*R'3+ME[8M0GR..#"Q[I6?*5VPZTFB\@$2"GO.4$C9+Z*>)(3B MH9!D"3M:#K:Y!ZG#QBYR9V0Y=XXX[9FI]6>+$+]#)KT_.X0$*"I$G`@A\3!* MR@HV[->S8F0Y*XY8P^7(=.=*GW:D>UK^HS!;+3(GV>/V,.#,W;FE"`=(.'Q% M..I(TA2;3N1!QT-MR3$3MK:A93_4&ZV(;*6`H%3WF>\J1Z"M8+G]'/$[R.:' M5[:&[`1D\8.4-7$L.;T`ZX0BZ*X3"8CK.#-;V7YC24:VB1V2!OWR8S;QDQ;L MB:(_-R:'8,H):"N@.\OO(%NJ,9IA@L7Z]GTU-2USKDS"`&N'(NJI=B187/N1 M=5TB[:AEZ]A!ZXEUW^D%IL[#U7>P!+%CD]*M'60SZ_@;^06,'^<+4IW(EN1Y MK:7TRBY74-W5HH?YS<^?>;#\@H""AS,/5E.,PTUQW=9*X6_8#?(!?V-Y<-#$ M.IN)!PXX\%N_@"?>K`?`F[T(X4;Y24YD=^2ZI25 MM9:3(Y@"ER38!BM^)^4?FJX@>]K`7;*MS1E^.R#0BN,1D(^4-N(#>T'_:\3J M'P```/__`P!02P,$%``&``@````A`)#@-!@``^18``!D```!X;"]W;W)K M&ULK%A=KZ,V$'VOU/^`>-^`^0PHR>H2/J56JJIM M^\PEY`;=$"+@[MW]]QUC&V,[S:;MW8=E?/[6GK6O=3\TW66K MHY6I:_6EZ@[-Y66K__$E_;36M6$L+X?RW%WJK?Z]'O3/NY]_VKQW_>MPJNM1 M`X;+L-5/XW@-#6.H3G5;#JON6E_@?XY=WY8C_.Q?C.':U^5AH2N+?O7M^NGJFNO M0/'.>?BCT;5/UW=`=QQ70&62A:LR! M$1C`M-L<&H@`RZ[U]7&K/Z&P0+YN[#:30'\V]?NP^+3B.DVX6(<&#AX7M< M#Q4H"C0KR\5,57>&!<#?6MO@T@!%RF_3\[TYC*>M;GLKUS=M!.;:;.L*3.@8K:^TBU\-OO^/H4$=X4D=K MM79=QUO[]QWA?Z=XX4D=D;5R+-=?3P'?>:5'/>'Y[];J4T=XSFOUD1G8/U@J M;-%IJ?#D2T6.^2-M`NH'SX<6:I"2F"HL+L=RM^F[=PVV+21]N):X":`0R%AI M$8WF8ONG6H,BPR1/F&6K0_!01@-LD*\[*T`;XRL4=45M(M5&LM@S"US!F#:6 M@40&4AG(9""7@6(!&"#"K`04]@(F*#86`Z4(.81Q"]LK2*P@B8*D"I(I2*X@Q1(1HH+&O(R*-/D5/IK&4U.] M1AVD!=KBC;3:T,Q)B\<<8K`4\>9>MU>0F"`6K&S.//)-,?/);,0RGRI$V6RS M))(Z3#X;,:)B221(@F?CQ;EW(W283ECLV%B,G2"NQ6-7D)@B]FR3*$BJ>&6* M3:X@Q=)+B`I.\,>CPL9B5`2QENW(,ATQ6WMJQ,.*;[C!"".Z)<3(,:?IP'?6 MCB,1IPIQ]@AQ+A![EN/X4I2)"]@S*^X8,XCOJ81"M&@\$_Z(/"ESXCP9@SA/+O+89H"D MSE$PIXE'%`0/3H\+@JVE&J&06".^&,@>CT78D:(HB/!5!L%*-K&5)J!5WC+DC MJ[>$0K1&D..ZGK)M%*),)1)TTI!;.Z42AX>GI<%3IK\>`B1"&Q M4`)9%6K%\QMS1ZX*L:*%LK9M6^))F1/GR1BTK!/"8T,+O2?*5,12*P@)'6'/76TN,@QA5P>8\*@@'RX^IZWEDHQ58DRYL6)<@81 M(A2XCB.58B$0B4KAZ>U_*T5'0!YPA"C$U[EG$$]]3"$/#D2>9^4,9U:(*&5: MEN-)AVVJDF?,[2YYSJP(.>P\-)C\D$OE0OM2W>%[GISQET, M>G"+IU0:@1Q\PI$WDGLZ$;Z8;N!?"5P?@QDP$%X_7\J7^M>Q?FLN@G>LCB&).'QL]N;HD/T:: MD.=NA"O'*37]\>V@ZK7:SL7O;'I_V;U\? MFO_Z/?PT:#;.E\W;T^;U^+9[:/ZY.S=_>_SG/^Y_'D_?SB^[W:5!%M[.#\V7 MR^5]='=WWK[L#IMSZ_B^>Z.2Y^/IL+G0GZ>O=^?WTV[SE"L=7N_<=KMW=]CL MWYJ%A='I(S:.S\_[['YF=GE'F#YMWC?=Y!_][O?IY+ M[QOGE^//Z+1_FN_?=M3;%"<5@2_'XS_.V^I1\E,R^TJ2]OC*U6`_F\<]BHUJ$^[,Z7<*],-AO;[^?+\?"?0LC1I@HCGC9"KQ5& M:A0[6I%>M6*WU7&[_4'NO4:1ZI97FUZUHNNU^DY[Z/4)U2CVM"*]:L7^A_3Z M6H]>;ZLI#;2\IO2J%1VOY0ZZ3K>G>KBFJD.M2:^L.6P-NMU.;_"+1CJ41KE3 M]>:F9CJ<#^J-UG3[DA`UU74HA0JGDDL?C*;#":3>L->/Q=/A%%)O;FLJYY`: M+NST@TWE+'(DC3[:5$XD1S+I@ZGK<"JI-Q]IZETQUO.IP]]<-H_WI^//!LW' M%-OS^T;-[LY(&>-)HXCN=1KYJUF$I@]EY;,R\]"D=M`$<::I[\>CZ[KW=S]H MNMIJF3'*.*;$A"74W*3,^C8(;!#:(+)!;(/$!E,;S&PPMT%J@X4-EC98V6!M M@ZP$[B@\UQC1(/I_Q$B943'BWATS*`7-"@A+L(IO@\`&H0TB&\0V2&PPM<', M!G,;I#98V&!I@Y4-UC;(2L`("$U-$!"/YM?JE9;'B-*B-=48(Y[9X>-"1LV? MUX'4-44F5Y%K4(`$0$(@$9`82`)D"F0&9`XD!;(`L@2R`K(&DI6)$2-:`R!& M:GJ_<6)39FAN)#?7@+ANQPS)6`O51>TJ7\AIHH:;,FFG2NT^T$B`\D`!("B8#$0!(@4R`S(',@*9`%D"60%9`UD*Q, MC(ZG3<0-':^DS8[7A&)="G+/RH2K$&>.#R0`$@*)@,1`$B!3(#,@/R$8#HJB&L:&IB&XJL0&TK*AHP^ M42=8HU,J&D_G:&Y]+FXV7Z.N*^U'Y#/RKE(!HI"1V(H8B6*,*&&4*YH-5`>` M\F'L%PTLS@NT-^&^&ZNC.H6\-\C7OX[3\X9F?T^TA"O5]AF)G4"C3K&.JEL8 MMVL=YT)4BQB5-T).QUJ%8Y;JY)5T6T,K)Q(6R"MD]I#:D=_00TK<2@&-:.25 MTAMZZ2K%7>NK/;FR-;SV=J!1GG,_'CO#H=.VVAJB5L0HOPG,!VJLD3?,>\1K M.=:Q(&&=W+G9(VH#?$./Z/VRQ'JL]K;4,,J(4H]X5D,F(B4]HA7%5J"E=-Y\ MZKA#SUIY0S8D6A$CR>(9VVY$Q:HR!&UN2SWR-^:.]4=DITZ&AFIX\$= MQE5*.JI`O7+J%*CCYA'_Y'1Z;2OF(==`M"*-.L65JUI/8T9JUO_Q2*ECS=2) M8<9,';4=_M\[2F^J)9YC=![-&[QFEZF-U;ZLZM+3-1N0C M"A"%B")$,:($T131#-$<48IH@6B):(5HC2@SD!DCM?DLQ^@7.S"]5RW'0J-R M&KF>-;=/:!=A12QU:Z8H+(UZC?SW?.;MNQSF:!"'#'A!K10S)&$:)8 M%/,GR&U[MY^(`)N9:F1$%)HQ%T5MV:IS*@)L>:%1J( MYJB8(EJ@XA+1"A77B#)#T9POU0GQAE@4!THC%AJ9-P96ZDWH2)B/.CFH^8S* MBG"$#;14?J2D\W&WX[8MVZ$8XN2+&(F[F%&MNT1+T4N>Z5[7M=>VJ1AB=S-& MXF[.J-9=JJ7H1;D;#GL#^XB^$$/L;LE(W*T8U;I;:REZ4>X\UVWWK)4[$T/D MSDR5JAL!MZ<^9U=U19\[*>[HU7)H+Z<%4O/_]23J>M9!)J*1D9/J.R8D7"%(IZ9'2Z?0]RY%H!R1'P%G_(6Z*EM+?NL#VPMHA3 ML9HRD;7-&M6U+36^.1Y\9M<\6"['$_I:,Q-^*4:V_M>G/\YR.U[$&02:6 MR)^9*F3\EE11XM;YMT`TMW!;)JY&DO,^(Y$*&,E%6\A(I")&8BMF)%()([$U M9212,T9B:\Y(I%)&8FO!2*26C,36BI%(K1F)K8Q1+F7&XK:K(A>OBAA1_Y?F M>>O^?L)2DFH^([DE#C323Y`<^\(]%)6R+VM&C%A*?,6,Q%=B^[)J/!65&E\S MEA)?EBPEWE:,Q-O:]C9H61=WF2A5>S-21'TD\(;A MFHN;PU4C:RM@[4LF+"79[3.2[`X8%4N4T[*LA%Q>7NA%HQ$D]K1MPJJP%I*,MYG)!D?,"HRWAK%(9>*0L1(S,:,1"IA5&EVRJ6B M,&,D9N>,1"IEI,VVK&WJ@LM%9'@G MQ\@>HS*BOBYEY+T<"7Y*2/#9FS:"BV>-L8,1*/,:-:C\F'/$[% M%GN<,1*/%LQJO6VUE+U/9J)+?)HILQM M5X`>7@$R*CWD0N0C"A"%B")$,:($T131#-$<48IH@6B):(5HC2@SD!D+=357 M/INKFW:WVR)\X_<(/'W))Q/-F!&5R/Z_8PV]B4AQ:OJ(`D0AH@A1C"A!-$4T M0S1'E"):(%HB6B%:(\H,9$;.OI'[Q<2+UW">1N51!,A'J0!1B"A"%"-*$$T1 MS1#-$:6(%HB6B%:(UH@R`YFQ4'=!_Y]1I&^5RJ-((W,46:?$B7>5DE$$*$"I M$%&$*$:4()HBFB&:(TH1+1`M$:T0K1%E!C(C1TN=$;E?C"(E;NU&"Y1?J12F MB^^O%U]"/>Q.7W>3W>OKN;$]?E??3:>L$KT,'>DGM=B"3V, M'265)?0P=:2>EZ(./0P=J>>=6$(/',E/51OI\2'YJ2JAAX'DIZJ$'NV1GZH2 M?SBB[R:@_V@XHJ\:(*>/EY#WJN#2ISG(1U4)?9*!=*H"3Q\<()VJDK$SI`A4 MU6#LMBF+BE]VN(:-?I;A??-UEVY.7_=OY\;K[IF&1CO_^L>I^&&'XH^+_J#I ME^.%?I"!1AY]@9M^@&-'GPQNJTW*\_%XX3^H\7?7G_1X_"\```#__P,`4$L# M!!0`!@`(````(0!MQ&][O@0``)\0```9````>&PO=V]R:W-H965TJ5CF:FKN$Z)X>B/JWT MO[Y%7UYTK>VR^I"5I,8K_0.W^M?UK[\L;Z1Y;<\8=QHHU.U*/W?=Q3>,-C_C M*FMGY()K^.9(FBKKX&-S,MI+@[-#WZ@J#0]SMRLIQK]Q\4^:K(&]*28S<#.8,-5,UY82P,4%HO#P5D0&W7&GQR:WN"D.OQ4U!K>A3K0">T)>:6AZH`@:&TKKJ*_` M'XUVP,?L6G9_DEN"B].Y@W*[D!%-S#]\A+C-P5&0F5DN5`XB MS@PYID9#.W@.[:S9B^LZWLO\>8#2`:Q#!(9I!-@@`FC$^#; M3W""JE`G>`X!!Q-KI+1Y!&\2RF`G@T@&L0P2&:03(*1MJVG;L&8?KS9>;]H( MUM6DWLB;BVD%+`9VBGOFKABR'4/&U!6R4TBDD%@AB4+2*1$,@"7^$^I.56`- M02^3)6"+^09#T#-+QI#1$H7L%!(I)%9(HI!T2@1+8,^96O)\+M#@/G,^XF`@ M\!B]0-Y"]&([!O%FH4)V"HD4$BLD44@Z)4*BWH\D2H/%1`?"3B&Z8VT5$BID MIY!((;%"$H6D4R)D!?OPM'QL3Y_1DZ0[%_EK0-CQ]Z"L-NS=;$>G&F*R`_'& MK6VKD)`1%R;6O?)S4ZS\;@SBE8\4H7B,F0I)YT4R!G&A="HD6$(OAY-C[D'J M<++SW&FPF#LC;G_KZ?W9*B0FTE9`5'-C3K&BA+8_> MBKZS?=-V8H*,6-.="*B<\BBG#_)K; M2)JYZ1##Q$7OZ)WKB7??R`5FSO<6*[U!2:MU0`[UCO7(WJ;8S;["S0EO<5FV M6DZN]$T)RKM>CIB]QH5S'W9B$)!X//=A8U4YO/9M^F))\0%]'7P0'U@^W#E5 MG<#VX2ZF\HWC;R`O]8O`\>&F\H"[/ASL#[CGP]$(W!A'"J^'E^R$?\^:4U&W M6HF/8(K9K_2&O6"R#]U0D#WIX,6PK\T9?@C`L!3-&>RJ1T(Z_H%V,/ZTL/X7 M``#__P,`4$L#!!0`!@`(````(0!@]AR"H`0``*00```9````>&PO=V]R:W-H M965TE,;--` M=8Z/17U>F7_]&;W,3:/MLOJ8E;A&*_,+M>:/]:^_+&^X>6LO"'4&,-3MRKQT MW36TK#:_H"IK)_B*:OC/"3=5UL'7YFRUUP9EQ]ZI*BW7MF=6E16U21G"9@P' M/IV*'.UQ_EZANJ,D#2JS#N)O+\6U96Q5/H:NRIJW]^M+CJLK4+P69=%]]:2F M4>5A>JYQD[V6D/>GXVXQ:=N`G06#53/>6$M+&!:+X\%9$!D M-QIT6ID;)TP=Q[36RUZ@OPMT:X7/1GO!M[@ICC^+&H':L$YD!5XQ?B.FZ9%` MX&QIWE&_`K\WQA&=LO>R^P/?$E2<+QTL]Q0R(HF%QZ\]:G-0%&@F[I0PY;B$ M`."O416D-$"1[+,?;\6QNZQ,;S:9!K;G@+GQBMHN*@BE:>3O;8>K?ZA1GQ$G M<0<2&!^0/''T!D<8!T';E03QR#P1'&_QU>!0XJ$*E`K`*)"J0"8($(7`FH[&]0@K`0 M)5@.6P8(TBAI,POFLE>!@PI$*A"K0*("J0!(:<.^_(:T"0OT%:$`'%'\9H18UDSBKAB'YPKR>\&&^^NV0,O7;/!R*>: MV9.YJI?&&X_A331>7UZL5.25M')@D<>+U5O+:C$(5D,H%NTV1:8!1Z'([HYL M%QP&J*_HC[6S6`2!'2A4$?.[4\4,FO/E2&0JUY[YSER]!:;,KZ>292$7L]'[ M#AY<:A$-D$\BHLST247ONQ5JSFB'RK(U$FYC.L_5"N)#H^,8/-_1MJ02T]4,XKG6'[32$ M(^P!/@OA$`#X-<`!&>83>X`)XP[]H5,P']?6/\+``#__P,`4$L#!!0`!@`(````(0#1 M^WO><@0``"L0```9````>&PO=V]R:W-H965T+S>Y%[;[R2F2B7/AL,?8^7J=AEY6'I__/W\Z>I[\DZ*7=) M+DJ^]#^X]#^O?OUE<1'5JSQR7GO`4,JE?ZSKTSP(9'KD12('XL1+&-F+JDAJ M>*T.@3Q5/-FI244>A,/A)"B2K/0UP[RZAT/L]UG*8Y&>"U[6FJ3B>5*#?GG, M3K)A*])[Z(JD>CV?/J6B.`'%2Y9G]8YY%LP"8%HM=AGL`&WW*KY?^FLVC]G4#U8+9="WC%^D M\[\GC^+R6Y7M_LA*#FY#GC`#+T*\8NB7'4(P.>C,?E89^+/R=GR?G//Z+W'Y MG6>'8PWICF!'N+'Y[B/F,@5'@6801LB4BAP$P%^OR+`TP)'D73TOV:X^+OW1 M9!`]#4<,PKT7+NOG#"E]+SW+6A3_ZB!FJ#1):$C@:4C89!!.(Q9-D.7&S)&9 M"4\S,[IOXMA,A&>/[NZ*@=ZWLC%.ZF2UJ,3%@]J$GQA M,)5C$,>C#A*["%E[1M=6#8^-!T^PN0=]0B8JS"#4IW:7LT'6)Q-PU$O6H=O.TUJID8$XB*Q6;L MB+U=5MA"6^EK(-!3Q1ZMMEX&H M7>.V73;J6F`N1-5BX[W?+M.F7;O2R\59_S*AZO&:F%A?079L`G<029(T1EY@A'U`=@9&<*(NGIT1O!&H[[_ M.R,AC*AOBL[("$;4MCHC8QA1V^N,1#"BSE5K!*Y4Z_Y58$+?+D%6;SR(ZM.T M'L_7^LK66G@#6GNE@K^]]H*[O>9.Y_#SW)..V3R>J4S;A>&J=DH._&M2';)2 M>CG?0Y*'JJ%6^K*G7VIQ@N3#A4W4<$E3_Q[A4L[A^VF(IV,O1-V\8"G9:_[J M/P```/__`P!02P,$%``&``@````A`)NAL_UE`P``DPH``!D```!X;"]W;W)K M&ULK%9=;YLP%'V?M/^`>"]?24B"0JHDJ%NE39JF M?3P[8()5P,AVFO;?[QJ#BQ,6I5)?0CB<>^[Q]?7'ZOZE*JUGS#BA=6S[CF=; MN$YI1NI#;/_^]7"WL"TN4)VADM8XME\QM^_7GS^M3I0]\0)C88%"S6.[$**) M7)>G!:X0=VB#:_B24U8A`:_LX/*&892U057I!IX7NA4BM:T4(G:+!LUSDN*$ MIL<*UT*),%PB`?YY01K>JU7I+7(58D_'YBZE50,2>U(2\=J*VE:51H^'FC*T M+V'<+_X4I;UV^W(A7Y&444YSX8"CGGI+EU06J\R`B.09;<8SF-[XT>) M[]GN>M46Z`_!)S[X;_&"GKXPDGTC-89JPSS)&=A3^B2ICYF$(-B]B'YH9^`' MLS*N'QL?7?]^NDMSZZW6W"@ET+^PZBM\VLS\QO2?ZZUO1APUO.`O? MXTR236<=HC8ON2IV%T@R1(SFG68J=)?3&3(6+8D:?N M8+.Y/DF2;-KID$$I+I!DB!BYEV;N=J,+9\[;=GGS9B>53&,=`EVAUV`P]\[J MI$FZ3D/$\`HGYCL*U;)-0QTTE?VLE-4)JK;^"K,#WN&RY%9*C_)T!/YZI6%] M=&_:!7&&;^61+H7/\2""[7`$GT3)9`3?3*,-Y!T)F$9)Z_P\01A!IX_PYQ&T MW`B^B*`=1O!EE"PE[NH$<"5HT`%_1^Q`:FZ5.(>B>&US,'6I4"^"-E`LN!=0 M`7>!]F\!ES\,R])S8/IS2D7_(A/HZ^3Z'P```/__`P!02P,$%``&``@````A M`$*"N::(!P``6B```!D```!X;"]W;W)K&ULK)I= MDZ+($H;O3\3Y#X;WH_*A*-'=$ZT(@B(G-G;W7--*M\2H&$!/S_S[DT554E1E M+]$]9VZ6]ME\7R`KZY.Y^_KC7^^%??_I? MYL-!5:?78WHNKMG]\&=6#;\^_/M?=V]%^:TZ95D]`(=K=3\\U?7-'8^KPRF[ MI-6HN&57^#_/17E):_A9OHRK6YFEQT9T.8_-R60VOJ3Y=<@=W/(C'L7SLFN-3[U].127&U@\Y>>\_MF8#@>7 M@QN^7(LR?3K#>_\P[/2`WLT/8G_)#V51%<_U".S&_$'I.R_&BS$X/=P=S'W^-/+J@-D%&Q& MYI0Y'8HS/`#\=W#)66E`1M(?S?4M/]:G^Z$U&TV=B65`^.`IJVH_9Y;#P>&U MJHO+?WF0(:RXB2E,X"I,C/G(G$^-Z>P3+K9P@2NZC.;3J3V;.Q]_%(ALW@>N MPF0^EK":-L3_A`* MJ],4?5(+;P9_?.QFV&*&;++^FXUY]37%[*5U^G!7%F\#&"'@::M;RL8;PV7E MBV7,G[CI8Z\#70:"#C0Y"'40ZV.I@IX-8!WL=)!TPAERW"8>N^CL2SFQ8PC%5 M2P2=%M"RBQ$H\72PUH&O@T`'&QV$.HATL-7!3@>Q#O8Z2#I`R2[TH-^1768# M`W*GG`U[IJ9SR6,,>)*VYJ=JR*H-:5-.R)H0GY"`D`TA(2$1(5M"=H3$A.P) M2;I$23\,1[\C_T*2+E'R#P.XDO_W%R,X:+/H)LV8GJ4@<.DD7A^EVR"4>82L"?$) M"0C9$!(2$A&R)61'2$S(GI"D2Y2LSCZ551:M9E40O@ID\]J*$(^0-2$^(0$A M&T)"0B)"MH3L"(D)V1.2=(F20E@9*(7)EQDCMC:L3_GAV[*`@H,I\YV"M6`Y MP1<9S$3-K""S=AI<$>)Q8L*CM35M3!UU,%FW05C3/C$*VIBNT5PUVK1!:!02 MHZB-Z1IIJZ5M&X1&.V(4MS$=HYDV3N[;(#1*ND9**[&]:7^FP("8DJ$C'R7EM" M=D05DY@](4E7I61T\:F,LF@UHYQ8T#-D\<[T`9D'F9VLZ84ZB\-)XV+FFY$T)Z=?.M5 MC%$RO9Y`5G?)8MA:5UQCE-UT$,-Q3,?4^ZM/W0/4];IO,*K//:3N$>IZW;<8 MQ49LW.,9,TOMX#MJ'Z.PUWZ/4;WVB6*OE@3;;W7'+KTD_BQNT-;OSC"=,8UM MX[4N*)!IMH/-"I'5(D\@2TY%:T1RO/&I,,`H*=P@DL*0"B.,DL(M(BG<46&, M45*X1R2%B2)44\TV7]U4]T\3;(>DIY0C"R>*F:7-?BLA,KL9YJ)..ZPQRF[; MP4)R82VB+!GE4V&`J#,G4V&(4=(K0B2%6RK<8904 MQHBD<$^%"48U0C7+;!OUB3H6NR[9SDMV_`;Y@Y+LCHFV.B:N,$H*/42*D$X7 MW-Z>\.EB.IE8MJ--1CY:2?<`4:_[1D3UNH=H)=TC1+WN6XR"5^B;+D0"I7V, MPE[[/4;UVB<8U=BK;<\V>]VVUZ>+#VU(V(&IWO$$4CN>UF@K%,IJ]@2R^0$_ MVR6N$9E-^SO3A>-8VI+"ITX!RJ33!E&/4TB=(I1)IRTB&";ZVE5D0;Y?C$+I MM4?4ZY6(*#Y(J8W(MIO_?R.*3:NLP:7!D=*OY_KA'@9)G2>0K50E[=;_`A]PU&];F'U#U"7>^S;S$*7J&O^47^9&IB%/;:[S&J MUSX147QQH%8$V]IB1<`(HO?J#RX"Q099/OX2OB2RGM[,WOR._,,@_Y9RRV;90'"QV7I3'"QW"$285>(X+!S&4!XX+YRJ41XX+QR24QXX+IQZ4>W,73A&UL MK)E;;^HX$,??5]KO$.6]Y$(@$`%'$'*3SDJKU5Z>TQ`@*B$H2=MSOOV.$]NQ M/3F(5GUIRL_C/_9X,A[CU;% MKC5M>CVDE^J:K_6?>:-_V_S^V^J]JE^:J+M,6/M8GH[G5>7KH.I47PS;-N5&FQ57O%;SZ$8WJ>"RR?%]EKV5^ M;7N1.K^D+8R_.1>WAJF5V2-R95J_O-Z>LJJ\@<1S<2G:GYVHKI69EYRN59T^ M7V#>/RPGS9AV]P')ET565TUU;"<@9_0#Q7->&DL#E#:K0P$S(&[7ZORXUK>6 ME]B.;FQ6G8/^+?+W1OA?:\[5>U07A^_%-0=OPSJ1%7BNJA=BFAP(@LX&ZAUV M*_!GK1WR8_IZ:?^JWN.\.)U;6.X9S(A,S#O\W.=-!AX%F8D](TI9=8$!P%^M M+$AH@$?2']WSO3BTY[4^G4]FKCFUP%Q[SILV+(BDKF6O35N5__5&%I7J16PJ M`L\1D3L=I[0C/&E'VYY8CCDG7WZGGT/[P9/V'YLI/""=B.%Y_"%CXQT23O"<^CXZY$:?4!T\;5/ MVW2SJJMW#5Y:6/+FEI(48'F@Q0*K]Q$/M5]%&H08$=D2E;4.LX<@:N#U>-O8 MKK4RWB"D,VJSPS:*A<\L2/P2V;T*`A6$*HA4$*L@$8`!3N">@+#^`D\0%>() M-H<=`X)K9,?XS()UV:L@4$&H@D@%L0H2`4C3AI?R"Z9-5""I"`%@V7-YGKO> MQH*!\"B9R28^-^&^0"1`)$0D0B1&)!&)Y!%(-U_@$:("+Q5\"Y^M[=KR?'?4 MZ)Y+N`EW"2(!(B$B$2(Q(HE())=`(E5=8L\F/'L_G">(3N<4-IE=3VPQ=5A3 M-2RX$>NV1R1`)$0D0B1&)!&)Y`/8$T0?C&^]+"$28WFB/>EJ!$D69B[*?C(! M$Q44;5,EVJC1O6CC)MS3B`2(A(A$B,2()"*17$*J5F5/FD'6_N">1%3D)>B) M$FM*EO*Y$?<`(@$B(2(1(C$BB4@D#\!.+'K@?JP18WFB/<&Q9D'A*>I^,M@Z M&11MCA)MS.I>N`TVW-L8!1B%&$48Q1@E$I)\;I'"0`F[3R6Y3DA>$(J4T'-E MC_F#U>"-OEJ!C@P%V"K$*,(HQBB1D.P-6#;1&_=#D&SJ2@PRU!]'2#GG8[3' M*,`HQ"C"*,8HD9`\/[+]*ZMMS28NI/_V7&0ONZH_#XW,>PH%+BU[:0TQY:NS M(QL^\<2<(Q^C/44V;`J\.K"F"SD>@L&*+7Z(M:+!2M1:REKQ8,6T$DE+=@XI M!`3GC#@!CF[<"[1L$+U`$20X/C]7&9)O4:,E=]6>(AOR%.\'AQIY+@&SLKJ3 MQI/E.J8]G2IO4XCE(];QKGS,K.[*)Y*\[#U20CSNO;[@@,5@"[,C)WN((5O, MG`O%"3XS&OKM&1+[C7B/JCN]]\S)`GF.6@S2T4/2,;,:I)5-(6$6G;3LM0_5 M5_!^H81#D1ASEH/.F-1*##K>D:U`0.6[('_;6,NEZYKJ@39D8QBD(H86?#%C M6CR8:$TUK-S.HDC,PPCML56`48A1A%&,42(A M>7ZD!GI\?GW%)+TL%$',"BE#.6CY%K=B:[S'*,`HQ"C"*,8HD9`\Y0]5=Q8N M[RC"]1W)FZ(S/UG?=3*HOE,.93MF)68;Q<8?;+C;,0HP"C&*,(HQ2B0DN=T> MJ>\L$T;_P7-%IR.7=Q3)Y9VC'+_\P6IP!B[OL%6(4811C%$B(=D9,&\Q4N[O M\&0G4LH[AH2T@M$>HP"C$*,(HQBC1$+R_$;*NT^<(6U.![@%C@,>*?9Q"]Q1;<>_'[YDQ'Y'7#S&P<&C^HZW[4X] MJM\=#WY8Q./9S3SXL0WSK>MM^SJ("\%5UBT]Y7^D]:FX-MHE/T*4F=UAK>XO MP_H/;76#Q`P76E4+EUC=OV>XM,SA\&F27RN/5=6R#_#%!K\&W?P/``#__P,` M4$L#!!0`!@`(````(0`*TQR!,0$``$`"```1``@!9&]C4')O<',O8V]R92YX M;6P@H@0!**```0`````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````"&>TMIIS&D98F:G5QBXHR+-X1O*[%0`FBW?R_KNCJC)X_D?7EX MOH]JOM-M\@G.J\[4B&0Y2L"(3BJSK='S:I'>H,0';B1O.P,UVH-'?@T7467%#@DT@RG@I;HR8$2S'VH@'-?18;)H:;SFD>XM%ML>7BG6\!%WE^ MC34$+GG@^`!,[41$(U**"6D_7#L`I,#0@@83/"89P=_=`$[[/R\,R5E3J["W M<:91]YPMQ3&ZWPJ37>9Q-0CP+_)IX`;/#^^>?L"P``__\#`%!+`P04``8`"````"$` M%'X!O3<#```'#```$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````"<5E%/VS`0?I^T_U#E'5*@F@9* M@THI8U(9U5+8H^4ZU]8BL8/M5'2_?N>$EJ2X[N"E2NWO[KX[?SY?=/F29YT5 M*,VEZ`14'^.VP)VY5#DU^%=KO?0G@Q M(%)(CXJMPZ#V>+$RGW6:2F;YZ%Z!:H+=J$:58"N0.J,6*5OA-[;Y:@R&]@P%=TADKP MH(:E4EA',M!Z1Y;;,K[V@W65U@BS*FQHCT^/+TQ1E:B1,:)$C?8!;"%[N.49'/8(^,/F_BSL(?QGWC6GKU M$7()UH=O*_;#2#+%2:RD[B/>*_(JC%,5?A-W/?TV[GKZ+Y/;QMNUB3N=W;:] M$6Q5MZ9):^+:F;'&7#SIAV(JKW$RV0R1[<4H65(%*8Y7F_VWA>@6YT>562?# M)<5G)MU@WF_8D?>QGNOCD]YQ]ZR+TVQC+0I?U8L/5?P/``#__P,`4$L!`BT` M%``&``@````A`&[(=20,`@``.!X``!,``````````````````````%M#;VYT M96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P`` M``````````````!%!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`2T=% M8C<"``!]'0``&@````````````````!K!P``>&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"+0`4``8`"````"$`PX;/91,$``#[#@``#P`````````` M``````#B"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`#G'QB]N M!0``@Q0``!@`````````````````(@\``'AL+W=O&UL4$L!`BT`%``&``@````A M`.+?>"X=!```>0\``!D`````````````````C1<``'AL+W=OBK7NGH"```M!@``&0`````` M``````````#A&P``>&PO=V]R:W-H965T``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`'M3?0;B`P``NP\` M`!D`````````````````VR$``'AL+W=O&PO=V]R:W-H965T`(``"T&```9`````````````````%XH``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`.BU!Y\5!```A@X``!D````````````` M````#2L``'AL+W=O7%DU=0#``"A#0``&0````````````````!9+P``>&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`$QB@]G_`@``E@D``!D`````````````````ES@``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-.6 ML.9?`P``E0H``!D`````````````````'T4``'AL+W=O0``#0`````````` M``````"U2```>&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL``!,````````````````` M4Y$``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`EL>SX7($ M``"R$0``&0`````````````````8F```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`+8NC1#3!```ZA,``!D`````````````````1*(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.I!4U:(`P``4@P` M`!@`````````````````3:X``'AL+W=O&UL4$L!`BT`%``&``@````A`.0ST5S4 M`P``A`P``!D`````````````````%;L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&E9<((A!0``HA(``!D````` M````````````U\T``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`#WO"MQM"P``6#L``!@`````````````````^-X` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`!=N?KAJ!@``!1L``!@`````````````````'O8``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`+B%O2Q+"0``\"D``!D`````````````````>!,!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`$WQ2VC#!```TA```!D`````````````````1RH!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&W$;WN^!```GQ`` M`!D`````````````````FD,!`'AL+W=O&PO=V]R:W-H965T M<@0``"L0```9`````````````````&9-`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A`)NAL_UE`P``DPH``!D````````````` M````#U(!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A``K3'($Q`0``0`(``!$`````````````````3V0!`&1O8U!R M;W!S+V-O&UL4$L!`BT`%``&``@````A`!1^`;TW`P``!PP``!`````` M````````````MV8!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````#H`.@#(#P`` &)&L!```` ` end XML 15 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Based Compensation (Details Textual) (Non vested Awards [Member], USD $)
9 Months Ended

Sep. 30, 2014

Non vested Awards [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 3,988,729

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 2 years 10 months 24 days

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Assets:

Total $ 22,601,202

Fair Value, Inputs, Level 1 [Member]

Assets:

Total 22,601,202

Fair Value, Inputs, Level 2 [Member]

Assets:

Total 0

Fair Value, Inputs, Level 3 [Member]

Assets:

Total 0

Certificates of Deposit [Member]

Assets:

Certificates of Deposit 15,003,472

Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]

Assets:

Certificates of Deposit 15,003,472

Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]

Assets:

Certificates of Deposit 0

Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]

Assets:

Certificates of Deposit 0

Money Market Funds [Member]

Assets:

Money Market Fund 17,727,260 7,597,730

Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]

Assets:

Money Market Fund 17,727,260 7,597,730

Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]

Assets:

Money Market Fund 0 0

Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]

Assets:

Money Market Fund $ 0 $ 0

X

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CertificatesOfDepositAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_MoneyMarketFundsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and Equipment (Tables)
9 Months Ended

Sep. 30, 2014

Property Plant And Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment as of September 30, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:

September 30, 2014

December 31, 2013

Computer and equipment

$

141,998

$

136,498

Furniture and office equipment

96,457

96,457

Laboratory equipment

1,769,589

1,760,633

Capital lease equipment

155,523

155,523

Leaseholds

37,789

37,789

2,201,356

2,186,900

Less: Accumulated depreciation

(1,192,930)

(1,048,321)

$

1,008,426

$

1,138,579

Schedule Of Depreciation And Amortization [Table Text Block]

Three months ended

Nine months ended

September 30,

September 30,

2014

2013

2014

2013

Depreciation and amortization

$

48,521

$

51,239

$

144,609

$

148,291

X

- Definition

Tabular disclosure of depreciation and amortization.

+ References

No definition available.

+ Details

Name: cpxx_ScheduleOfDepreciationAndAmortisationTableTextBlock

Namespace Prefix: cpxx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loans Payable (Details) (USD $)

Sep. 30, 2014

Schedule Of Loan payable [Line Items]

Loan payable $ 10,000,000

End of term fee 77,056

Long-term debt $ 10,077,056

X

- Definition

Amount of fees associated with end of loan term.

+ References

No definition available.

+ Details

Name: cpxx_AccruedEndOfLoanTermFee

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: cpxx_ScheduleOfLoanPayableLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LoansPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and Equipment (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Property, Plant and Equipment [Line Items]

Property and equipment, gross $ 2,201,356 $ 2,186,900

Less: Accumulated depreciation (1,192,930) (1,048,321)

Property and equipment, net 1,008,426 1,138,579

Computer and equipment [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross 141,998 136,498

Furniture and office equipment [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross 96,457 96,457

Laboratory equipment [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross 1,769,589 1,760,633

Capital lease equipment [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross 155,523 155,523

Leaseholds [Member]

Property, Plant and Equipment [Line Items]

Property and equipment, gross $ 37,789 $ 37,789

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 21 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8

Geographic Segment Information (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Revenues from External Customers and Long-Lived Assets [Line Items]

Total Assets $ 23,388,467 $ 23,388,467 $ 27,472,750

Total Net Loss (5,479,817) (3,677,412) (14,548,512) (17,402,337)

United States [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Total Assets 22,226,025 22,226,025 26,190,516

Total Net Loss (5,046,236) (3,274,731) (12,977,790) (15,649,089)

Canada [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Total Assets 266,844 266,844 284,563

Total Net Loss (433,581) (402,681) (1,570,722) (1,753,248)

Germany [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Total Assets $ 895,598 $ 895,598 $ 997,671

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements
9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

3.

Fair Value Measurements

Financial instruments of the Company consist of cash deposits, money market investments, other receivables, accounts payable, certain accrued liabilities and debt. The carrying value of these financial instruments generally approximates fair value due to their short-term nature.

ASC Topic 820, Fair Value Measurements establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.



ASC 820 requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.

The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:

Fair Value

(Level 1)

(Level 2)

(Level 3)

September 30, 2014

Assets:

Money Market Fund

$

17,727,260

$

17,727,260

$

-

$

-

December 31, 2013

Assets:

Certificates of Deposit

$

15,003,472

$

15,003,472

$

-

$

-

Money Market Fund

7,597,730

7,597,730

-

-

Total

$

22,601,202

$

22,601,202

$

-

$

-



Non-cash derivative instrument charge

The Company recognized a non-cash derivative instrument charge of $7,473,108 during the nine months ended September 30, 2013. The charge related to an obligation to issue additional shares of common stock and warrants to certain existing stockholders who participated in early closings of a private placement that started in 2012 and closed on April 29, 2013. The fair value of these common shares and warrants was recognized as a derivative liability with a corresponding charge to the statement of loss. Upon the closing of the April 2013 Private Placement, the derivative liability was reclassified into stockholders’ equity as the obligation to issue additional securities no longer existed. This contractual obligation was fair valued using significant unobservable inputs (Level 3).

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 23 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5?8C,S-5\U.&%D M-3DX,F1F-6$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D]T:&5R7T-U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D]T:&5R7T%S#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U M;6UA#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K7T)A#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D=E;V=R87!H:6-?4V5G;65N=%]) M;F9O#I7;W)K#I%>&-E;%=O5]O9E]3:6=N M:69I8V%N=%]!8V-O=6YT,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;W!E#I. M86UE/@T*("`@(#QX.E=O5]A;F1?17%U:7!M96YT7T1E=&%I;',R M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K7T)A#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K7T)A#I7;W)K#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N M9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;'-?5&5X=#PO>#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!296=I"!+97D\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO'0^)RTM,3(M,S$\'0^)SQS<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'!E;G-EF5D(#(P,"PP,#`L,#`P('-H87)E3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D('-H M87)E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&-H86YG92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@Q+#0P."D\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5?8C,S-5\U.&%D-3DX,F1F-6$- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S$P-F,P8V5?,C)F,E\T M.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO6UE;G0@;V8@6%B;&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA6UE;G0@;V8@9&5B="!I6UE;G1S(&]F(&QO86YS('!A>6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!F:6YA;F-I;F<@86-T:79I=&EE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3QB'0^)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%2 M1TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/&9O;G0@6QE M/3-$)U!!1$1)3D6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6XG/B`\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M2!D979E;&]P:6YG(&YE=R!A;F0@;6]R92!E9F9E M8W1I=F4@=&AE28C.#(Q-SMS('!R;W!R:65T87)Y(&1R=6<@2!P;&%T9F]R;2P@6YE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@:&%S(&EN8W5R2!H860@86X@86-C=6UU;&%T960@9&5F:6-I M="!O9B`D/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`D/&9O;G0@ M2!T:')O=6=H('1H92!(97)C M=6QE2!S<&5C:6%L='D@<&AA2!T M:&%T(&AA'!E;F1I='5R97,@9F]R(')E2!T:&4@0V]M<&%N>2!T;R!F M=6YD(&ET2!O M<&5R871E2!D97!E;F1E;G0@;VX@=&AE('-E M&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4W5M;6%R>2!O9B!3:6=N:69I8V%N M="!!8V-O=6YT:6YG(%!O;&EC:65S/"]F;VYT/CPO6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6XG/B`\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@=&AE(&]P:6YI;VX@;V8@;6%N M86=E;65N="!O9B!T:&4@0V]M<&%N>2P@=&AE(&EN=&5R:6T@8V]N65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^/&9O;G0@2!A;F0@97%U:7!M M96YT+"!V86QU871I;VX@86QL;W=A;F-E(&9O6QE/3-$)T9/3E0M M1D%-24Q9.B`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`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,C`L-C0Q+#@W-CPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/E1H92!A8F]V92!C;W)R96-T:6]N(&AA6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@65A2!T:&%T(&EN M('!R:6]R('EE87)S(&ET(&AA9"!B965N(&EN('1H92!D979E;&]P;65N="!S M=&%G92X@05-#(%1O<&EC(#DQ-2!I2!A9&]P=&EO;B!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^26X@075G=7-T(#(P,30L('1H92!&05-"(&ES28C.#(Q-SMS(&%B:6QI='D@=&\@8V]N=&EN=64@87,@82!G;VEN M9R!C;VYC97)N(&%N9"!A8F]U="!R96QA=&5D(&9O;W1N;W1E(&1I6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UEF4Z(#@N-6EN(#$Q+C!I;B<^(#QT86)L92!S='EL93TS1"=,24Y%+4A%24=( M5#H@,3$U)3L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9.B!#86QI8G)I+'-A M;G,M6QE/3-$)U!! M1$1)3D6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I M;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^1FEN86YC:6%L(&EN2!A<'!R;WAI;6%T97,@9F%I6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^05-#(%1O<&EC(#@R,"P@ M/&D^1F%IF4@=&AE('5S92!O9B!O8G-EF4@=&AE('5S92!O9B!U;F]B6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M3&5V96P@,2!A<'!L:65S('1O(&%S6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE. M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^3&5V96P@,B!A<'!L:65S('1O(&%S6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@ M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^05-#(#@R,"!R97%U M:7)E2!R96-O9VYI>F5S M('1R86YS9F5R6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE. M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XR-6EN.R!724142#H@-S`E M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R/B`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`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\ M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M+3PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO2!R96-O9VYI>F5D(&$@;F]N M+6-A2!W:71H(&$@8V]R3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V M8S!C95\R,F8R7S0Y9#5?8C,S-5\U.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-S$P-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA M9#4Y.#)D9C5A+U=O'0O:'1M;#L@8VAA'0^)SQD:78@6QE/3-$)U!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[ M34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]2 M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E2!N970@;W!E6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PT,3(L M,S`R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T M<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,2PT,36QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U!!1$1)3D6QE/3-$ M)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/'-T M6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T M)SX@/'-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z("TR,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C(N-7!T M)SX@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)W=H:71E+7-P M86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^-30Q+#0V.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQD:78@6QE M/3-$)U!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[ M34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/'-T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,30Q+#DY.#PO9&EV/B`\ M+W1D/B`\=&0@"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PW M-C`L-C,S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,34U+#4R,SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,2PQ.3(L.3,P M*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,2PP-#@L,S(Q*3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,2PP,#@L-#(V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M-#@L-3(Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^-3$L,C,Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,30T+#8P.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2`R M,#$R+"!T:&4@0V]M<&%N>2!C;&]S960@82!L86)O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%2 M1TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^1'5R:6YG(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^-RX\+V9O;G0^/"]S=')O;F<^/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN)R!V86QI M9VX],T1T;W`^(#QD:78@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^3W1H97(@07-S971S/"]F;VYT/CPO6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z("TR,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P M<'0@,C(N-7!T)SX@/&9O;G0@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A M<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^-C$R+#$X,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-2PW-#4\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@06YD M($%C8W)U960@3&EA8FEL:71I97,@1&ES8VQO6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#PO9&EV M/B`\=&%B;&4@6QE/3-$)U!!1$1) M3D6QE/3-$)T-,14%2.F)O M=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/&9O;G0@6QE/3-$)U!!1$1)3D6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6XG/B`\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$58 M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M)B,Q-C`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^-C,V+#0Y-SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV M/B`\+W1D/B`\=&0@6%B;&4\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`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`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,C6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^,2PV,S`L.#`Y/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4Z(#@N-6EN M(#$Q+C!I;B<^(#QT86)L92!S='EL93TS1"=,24Y%+4A%24=(5#H@,3$U)3L@ M5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9.B!#86QI8G)I+'-A;G,M6QE/3-$)U!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M("TP+C(U:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0@,"XR-6EN)SX@/'-T2`Y+"`R,#$T+"!T M:&4@0V]M<&%N>2!E;G1E2!T:6UE(&)E='=E96X@1&5C M96UB97(@,34L(#(P,30@86YD($UA2!P97)I;V0@97AT96YD86)L92!T;R!$96-E M;6)E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@3V-T M;V)E'1E;F1A8FQE('1O($1E M8V5M8F5R(#$L(#(P,34@86YD('1H92!T97)M(&QO86X@;6%T=7)I='D@9&%T M92!O9B!$96-E;6)EF5D M(&%S(&EN=&5R97-T(&5X<&5NF5D(&1E8G0@ M:7-S=6%N8V4@8V]S=',@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P M="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^26X@861D:71I;VXL('1H92!#;VUP86YY M('=I;&P@<&%Y(&%N(&5N9"!O9B!T97)M(&-H87)G92!O9B`D/&9O;G0@2!P6%B;&4N(%1H92!E;F0@;V8@=&5R M;2!C:&%R9V4@=VEL;"!B92!A8V-R=65D(&%S(&%D9&ET:6]N86P@:6YT97)E M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^("8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R8C,38P.R8C,38P.R`F(S$V,#L\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF4Z(#@N-6EN(#$Q+C!I;B<^(#QT86)L92!S='EL93TS1"=,24Y% M+4A%24=(5#H@,3$U)3L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9.B!#86QI M8G)I+'-A;G,M6QE/3-$)U!!1$1)3D6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)W=H:71E+7-P86-E.FYO M=W)A<#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^)B,Q-C`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`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,RXQ,SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,BXS-#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,30L-C`S*3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`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`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\ M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)W=H:71E+7-P86-E.FYO M=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,24@8V]L"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]LF5D M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`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`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,3$W+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`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`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,#PO9&EV/B`\+W1D/B`\=&0@'!E8W1E9"!L:69E(&EN('EE87)S M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^-BXR/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,S@L.#DR/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M'!E8W1E9"!V;VQA M=&EL:71Y(&)A2!A;F0@9&EV M:61E;F0@>6EE;&0@8F%S960@;VX@=&AE(&AI6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P M="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@86UOF5S('1H M92!F86ER('9A;'5E(&]F('1H92!S=&]C:R!O<'1I;VYS(&]N(&$@65T(')E8V]G;FEZ960@86YD('=E:6=H=&5D M(&%V97)A9V4@<&5R:6]D(&]V97(@=VAI8V@@:70@=VEL;"!B92!R96-O9VYI M>F5D('=A65A2X\+V9O;G0^/"]D:78^(#PO9&EV M/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E M.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R M7S0Y9#5?8C,S-5\U.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-S$P-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D9C5A M+U=O'0O M:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4Z(#@N-6EN(#$Q+C!I;B<^ M(#QT86)L92!S='EL93TS1"=,24Y%+4A%24=(5#H@,3$U)3L@5TE$5$@Z(#$P M,"4[($9/3E0M1D%-24Q9.B!#86QI8G)I+'-A;G,M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^,3$N/"]F;VYT/CPO6QE/3-$)T-, M14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U325I%.B`Q,G!T)SX@/'-T6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F M;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@;W!E6QE M/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P M,"`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`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C8V+#@T-#PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M24Y$14Y4.B`P M:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P:6X@,"XR-6EN.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z M(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X@/'1R/B`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`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXH,2PU-S`L-S(R*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/ M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH M,2PW-3,L,C0X*3PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^*#4L-#6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z M(&)O=&@G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!724142#H@,3`P)3L@1D].5"U& M04U)3%DZ($-A;&EB6QE/3-$)U!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P M:6X@,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I M9CL@1D].5"U325I%.B`Q,G!T)SX@/&(^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@ M,&EN(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I9CL@ M1D].5"U325I%.B`Q,G!T)SX@/&(^/&9O;G0@'!I6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@36%R8V@@,C`Q,RP@=&AE($-O M;7!A;GD@96YT97)E9"!I;G1O(&%N(&]F9FEC92!L96%S92!A9W)E96UE;G0@ M9F]R(&]F9FEC92!S<&%C92!I;B!%=VEN9RP@3F5W($IE2P@=VAI8V@@ M8V]M;65N8V5D(&EN($IU;F4@,C`Q,R!W:71H(&$@=&5R;2!O9B!S:7AT>2!M M;VYT:',N(%1H92!R96UA:6YI;F<@;6EN:6UU;2!L96%S92!P87EM96YT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A2`D/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M5&AE($-O;7!A;GD@:&%S(&$@=V]R;&1W:61E(&5X8VQU2!T:&4@0V]M<&%N>2!A="!02!B971W965N(#(P,#,@86YD(#(P,#2!C:&%R86-T97)I>F5D(&%S('!A2!I;B!T M:&4@0V]M<&%N>28C.#(Q-SMS('!I<&5L:6YE+"!O;FQY('1H92!H>61R;W!H M;V)I8R!D;V-E=&%X96P@<')O9')U9R!N86YO<&%R=&EC;&4@*$A$4$XI(&9O M2!I2!A('!E2!T;R!A('1H:7)D('!A M2!R97-E87)C:"!O2X@5&AE($-O;7!A;GD@;6%Y M('1E2!T:6UE(&)Y(&=I=FEN M9R`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B2X@4')I;F-E M=&]N(&UA>2!T97)M:6YA=&4@=&AE(&%G2!S:&]U;&0@8G)E86-H(&]R(&9A:6P@=&\@<&5R9F]R;2!U;F1E7,N(%1H92!#;VUP86YY(&ES(&]B;&EG871E9"!U;F1E3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2`R,#`Q('=I=&@@=&AE($)R:71I M2`H)B,X,C(P.T)#0T$F(S@R,C$[ M*2!W:&5R96)Y(&EN(&-O;G-I9&5R871I;VX@9F]R('1H92!L:6-E;G-E(&%N M9"!C;VYD:71I;VYA;"!A6%L='D@ M:6X@=&AE(&QO=R!S:6YG;&4@9&EG:71S(&]N(&YE="!S86QE2!M87D@=&5R;6EN871E('1H92!A9W)E96UE;G0@:68@=&AE(&]T:&5R M('!A7,N/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^26X@8V]N6UP:&]M82!3;V-I971Y("8C,32!O9B!A;GD@2!I6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R96-E:79E&-E M960@/&9O;G0@6UE;G1S(&]R(')O>6%L=&EE6QE/3-$)W=I9'1H M.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q,34E.R!724142#H@,3`P)3L@1D].5"U&04U)3%DZ($-A M;&EB6QE/3-$)U!!1$1)3D6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U3 M25I%.B`Q,G!T)SX@/&(^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BQS97)I9CL@1D].5"U325I% M.B`Q,G!T)SX@/&(^/&9O;G0@6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN M(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[ M/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@3V-T;V)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG&5R8VES92!I;B!F=6QL(&]F('1H92!U;F1E&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!S97!A65A2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5?8C,S M-5\U.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-S$P-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O'0O:'1M;#L@8VAA M2!;4&]L:6-Y(%1E>'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#PO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^57-E(&]F(&5S=&EM871E&5S+"!V86QU871I;VX@;V8@ M&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T2!497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^5&AE(&YE="!L;W-S('!E6QE/3-$)W=H M:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!# M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`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`G M5&EM97,@3F5W(%)O;6%N)RPG2!O=&AE6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!497AT M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@ M65A2!T M:&%T(&EN('!R:6]R('EE87)S(&ET(&AA9"!B965N(&EN('1H92!D979E;&]P M;65N="!S=&%G92X@05-#(%1O<&EC(#DQ-2!I2!A9&]P=&EO;B!I6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^26X@075G=7-T(#(P,30L('1H92!&05-"(&ES28C.#(Q-SMS(&%B:6QI='D@=&\@8V]N=&EN=64@87,@ M82!G;VEN9R!C;VYC97)N(&%N9"!A8F]U="!R96QA=&5D(&9O;W1N;W1E(&1I M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5?8C,S-5\U.&%D-3DX,F1F-6$- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S$P-F,P8V5?,C)F,E\T M.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M:6X@,&EN(#!P="<^(#QI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M24Y$14Y4 M.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P:6X@,"XR-6EN.R!724142#H@-S`E.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X@/'1R/B`\=&0@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]2 M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^*#$W M+#0P,BPS,S6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,3DL.33X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5? M8C,S-5\U.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-S$P-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O'0O:'1M;#L@ M8VAA2!"86QA;F-E(%-H965T($=R;W5P:6YG(%M486)L92!497AT($)L;V-K73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,36QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@ M"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!D;W5B;&4[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`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`\+W1D/B`\ M=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T M<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3W1H97(@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-2PP,3$\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z("TR,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C(N M-7!T)SX@/"]D:78^(#QD:78@6QE/3-$)W=H:71E M+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5?8C,S-5\U M.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S$P M-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O'0O:'1M;#L@8VAA2!0;&%N="!!;F0@17%U:7!M96YT(%M!8G-T'0^)SQD:78@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4')O<&5R='D@86YD M(&5Q=6EP;65N="!A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<@ M86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)W=H:71E+7-P M86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q M<'@@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3,V+#0Y.#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`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`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PW-CDL-3@Y/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,34U+#4R M,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PQ M,S@L-36QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U! M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`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`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!# M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)W=H:71E+7-P86-E.FYO M=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-3@Y+#@R.#PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M24Y$14Y4 M.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P:6X@,"XR-6EN.R!724142#H@.3`E.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X@/'1R/B`\=&0@6QE/3-$)W=H:71E+7-P86-E M.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^-S0X+#0T-#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-C(T M+#0W,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,30S+#0X-#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^-C`L,#`P/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^-#DT+#8U,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,30U M+#4V-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,3DU+#0T-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BPP,C(L-#8R/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQD:78@ M6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,3`L,#`P+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5?8C,S-5\U.&%D M-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S$P-F,P M8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQD:78@ M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%2 M1TE..B`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`P,#`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`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,RXP,3PO9&EV/B`\+W1D/B`\=&0@ M"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,2PQ.3,L-34V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,BXW-3PO9&EV/B`\+W1D/B`\=&0@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T'0^)SQD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/ M33H@(S`P,#`P,"`Q<'@@#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52 M+4)/5%1/33H@(S`P,#`P,"`Q<'@@#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L"!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S4T+#(P-#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C,U+#(X M.3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^.3DV+#@P,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S(R+#`V.3PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PS M,S6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3$R+C`\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3$X+C,\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`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`P,#`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`P,#`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`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)W=I9'1H M.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO6QE/3-$)W=H:71E+7-P86-E.FYO=W)A M<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,C8V+#@T-#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A M8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@,"XR-6EN.R!72414 M2#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@ M=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R M/B`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`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$ M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,2PU-S`L-S(R*3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,2PW-3,L,C0X*3PO9&EV/B`\+W1D M/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^*#4L-#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/ M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!;3&EN92!)=&5M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!-87)K970@1G5N9',@6TUE;6)E2!-87)K970@1G5N9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R M,F8R7S0Y9#5?8C,S-5\U.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-S$P-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D M9C5A+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT+"!N970\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q M=6EP;65N="!;3&EN92!)=&5M2!A;F0@97%U:7!M96YT+"!G M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M2!A;F0@97%U:7!M96YT+"!G7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAAF%T M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X+#4R,3QS M<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y9#5?8C,S-5\U M.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S$P M-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O'0O:'1M;#L@8VAA2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!) M=&5M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2!A;F0@97%U:7!M M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6%B;&5S(&]T:&5R/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XR-S8L-C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'1U86PI("A54T0@)"D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M2`P.2P@,C`Q-#QB'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO2!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG-2!Y96%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO6%B;&4@6TQI;F4@271E M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M6UE;G0@5&5R;7,\+W1D/@T* M("`@("`@("`\=&0@8VQA6%B;&4@:6X@:6YS=&%L M;&UE;G1S(&]V97(@9F]R='DM='=O(&UO;G1H'0^)SQS<&%N/CPO'0^)TEN=&5R97-T(&ES('!A>6%B;&4@;6]N=&AL>2!A="!T:&4@ M9W)E871E'1E;F1A8FQE('1O($1E8V5M8F5R(#$L(#(P,34L/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!''0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO&5R8VES92!P&5R8VES92!P M:6-E+"!%>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!P'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6UE;G0@ M07=A'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#,U-"PR,#0\'0^)S8@>65A7,\&5R8VES960\+W1D/@T*("`@("`@("`\ M=&0@8VQA3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R,F8R7S0Y M9#5?8C,S-5\U.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-S$P-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D9C5A+U=O M'0O:'1M M;#L@8VAA2!3:&%R92!"87-E9"!087EM96YT($%W87)D(%M, M:6YE($ET96US73PO'0^)SQS<&%N/CPO65T M(%)E8V]G;FEZ960L(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@ M8VQA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W,3`V8S!C95\R M,F8R7S0Y9#5?8C,S-5\U.&%D-3DX,F1F-6$-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-S$P-F,P8V5?,C)F,E\T.60U7V(S,S5?-3AA9#4Y.#)D M9C5A+U=O'0O:'1M;#L@8VAA2!!9W)E96UE;G0@6TUE;6)E'0^ M)SQS<&%N/CPO2!!9W)E96UE;G0@6TUE;6)E'0^)SQS<&%N/CPO6%B;&4@9G)O;2!T:&4@ M86UO=6YT(')E8V5I=F5D(&9R;VT@;W5T+6QI8V5N6%L=&EE6UP:&]M82!3;V-I971Y($%G'0^)SQS<&%N M/CPO6UP M:&]M82!3;V-I971Y($%G'0^)SQS<&%N/CPO M6UE;G1S($1U92P@5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6UE;G0@87,@;VX@1&5C96UB97(@,2P@,C`Q-#PO M=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@ M87,@;VX@1&5C96UB97(@,2P@,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S M6UE;G1S M($1U92P@5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)S0U(&1A>7,\2!!9W)E96UE;G0@6TUE;6)E'0^)SQS<&%N/CPO6%B;&4@9G)O;2!T M:&4@86UO=6YT(')E8V5I=F5D(&9R;VT@;W5T+6QI8V5N'0^)SQS<&%N/CPO6%L='D@<&%Y86)L92!F2!!9W)E96UE;G0@6TUE;6)E'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'1U86PI("A54T0@)"D\8G(^ M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO&5R8VES92!0'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM M;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC XML 24 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loans Payable (Details Textual) (USD $)
0 Months Ended 3 Months Ended 9 Months Ended

May 09, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Schedule Of Loan payable [Line Items]

Amortization Of Financing Costs And Discounts $ 165,232 $ 74,751

Adjustments to Additional Paid in Capital, Warrant Issued 320,752

Deferred Finance Costs, Noncurrent, Net 589,828 589,828 0

Line of Credit Facility, Frequency of Payments any time between December 15, 2014 and March 31, 2015

Warrants Maturity Term 5 years

End of Loan Term, Fees 50,396 77,056

Warrant [Member]

Schedule Of Loan payable [Line Items]

Amortization Of Financing Costs And Discounts 57,670 88,176

Adjustments to Additional Paid in Capital, Warrant Issued 0

Term Loan [Member]

Schedule Of Loan payable [Line Items]

Debt Issuance Cost 357,253

End of Term Fee [Member]

Schedule Of Loan payable [Line Items]

Debt Issuance Cost 592,500

Hercules Technology Growth Capital [Member]

Schedule Of Loan payable [Line Items]

Line of Credit Facility, Fair Value of Amount Outstanding 10,000,000

Line of Credit Facility, Maximum Borrowing Capacity 15,000,000

Line of Credit Facility, Remaining Borrowing Capacity 5,000,000

Long-term Debt, Maturities, Repayment Terms repayable in installments over forty-two months including an initial interest-only period of twelve months after closing

Line of Credit Facility, Interest Rate Description Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015,

Hercules Technology Growth Capital [Member] | Warrant [Member]

Schedule Of Loan payable [Line Items]

Stock Issued During Period, Shares, New Issues 158,006

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 2.67 $ 2.67

Adjustments to Additional Paid in Capital, Warrant Issued $ 320,752

X

- Definition

Amount of fees associated with end of loan term.

+ References

No definition available.

+ Details

Name: cpxx_EndOfLoanTermFees

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: cpxx_ScheduleOfLoanPayableLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of years at exercise price of warrants to purchase in period.

+ References

No definition available.

+ Details

Name: cpxx_WarrantsMaturityTerm

Namespace Prefix: cpxx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).

+ References

No definition available.

+ Details

Name: us-gaap_DebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net amount of long-term deferred finance costs capitalized at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredFinanceCostsNoncurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Fair value of the amount outstanding under the credit facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13476-108611

+ Details

Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityFrequencyOfPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityInterestRateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Disclosure of timing of required repayments, sinking fund requirements, and other redeemable securities at fixed or determinable prices and dates in the five years immediately following the date of the latest balance sheet presented in the financial statements, and the amount thereafter to fully repay the principal of long-term debt. These disclosures may be made either on an individual debt or security basis, by type of debt or security basis, or on a combined basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 25 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Based Compensation (Tables)
9 Months Ended

Sep. 30, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity of the Company’s stock option plans for the nine months ended September 30, 2014:

Number of options

Exercise price

December 31, 2013

2,578,252

$

2.98

Granted

499,100

3.13

Exercised

(42,936)

2.34

Cancelled

(14,603)

3.17

September 30, 2014

3,019,813

$

3.01

Exercisable at September 30, 2014

1,193,556

$

2.75

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The following table provides information regarding stock options activity during the periods:

Three months ended

Nine months ended

September 30,

September 30,

2014

2013

2014

2013

Stock compensation expense recognized

$

354,204

$

235,289

$

996,801

$

322,069

Weighted average grant-date fair value of stock options issued (per share)

$

2.22

$

2.11

$

2.68

$

2.14

Grant-date fair value of stock options issued

$

45,732

$

59,080

$

1,337,588

$

3,314,341

Volatility

112.0

%

117.0

%

114.4

%

118.3

%

Risk-free interest rate

1.9

%

1.6

%

2.0

%

1.9

%

Dividend yield

0

%

0

%

0

%

0

%

Expected life in years

6.0

6.0

6.2

6.2

Intrinsic value of stock options exercised

$

-

$

-

$

38,892

$

-

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loans Payable (Tables)
9 Months Ended

Sep. 30, 2014

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

Long-term debt as of September 30, 2014 consists of the following:

Loan payable

$

10,000,000

End of term fee

77,056

Long-term debt

$

10,077,056

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Based Compensation (Details) (USD $)
9 Months Ended

Sep. 30, 2014

Schedule Of Share Based Compensation Stock Options Activity [Line Items]

Number of options, Beginning balance 2,578,252

Number of options, Granted 499,100

Number of options, Exercised (42,936)

Number of options, Cancelled (14,603)

Number of options, Ending balance 3,019,813

Number of options, Exercisable 1,193,556

Exercise price, Beginning balance $ 2.98

Exercise price, Granted $ 3.13

Exercise pice, Exercised $ 2.34

Exercise price, Cancelled $ 3.17

Exercise price, Ending balance $ 3.01

Exercise price, Exercisable $ 2.75

X

- Details

Name: cpxx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 28 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Geographic Segment Information (Tables)
9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The geographic information about total assets is based on the physical location of the assets.

Total Assets

September 30, 2014

December 31, 2013

United States

$

22,226,025

$

26,190,516

Canada

266,844

284,563

Germany

895,598

997,671

Total Assets

$

23,388,467

$

27,472,750

Net Loss

Three months ended

Nine months

September 30,

September 30,

2014

2013

2014

2013

United States

(5,046,236)

(3,274,731)

(12,977,790)

(15,649,089)

Canada

(433,581)

(402,681)

(1,570,722)

(1,753,248)

Total Net Loss

$

(5,479,817)

$

(3,677,412)

$

(14,548,512)

$

(17,402,337)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Liquidity (Details Textual) (USD $)
9 Months Ended 1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Oct. 28, 2014

Subsequent Event [Member]

Oct. 28, 2014

Subsequent Event [Member]

Warrant [Member]

Nature Of Business And Liquidity [Line Items]

Accumulated deficit $ (147,013,882) $ (132,465,370)

Cash and Cash Equivalents, at Carrying Value 20,180,490 27,641,470 23,589,516 9,648,008

Stock Issued During Period, Shares, New Issues 7,602,823 760,282

Proceeds From Issuance Of Common Stock $ 104,387 $ 32,499,986 $ 13,500,000

X

- Details

Name: cpxx_NatureOfBusinessAndLiquidityLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 30 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2.

Summary of Significant Accounting Policies

The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted.

In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Basis of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.

Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.

Loss per share: The net loss per share for the nine months ended September 30, 2013 has been corrected for an immaterial error in the calculation of average weighted shares outstanding. The revision is as follows:

As Reported

As Revised

Net loss

$

(17,402,337)

$

(17,402,337)

Net loss per share

$

(0.87)

$

(0.84)

Weighted average shares outstanding

19,977,071

20,641,876

The above correction has no impact on any other prior year financial statement amounts or disclosures.

New Accounting Pronouncement : In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation , which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40). The ASU provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Schedule Of Net Income Or Loss Per Share [Line Items]

Net loss $ (5,479,817) $ (3,677,412) $ (14,548,512) $ (17,402,337)

Net loss per share $ (0.21) $ (0.14) $ (0.56) $ (0.84)

Weighted average shares outstanding 26,078,532 26,026,793 26,065,006 20,641,876

Scenario, Previously Reported [Member]

Schedule Of Net Income Or Loss Per Share [Line Items]

Net loss $ (17,402,337)

Net loss per share $ (0.87)

Weighted average shares outstanding 19,977,071

X

- Details

Name: cpxx_ScheduleOfNetIncomeOrLossPerShareLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 32 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Assets (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Schedule Of Other Assets Noncurrent [Line Items]

Deferred financing costs (see Note 9) $ 589,828 $ 0

Other non-current assets 22,352 5,745

Assets, Noncurrent $ 612,180 $ 5,745

X

- Details

Name: cpxx_ScheduleOfOtherAssetsNoncurrentLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net amount of long-term deferred finance costs capitalized at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredFinanceCostsNoncurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name: us-gaap_OtherAssetsMiscellaneousNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 33 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (USD $)

Sep. 30, 2014

Dec. 31, 2013

Current assets:

Cash and cash equivalents $ 20,180,490 $ 23,589,516

Restricted cash 285,801 287,657

Other receivables 6,335 1,417,313

Prepaid expenses and deposits 679,681 491,465

Assets held for sale 74,086 74,086

Other current assets 541,468 468,389

Total current assets 21,767,861 26,328,426

Property and equipment, net 1,008,426 1,138,579

Other assets 612,180 5,745

Total assets 23,388,467 27,472,750

Current liabilities:

Accounts payable 183,174 1,193,148

Accrued liabilities 2,022,462 1,630,809

Current portion of deferred revenue 542,986 542,986

Total current liabilities 2,748,622 3,366,943

Long-term debt 10,077,056 0

Deferred revenue 180,996 588,236

Deferred rent 47,626 53,084

Total liabilities 13,054,300 4,008,263

Stockholders' equity

Preferred stock Authorized 20,000,000 shares, par value $0.001 0 0

Common stock Authorized 200,000,000 shares, par value $0.001 Issued and outstanding 26,078,532 and 26,035,596 shares as of September 30, 2014 and December 31, 2013, respectively 26,079 26,036

Warrants 1,083,193 1,083,193

Additional paid-in capital 157,372,043 155,953,894

Accumulated other comprehensive loss (1,133,266) (1,133,266)

Accumulated deficit (147,013,882) (132,465,370)

Total stockholders' equity 10,334,167 23,464,487

Total liabilities and stockholders' equity $ 23,388,467 $ 27,472,750

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39896-112707

+ Details

Name: us-gaap_DeferredRentCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of capitalized costs of materials, supplies, and other assets, which are not included in inventory but used in production.

+ References

No definition available.

+ Details

Name: us-gaap_MaterialsSuppliesAndOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.10)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_PrepaidExpenseCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 34 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Based Compensation (Details 1) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock compensation expense recognized $ 354,204 $ 235,289 $ 996,801 $ 322,069

Weighted average grant-date fair value of stock options issued (per share) $ 2.22 $ 2.11 $ 2.68 $ 2.14

Grant-date fair value of stock options issued 45,732 59,080 1,337,588 3,314,341

Volatility 112.00% 117.00% 114.40% 118.30%

Risk-free interest rate 1.90% 1.60% 2.00% 1.90%

Dividend yield 0.00% 0.00% 0.00% 0.00%

Expected life in years 6 years 6 years 6 years 2 months 12 days 6 years 2 months 12 days

Intrinsic value of stock options exercised $ 0 $ 0 $ 38,892 $ 0

X

- Definition

The grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

No definition available.

+ Details

Name: cpxx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 35 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (USD $)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Operating activities

Net loss $ (14,548,512) $ (17,402,337)

Adjustments to reconcile net loss to net cash used in operating activities

Amortization and depreciation 144,609 148,291

Non-cash stock-based compensation expense 996,801 322,069

Loss on disposal of property and equipment 0 126,633

Non-cash derivative instrument charge 0 7,473,108

Non-cash financing costs 165,232 74,751

Changes in operating assets and liabilities

Other receivables 1,407,230 1,990,932

Prepaid expenses and deposits (189,470) (134,177)

Restricted cash (38) (250,037)

Other current assets (73,079) (530,391)

Other assets (16,568) 0

Accounts payable (1,007,161) (22,332)

Accrued liabilities 400,843 208,124

Deferred rent (5,458) 23,148

Deferred revenue (407,240) (425,339)

Cash used in operating activities (13,132,811) (8,397,557)

Investing activities

Purchase of property and equipment (14,456) (82,009)

Proceeds on disposals of property and equipment 0 51,776

Cash used in investing activities (14,456) (30,233)

Financing activities

Proceeds from issuance of common stock and on options exercised 104,387 32,499,986

Payment of share issuance costs 0 (3,079,611)

Proceeds from loans payable 9,827,216 0

Payment of debt issuance costs (184,469) 0

Repayments of loans payable 0 (3,000,000)

Cash provided by financing activities 9,747,134 26,420,375

Effect of foreign exchange rate changes (8,893) 877

Net change in cash (3,409,026) 17,993,462

Cash and cash equivalents, beginning of period 23,589,516 9,648,008

Cash and cash equivalents, end of period 20,180,490 27,641,470

Supplemental disclosure of cash flow information

Interest paid $ 311,458 $ 79,388

X

- Definition

The amount of non-cash derivative charges recognized during the period.

+ References

No definition available.

+ Details

Name: cpxx_NoncashDerivativeInstrumentCharge

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the period in the carrying amount of capitalized costs of materials, supplies, or both, which are not included in inventory.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInMaterialsAndSupplies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other obligations not otherwise defined in the taxonomy where the payments will be made in future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherDeferredLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromIssuanceOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for the payment of other borrowing not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfOtherDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Receivables (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Other Receivables [Line Items]

Receivables related to the sale of New Jersey net operating losses $ 0 $ 1,412,302

Other receivables 6,335 5,011

Other receivables, net $ 6,335 $ 1,417,313

X

- Details

Name: cpxx_OtherReceivablesLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount as of the balance sheet date, net of allowance for doubtful accounts, of account and note receivables due from other than related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsAndNotesReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amounts due as of the balance sheet date from parties or arising from transactions not otherwise specified in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 37 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value, by Balance Sheet Grouping [Table Text Block]

There were no transfers between levels and the following table provides the assets carried at fair value:

Fair Value

(Level 1)

(Level 2)

(Level 3)

September 30, 2014

Assets:

Money Market Fund

$

17,727,260

$

17,727,260

$

-

$

-

December 31, 2013

Assets:

Certificates of Deposit

$

15,003,472

$

15,003,472

$

-

$

-

Money Market Fund

7,597,730

7,597,730

-

-

Total

$

22,601,202

$

22,601,202

$

-

$

-

X

- Definition

Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13476-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Current Assets (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Other Current Assets [Line Items]

Clinical trial materials $ 541,468 $ 468,389

X

- Details

Name: cpxx_OtherCurrentAssetsLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The carrying amount of capitalized costs of materials, supplies, and other assets, which are not included in inventory but used in production.

+ References

No definition available.

+ Details

Name: us-gaap_MaterialsSuppliesAndOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Current Assets (Tables)
9 Months Ended

Sep. 30, 2014

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Current Assets [Table Text Block]

Other current assets as of September 30, 2014 and December 31, 2013 consist of the following:

September 30, 2014

December 31, 2013

Clinical trial materials

$

541,468

$

468,389

X

- Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amounts of other current assets.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 40 0001144204-14-067700-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-067700-xbrl.zip M4$L#!!0````(`!R`;47PFL"TR,#$T,#DS,"YX M;6Q55`D``P@<950('&54=7@+``$$)0X```0Y`0``[%W[;^,XDOY]@?D?N-Z= MF3M`3O3P(W:Z>Y'.HR>[[B1(/(^]PR%@)-KFMBQY22F)YW#_^Y&R94N.[,0> M6Z:4:G0W9(FD6!^_*A9?I0]_>QZZZ)$P3GWO8\4XT"N(>+;O4*__L?)S]Z)Z M5$%_^_3=GS[\N5I%7XA'&`Z(@Q[&Z`P'N,NP_8W'^9%Q8!PTD;PPJU?^8]74 MC1KZ;[W6-FIML_4_Z']OOOX?.K_KHBIZ>GHZ<$0)053"@>T/4;4:O^M0/GX0KX^3RZ<.G65()FX<3A[. MDKXH^LF*TAJM5NLP>CI+RFE60E&H#[!GI^I"5]1],3WE M?LTTFJMR3%+$&1PR8L26#;PT3^L0,YOY+CGL83NHDN>1BST)^?A"_(X+LOW0 M"]@X#1LG]D'??SR M[4%V>ODD(P/U'@D/LK-,GF5(XV%J\^P\T2.9Q4AGX=3.SB`>9"4/1FQ)>O$D M(T/(JWV,1[,\/FA2#':P7A$/E8X'8Y*U/%JK,4'S]RIH$-1T,14G/I>0)X# M=$?L0%B@R$R(5TP,A3U]2`6=;W3C7OR5K=3U]=:]I4?7DRK-F]V MESKR?H\2AJ)JDY28,>2GE_^H?-*%!EMFL]9H?CAF69)52KP\OC7%<%KV2F!K M"6!K102VM@FPM=T!6T\`*ZY;10:VO@FP(E-K%\`V2V0*FBJ9@F:)3,'ZP.[. M%)SP:Z]P@$[([$85:- MBV%]MLF7^]F]2V\4!KQ#'HEK)(N:)?@\GEW^)%H?,WLPCI(7FW=OE>]%^I>` M+2<=*$2A%<($A5A/(4Q0B%(KA`4*L9Y"6*`0>U"(^?3'_5??(^.OF'TCP47H M.1R\Z]>HDHW87EBRVZF@!$NVY`V_=[:5R:<&-=C8!P8U*(\G#6JPL><+:E`> M__G=J$%B+/G.Z5MLEN0VXP"NLS+&$EQGM=0`7.>]J`&XSFJI`;C.>U$#<)W5 M4@-87=^V.U-6IL"R\[9[_+(R!=9CM]TI%I(IV>>5@#&%9(S*Y[<6)LI/_:'` MB;#S?X=T),5.DNN&^>(=P?C&%2P_\9Q9HL_C[GA$BLVL-PDWVWR1#5,)9X^3 MBR@A\V@0,B+0N:#/\HH#/;+HL1RIBE*YR7'" M.0GX3\1U?O8[#QHZ/U/ MA-FA2WB7V`//=_W^^`OSGX+!=+0P@JQ;3-9OW MY>M->MGC,V5FGN6WRI$>*R;#7NYM&`%\+ M?*V"37&D>[XN8<..C[T2,_&-)(BXF88#?*85S#GWG.N>Q.N"$&!/Q)Z7D`"# MEG^$`UPHY5PHE3\XLN!Y7?G>+X0'Q#EYPBQ]#CJZ4_R)T@4Q(KYD2OT^/!5H M\#TTN,J]RH)!^-FC`J:HF^:9_L@7XO<9'@VHC0M^?&^%2!%I7D)1,A.Q>-P. M>]C![[S1DR"4N[F_"`\;>^-WWMXI%$K8X(G%@P'";I3P/>$"CX2QN4>ESXC$?#)'-?!@+!3?SBD@7Q4 M\!UAV=)$M'H=D.5DVZ0JLZ9(1)=/-ABXZJNHC9^!VH6B=K+!@-HKJ-TAX3Y?S9=D.'>OV.[_4#PH;S1\4F[@:B3DQG M%GK;]23!'RB,%CWYH$.;ZE`*.]"@=Z=!JV;JBJL3NZ4>S+D5D>@KYNV`Z#`# MER_17WP!;#(02[DPT\AW=^'#OX@==/UK=O*(J8L?7'+ALVOQ$`>RDYHO- MX@U$G:S'I6#+CUG[.,9T_B0`N")/?R>,DS$092VB9(%7;KK\@CW;#Q\)\WL] M:A,^PC9YF,SZV%.M&4;R`I/68M*:N):09(GS-^6/2U6XD%#Y?8[#ML-A&,TN MQT[HB)&!!.Z17`HE&4*"56[.W)(`4X\XYYAYPK9F;T%\EP3)1J;< M;)##5M^["WS[&Q`A\66X-"CEYL")XU"Y5(G=&TR=2R\5R0KX('J.50"5C!O+ MCE*!G5#*3J@\K[:$0F!FBF%FBD@M&`<5>AQ40,K!,$K5893*9'JQY`1>E4I> MU3X6"6#^5KGYV]S:'ESB8KC$>^$&^+2%]FGWP1EP2E5U2G-A@Z'/ARKBVCR: M?C@Y?.#DWZ'$Z)$L>!KI1\4/R+Y4H"4)]CPX,?0-!B21^B%WQ[=DY#-A:C/-2YR\X#S*%F?V^!5,]D0HQ0+Z;O:=!TI8- M6/D&:BJ;T"6,OWXD[,1U_6A_^/5(CF@664\=BME8?B_[NA?-?42\AZX[9^8O M:XEY+9:V)6C`=FW^SYY#V*^,!NG]L+<[=$IO01WG(KRLX^=D5 MIAY-"7I+>DNW7%6BNE[(L%K.O5'Y](,;'`LY$0_&KK`C7T]NOUQ>M9$^"L2_ MYV-T<7W5;2-#_NX*I>?HBCRA6W^(/6UR0Q-59+2'*C_T@V.T4-QIY_SDMOW@ M!X-)2=6+DZ^7G7^V%XHZCI[=7?[7^>15QYS^3MKHZ*!./608!SKUYL4'4N;X M!9W+J_/J3^>77WZ2M33JWQ^C7R_/NC_)@79Q'7EL4CJ]6>_1]AQXM]/U`D&'ROR38GJL?FE$U?S MYN3L[/+J2_7S=;=[_57`2[UC%-_LG%]TI[>F==U$OE2N[O5-=*>" M'H58?6&)`W\TJY-9>ZT]9BTM(([^"=C3<"VV=P9BID!L]IZ>8%_\HH4&C1+5 M#F2J0YE,_HQ^B+K-\A\&SA^`;GVL<@>(!\SW^K'LK\$5:3F:JSE_B5ZZP*5@ M'B8X>1BISS9U-0.G*8'?3HT?\'!T_!>CH1^OIL@6JML]_ZU;O;PZ.Y=V+5:T M#!G6J'Q6FI@C/R[4YT?MQX@F/Z9YDGKA3/X)!=B<`@ASY/>$Q1T%$T?,TC4D MS3K"GH/.1$)Y=XZF942/+4UV#9SR(,HN2D4]WW5]&4N@743$\Z,+2M<^8:07 MS'ZR5WHAG/PW%7R:NR5[I\_7MV?GM]73ZT[GY.9.O-(6K8)'G!RCZU_.;R\Z MU[^VT2/E5)3]:G>4Z('B>LPZ1G/T7,FPK9%L)YW++Z*NMO`V"(M9V?UG1U3' M\]D0NPM6+X@0\P1B+$(,B>I?W[;17_3HSPM>'R,A2O?R]*03OTJT0N`/IPE_ MG=:QIL][U$;]^Y1USFCSUSL.584SMB#;TT`,XJM1R(:VYS\Q/)J1*>XGIS5& MQN@9<=^ESI3*TVHRVA\$FP"R!0`$`I+IHOJB)S9?H#&S;@D[IFOS']+>`0?* MS8',KBQ%`>O=4B#ISN5MZS^?G/[CR^WUSU=G`@S;)J37*WD'D)/$V[`(*@H\ MM4C1""S#'`$>;\5#+RD@P`#0"-`(Y5T&E_0VB?:+TY`ZCDMR-"**TR)# MW+]N(.6*@=+"M',M7C/9O^@9YK%:N!8&0@.A5Q#:T&J&J5FZ6;B6WB&Q%>GL M\YT=>+%4LB]&;"QV+J9NO0E"Q7F0/R"[LYL[1"G#;C8TRZJ#AH"&@(8LT9"Z MIAL&:(AR7D6^4P@%'DKLTUA:PC8X?O@@WZ\.(CN8@'WKV&M-G!0>GFUSMG:O M7@@HECK<`,7:KF+):9&F9FVT1Z*TRK5B%VPJS[:VC?<.)C:> MQSM\I,CMR4;V*$W5Q6,_#-H]^DR=0@ M/@.1_GI?R!CQ@A/.2<`W/Y5@[N14`AP;4/38P'J[XNL9APC>N`T>SA1,9TFG M>HHFBKHQGKL]5I#:=UTUS8.ZQ"KKL,'DF9*[QXMWV,"><@-'W'C;>0,4'S.( M3QG`(8/U*K^K0P8-.&2PW).TU-ECJN;$;ZDWF,,A`^``'#)XUX<,%.H`"K0< MJ*+`L*4:ME2#1H!&@$84VV508QEK+8?AU*4>M;&+`D;%_T,L6E=4VZXOXP=NOLAN0>@_1=?P+:ECFR_ASXGZQ]:^"[VG MX+6UO0:$(EQGVT!LB:)5WYD9>@FA$AL'(!YA5IJM;!%(\8#$/-@T*"&BGNV& MTJ3&NPT&Q'50**.4(WORC5+AVF!.5H8OG#?5OJYV39$L-J"I]9C,)RUO]_)M M:H#(B2M<;84"9ZDT-;G-!>W-$8%=#4`"V-;P3M6XY22 M2K-'BC3@'HY%[6QZ5(D%6*-F:*U6GJL(P&I@]M0F>^FUE8\^H:*XN6\N*TMLE98P=/5FX=H;Z`WT!GH7N'// M-W90!S_XT;<,Q_OOTE77D'8FTV6EH==B^I+BXP_`\P7-<:%L34 M4:]CSW?4?IK:91J@$^JY$3`CL7\J[#<$FTJ#LL)%:%-JN"8,K7ZDU4R8S@#E`N7: MNG(9UI%6;^YM645%Y=KK-PWC^FXU`I9I+?G,UT;!N]X8[4AI>"".4DZQ-9H) ME:RI$PA?S7%S5@@=50+DF%8R0$[]A;#=`2-D+O%0*.R`SW\3SR$.-'&AF_B* M>M#".YOY4`D'L-0;J'%Q@IV]INA+(MY!LT.SOZ-F!Y->&.'>C6YO//GS2GA+ MB&$*''C7,4R!`V`'@`-@!TKZB69%IV$+>DA;%8%5V3E>>#S@@[0E$1@T`C0" M-`(T`C0"-`(T`C1"%8U09&/\[@Y)9`TJSQ*GZ:)@_'CHLX#^#L?KEHH+GRM7 M;;]NSI\K/]+JI@&Z`;H!NK$(3]W03`L"`(%N@&YD?+VMIC5T4`Y0#E".#.4X MTLP6>%5PQDF9[[BGCQ]-SQ#]HNB"/+`0LS$R=HYS/$L4L$ M"8.!('T@E-+_AAZQ&Q+D]]!?M\F;NM[4&J:9:H\#=!*@V5Y59.F:%+@653/S M,\WRL37!XV5UY5U&AD)@ZO43*,P%?L)\NT)MLZQF3=./&B_Y.M.U6=MR&>"( M^RYQQU)N;E,A'.U1>RZJAIX&U!X@RD7C$RZGXP1GN/C+2<#1@+C.O/E]+\). MEBTG"J/X20_8Q9Y-$!\0$ARHHT4(NZ)5/U;^%7(A\GAY*Y3)(IR%3%):\)J@ MR6$=%)W1>:D[5G8+1PJ.=ZWB1K.IU#YLY=SY$P: M-;)EKS=L[14=S/P1N4/1N5?153B$1:=2XXUQTO%HRS.RQRA*4W7QV`^#=H\^ M$^?X3:=9)W/@LRMG5K/D)9M?QM[)A\.05_L8C]HWTY[I1EB;X,1SSF,#=D:Y M[.E"1KKD.?CL^O:W3]_]Z;L_(?0ASGMBVW[H!?P&CV7!(K>XPT+B="A^H"X- M*.$9Q4@[%X@?MZ3WL7*C&_?BKP2XZ^NM>TN/KBN(.H(+V`ZH`E MGPHC_,"HQK''JY%&I!7"D(8Z0;E7J#3W^%,'MA/K+#.7/AZMQ`.?Z+QW?+-S M?K%P!#P&96&0D\H5K9:).Q5I%:.^)?!'\Y,VM=>:+`/P!;@6*9&!F+E.=W#T MFBW('`V]%;KULN?6@64,`LO\4L7N2/2>#.22#]8>$"K#W^B)WP>,S1\UW7?Q*VK)T96D.EJP(R(K_*0R21 M/>SOWWH8/I6$>S<'6)8C\,H)E24'E6<_X!33.R!!9E>;X@"<8MJ'M2]J)%;E M)8;]IX`'[,<%!@`>H!$JN@R*[YO)+U,Q MHKV*XN8^N%/XDPYK63_3L+1FLUZX!@=^`[_?MEO?TFI'>W-:5>2W(KW[?L;F M(^;W".>B2\I:K0838>HY&04ZD5]:?W._HWOHQHJ*M?^OQM0G"C%&T8: M7@Q8?$8>LN(:KQV0N*YJ0&).?R=M=/3_[%UK;^.VTOY>H/^!",YBMX#LZF+Y MDFT+[&;3[19I$F33]GQ;T!)M\ZTLZ5!R$O?7OT-*MB5;N3F^4,X`W<)V)(HS M\SPS0XH<-ET>$LMJFL6ZI:^BVK`ZN6+]8L,+O+ZLA&^MJQ\_K[AOKZ(6\A-K M^6)IY/=G$7"*7!9>`.M7%+E4E;7Q0%'9E5+)S]/%0Y5F'U#$IB7<2-7DE]4S+A\@HPH?,9_P,(T()?!E3`+``:%#P=C\8)C-GHS@EL/_F`>!/$I6 MG4OQ&Q/>1+ZPN&;>*(R":#@EGT5T"W\ZH3%/:6"0+Z'7).\R$W5MVWP_NVG^ MD_7^!W76`AEPD:0;[KY9W?V\`/1"A?*`F<%$G>!`4W54#P0=0U4SX`D1+'\W M(\^CX&$"D@52WPF);IB06D^GC?0VFAT%P4,OF,BP!0W`%T@S:"#-II9M-*(P MF)(8>AWYJB.W++B9GR)!!W#5K`.97A9'XVSVX(TGJL:#?WU&?$%O0QB,P/]` M0P5LD"7QXM`P84\%?2I_*PI4F<'Y'S MYU<2"]D;]4>%WID]2-$>D,VQT%=/!9(MNIQUSU`9'UA"RMG`0`P@0Z"(V!TB=2 M".A(+*(;[H/H+&0"L'0;B7_464D9S30ZYN?)GJ[6QJ?'6& M"S#>LV!1.O=&7K8&1A6KR@P>4[GX.YT2>4*4[,'2/9VE)G^?A"S_4[=)/H!3 MRGN6R0BC./"`H?)OBX?,SIT"@0"YP'B#'YRH,`;BAVQSZ!Q'`V_SA67:SW2GW$GB: M]71V?)=B"3QWP"'03QD52>[L*1?E8_!RM6[^F"W'-HV.6S[B2KF*`0^!M]G! M>\DV'NQV#-MUR@^&!$GZ`IG+RI`:,B^=9Y5+B9D\?DLP3\X2*$?BLWZJ\*B\ M3=9G*<Y$; M1G8&?&'6N*IN)?]2U9F-GU4("FQWS%7+;?0AW:YA+1_#)D<32@\C<`KJD4\Y M[TS&BCA3;3"=1Z-%$CL)%R:JTM_&#YCK]HSN\N%VDIQ9EIZ!4"VY*@;;CF$NORP00X\(!+ MAP'!+_(`,/+I[_@/#Z5=!ER07Z&RL'14'D7)TSY!NF0EPY)-&7*(`_=7-I!E M7^`A873C3S*>YB.G+,I4:&ON+/,%B/*`T5SKA9'JT[RF&E$][CJO2]EQ]M@- MGU-K.+WVEMUDIV.8[M)#E)@P7!TP5CP;\@5>LXY>AVAP2A9^PD_X"3]M_5/1 MV=7/56]TG%Z2_RP*APT5^U5F?^\YC?E!C$G%28PU5.?NL+"MDP[;NIUTJ,=" ML'M7[[0ZJ\MWY"M9W));#W'K7^Y_QP6!55G,?9;&U!'9FFPGV-ZVDBHW=UJ8 M38`1[[[PH./V$MR"M2&%',H6K,)L$5)$)Y>YZ\RP."K""(H;17"CR(8WBD!N MNE]GJR.[]KI39+5GM=DUTJE:,KK^[I$V[AXI/EFCW2-UW*WQV*RF93[R%A)W9)3T]56N.&LH MJI.B-UA5HA:;,YZR#4.CB>\ZO02Y+K[0(+D#G(S'5("?S!9X2(=^(Y>&/+"2 M,5O"F"^HCP.YWV>V(.LI"PKP30J^29'YY?KGI6]^<.QLHCS)[8BGK"$5QH[# MZ%;0N#SD65_@.DZ5Z61>"\274`?;0,RV5U1Q/I$>:J&0:%#XK/S<.F7IM=+` MEO"]*TQL'P.G^6+\A5K4JOQ7:_>73XBNKX<=38ENQ.O72N)-ORS71>`-SG>^ M;GU43&$>A$(0`<@(9(3V*8/F"PZJ$H;E[?+.OE[TZ+W.0A]Q=[ZB\%`6C=B& MV^D:MKNWBI+U,7G]"*W7(M(=`[O9PXKM^L7QW0[\/\OR!LS?%PYTS.=T%/>` MHO>NCYCN&18ND]==7#RT:DU\.\W]#;UT!+^O[BZH M73JY3Q>QU4W,+TZP][F$29O=S"_&U287/CF&:?6,;@W7N!QLJ8#]X>,`2@7H M1:ZF:2&OM$MH:K3]0'-YM9ST?7$J7^4"BIY,ATGA79I_?7UL>J6U'OAX)71X MN?F1#DB'.B<*>UGIH(H`5!Y;5KM4$B="ZC!HU7@P]BQ7:AE6SS%<+()Y`#S9 MYGZ'5TH/N]EQD1F:5"R<]?=5UT6J>Z&M_*1D>?3C0')"5<\2;$B%.DVM6%0K M693A*AS;E1VRFV#YK`<[G]TGG=[HB.1%^K(MUQNM+/G2*EU+]26Q+M?"87>* M1:M;VNR^UW,\HW/-,=LM5EQJKPA[+<\A7$B[#P/>(/I];7>C%,8V:FQTC$T(:(8WAJFY&UH/;&YWF M?=&[Y">M-GND].V:KPOW`(MU-7``T6Z?JZ&1,"N$66<)M$Y^]``8@9#'&($Q M`F.$MH1YO3&B_@,J?`M5']FV1>&ZZ>&00QOB%_%[D+(A?A&_=98-\8OXU7YO MSO8VM5:-#=2)NP",Q5F[A-W)SXP(YD7#D/];PVIGKW1#XW/$U>L0A1W78W); MAFWN;=O9]H3==/!&%NMD761Q>=;2<0V[VSL\.R.+:RPNLOAY+.[UVD9W?]6$ MD,7(8F3QRS-JVS;,-L9B_:83MK<7NVHZX6\F`\A=5RFPZW<8:3V3'*0P M4G@[%+;J5_44*8P41@HO*-RNW_')2&&D,%*X$(4/L&!D[><9=KMLX?-SIA5J M-RM53P^(DZV[.A[=-3K.WB83=)QKU5%<)#&2^`$2NSW#[)J'9V8D<8W%11(_ MC\26X3@=P^WN;4X!>8P\1AZ_?/F"X5@MPVGA,B3])A9VNX!A_Z3'>=/M^3@- M3FG:[63I(=M7RPP%V8OL1?8B>Y&]R-X#MB^RM\;B(GN1O?6>$]CM8H._HH"F M/.#IM';30_7T;/4YU_U0)D`MRVZ^CI>1;VHG)7(8.?PT#G>0PYI*B1Q&#C^- MPZWFZZA+A!S67%SD\-H<[C;7*:>NN;F?S6%-Y@IVNW[@BB?_-`:",<)E34R6 MI$30E-5N#JF>SNX@ID1KM1O+:NZMZ,M.YT?WEJX@@Y'!6V9P^_",C0Q&!K\: M!N]QZAX9C`Q&!F,6?4@3!KM=7/")WW"?A3Z9?@YG0G<]$]I^)>\R:HQMI#)2&:E\$-A&*B.5GT9E/+M(GV>]VLXI?X/-, M22=GIQ^NCJ&#H[(JKI4FSD$35TH3RS(JY7XY_W1Z#J*83=OEH*T_/EQ]_@+R MFCS,_L7I0JY!%*:SIRZU=E0AL+Q<_5R+SE^/&!D^]5!(PA(`&I6K*B8)#X<$X\EG0)/(I)]$XIN&4^"QE8LQ#:$3>GK>> M*;%K6YWWV8J-/DW@"FA*7I3P<0R_9(%1,I$K@6CR41,H8DD%1/9>K.&Z*H]-6:@I>-(I/Q?Z(&T7)DE M"J`EIH"!*?PDJ`Q4?&5QRL9]>)9C&L0V MK9:A+DVC%&#K@4PL3*@BJA=)>+)`D3J-(+J$#=DB?,N>"[^D9,KD15XT#$$' M&?ENF11.?@&9Z'#6ZTS$O*LIA(D@('U6O/F6)N0_E?J?!;.W2[9^:[P%U?#! MVY6(I>SD&+UNU^C8O1+&5">H%:4&2!;(KT,OV'!]!&25GY1P5]! MH1\)GXF?CR"^YAU68?;8,LTW[XFZIA'0:31)CP?\COGOCXC'@B")J72VZC[Y M/::^GW^?MR_FG_QYSXH?Q>+C+!;_].,D:0PIC8\_\<0+(O!'[&)P4D#/58:; M$\!0\G5$!?LH_=ME[@VOV5WZ,0!>_/+]=]]_1\A/L^:^LJ&\X(K%DE3A<-'\ M_!;`)?C..[AF\//1I6E]@_\DCJ\CL_?-,=7G(\)],"D%U?O?.D>_+#F2.??C M%/[E>6%F3[)D>2/[P0#B@/W)T2;]4@*@/R;=)O@C8EE-\$*%%R/*ZOD#SKZ< MGS;F+U`L%RS^]Y=/U[_)=J3Y2]@]H0'O"VXD-$P:"K5ET%H`VB*<'H')(FLM MIJW%5SSSY'26<7^\N+Z^^$.YUD4:?G;ZZW7^4][WF2=>2M1+=UU?7*I?CJ1/ MYU1X^25U+=N[0F-V,32`[X["X8P2CP4*,.LJ[!A7,BD7$`ZOQBG5#U`IEZQ0AP$ M'94"05\_0P(.%S9)`9@ADYM6&_,/M"-+^?I:>R2%(F(#`M_`; MW.Y-!'2TN=G4I(04-:1;=+W88]J'W"%/`VF2L#19$2(>31.EZ[DTLS1478^C MD`<[3\J]+P3"I=!:C/PKPLE_N>#YW6V9`7R\N/IT>M4XN3@[^W#Y%1[I14%` MXX2])Q=_G5[]>G;Q]S&Y@;$$M/VDS/`%JS<\)L>VZ\Q,;7X2RG$W/*VJDW"; MF#*&X5C*&A(,[#B,;L$QS,$TRS;R'A,KOB-)%'`_A_*+-;*!.4;GS9&$.O0? M$AIW11W7TITM=/)!^:E7:_67+\S220]([4.@=MXA-3JIZ,W]"K**S+=7M#6? MYUJHS3&-Q1!D,);41;M,+"^KD M`A]A>-WT@#9&&^_%66N^U*3*?Y>F%-
0W3:LGFFXUMY.4-`1V9I$\.WM-JV*X-DKP'W!`'>-[SUO/>Q=XW:[ M;71;>SN9$O&-^-XNOKLMPVWO[=1&'?&M21C?[4`\7S.#Z5R5N,][F:*Y]7>O MD$,9]71[KN'VNL@1Y`ARY!Z.]'H=H]VQD"/:Y1.[G190:[K(VDNY#C:Y?-0_ M..`?_&C2E\_71R-;6.;RU/G39^I)XX'9VLJK&KT@>2$(/8'755B-B+58)WZN!5J>X M@,RR5O1QSM*%2LZB!#>0U)?7'>3URWA=D[7]CVX,&PG&%@H90\P>)8OO+/37 M*M2,"*@-`LYYN`J`UVKQ^CMV3-A>3<+V&+/OV?J'9D>SOR*SHTNOC7"OAMO; MVN-5G\W2M6)GYSC7,5MNPG?8/M3,PXAGQO()GQ[`[ M+:/C6(AGS<5%/#\%SY9M]#H=H],S$=":BXN`?A*@7:/=ZAEFMX>`UF\\M<5= MK16ZP6)7]XN[AP(`>I<+VE@!`#TT4N4;6XYCN-W]I:[("&2$9HPP;:.-C$!& M("-F^;/A=DRC8]O(">0$D8+6M_B3M221^$ M()5>0"6K9;BMKN$BEY!+R*47<@EBDFD;CH,IWCK%^5;JY,U$?KM4UNZM\39A M@@_>KLB5U=.3#6^SBEYVG\30Z*A:E)<_Y*BR\[,O"D6J1E\_$CX3JH+>;/>> MM->QK.?WGJAK&@&=1I/T>,#OF/_^297WLGF.^2=_WIGB1['X.#/J3S].DL:0 MTOCX*QN.69A>L3@2*;3\B2=>$"43P:[97?HQB+Q_?OG^N^^_(^2GV2TGT7C, M4WE7\B'T3\"`J-2W[BA`:\+[B1T#!I*+J4V6(!QHKH M>005"\=7JA,I*IS:K-SJ+!2H,I.S'\].?UVJ/&DV'>F0EHJTEFY2[EGJA=R` M5,/PYZ,TBN==6D"VVLD^NS]9:FKM()K(C3T23*"-H/)N,^I06Y'W!L1=A=S`>+RI2ZX37(- M71!L3'D(2(+\*^3CR3A_>DRG.=@2$@T*MSJFH20@M]!E\I]-IDV.:Y@]LV3> M"D^AO;'KCM0_J`#1"0/B-1'^(2E5O40-U2VA3^*>^0@EZD=!Y8@X/"81@&O_=I M^$^F.*![S+Q4WL=!%0GS)N`10JMR`?3L?1!+0!C6Y4-;9I M&C#Z*ZF&^-`;,)Q\[("+)"531I4\\I=^_>?V5],:&01:QZ>,%"=BM]<9K1G`R`LFB419`-`, M2QF)"HJ7$'0\EH(3^C.$RT2B(J**KSGNS`Z0@:8D%M$--)DL1>5T5'B(FCQ. M9(1-HC$\2P5^S]):Q4';=R=VYV5'<220M;T!V%>,IL`%&BDS0 M()@2;T0%]2"%X/_"HT"-64\G`>A"3FDEJ9AX.=$%RR@'>L!C%O"0&1`C M@DSVT=0743R*^MPC?@2BTSL6J&;%9%A6\+O?/EV>_R"[-)9"0#<(AZQGTO^_ M/`E*1_!]#H?,NEW^!IV4.LJ!.^.,-*P!D MT>(MV#$'_G*S,T9(8!:4=1XMM`&>'^X0L^[\"#INY$]M M`%14PW/O/*+09%_B8[[4BLSV02EY M(/^!,,YB9P#:X9VB)PG@ZZS/ZQD;MI/@?!K08LOF&XK4DM2,E5]_JIND1%UX MD4113;D6.[N2Q4M5=3UUZ^IN#U1\;#-@@'!BIC8V5?C08;AFL.L#A"/0`NH5 MXP4;Z@=4JWPZG-0:L"`@M4%">,S4P^F$P&(A@2 M^O`7H!SH:W+\K,6LQIZ`C"'ZB4'C0:HT0"JP&">YOY8QX0[FI!*]!F-J-,(D ML@^%@0WA%$4-":GQRV$ZEUHRQ[5`%VB00P;VV)LZ.S8$*U''[.?\T#`CO4`< MI8692##X"1_9&U*D-IM=+,N^Q+"LD$O>V-B05?M^JJ%P010!!NBD4;'%]YEV MY=`19:B<&N&\NP?%`!@P7QL&-!UG-CN]8P0TT@+T3^,$^JQB M$O9=YLM!%:+`9S,T$&8#R6P(4KIFM&3>F*.(54BK[O\[CF)W,"G.FP\[@&4' ME+&Z+HLJ,],[T],D0OUBTW1-DA,T4VU8S+.$"\C!0,O/Z)3`1/B0Q5>*].G\ MXN)L^E7^]#'Q!,^):X!X#S`0)F$3C>IR2LQ4CSH'E_Y*([TH@D%C=-&@!U0Z MY>9X%KL6NJ6\M8"74ZI6%+YH_`47TU]S<5CJZ6=!EL""K&@^0`.:TAN.GT&. M%$O3.)0^@80@-/!-A+HN>!@-=.@@T!D@8-2SW2%$0VZ4QK>Y")I%,%FXG:4+ M$I-/]DU?969.A#/@*5]O8V$20WDBD=3W9L9@I@&^LR#NU8*=15DT(Z%C'4<$E![O(^FYFBFT$;Q9M#J@H0/`#@5%&@?>DO'?9`A& MC3%*_PFWDR%D@T-;>`SZ+@&U2V5@:I_FC-WM[>.$S*$:$"Q.6^%@B0O M2W-YN).I/L,(F^&84)BQ)#)G"F9!:ZZ.G4U4+,1>\4*TRNK7_QV[X2S7I&^U M:83^*D#V&KL`86K4F!3@IU0PHO`A]XU"AE[0["S&/#2&8(Q9JNH#;DP3\*9.(>U* M0OO'$^%Q5B1(TV`ZQ"OCZ+@HNLP/I)]-5\`HVU[S*:.TG#(R)T+59VKQ5\@B M2O)(R,^R+#*:0T;B)J8UK7S)89KT>RYHKD/#7_*=2<2F8!BP+#6;19J)"X0` MR0D5"@UTID.R:PG))PMZG#0KSD]Q93`J%A30G>03,5N!EMX*$DXZWN:S5>"! M\LG"%^K)0),@AV^6+_5$7X.QJ;@S9L19X$@KE>[`[6>W.61$DKMH&>F5^&E2 MPI3I0_11"/K@C].X);&,S.*Y0W;/0MC",BA[R)1K5K3*,A;WG[1*^/2:*^.S M>,/^.PDU6")+TYPYE::ER&D0\X$*.4%LTW)>49*9AI=QO#3*E.:A_<:F M)U*)A@00E9KX%!@C.B),R!&=18=(O2+LZ&C/Y7H-E,OMES[K>F9*<@^?^I/- MFRTM7ILMUX^H]A_3N773\W,[1K5S13^?$*6??D./A!75IO MJ7[2,&.6C!'/3;(MIZ99Z((E*,;R(N[_B,C=X"J*6<@8K8UT64*H[P'J?R3U M2)*-6P'&ZSSJ-`D(0C*R9SEA7!/W]"(:-=#(E$4Y?YQ`\/;Y[.P^2[9HB.'; M+]/"[Y`&&U.ZLU++>#A*<,DF@6W6M9`&-S2%H,'K<&I6X'J2=N)ZKOWL>K.) M$5;[GCJ[U!8F?C`NO"]Y$^6S/NO9RU;11]Y&292?2U+#;"4$G3!P`VJ?DF(2 M2`A2SR00<]P!S919X!B_!E%.4)`NN2\^C1UMR@DMV*029CT:,Q'/1#L+?Q9& M-EK#IHN4,1IKLC2$%H5>(I%),HJRXECR6Q+W4F-$+^CWPS&9D[,HN&"'W3"9 M(O*9Q$`B_TPIFY;5Z(^4M5&2S7RWO7%RD>UYP0]::F4E0B<+]8!4V@=`9ZFC M_.6T>3$&DW?\;--"//4#,"[IHY+JZBQ$.ACC/V_0%\T]6*NSQ$/#2^_#P(>/ M_63($T>Q;>@GR[PZA'5F0CKD"NA+9T,JS(WI-J'?J7`SZPI+>^:OIY8B]\;' M&,!DATXDG`?P?\*'Z[/'\X^""U8=4+?RPC]&S-I^.'O\XZ/P-3AAKSB6)7'& M^E4:EJ5`O@#+0%MP9Q1,UY;!)^9IF!*+0#4U7*R1PA?.X(].YGK^A#B30?>& M-5-'L7`%A#$?\'D,MM!/&NJ>@A%DZ#U*S5P@E9/?M'\NBQTC-B$#AB@A`\B; M&=69Z0]SA*8F;#;%'['6"I)1]$S+(L.`39VOE.%%X#!WP"0$DKSXF%)NT0;3 MR]R3']F3,U[%S+_`<,)`53\\J1C8F213Q^).1Y&1F1805C`-[AC^GX7=TUF< M$K[9''?J4+)'3']DE$]#C!.JH5D!5$S+,5,JIV.3^M_ZH@=5^2!_I(XS8M,N MH!XT$DX^*#E7I'RGFLD+WB$G\SXD;"$_"3T@P>,(#Y*.JF! MI!@R-2=)U-*W+=T/H=3CQ4SWZ?L2E71R[:]L&4_::,`",$`8>7%]UN)J#VA3 M_ZP_6D];65D@8H<>A"1.,,JZQT9T>BYF_>T_$=-(K,R M::LBLZ[3QME50X\39.U/D)V-7R`:R'L]:B8S=P8C.W-8>LYAW2?F8NJQ9I[J M<3J^)<^"<%\/XZ?8Z;`BJ0?:^D)!>RQB9+1UTY;8V%LRHBD$3*\_\-ZVIZ6-&Z"\@$>@6RZ;P-$ MZL^TL6S:&CGW;#M]*.T\8K'TF"23^B^,NW[*'0OVV6.R/L5!$,1^$.=S-S"Q./:Z3^:/5=CXDJ9X5^ERJ"/2R>N@GIM,)JRV8DMGR%3615 M.AH=N+P\`N?9A[S0BRC'O\/U/4FSI%SA ML,[K&Z)95KZI+)=4YVE6RVE6]9ZER\:6-#]`]!^ZM.VV88EKY=3W])XDSVA? MDXS&N2@:`[V""]/0S<:X2`%#)ZWNJ*UYF!62OI+X(EG#4'\$C%+:#5759Y37 M>G5#]!;)VBRE5]9D4Y75+4F^IS5`U[E*"I/I1?"$K^"OUI5OKUR^IF7T M_>8F:"V2K55*JV;)FJ%O0^L9JRC?#2Y="+(BV_LL%0R/(N^'M2]IJV3T.*:KI\@42_4'I=RQZAHH M5F]&>N$+MZ"L2*;E[A/(4GO6!I0ETE];>2OY5"77UK(*9V:H M2D]3EA2MT)(FDQ3WGLULPU4V3T$WRJXMEG(?!4'L/$5E+]V.P"*953@E6>WI MIK49@4R]$AEOX'Z4"OY/?:(E'+/82B MJKV>9IB+"E[WK05LJ^7&6S$U4S%UJ?*M:3ASG[3WK6M@U')#+/=4V=26@Z?Y MMVU*4Y%DRDVP+%NJK/4V((K.J-[.)E37EE6%,98413.4.;I6OW$+THI$5FZC M94.5>I*U`6F7Z1SQ`RW\C-=7KW)#K6N*E0]15K]M4YJ*9%5NFS>C:1NU*K?( M8`AZAI)3J^I!VT:1RHVQJAJ&I:EK$1/X+T\D'%Z2YW@#?Z65&V=P]:8IZ;GQ M6OV^3:DJ$)-6;KRE= M7R2#N/M'%IO=JC5FZ(I;E"Q^);-B*D2![E1G@]0FA7 M>^!O(`Z](BPVI'P&L_B:]$2<;4MYZ5)'QEQV&=E+]>V`KAN[&,9V^ M#+S7_C?#R0 M9'N:*SNDW2M1[G'@7]W^&H&$7NXRCF7-!&XAPLE/]E2]O0EZBT1=[EF.9152 M6%TUI6WH9=8W:=**KEB3UK3*?$_;$@+_+(Y#]WG,YG^?`AKB`?UAX'EPR;2W ML.X8&%49@JIJCOG.A>*@?-8?D?]4:R8:E\J MPE6]>7M*BR1?,<&^5+A;E])KVPU9\'(^.;<]VI[T^$I(S.9K7)I-;MI:;FB\ MMI;O9+>:D"1[:?I!;JEXUD'KT2[(V3*404"71K#%)JP_9FX;Q73=2Q^B))>N M5(GIAE$A6RA!5JP.Y+Y'K\4&0V&>^MPY$0LG8>0/ZEABCOY+&4_O-FF;4GKZ MT,7=[>W9_2.\DFU(-(K()^'NSZN'Z]N[OTZ%[V[DPK-K]2]M<4`MW=J/A)L< M0-3\:;1*$P=W\'5C72`,2`!%050?Z M?1CL)7%0_S$3"?,D..8'/N8?;JD_FPE%WN0(-1SR+@_Y1B=0XI!W>?/U\_)#2EW6@[%\ZTK)X9%,T%5-4T@.\ M$!^(#\0'X@/Q@?BHA8]CA`7"`F&!L.`__QRP_W2B-W6__':FHMOL\*Z:9\O; MJ=;$46($NR&/%0:QP_J!<$`X(!P0#@@'A`/"`>&`<,`TLLDT,JV`7%Y=W#V< M/=W]BMK"-[NMK!;BT#BB\4-U1G7NW/BB.J,Z M']#XHCJC.A_0^!Y^IM5NPVC[JV6XG[CED=V.FK5VVP\Z/+ZHSJC.!S2^J,ZH MS@J6*9HJ;N2`*$&4($H0)8B2SL7>B`Y$!Z*C2^C@ M)#-M=Q[P*8AM#^L3O.P,M9/5K;6.(#B`C:/V)[P5IE511$.2147"^1E$%Z(+ MT87H0G3Q*#R>T@($%3]Z@:!"4+62:_\2VZ`3LZ]S]V2/I2*BE\'0A`X)?SL" M*E*!,6).94GZUR>!77/LV9-@')\.W#?B?#H2^L2C1X[T7?^%W4>_CVS'2;]/ MGQ]./SG9IU_R'\/9QXSB7W\91\>L\/.SR?GMF?[??+X2DC\.0S& M(WC1$WF+S[V@__?O/__T\T^"\&M_]/9V^MA_)<[8(W>#N_B5A`^D3]SO]-G1 M$_W?Z4U"/_!C^/)`!K\=W4OR-_@O/93U*9"L;ZK$/A\)KO/;T;7=CUWGFZ$? M_9Z.2B:F+VF0%]!@1ZH`HG)'T3AD83N0)@;Y.QQ M%[=79P^G`)37>65<>-2G12V;DN'ZR3]*SHFBN_[1:A5HX)T,4C=?+Z\HP\G+ M/@DK")E1,`!Y9V]=>!J[B`V7$,[&2[!9&_7RN;F"[3M"MO]/[NSD=",@D0YM MY$8QNQV>*@P"SPM^@,HD"UPI)5.]XUXN"_#?)?'"//64]+]N+I_^0W_.F]_$ M;"R"(&.._DL93^^VJ!U)#3^8S-NS^T=X91]&Q1Y%8`WOP$Q>W][]=2I\=R,7 MGEW+P&Q15>3I!"=#/^3CJ;@X`7[CA44-"*#B?*ZI=7B.'D`"KT.U9H6=1D152Q/X-#9]]N=6!IJF1?&L%C MSS%VY#=;-L. M;/#:#CS7Q'FL*"^Z.9@C!]"A,CZ/#&,K)+9"(B(0 M$8B(;H<,?)2?UPH8+CS7=_NV)\2A"_\[M&%TX0.V_![.=`3.-S37#:')HF;T M$!P(#@3'HG@`&*+:LQ`-1H4DZO'E+W-2HQ)MRM*<%3]6')N>L-I<(3ERB$N#, MY3LM0[9CZR^"X6@,XS0?H;68-?*4('(R@'OH6-Y9!82+.199DT7+:K-0B%J- M6KUSK58-47NW6LW)_&"[^PEXZ&`S/W(H MRYXM,'2ZV;GQ1O5&]4;U[K!S;W=9_ZW]'(1V'(23_;MT'J=O>63W@&Q>VWND MF88EZMB@P#N[J.%;:+@D&BHN=^?/L;>;M5_D6Q/V[]MY#/AX9/>`+%^[^8RL MZZ*N[,WNH7ZC?J-^OTN_WG+"3OWY:^`YN#Z'ETU+^4YS>-FTM-U$2#5%$_-\ MA`A"!"'2M8"B0X<)'FQLR2.[O.V,P'%JU63+DR(JDBRJNM$YA4%$#[:P(?< M,T1+DCJG,("XH=WM,%9WBZ<67X6[26V90I@YPZ3Q ML^,WG]6#51L)\;)-D*+FMPG2EYA]>@T)F7$\!*OX&LV^$]\A#@YQIX?XJ^OC M".^L_L.3'-!2;P#C[FSY5@7T@GW_<-AQV-_1L*-)[PQS[P;;&Y?`*C;YQ)U< M40?>]4ZNJ`-H!U`'T`X&>>F?[[P\\.3-`V$8$8&(0$0@ M(A`1B`A$!"*"%T1PLCQ@=TM%5B65^1XZ=B2!S;KH_L%%AH7LXKG,O'4MMWPN M:^,'EQN>QKTT5'+\281!X7O`#%/4TAS(^/]&AHI*:@H3[<6N1>%S\ MQ\GQXMA_W+6>LV()5#25%:PMF'[!QL-WH`0K7>V<#F#CX3ZL?5>WD.*>8YPR M1GG@%#IJ`,H#$<%CR,!YJ7M5P)#5=YX#?QP1/%N+C?>.[(].V13,[XC?+?[>VT)Y7$K3A[9 MQ2.!-[1^BJR*IJEW;L!1OU&_ZS78J*+6VUO0RJ-^<^+=]Y.;C$@0*((7+KM M"0."63KO[!Z0Y6LYKY%$:7_GZ:%ZHWKO5+U52;1D;)SESZ_O)VOO>Z[O]L&G MQZ$+_TO>1L3?8PV>Q[B/1W8/R/RUF]=HEB8:^M[L'^HWZO=NHU?5$#7+[-R` M'[Y_WT_>[H3C%P&(&0_L?CP.7?]E[SZ>QQB01W8/R`:VO3A0%W5C;[5YU&_4 M[YWJ]W'GAOKPO7N[V?L-;8`D42R,[`E;*HOA'M?L'I"I:S>=Z:FBNK\-8E"] M4;T/TY/SJ-F<>/+]Y.EQ:#LD<^>1$,2O),0P;XT=;PK6SG*N$NT+Y%"2(,4T M1*/70XP@1A`C184P2Q7+G-AOD:BVS(DJ* M(FK&WI9"(;CXT0\$5[/@DD5#E<3>_O;!Y1%Z>Z^_.6;ROYR5Y MCK?-W)<_W=&?G?'_(V\%^.8Q(.!0>&KGA+SW3/SFC%IIV43]P4L^5- M,0W>-L7D(V8H-/2:N6SI;P/;Q]G;;K#;_9TA6EX[RE90[7,5%8^:S4GE:7<5 MR%5F[LIWF->F3GY`]F;I>*Q$8K4>J_5S8C)-4=(-A`AW)K/MR#"?%:$'Q9HB MUA0;KBE";+I?8\LCN@ZYJ+A<&BPN(SZ^VB$YMR/B7`1#NE**;63V&,--=R/Z M,3KKQ^YW-YYL6VR4>2TV'L:Q04_Y4J&0%KG&PZ$=NO\`*;22:*_Z1!@"&:^10'R'."NJEUBCQ!HE MM=P\'6FA-M$CLNI<$VY.+6D]">5I>*O.;/DZGC^Q)1CD/BU;B,/=GKNL'=9443=[(F*CB><<,YN]]NS6E;L M$PN7S?+GQ]M-_#^'-@1F3N/"HW)TZ\W60\F\39FQO')'SOBK^VF>-C>%>8M`^:(EJJ\1%'EV]V#\AG MMYUXJW@*-'\^N]W$^\+V:6,9IM[)V.GRP*T#['VV,'&S3G!KO6JR M\4D5)=D2>QWL<3G81;C[TX\#6(3+%[A.)#R%F+^`ID/+#SCGE\NB[]:A_"H3 MD+=D/!2%VQS^S>71=*B=[@6VZOU>=')G_;=OXF-PN"[ZP`A MKC^@L&<;A(7D!<:>7I3?-RR:[33FC$/V"'C@"&0?.!'N$%9*?'(?M>NO1X+M MN2_^;T?)JO)&M7;;CMQ_(^R*MQL\$`GRD;S]NJ*7I^4RECB=FG MUY#D=I1*=D:8#VXU6LK>:+J_54%>QN^^&,Z)[4(M-)7`` MWFZ?#=\(F"7`;-+ES9,=/0!$H,JCCT`?@3Z"6\"\7Q_1_80*9Z&ZP]NN(-PU M.1RR:T/]1?T]2-Y0?U%_N\P;ZB_J+_?+CW9X)ON*W(#U\H)BS/J%!?)&/Q,A M)/W@Q7?_Z>"&;N]TS>8Z[/)U3D3+6T[IFJA(>UM9MSMFFW;>B&*>1A=1/%^U M5'51Z5F'-\Z(X@ZSBRA>#\6698B]_6V8A"A&%".*MX^H%464#/3%_)43=K?< M?%4YX2]"%9HX@OV=A/8+$5[H:6S'CAT386"[H?#=]L9$"`8+BTC=*!K#71]& M!"1%%QWC61FI)AS?,".(.LXL@7@_$LJBJIJCW]E930!PCCA''V[7RYC%`0O8A>1"^B%]&+ MZ#W@\47T=IA=1"^BM]LU@7:;#?X,/#MV/3>>=*X\U$W+UIVCZP^E`"K+RLG[ MF(S\5^>X1`PCANMAV$0,<\HE8A@Q7`_#VLG[V)<(,E<#:F;QNX@2J*=6HTEG^QM MTY=6ZZ-["U<0P8C@'2/8.+S!1@0C@M\-@O=8ND<$(X(1P1A%'U+!H-WF@DOW MN^L0WQ$F+O%PJP+.V3T@"]=N410G)OGD$O&+^$7\(GX[PB[B%_&+^$7\(GZ[ M/]1=K0^TVU!P]38B?7JB@N<.:%.!,"%V&'6N6M1-.X>5T+8KH<8[FU9[8L_#H(L[9 M11`CB-$)KU]`^"6VGSTR^SIWSZHO3%[T'J`P=$CXVQ&0E$J/478J2]*_/@GL MFF//G@3C^'3@OA'GTY'0)YX7C>R^Z[^P^^CWD>TXZ??I\\/I)R?[]$O^8SC[ MF)'_ZR_CZ/C%MD>GC_U7XHP]/$?J!'\.7!S+X[>A>DK_!?Q5)UIX"R?JF2NSSD>`ZOQU= MV_W8=;Z9ZM'OZ=!FXOUR]O#Y!E0#]`7^I7!+]$=X8EKX%;3P@6JAF/Q!%!Y) MZ`Z$.4W)'G=Q>W7V<`IZ]CJOT0N/^K2HJ@PC-U\OK^C+I1-%=T'II[2Y?O)O M%,]>.@#>L[X(=122F)V0* MSW1,!?@YACM'KY/([K[D4R`*0=TF\,$\] M)?VOF\NG_]"?\X8TP?RB)F;,T7\IX^G=!C4"YWJ_CJBJ M`_W^;T?ZDCB>J#F;R>2,V:EW.^K;SV?P)`>$]B%`.R7HZ>Y^)37%`I+SR%>6 MI/5(1C$9/I-P)C95$F=?:!C8#1W96$*H0MNIT"7I+VJ0/*]!F^SD=QA6!EU) M9YAKNA[7)1-8@?"NR0''&,<8^YCJV>\_?)>NC'J,[9CL;4D4SK+@+,LN9ED4 M15040Y04O7-#C9J-FEVFV88H6Y*HRWO;>)1'S>;$@^^N27N5![^P?=NQ]Z4& MN-AB[W'K82^V4`Q#[&E[.]`%]1OU>[?ZW=-$W=C;82<\ZCI8NZU4.,($80(P48L2Q3-$P9,<)=/-%N68#U M=`D;MW(=;'!9:1]4L`].,'ZF[^='(CMHIHIJKR=J MAHGH0G0ANAI&EREJIB*:>O?V/VLID"E;*(5K2':SAJ2':TA*@M`#Z*[:J4?L M1)=PH00T,]]`)LM+\OA*XIE(;H,(%Y!T%]DM[]R8=AK2,A,($/P MV:_1[#OQG8WV-T,-Z(P&?'7]905XKR/>?<..`=N["=BJD%VP]`^''8?]'0T[ MFO3.,/=NL+VK-5[=6A^T(<%VN[PADOV<8QQ MC'&,<8SYYPW'F..@B_,U"ZOB,-Q>I4/L\K2&E0]^5W1F?M!%23-$134^=FZ` M49]1GY?T61454Q--549]YIQ=U.F]_H2LB`A'! M&2(D1300$8@(1$06/XNZ*8FFHB`F$!.(B103IJZ*BM9#3/"74K8[19=LE/25 MQ,*&BY8/ML*PW\UU$Q+[,DF%NL02@BE;:"DBH9IBIJ\ MO\`=H<2/AB"4MH"2K(FZUA-UQ!)B";&T)9;`)TF*J*H8XFVR.5_VA8F(;4#W M'(0."=GV<-G2-$K,*=VL[I/`KCGV[$DPCD\'[AMQ/M7:5BY)XJ>?G.S3+_F/ MX>QC1O&OOXRCXQ?;'IT^]E^),_;(W>"1O`R)'S^041#&\(X;?T`'+78#_WR2 M_OA$WN)S+^C__?O//_W\DR#\FCWF@L`]`[=/6V#O!I?PC,B-S^(+.PPG\*P_ M;6],A'[@Q_"`!S+X[>C^++KS9>6;*G^CR]2^K7S`%[:)P3BBK[CRW!>ZW=Y- M3(9WX>C:[L>N\\W4CH2Q[R;O_./Q M\DAP2-\%58RH"'^7=4E2-5.9R:,.(QPS_VWZMQM_-(ZC6_*=>'+^4=,+SB?3 MC_]Q26B'_=<)NWQ9B#H*T5.V%:)1*D3IL*6G;BL]?TEZ9VS:-Z)4'B9LP=Q^2`0E#XCS&0?_OQU<[)-'9 M.'X-0O6H+'_YMJ06(-V2VR;UW@[O M0K:^VF&C<4]"]H#ZTET(:+Z-2/B-/2)/N0H:<"))WT:^#W[>CUDH3N=SMVOT/\$L7AF$Z? M7,"-+PO8D>1O4D+E4S"5[&ZB'UFJR.LU4Y6EWJ^_U.-C*UE>C\CPZ'Z.5O7!+Z@J5IV)"29,5=2X#6(?&N_B5A+,K MHC6$5IX8&JJJSVA:?,WZ9!1*ISP)U"59KD_&?1B`LX@G]Y[MQR"_J_^.W1%5 M/\B6HW5D4Y6U`1NZD8^;RM[;')7?P*0`MDDXO26/[\+GGD^>)B.R`MP5TP:: M;%F]/7!Y/0Z!*LBRICCX[!$V2^,[9T/:,_\SL/JY/$+W%4$.%I/L7+,U2&B M0<*U'.$+"JF4ARBRIAF2U3KA9@V)E\B&@]7=E64=QH%$2V MQZ:>;_R^-Z:5+#K/!;2Z_I@X=P`5=NMMX+_L5N1%9*< MO2RJ502=14G70?AH>V0[L52$1J:I*76"^RD/37*],C9LA.ORR&A!&39BND^( M$UV'P9`2>S>H&0:T,^;ED90.@S[/?5U>%L7PV79]NK?`G;_BQGU*0"V/J([! MPFIY"UJ/D1618@B6XCSPQY#!7%0;O04BRP,C4^MIFC87]2V_;4.2BB)1M3SD M,11M;LG#.B2!8.W0W41,5548R'/T)9H67K_J M;43\:)VI);7<;6J69NAR.F=8]L8M2"N47+EO,VBYSER#M+F9J6SF[MZ>T.DI M&DXGC[AU[6?7;V%NK`X%#9)>)&6M(B>W=$U;G%W ]:%HG_ M0G^Z),]K&#VMW$V`2%)25KUFD036\9"TC5R.0\@,[DGH!D[2`_&5_&`_%06V M!Z$P`$5I$W7K<>3%O@O"0$8_WH=_HOHK\/[`QE"R@0W[8/[DJB" MY\#T%9PZ,`XOA[VW7N?%3MM.'K&H1 MY5-1@Y%D>4'B/I-K9B7AM7H^]?(:@MZS>OG2 M;.6;R^+H+W8,(1U-0![(R)XDVYJ$P\5AT'/#T+#5UO6CWT/Z;I;IN#[\%YRM MYS%D",%W$@H#B$\FQ_&/0!@"5:\17)(6Y@6;7@_TVQ[\?TP@((V/`]^;"",6 MHPK!0(A_$.\[R6ZU!W"50)VK@_XBF=2*?T+RWS'Q^Y.[P7UR:RU1+H@$ MG)7M3]B60,(S`0:(+UR2/I.G(.NB0.\!WAWA"^UP%E29_4FOB&N6::O#TDTJ MUP?`UB6)^J$[6C&-MTL-,8]^SX@0W$C(=(6-*`RU'0N090LO(;'IV,*06R>F M_B\A"*EZV,S.@N<(X5?AV8[@XQC,`KOGCT=A%%(ILQ]_N/'K5(V$O!H!G\1W MV%OC(#<4B=C%_W_I6GUJF?.O70QX:YE M?!?>6%[)R6?Y2V];BY8:T\1&>6E&EU2KDI9ISDOCGW.J+-2)$#]BV=$9%>@+ M26889I>D:#K[88=.LE8YOQ[BZYCI2NT*DU%G189N]I1\--$XO4T+Y#-3Q1L_ MJ1VL:)&JHVV&4BT:S;+DO.?>`>%K5878C^FSLO"X5AB[P+I:@W7%4NO6;5:2 MU?2@7P?A@+!635I(N'H;N[Y;XF-M\45K&?7Z(JQEH7HU1:F>K`7"YGAJ7)S9TWS,C;K5@%!:\T6?6N;(M_8JA8*5:XMU/QR?UZM:GVOUY#X M:FU4PG"?[_1IB8]%\3V0B-!J#)TRHRO.`]8;EG95K-\>;U85*"V]9^1BEM+7 M-T%KF?$HKUA:BMHS]39HK=$$7[%_KZ(J>B^_[F#GM);)M:(92E6UN:4\M6AE M!9#55^8P\I<;O[+F%;IA&AB2I^!N,(A(S,K+-TEUN2A]*Y-^1?^4HJMT#4*# M-+;'=ME`EO=F69*I:%+'V*Z#M8JE6ZIN:D9'V2X9[8I]9!G;YD[8GO8M$Q\< MED<[S9RAZ[M1'+)=2S;V1A5[O:J6HDCYQM8*`IJAMVP(RNLOD6]'GW#,U358VI[>Q!00+9)<[_V-9,>:60&_6_[\5 M]65"K[UK?HMTUU'NBK5&BJ1;>Z6]3.:U=P#=C.[\:L6ME]16[.A9MJ1VC86= M6R^@M2K\8\D"VL;(K*&V5KG/*UDNVSB59<(L]W0EBV,KJ$P7.M*S;_K!D-P6 MS]B5R;#1V$Q'WQDP4[_M2>CVS+FG-[=&Z0&*Y#]MP;]6MJ"T3:&5>U0*= M=72R\MRO%NDLDV=ESK39GKJ9+F]:Q5(J-LN4-5-2]&7L%!0IZI%3(J>*32W! M,$NJW!`Y-=2K8L?)%5YB*TK*!%.URL":V_>J@IRO)-XBA5$J=GL\EO\_>\_^ MV[B-]+]"[-WU`3BNGI:=H`6A8K2P9>B2;^^MOAI(L M2E9(6983YS8%BG5LB9P9SHO#X8QE*)JNU;#!.V?'SHK34T M35A&NE>Q+*-38$2DD>U/#<5)NNTXD=XC6P*"^P?VA'[H1=A_22N,71EU8M M1OCL:?:>TN=#Z1)`NH%;1-:F^4P`-W_(NU6XF_!FTZPA@%M]*7HW8.-JU3\1 MW+P67!/N2FI#FJ=X.66O<@DD&[.]UJA!SL!0A_PE[';0;15'T9(UR$O7!LK` M+-VKWR$<&XA3J7C@\SAJ`VND[S2.HG5LTJIGI6E'-SB./2_`/KU.??I2:Y]7 M4C-0!WTSX()@S<#H%'C1@HA-^F@T&/*)*N+7#=./_";**N+5Y&K+6X97,EF1EH;6N+SUNKDDEU1IU M'5.<\LIYVP9_%V@E8CA9XPW=,H?#;X!6372>I"3V2!DJWQ"E1%PE]J4-T\)- MS8M2:F-5N1QQ'$7)/+^^L:`3;(\9>#`,J^F$Q1W6UUB\^[Y(5GITJGUUV,4E MVN8X[`[91&PVE)+-Z,)5?DMD:Z+'1E*R65U4-7B+9!-P6ZD<:SW9M/\ALEV[ MT=^G(:5\29GU-5NI2FP-T92^HHZV1+0Z#':%9"(^TZ0DVQJ?[2+)&FBT4N'= M9[BLBYH+;XUD(BXSOB'!S-7GL?O@.M1W6NHR4T"R?\&Z=";%\G-I":8T^_'(U^*)]4K7C"DFV`N&K MTT+`,Z;RC="B@;HQ54:+;X(,(I;07I<,F]<.*4H&W0:Q[8%/%;I^Y$Y:!L\E MQ8H[K';8!/X=HIF(B<1!='TX''5X6/-&Z-9$!XD#ZM\>KS516(TO9K\&S4[F M"R]XHO2&A@_NA-:#R;VF9]FBG.G]%'PZ'%W]][$3Q?C+CI\IX&8?85/M?(O6I+ M;:P=K7U1E4^:V")]M+#\/! MR9O`S':S6]G__N3ZV'F.A_X:-T:L.]<5;'$F-`Y\6*$'&D;8*^8^I`PU_@UV MS1V\S[F;=M>J055T,JGA,1L6HG@>EZZP3?OL;1U;T:$BP]9\"6S/:?(WG;OV MV'?.G^:+63"W;X*)2]OC)3KY4QE>C=%:@H!!0=?/-C4Q;'B:]ZGH,W<>*4J'"5A!/\M7CEY&O67@V[HL7`<\5/-<1HVG7S&1+L M%H4>@Z[I(RH&NV=^^,50UZ!/?K?PUIUC=[JT=.Q5B'9]GCV?MJRM[1R^1>J) M+'>%'J+D,Q4S]G*UO2ZR;X12`JM?H90HYXPU#3`[(54&46$:+WUP[K"();9G M.+*C61:(O@Q32^HV;''>NK9IW3D'^H],$^U1DG)YW4#RN MGA=4HWZ9#2IIE*PRZ$UR]Q?8CMO@,AP_V*Z'*P/`E:>MH8+D9,M4^.UT0R2V M@?L)MD^^H(^_@1=!G[JD@.32AZYH_`7M5R3!'^!Z!`FX4<$4/`0:+>P)O4N] MDTG&&7-&ERZI(XX8J:HZT(<;4^>Y9WGWC.7#XAS!LKE:WS+.LU^"EBCV==!7QRS,LK8-\>F.1UN M*"#N?`$#]$H4$(>]&E.@P*,Y[K:G01+&LU=$75+C MLBGJ!1XKB0=X!CP+/`=`3[N+"\]7-FHEKTEJ.JO*4%?Y*BNKP&T(_G@R2>8) MVP/G7MDBI#/J1ZQ,'X;]VJ(FJZ:FZKHVJ'8Q[1*W:QK;KD^=O%Y26T2D!:0U M8V#JI4M;7:."SG+@LY?:8B'IAC105CK*=LIGCL,._FWORG:=,[_4%WQ]9"2. MCVF.3'W(%V[M&J$*/+(",,;`,/ABK0W`P?P+OL';MOF#=R@B-GE=120=2%N] MR\-#64O5U=;$+'VIFX;)FJ3Z)(BXR]`A]2( MO*KJ;-!,W0"/5BXO`ERV5TJO"PHT3FQ^[;J!FUH):6GUG4&T8WL@Z4SY>A46 M7USSBQW&76*!CG2\I/[\YA@[?R51>I9S&SS#MIG8IBIS;2]?E]2LUS7%,KF3 M@+4A>A&4.E#4DHKYRLZ38#/U+:G1O_OH=ZO4)4T"WHA4;$_52]H6[#Z[=&4` MFKMWF]*A1>+VYDJQL5/7<<[YALJL<Z1F-K>J/:FN'%4.I( MWC5)B;&]V*^G)ZZONU/X#&\.QVQMB'1!%.2UN]@IE>[&*QV M8S3Y$$]#.#J&7[#)K[8+J,KVP"RE^[5%`$0TQ/228YK^>^8S,;ZF$^H^8")* M"])72_*O,/QHI(QXX.5`=`:VB.*2RV"JH5B:KG0+]E5(%V`)VG:ZT24EYE5P M*"Q+!'(9@(X`%E%98H*'(\,2TGA=@*]I%(W-%L=2!D%':`!TFU#EW[3LLH]V*O0VQH=64H:H9$J@K0'0(N(C@8E-K*,J0 MW[5T`S@SSL=T2L.P>/.I!=4E.V!=-80*LAZ.CN$7$5^2Q&D:YE;@SU^YI@_4 M;U$14#O.KLZV6$JQI1YJBL))4W-(.L=! ML#ZF9)ML&'Q[Y@UP"(,)I4YT&@9SO%!Y.>UP(4RQ'3=A"\592Q'-US>NFW1Q"$2$E9\9#PQC4>&D- MP+RFB^7#V9ZN#2=*JG?J2N7Z>>VTF\`F(E[CA/Y&4#UC\`HMT+'S(2G@J0T, M3=$M4VJ1&P+X(NB*5DO2^-XR+%4WMH7MR71*)Z#33[Y.9EB;!BNG7?HX`2AW M_`=]T@?P5EL=1TI*@@[Y0YIU(-D"%J(5DNR&AT,^>V(3/.J?2B^65&,D+59# M4,ZS!("-;<^AUMBJVR- M]&$IR%N:KATT(B:5Y&:K:B7F+`3GPL9J/6"G-[`UEOGAE^^\^,!Q'T@4/WGT MYP^?QM):.M'GM]E7&>Q*7P<6^^4!`W-Q[_^W2%RC_%3A=X:";_Q/J(:(8,DQK&J2Q[E;-K5E[CN6T*DI9/5&%=]I#: M9P3"Q[9`NO5I]>($NLO1EE$J56,DF)+#)')]&D7$]AUR[H*5<-SX:96.=U** M_L0)V$],%W2IFFJ(E7%Q<_[XSIXO#OZA#I0#,9]TKTDUN2J5`7^$)7*#D%S- M['!N3V@28UUQL`/@./7)#[!O)"E^0TU3#C"?TO:?EM^H!S_V0'3C&6$7"YGA M`@A8@:@>N>C_UN\Q#EC6S^N1P_X1?.D"9Y!%:4ZP>&QP,*2L>"IF@/I`"7Q_ M'@!;4>9\NP^4X&[67N`Y?1R0&/PZ,."L.'"?`(1W[I5'OV:K8AD'/7R>5$!7 MK8.(+,)@$;HTMD.8-4SN"3.^)*:3F1]XP?T360!UID$X[Y&0+L"`LTV&3?P` M0"3V`@:P)S,8'R#`EI580!B@F@>>'::#12@-.':4/O7H>AY@Z&%-9A@H>O)I M>.]&0`%R1WTZ=>.48D#/OR,&N$,C-Z1.!AM0%Z:W_6`O`IK1%.QLO"?R0&?N MQ*/I5'/;]3'=-QUF^?H"/C`TV+KA3_%BQ+9C9*U20)&1M0_("+Y`511%,-ZU.L?@:2,0&?G$R]X#$B MTS"8DZ!P*".L!X[C4%:ZH$_&C#=OX$^60$UTI4?0K2S)"TSNP!3$+K+B@=VF M[L2-\>U_UN*2&YKO*W3[OO<]LS7?EXW-TM`:5E\IK169@[@P8'EZ4-;Z,< M:Y._P_LV!*O"@W)!_0<`,[61^$"(Y;(L*5(5B142,<-_!UHCP1+":($1@SD% M^N+9\IQIUL<@_)O9WPS*D+*GQ/?A:4ZY@Z5/R1&Q@J>@+;PI M `,GBWW:]HN\'1C=)BJ"G#!J!D0C<"W\Z.HF#BILN.GA@^'8%A<[')R7.^ M,9,B]`=@4+R!%,/3S!Z"D4$;%C'[%F:EXQG+E`P-@!929L:`%?T`@4A"=)T+ M^:QSE)\;$%7#7\P6%^P]F<"^;YIXF=7,[&"4O\;0A6>#._1-0;_@X^B`A_0^ M87N1IU39@5;H$6:L813$/?T6WL]-:SXGJD\LPV1[H!H?7-0.?7+#$WE$D MT_PH9?FV#ZH-!KU[*JN3()4UM_`S4,Z8&@BX&=W_T&?,?1]TS'+FLH5,!Z1L MKP1+0?T'-PQ\1E"06=S:.,4F)%U_=MS`I@>.@MW%/9H!A^+"L]?\3/I9>\^E M8:%9V\\4<-`,4>(A463^?/Y'$7_CPF09Y[.(S7X:=F//['GV$^P7]J?N5^H< M2,-IR_'#Y2=G"0S_,2P^YMM_[L1L)7*Z+:?<3U/7(J-(3:MQXYC6+0Z_=-PZLM!:)%=;JV0MS_0>37T]S\^>9,X:+ECBVXF#G2B9\875*,*-'K\1NCDY*NV!\)UH%B2>@]Y22&T' MW19`YZ_$9XW6BD!B,QS]('5]L/L698/5N9QCWT_@W6NZ"$+FWYP&X;Q@#E79 M^WT9RWG"C@7H"3GD&/Q)W#\63^HJVY'I?7)$0^9SNCZ&=!F1TDU5$,0(5(GJ M/C[BL5A-`6@M3LM5<5F8#*P;! M"\@O`WOSXWA\55J,@A>"N1O#2.^;NQ<&_BSUM/%\`OD'9&Q>1#LRB&J)$(=VY&9QWERZ@!?V5XGEKF7#Y;*:607&89DR MCRKBG^[6,38R"T#Y[P6/&+3#P(WKN,#:N/M[YO@5A@@7Y?CDT=6J6<[?_OP[ M.8^=5$Z91"W#15P[5,YV4,]E#6BEYJ.K12N'E]^E[8U*V^>(J>`\7EVS#6D, MY#XS#JGK5#)<340/'T(7#B^+%VX6.DMYQ#SBK3+&V>V_:0$W$QX,?E@ M,4:67Y`9&/0ZT4^;+R4;GJ>9R?2X2@'YP4#A.V;J"`TMSO[<>^E,B&=SU//) MZN"C:?F8B#BL8CWW'/,RF8$%%<'Z92TMZ-Q^`LCQC"(_RL``]9)0_=)&U,8, MVHS"."9'XH*T;NH?K:YLM(9:[2%B>%R(F1[P,M8JZS%*1E'N:*6_A45IHAXJ M8JRAP-.YAUD-X"2QM]BR(N?3H4CC9 MY74$-9B#`;"_XBS%XS`F.\C;N[/3'@=%@>T\"INR!F[DW_7ON_YMKG]9H5'@ MUO3X>']K'++5@3?QR_`TVBL18>GF^ZY/"2@-;-J9A@)6SI)U=G+&/"#8I8?% M-L'V04O,L^)"!,0;OLOT&'ACDRR@PHS``VPW[F%S3]W[&;Z>'^07!0'S;<^# MRT(KF.F&^QU4(E&-8_KJ?+U#0DG*T'/Q\7U M\4:B M+;YROR_#V@RW\?G91X`5FUG3,!>8VR_G`$ZZC:X$G&-&,4R##!G%"(!_>;U/ M_I'>05P1N0,"J-R>'8W/\ZE@%>)@GCWX9P:CH12'*X;)438_]RNON3QFOZO( MJ1W@]CAS8[K'>C[O^\%C:"^6S)0?4600$W7QE3`/)V/EC2G2`06`!,CJ`+^/ MW=6KY!A'!4&N,[?R?=&_J45_P`96W^R:\T=B[;2Y1Z=Q&RHQ8NT;OK$.-?[8@ M0HC>[ANF@K)*AA]4JV<@BG[[Z6=@B*Z M\EHLT1KOMZD8M[?,.Z7YMHAFG6I3^L/74VKO'/S.P5UPL/'.P;MGEE]VK_YG M?M:0'SZLGCF\NVZ[C>Z+A"P;JKM*VKR1WU-Y?1K4J$!UU!M95D^QU#>WYN\L M_L[B35A<4WH#0^T-K<&;6_,7LO25BRK;SY#9VL!='937'>B3[*(39FB[TZ?G M4U%>[WR_2[#959N[``M]I+D;L8;W`C8H1.1PP#^(3^:Y"S7\JUH.>6UF14. M047-;UR"RF@JR01FRR=:%&2RTLF?C&D;*XPEI_4>6/2$$+@7^$:8:@JO39N8 M_"@HGP"N*ZHC"53_KG]&A35K:J%7DMP7'^$%^"U-QHWR2?C,W'H`W-*$LQ#K\,$'"W./,V@')LR M/Z?VKDN$M[[/`!? M$L/;C"9@7'0\=R#*SLTB/RETY>9&RQ#K7F'Q*8&;3'J;>G^/@/%GMH_]29.T MXEJN[\D959Y<()"6R!#1-2TV5*EZ=6YL_4Y$R>#=-B"+K,3$>7R.3Z>X4SN-P1YL.2\`-:A&;+D ME`.6YN'%TCZV!T1AGAO#OVD5H$+;Z:6)^1IW%&M4#KSD#G7!G3CZ()I)CYA7 MG7K>PU/6X&X0/,I'1YKYXQYI[9PDHHN:.`E+K,008K2Q)!5/SJ0'6%)/U%_# M4!-0'K+WX1@]'B3MNBS M(]M!,SE[/A43Q;'!TKE8(4O1T,Y4[EFL+D^YFL\%Y8&H+W^66>U;BOATZUK$ M)^1_L"/2PVKI1-?WM'P-#56@1Q7H>8?Z,V9%;%FPKHRJWO,%(Q.15V]\9Q0# M4S[=P$QLO9^65>7[E@@J9(LMP]B;59N,R-\^2,J;):K[`Y3Y&1AI^+\ M;%+Q\4'6CH1^Y14OXKPKRT[V]BOISQ6^R$:YL.KI/( MQ2B@*EE="0N5PY,*7KEV1YF$Y;(*Z**E:P411\.`,=E\.&D_3.O^CW%N%H=R M7I8TE^OA_4^A?EP/RHC_)G2O8^ASDA7-I!0$3/GR$1:G@),%NV3&_#/V(E'I M5E1S%:%93#1EB)?OR`LGL#IL9;LJ>*Z9>*EP8SF%2P=N3BI>0'@LVT!2ABX) M1HEY)56613&N+`A.UB.P_WSWXV92R"L\*K6/KX006O'FDFJRIZSP2T43@[$8B).W_=QI!";1OD:1I\<<:E0@8S/7_"-D6BGH^ZZ8A2%!LTDY3&3MM)BO.)'`87D$1%:MQP]F"2+);1'D"D MN2:2',RF$54.N!$'-)=SP*HD(AF;L]HN(Q8-/5M>*##QNXK1/#>$3PKR90-\ M\LTN1NUM-I\DU-P(!/Z1B4I9N2Z6;E"R*G$E92$?N%$"/J8GG#`P+S6/-R-`C%@1O>0,5 M>Q8[OH/"7"M'1L`&-+#3,E&3-!4>H8-!(*[0\;)++W+Y=^8+HD`]_XF7WLQ. M-;?/^-+E,1Z$IC\P%$X,-]W^ES.29`9!)VL-5-8'2\N2B;V:O96"G8K( M&7DAQ1,3=3\KR$P)3*]?$75TA-V*0#W9C\L%5%RCX`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`>^\B#IJ?:(NE:'>Y73K0E<0[$#AJ,T)KR*T M&D;S0-.;AJ;V9Y1W*>]2WJ6\2WE7'857IVF!3'WR]!>!IWY7$!=7LE,G, MI%>48TKZE(`VP@9/29G'SY7GMBP:#HD-NGFD$7]DA+MA%,0C!F]:0QH,V#2# M?`M9?4EA->)G'AMW0T9.O9%/W3$)F.4-7/X'LPF%P+.`*A%)_I=5^FVWV>Z: M35WK%1W8C@/N#D@$Q+K<960$/PQ#PEP;:)VZN]C<(\A60F+`'!K!8Y%'J$N\ M!X1IZ!&?!A&WN"^ZQB=IX(R)Y7@A/"XZH,07@F7$ M=ZC%A%2C(44QPKOR+6#&$)WCB_`5$'0";SG$.,QSVJ<$(_4B85"0$HAF]`O M&2HP\$3#@J[AY[R6'4X?N,.C,83]:`B_65X`;?B>:R.KB5A!"J@.(#:2M$// M0&2X1_[IHW!1`9+;A*:4`__ M]E$2\N])^\'DDSVA+/\QR#ZF@_C7_3AL#2CUCRY`(/]">9SQ$'4?@]7?H M;P[HZOC/?_KSGPCYFCY\$W@68W9X`2G,)2B&NA:[[I\*J[T53H>BA[=_L/ZO MC1M=N]?T>[R8_,Z#ST9/?+Z_C4'(/V.PH/-'^.>[B`-QB#V4?KH;^^P$5-L@ MW(88!2KE]KW9[35`4UQV\L_;LP;8H,4AXPI_;;0ZC6/=[(CL*6-R+MTIHS;C M1V>>)<(E=E[D!YB9\*,=WIN:^%PB[A`(T%K_^+I?;BO?QPE\:>,/%PX=O+Z3 MGM8X[@._3/92:*V*E1OP4<\^=^TS=.#7=Z+MQ?(I#H!>0&PC=(XBX,0Q-H')RZ5J2GJJNIDDY91@+G4L8=9__ MCXV7H`4\"IQ)-XUN^Z";[[K4=+[OTQA&G[R2EK>]@\9QJZ4;+5.7?<]J>IKU M"^ZPX!1^&GC!,HQW&\>W$%6@$?*#^5X@DH8D[\K+H=!/GHR[@&*POAV/'CQG M"0)Z8`4W__ZW[*O06(6>LV!V*]*':QB\(IH,__FN3$K5]?O=;VJR\-<:)5I M2#ZZ7EY=-(Y-\Z`'(;93,(47>B\/(N?I-=^!/\E"Q(R926EY+8IOVA"2@HI+FEL-O7?_.1CXSD MZ-U6`MZUX8HYX,)3,)=%(GO.A$#Z$+`7G?"0(>2C#XRY,E>W1<(V"//,27 M(#G&)-AS'.\I*7;WO_AS?NE0YO?EP),RA_\E MC"=O=S'A3Q8M3Z^_?3NYN84N+=`)]4/VA5S_Z_S'Q;?KWXX(*@W:7F@F\`9$ M3)UN'VYW=OEJY17P]C3D$6NA,;`CUWL*J#\QI@5Q<>O,0GF!\@+E!>K0P_LD!=GJBL+FU)O=&I0;5:%- MV^MM+J@I"U86O`H+;BL+KM^PO-ZY^F_I7D.Z^3"]YZ!2MWJS6ZUCQHZ\U>]V#K=+ZK)R'>K>%5;917;>@3ZO"! M^VOCOW$8\?ZX,9.1S>WOKY)L!%G0!^^1I5@.!%L@OL/U"!_YU(H0!HYX?2"3 M!8@B]P(R9C0@?>Y2UT*H1P;+IB,O1M`W/&-GL-P%`@\W5_7H?+ M$Z8;]Z:`L9DEPHP7"=,6IRF5[27N@K(PNJ%C%'R"EGR%J,P7*>J9IGF8:;*Z MMV5IFBFE]CPIO98>*V`T9&=,_O_2O4:OO/)<2[X@+Z^;@40TX.+'3Q$VXK3!;(]'BCT)(*+:G0DK7!&2FTY!S>/A)P3J$E/Z#2 M%5KRP^W`*+3D=K"K<&(*)Z:\0'F!\H(/"-EMP>P-I;@"ME$`S,U"]=RQLQ M43]K`8C1_:W%7`K-WR`PP8M#9YQN]A5*9Z;HP?3QZ<*9AR\4SM0:QRV]V]8, MT^QFC!>(G5?([6\TY!8(Y(P[,>8\Z^7ML,C;O<^">T%6GDL#N,2YY6PL8HF) M,L]I0G#- MD+IA2R"VB@%>1^1R+G;.B8G9B%8`Y@05XU4Z&J?[Y@+7DW[Y[?RB!/5)L3NE M0;SPEEC[AF\:6(99@*TCS\^NOVO/4U*%W$OB*AM!A<2,/(HJC`(/YF&#Q1!V MW0H8=K&%!?*`1>7Z>D'67'HB/A`9():6XPL)QJIA>"W#V.N@C*K<7?Y62SC> M.V`)JYY9";)4V@25R&4JZNQ/X3_;HAK^&;.2;_4$%0H#2LC#*"U7+[&:$.<4 M6G,C:,U#A=:7EL*8EQ!H-`%NZ<%P7AE>(9OO8\JA85-\)@2@+ M4!ZA/*+V*4/-`515"<,9Z[,@P-.OLG"$N-X'BPY\"ADC5U[$R*$"'M64AM4ASO5'T2HTL4(3*S3Q M$F-GG9A32%*%)E8VH-#$"DV\%0/`%FT'U)%AA9U4V$GE$!G:56;_.K!6:N'ZCN4(3U\TP%%1R10+9%:BD M0A,K%U$N4E\X3AT]I";9A4(3;]X4%.1101X5FEBYEG*M>@BO;NE+'1UKEROT MOXSB+:-_T_V/"[']P4YQ[R-[#6_5*\!^3\)K5S?N35F^O03W-5^LKJ]EQ,[M M](6JZM]YB`*D+O/BW$O39,Y$);=?)-,P8#)T?,J:)TITLZ+M';`K=]" MZFW\$+*?,?QR_EBXLV$)K/=!7;'>(?^#'9'>7H>[1-?WM'Q]^@]1DM[$X+I\ M1?HL0KVME/M6E\A_2&4P#W6NFQ7E\2=O?ZS*^`L++8M#1`:B942XQJ+XVW8^ MX44Z^:):NH'\F5ODN@^#-^(DO#XY]48CSR6W$8X9>*3D-QH$%!1((H_]P+L@EUU;DX7D?HR=/`37%*1]0CT_=,8SY(]]AXK)& MXDM=>SE=5_:Q[/T'W>:!9C1[AED0Y.1VR#X2@S833BSK*6=9?FI9L8]_KI:R M`ZUI](Q9=/$H+-#6)-RUG!C'<2%,]LP"BP-IH)Y^[#CI4:K8A4S@*>`1"T)I M1CU#[WXA'MXVY#B>N#2+>#Y>JE7!(G4))@OX*W56R_#AH=X\Z"ZDB#UR-V0+ M*>F)!4Q:#Y@3B`*3V'"E="='U1+C]-R$KDJR:$I80;+:GJ[AX[3ZS:)`:(1> M$7!+//>757*B[QUVBIWA'>8H,2GOU#\#9C'^B.[I^X'W#-.`B#GC%=-B[I5H M&7''09L$);HP&X2>+<;LD/1AKB\LNQPJ:!]LG/AT+"VZ3_H,,WOV[#,W!%)0 M(1-OP!?27^9:%_96M#`^&C&;2SF$S*>!R.>%)8J?PS`&>T2C((B&TDY`5*)F-&`Y#(9>;WQ6"=L`;V7(XNS?Q? MU6%SI?%#AW%$:\\,F$4M1IL5=T5N7K787C^,^;1&%T:QB]07(68>HN*J492NH:H'8QO*2Y8BIZ%K-YL5(?SI07I#F0[-9+6$C;U3PSPOXD`OYA@WV:$^B+W M:>IM&`3>*M93AX;A=3\A]SKX@?LSY\EP<8.CQ>3',/DUU"N64S?HL;J^X#VL M.$QE\EJ*\UJ*;]W&::Q?WI;__'R4_GK^['/(+B'(W;%1/4<1W6P'@M,C`Q-#`Y,S!?8V%L+GAM;%54"0`#"!QE5`@<951U>`L``00E M#@``!#D!``#E76UOX[@1_EZ@_T'U?7:4K<261(JRY8AR/L6KY8QFYAF2,^20^OK;;!)Z4V`<4W+: M.=C;[WA`?!I@\GS:^?YTU?VUX_WVMS__Z>M?NEWO&Q!@2$#@#5^]"R30$T/^ M#Y[2>P=[!WN_>.K'8?>.3KN'^P=?O'_N?SDY^')R>/PO[[_WM__S+A^?O*[W M\O*R%T@.(N&PY].)U^VJ]X28_!@B#IX4C/#3SEB(Z*374^UG0Q;N4?;<.]S? M/^JE#3OSEB?3',$%=3+A`Q'^G4FR*Z`Z.CX][R?_* MIAR?\(3^AOI()*8JE8D` M)^(U@M,.QY,H5((GS\8,1J<=/YK-$C/O'Q_M*_J?!F(,[`%\P%,T#(%W/,7K M^\/UBL@^A$A0%HT1FR!E_9YJU19):Q!DG-*.`UQH+K\ M&0I5OWD<`XAJ9C)PJ4'&*X39WU$8PRT@'C-0SL$O0"`<5A/3S*@&2;.=:QTA MM3RVU$_7D='(9RN]=ATI#5QJ[L/K2%=(7W./?I2S[]S+!Z,;RM?OU'E&6Y3T M'/'Q54A?ZA%WB=NVQJ+-!Z'Z1I\^YU5'[Q6Z>N58>P#,D+])Y:/0C\,D0+N1 M,JQ(!S,!)(`@E4]QVVSV2B(U^=:0^BMO"E6,2-FJ(18O2@+!$>+#)!J,>?<9 MH:BG#-2#4/#T26*R[O[!(BC\:?'XCQ2'.><0#2%,WO='MD%JDB;$.X\92R*T M$BG?VBT)NX1@GZW*C9B?LI0_<_"MAMB+%CT>3R8)MRZ6?3ZE'S$Z*;;;XH74 M*&_,Y:MII-BBL.-1%@"3N9-,G5X`/X^%_-T4`FH\D_.N^J/FWBD*U0#2%^>( ML5>9TR5CBP$92WIG$,OX6A8X2W4>8`TGX!-+F`H MK.)D'8%;0&EG*(WT[>E*5B`9:-J!DT$!ASO3N]1$G,N_V`ZC]\9M`^== M*"A@OHTDQZ*(P1@(QU.0QJ$34!6E=R`&HRZ52E8N7C82C.'8^1;2N#U%K$? M(*YB$E2H$2VE;".>I4I9Q[\?/.SI#GLU,>)]>%UJ,\K=4=GIWX4SUP>5T+G0 M5ZK`9BB^+5+/X0$P?XQ9BZ'^Q'-;8)D>3O$!+;DZ`_4>GA?Y+G6DWMEDXV M?$5+W:,^`Y0/M=UFQMJB`^5-E&TN;>);5BHT5UZQ?)N&0=2B2S>:W`O6-PL4R])7F]3/R:#S.Q;C))%5*W92 MO2429E6!R[]U^?Y*3!D:]$3=WR#$:RC;D`IQ(7 M!Y"UBG0K*>7PY)E6AZ0["G/-#6CJ"-H"G$[^K=3"::)<5:"#^/@"&)XF,_0U MD7-UK$;R<7^LAG;S?ZE"S>;<38@:ZVCAMD>^*F9G!X^6WS9=P&Q]`: MG+X`ZI8LG.YF3K<=5-=(_YQ(#?IAPES.JG+&A3,Y1`7JI(`,!Q+9RX,?6P8[ MB[RM`1P^A_.9EN6VXP3UK>#5N,^R^QEHC4ANEK(Z<2OE\J0S&%UA@H@O=4XV M>=36D+IM,R;F&^2M6>R<`U0W@<-W7F;S#FD5^ZIH&^*=A=]&^6+@?W%DV2HK M_^K=RY5PSY)^(M2SJA=C_JNCF*_>BG]%68%]*GF"'<-/Y!]V!BGVFF-'O>;M M?F=UAIDO5[5E\(C_0F4#C"TZ4\>6UR%SH6P0C;.:]3V_4#/D#`KZ3="G;#;%VB"I?=]8DJ5G!XE-!8YVUWI>X)QIJQ M`YZSQ0G&V@P.%R:I+LB%;'E.4<]A=#["U@/V]):YT_Y(;1$Q$NPNW06F7Q_=%V#L7 MM6+O+J;:78A-6KM\F.8!HC?1%^MBQ@ZL:;^SP&KT=?G^/_A05GZCH]D[:K?TJ<&/5^*,$HFY MO0+9]@[TDE(X-)]+S*KB<(JRD/@1A8A5<;<<08OARNGB\!K40F0YQ=01M0JQ,%X>/:"1I7J903)T^Q#)?[7J7RGP]OP6M M`QW#"(_N([X&E1Q.FI94O<5<=IH0$:!Q9;?4$K<-3AN=-KPQ^FM/O7F(."2V M^3]02P,$%`````@`'(!M1793<,\$,0``<_L"`!4`'`!C<'AX+3(P,30P.3,P M7V1E9BYX;6Q55`D``P@<950('&54=7@+``$$)0X```0Y`0``[7U;<^.XDN;[ M1LQ_\-8\5YRI^G!"Z%%DF>_O#OZZ?#=`?_QW<&__:]_^1]_^Y_OWQ]\(1FA84GB@^?YP558AD\TC/XHEO4/ MCGXZ^NG\@/TP>/\M?WD_.#PZ.?B/PY.?CTY^'GSZ?P?_>?_UOPZN'Y\.WA]\ M__[]IQA:*.L6?HKRZ<'[]^P[:9+]\1P6Y``$RXI?WDW*XQFI!I^#[)BC+,HK=:K!E> MO:-/GSY]J/\*18ODYZ*N?Y='85FK2BG7@;`$^]_[9;'W[%?O06''1S^]%O%* M+B@3EZO/M!LX_=#\\1VHZ^#@;S1/R0,9'=2R_ES.9^27=T4RG:4,8_V["26C M7]Y%L]?7FI'#3\>'[%/_>IEG19XF,6/TLT5\?;M=@1B0- MRYS.)B&=AHRQ#ZS4!TDK'T#"GC)^"\N*DN'HD M#).T>"*O916F1D*;-&L!Q4V8T-_"M")?25C`AZG6>26M6)#QGN8S0LLY#.5K&,DSQE47*:7MN)7SR):@1ZXE[3*8=)JS(/5% M%-&*P'0>/B=I4B;=1I.D%0LRWN5A!M/?G`W4+M)QZ[N1JPO3LF8L2/E8YM$? MGV'O%%_FTQG)BGI+UD6/BI8LKZ>/L-UMEI#AZ"XONF^SMAMRK56SF4G5E&MI MN_19O08M2/Z%Y&,:SB9)]$C&C,3;;)2#*%W[L%9[5GKR=)J4=:^#&1RZ8PDV M(MB*;U-C%[4;M.IJ-`Y'-?>3/(W!CF5+4SGO/S3YK3J<42[#8G*3YM_M3"NM MUBS(?)5'%6N8+?W`<#EO]5$C<>4-V9A7JNDTI'-@+QEGR0@L$_A8%.55W3'O M0551QQV%85< M2;+R0YQ,/RS*?`C3])T2H<#-L_32,/_.:0V\;JVO2/`SK$W0V]_'9!16:6E1 M0$[;%L7-IV&2N9%VT71O8>MVWD_)])E0FY*NM]M7S`E(1*/JF;Q?J<"BL-S6 M^XJ6%U;&T;'`E&/38)$O8,G`'S:U]"&8#DL4D7GZ*2=3/L5D[7N&C:1ZM M?2EEWN&<$9A\5R#JHKWXS"2EL7R-_5<^?[P:.$._M?%KX/5 MV@SPR"W\6"R_DH;/)*V_'8@+!Z>#-V5YDOR)F8,Z4M<%@Y-/:Q*_$7Q!UV6' M3K9L=='?C&;V$5=22OBG;7+-"R*Q6;VXC71ZG:;=8+30X=<2N9# M";=O="EXY8+A4^QMC+5EO%I;:#DT;1<.3H\<\B/:`TC(X>J M>1E2.D^R<7UZ*IOK=.H'IZ=8N.-1(ICNM)'Q*3WW1>D#`6Q)!%9/7W(-6PI. MS_:/YBX8^81_]#:_-EY(YH#?#"+X1LJ%*F3SK4[]X/1\_\C51\:G]),O2N\I MF85)?/W*3K+($G`6?\NS2,FGNG)P^G'_R-2$);#>#_WN?H:CJZ28Y468?J%Y M-;O-HK1B09KPVZ@^-*M(/)RQZ$R06V/(=FXT.'7IEW$UCOO!%72)(U]=XBML M[VD2IL5C-9NE"5G-3Q+&A76",Y?.&4>$RM$(^/+FGEE#IVNX!&=.G3(N!UH; M@8`+;YZ8913:?1HVQ\C+4#18T*5KHKA:<#;`PI2&::E$(F#,FR>F=0ZMM7WA ME@_.$/AEM#D20Q"0X]DWHYS3@K/]\[[4,@OT[_"8M.?5]E>)*P1D";XA(]TJF>&`$A'GW>RPBE?4='>L5@C,$QK!" M]7+W!@>/@"MO#HWM>'PMNOAU@C,$-FQ7QB20!*?2WEP75V1$0+KX@;P0,*[5 MC/$K!.<(+-1.=$GP"+CRYE,P&EF<_G>.P%KMQ)$`BX`?;SZ$NSP;/Q$ZO2+/ MI989Q*\0G".P50UW%6(@`I*\.1'`MOTF;E M)?R;Z-&T+!R<([!IN_*S!D)`C#>G0@N4WB(4G",P:CO;2K7T`@Z\.1JV;R]I M6+/B2L$Y`FO6,+!7BD7`ES?OPSU=C.U:;E5D!J=T<([@@%ZA=.'!+A>,@")O M_@9VUS'/M/C9+!J<(_`Q="*'BT3`C#?OPN\AI6$3Y_&0C"=E,:Q*EB>(G0Y+ M6))5"\X1^!@Z,:9$)8BM]AAHLHJJ95RJY5-1EA\NF,D@D+/7\AMUF43PE+:O"-E,/14_@J=_"9 MM!1\1."CZ$9O!Z`"VKTY,![8Y=R,Q-?!W;6%4LYB7*T#K2YE4-/B+PRG0^WQ8B$C"X<'L` MS@_K-Z`=WHLVR)UH=%%Z.U4$^TT@^]R=Y#*T?N7@]+B#V=Y!7-$-:+V*P=&1 MRZF,>R7:5(GK/=P$%YY+TP6)?AKG+S"@DF9&@Q\V)S+X57!'QF':9*$17(SF ME`*P+N/><@^5H[VAO)']Z`F^ITK0P*\!*%TZYQW/25K@D-UHYLBJS`H@K`,( MG7KN]=,WR!C0)JT-"MEE9^NTX9@<7?&GFCF]G95M2/UUS9I3<]B4!X08SF3D M`TB+M38>9%>36>Q/N8C]T5C@>,4!E\N3F!VM;F)DR&X>;PJJG"#Y%8*C@=.S M&.U%3:QX/:+:<+!=+;;(%:Z5S!YIJC7,XR5@$B?5E`5&?LM+4B@7,6YY@(C@ M3$PV9OB$25QUZY,-C5$;->'-R15 MSIC<\L'IL=.MHWG"/3$!?.8DL+!='[;&&*XESCYURJ7.F[MD$9&D7.+6R@$D M!!%8DH'"IX>#`=L=9->1'$<#CT?V_4Z\3%%BN\.\FW1^1P./9_1V"#8`BNW: M_TF^,]5I(#AU:\'O@F43I-AN3-_3 M/"(D+FY`)TQ.EK]^.&J%8TL85M8-3GRF4[5#KB9(^:7JG4;>2%__]/`HP4J> M]O,(=6XU&"HW20:_2\+T+5=T6&NQN)-$[=AJ.C@Z]C;RWF2?\Z17O8.@4QU6 M%I=G?M+G$>Q0PQ^3^MC_,O%"`Y>N`J.W$_3)62=7"&N_HH8&3LW);E%#@RT[ MDB_W?D4-#3[A\+7T4#G:J*'K-!DG,%#95#RD]=B]R>EJ:`]K016N:>TV8*I' M\_)+U]FK(VAD$4<;Z$<; M[W1):%F_.%H2E@2;S/(B47O3);4`+8+;=F9#4^#'4X%$%A#U-<_(_&M(_R#E M397%&L?^W`J`#<&U.!L$RO`A"XUJ[4!6/_X](12T-IG?D1>2*O9=>@T`=N]7 M3&QMNDP08XNNXGKKME'HK\`Z[8`J_%YNZ<*<@GM]W-ABM+QU`5P[,0]]01G, MX"T>;"7U;3:KRJ*&?Z1$KB'%%C^V.I2ZS8J25@WPY>^:QQYXNU.= M%Q;Z-AT7T2,^*AK#%P'']!@9Q4AK5`3B"V'P[]!DX7[A:P!8GM^EU MT&=>41/@8O"L.21=2P'88N8:S*MIDKT8F.9L$94P+:P#$#$XWQQRK(`N#Y7; M:4C5)2QC>9K$+#*W#;>X#UG>\@DI87HR3&1D^=[0G4:X%"?AU-&)-T?G2AI5 MJ--Z01#9I2$K#6H2*9#?OWERXPE(LD#<91H6L"3789"Z]]0VZX!:7)JQ1GYH M'F$*:OEPG(0L]=B&MH14>A&W"P,F9!?1^%H7;!\%>)P$.WGE")<[UR)9:,.D MUG/*-P'_%U4YR6GRS[==AC*S_F;%X.@4@;EOMMCI($(6[;0N,FSEAK3&'-?; MT7M":Q3:+(H:`.P(+/0^;,J1(8MF:EW-,!B0DEJ`$H&Q;<:?$@ZVV*,W>3N, M0XW:@!J!-=V91#DL9-%'6YVON1MG,OJ:&H`.9YIFDY'7AH(LU&A+5KT'3635 M`">"1[9Z4K:%1QXTA.9V7Z>$VI9/0Q?/IV?MUV<7HL;#[(&PI_Y`KU#@6Y[1 MY7\_AT5B=N//QG>"HS/_`1X]@&C?$>S[#1@%+CT`>A<)[3&N.+"VHZT?P=.W MLUC44^_)%QWU`D57TU`+,E^BIV#%,QQY'DV(4U"OCQN9I]);#\#EW_30%=#Z M01W$PITA\)EU&*L*ID5(K7E&1>_-Y%D4%I,K0I.7L*R?@UL>YU^"@3$6OS>C MJ@CR(W"L.-\DFBA#ZA#=J;%8/P,(H`G("UN2;EE@!%UJLVV9]2:O`%KKX`(1 MB/4834A]%TE1340<>=!!SI*XW12+20_A''2A"%EXS>(\!.#$M]F M+Z0HF<2?YXLC14YIE>UBHWU0M_?P!OUN(5B]["D"FS&C@TR,2[W%M=$^:`Y' M^(7%?M"CH^FI"YO-M"\=#9F-M3<]#JUI=A%%>=6\TUXGP7\3_AN175F1U@N. MSGUG[33:&!F`0A:CL@E3PMAF4<#CT8;N3A(?![(HDU9/VI07NM(EF)7-=EEC M>(GK`W*/D2=6AID*G#0.9?>V\D*VQHM@W5I>:UW/7N97`=UUB.[0LYC;7S0Q MF;?J@9`N0P$4-K-,<6JK60`&C]GL.)WH.8ZG/O586:=3B&>_\HB>^WVM4ZC% M;65OR[U?>43/D3RPV4/E:*V/KV%):!*FQ6,UFZ4)66T))%LC81U`ZO&MEBY+ MBR8DJ#HD[>\ M7V]+FU!.Y;U(S2:"HX\NS0AI])8N"?QQ8X80S^[,08__/&=O'BJ.+#1J@ZI< MGM>:W;:SRQJE$;4#L-GM<^-M!FR)#@3:C(7/X[(1C' MSG6W3*/=[++W^RK8Z*WD5B=/YM<`E`@N46@//#Z;4FS(O.PW%07U5I0`S)OD ME?VDSIDLK@08$>1:[,F?"IXUA[S`+7D7/N>4E9ZKQY.\`LB+(%-B1SITH"&[ MS-D8QG\G:?PKV*#T,IPE99C>D;#0&%7JRH`909[$GJ-+%R:RJYVU@),\C>L0 MR^5_;J41$G(9(.?4U(K/XLOICDMDW_6OQ="E)]J6_D$*!!!RH5^ M7<2N+K#EK!>**X\JDE4#H`AN$CB:%U;XY(GFL3C[C_8RE^&G_;ZML`1 M+L>V1;+0>J]U-JD2&G6J!X-#I'D-Q0N?/JZ]B.+PF"+(=3#'X-#?]F^'P1R# M0Y=64M]@CIH$P3[#".&/L+ET'\PQ.$3SB*,9O8;F\R9D9)M2]V?]@T,<#S9J M,]3]B+^&BFQ'NQ."<>UY=\,TVNVP?A#'YI'LX'!/#O_K@<9GCXO)=9*:QRB! M+[*GGC1/_(450-X].?'G<*`##=MMR-5I]DU.'\.4&!SSK]4`='MRMB\9/%)L MR&(UKI)BEA=A6C_<=)M%:<6RWK*GF&!_G605B8>@BMK*ORTDA5U;2!,# MIC8J`#;?^=7Z4<7%@\VSV(@*>^L1*8I:J!MBP)F@(F#UG5FM'W=27-9\C/)- M_B649.^>/['4)M>O,YCTN0D*E75`:H_68.>=M!J2-6>=G(@K6HVOV)L">6UR M7N9%J>*!5R4X\9XPL@<-8D3('&NW8#A14I3WX9SMZ]53&;\"8-O3*4R&!YL_ MK,[2M,QGN1"81?]M(9?PI]T&3!H>W[OL0ZDA1&RWF;;EU-Y@;-'V;*?V71?OGEAV!<6'U!Z,.6U@L%QAXZM)>!2!9KNRZTJP.O. MWW74UIC4=RF`\I?Q6@Z\/YBH1XB&OW+@ZI%#9UZT8[^/$0JUJ'*>';MZ3-"A MIA'[*_54CM9?V1ZQDGU.NQC@\6USF*\<8B"N`QH7^ZGK+&ZD?2)T>D.$"[6@ M.,CJVSO2<;F6`D+F:&1A5TR^*_(LV_6WBP$.W^9:G]&P"03/4PRVL[ MW>2?N'B1PY.NIW,$F7[`V_)T-6O9J)XDF69[FX_D7FG\O M)XL,@O(+,UJ5`8_'33Z_0W.6"0,LR.(/5@D(6)!H.6>)R-//.\.H! M4N]YW;NL%@;@D%D,&X(J;X%RRP,R'%G:-?3/)TX""]E=)VN$X5BNW#&G6LV\ MW3;Z/:0TU+B2NU8.$"'(IBX9)GQV.!BL!3((]A;,'\`F;?DF8KT42(;@NK.V M=H4([`4>")1;>\$6'C"Y@K=+@H@([C.;*5F$`MO9?YV?Z[8H6`A119-L?$]H MDL>/DY"RYTJ_UW^2;\MT&@#POA\O,_?'=($HCQ+P$-O12M35>L2[C@^[R.+Z M#BZ+6I&%>F@V$0Q.?0=O=^?8#*2`96\)6AC$X>B2DC@I;\*(A:_,;\*$_A:F M%;M3,V6R#ZNR*,.,7;V6N?@-FP*%^`Z;[,YZ-[`"]OT=97)0?`U?DVDU_9Q3 MFG]G'3FGRR*IZL(X&M*'9#PIKU\)C9*"W-,D(JL_%HN_%D<2^CNU!ZK! M?O`K[@4]$`LZ@[^'AN)_5$59/Z/RE%_$<=)(=A\F\6VV\`,OH#2;5]D>S[0M M4(GO,-\>F[UN:`4=P)L_B`4O,/E@JTI$MUZ$90&21\]%3P(%:`0$>;OK*@4:@=+M!=QL1B\+`T2W"H*`^^_T@X@[-`HD MN(@QUI=$,P+9L$&`Y=*0UHE/[DP&9^STU,-?)KCYS*7QW25^O4\UNE"#BS_BW0+!XCV=+RZ%A9V**\>Z+\4AL\MUD3:J-Z#[2[441O(@N+[CH2; MG(Y(4E8`FF50?YTES3,6J\'A<-)2?ALTCL<#@VP*TU0>LAL`?5$O!B,SX)QO MZK:^!1K%$S>"K#L*E(4L=Z/%K>OOA(76D/CBA=!P3-8B<'9C:<@D`.WCB6Y! MUE6-5(@MH:42?&&T]775B^U)`33@"?/9=4^VK49TEW?Z*F")T7N'-A($R,`3 M^82M3W?0)+8[2\[W]IXV'[WD`JKPQ(4AVY)84"RV&UT6#0I/O5U3@F#P\;_] MK#94*+^5MM/PE$N0/4^3.`2!5_D9"A934QA&IUA..2.+4!$7!OUZ=&$OI!%% MG_`+@L@N;VIQHTI4"A0YDK?EQA,%8H&XQ8VC>A+137&T60?4XM)UIA4O(B-, M02T?CI.HD-YWZVHAEZ>"Y*&D:RVT_".H`402X8LR5.`099Y,8#*0BH8\*R7KP]*+40 M74*9M!X@]6B]:A+!9T\#E[6P!T&T,E^$EAWQ>U).ZD>(;JK:,?^4#T>C@C3/ M@-TVU^IX1]$66P=->`S9ZL2P=?3(@AN^D`RTD;*7J.(I<,$T`=8K48]E1CF_3\,F[>%L8?T(Z=1J`+![ M#%?JQZH!0&1GZE=D1DF4-)XAZ)6M/%021B6U`*7'J)]>-"I183M.7J&$=2"? MDCMYE"JG-,#RF%&G%UE"--A.2;_E6;XNZP*FAAVBK`N0/08U=;-'-$%A.Q:\ MR2E)QEGS*&,T?X(=6@'"@GC+Z?\S&4&9I_!5PJA!*Z`&!*ES-=GB4VV,%MLY MV/+*.2P']2:\T8"$7WX%`(<@3V\O*F7`[&4D%%B@+#=+6$RN"$U>ZOWR;082 M5[7G:A+2L?!>K+(B`$#@T.G$C`E`;!D$E[U);0MNE`0X"#PY5D;2&B)LJ?Z^ MD5)K4[E6#J`@<,(8[D:V`6#+M'<=4I8DLK@G='E>GT1U5N"T8F?RZGVD9@O! M\2$"QXH9?T;0L*704PC?G5&`B\"98L1-)WH;G/82[XER_ZR'OS1W)(:CRWPZ MS;/FTEDK+ETR('NT!E`1.%;T!F=OF-@R[PFPU"A:(/3';[<&03F^,R#W894_ MQ/NH0I['#T]2I",O<6==X__N=.+4>C<.#/J[2J:(N=2)>%>&Q-GZ!BC*I?=` M'DUGB6;^T+>L(CR!>V[3-QT?NO19F(7CV65PO9L(L>]51J?C0Z<>BTX9G6HM M;BM[6^Z]RN@$$N.(K^NAUA M\`P+HJBFBXO\,U(!"/PMSR%9NH7IT`!+N94_:^#UA&$ M'"&=1TW5B"Q2U"KNAZ3XXX82TL[ZOZNNR_LV:!Q#J-7^=%RQ$I'%P#H9KE?) M2Q*3+/8QX[:_#1I'$$6V1]U6K$1LX;\UIFX^"DI&$"2W M@Y[J4'O8@I\MI:!X2R?TE)=A"BL*3;(BB5S["'0^#XI'$$&(=((UUJ,\ZAO/ M@>X3M%J!A/]]K+O=CP;^#)#].M8=N/1T.S_6'8@3#]E5$9YCW1ZG)S4F^(HB M!\M:.8#OTN?LZZ!W((SVXZ!'EJ:E._@W;%G,+H9^"Z=$F43$Q>=`KTX=Q]JI M8CAL=]Q^=-8"L@0S/TCOPG$(CZ:;H3W2?R`%[,"C.DT>['6_KMD8_!PKV^4! MX3XX]#M/$?R^(E&%M1-[\66XW^#KI)&\$+(F+@QR[H,KVQ)E*CT@>S5H"4BQ M46P7`QPN?;SX]HG;X)$=XVHOP5O=UZD+5'MKMJU@.1%M\9$=2O:@`M<^ICLG MJ@V(O8M2+-D->Z@]@J&LG.Q`=+>"!,?'/TAXM(=>+=$HHG.G M+R0?TW`V2:+'QI%]FXUR*-$Z??)Q[/1`7DA6D>(&>L,U0*.@J,NJ*/,IH>S= MB[L\&]_!XA=?%`4I"YW#IJY-`F4(;@X:2J]_KM2E85")MXS[_6A4'2%UU\:/ M<&ZTNF__-BN$J6X>_\TZH!8\>?PM$"SH.G+XV`Z4FD[7EE7MMQ?5`83(7@'@ M)P>1OL,^C@&$3@A?@5-+9X^D?A'M\N"9)BB$*4#P6."T*$ MQ/5IQ&68A7$HUW*[#$B%P*]CKM]M#*XOKGTAL.G/YG+5KA4"N1`DQS/7+0<$ M,G]^L_60Q>W4!8+C$P36N8O]>!L?,@=_MU2%QR<(KO.Z8(H#4^KUW_'3?--I M4M:'?P#O$@RP)!N3+$I(X3^PEBEL320='X:X4G!\YBVR8TLJE?>!7P&ZCTN# M4>I54"F6W_ME.'X$?\`#\[`J[/]5&8"-)BY`1@R?R@T8R.SV6CIUQ-1;*4"! MXVQ_0Z\2Y;<%1V9]=U(_+@N["P]H0PF_@@ZGU53)R%HY0(3`%MSJZGPF.)(C MR\WS-7S5XZ!=#I`@L!EU.=B6'%GTW@/;][(S3UJVG[LH/L_;?U$MX-J-@`Y< M!CFX7N$-<2)S"K2%5+I^MPL'QZ=.G07Z&P)#&M1DM@$B\Q98(`W9-L(A>[L+ M'/Q,07?%Y#)/J^ES$EZ&643H!9M(%`Y0947`@<+3PQ\='&^H)B)L087+1P\? MJ^=_D*A\RH?TXB5,4K8(W.1T]5[;'0D+97"[:5N@$I=WVARO@QWA8@O),X*A M#LRI>&5!3`1YQ&S2($9I M[[4\`1F_P9XNKUX(S4>C)"+%+(S(<[/MBQ:=H]&$G"?#9H)3IZV-><5"0R[,%Q]M?,2)L+_%M2JK%@>UO/(E>X]HSV2%/N_.SY=^YIDD6DS+-?LP3FZX*]BC&FI#YIER]RZIH` M!<$1AFQL<)8N75CV7L(3,'-'JC_(-`E9N-%\.IN`V(\YS-O:!&DW`(`0W,@T MY,D0G?Q!.@\V=T6C"6RDW@!?OT9IQ1[48\%E):'3MS^IO'*F;07'9RY/.%Q[ MY;K!%?0`?UX7$QAJKXMY:Z`6IPYX?:]<-T(M](ZV(@3]PULD#8K^@6N'A:&C MJ/9F`WNNH7LFWA,4(8]E%2M\0]S"(#""MV@Z#TG>]DP,4\"'/>]0\^WON38; M:T5!2`3YV.QSP0$I8,+>%9R'?!ZFS8,K][#5`%'#L?#!)VYA$!2!V]0LEEJ% M1J#V#EX9@=I7.VN6V3[)%OD>RB0B308'$0.J>B`^@KM]'0^6*O)`TG[%.<5/5#Z2+ M&-@N"2(B<)ATT+L(BB`XW9Z39/DH_1-L(HL'4A#`.KFG[(;C="')Q32OLO(^ MG`MNVG1J!^`A<)ET8*H;4`&/';PG`AX7`<1O*]HP^T;*QS`EQ4U.+\-BLLA6 M-*3-`@A@15QV:2LX/D=P0;0#G]W!"CCUY@]9/V`L;JJRHF01W+_`4%Q)7Y71 M;`'@(P@\[':-S@BB@&%O'HT[4H)]40Q'EY3$23FLRJ(,6U..A%I550",P-#M M>#52"YN`3&\7BQA.&D;L3O#P.4W&31JTBMS"_/-:/GTGZ0OY"F4F,L^U?B.@ M!`36"35$*J/9V?TDL_R.)\BS^=]A$="+YK3H`1Q`"8YO>37P"8KU%N(@E M?YHDM#NOJ]H`>^^\+,;P!*QZ"X81"WZ35[2<=*;UK3H`WSN'C3D^`;$?O>3G MR(H\3>)PF4NJWM*/ZG3`DSP%P8HFU[67A^^6`MWI/&2W53@X_N3O';\B?B!`KD]W:>W#]"OHT5KJ;;LPS#>:81I2FM!^IQN4Y-L?[YQ$E@($ M'>KFF=YS8EME`1F";;QDN(AV>EP#Y`BV*`; M,Z:!"5E>D=]#]KB".!*76PZ0(#A?-6:'@P%9YH^+.$X:6>[#)+[-+L-94H:I MDAUI/4"*X%36F"T-3,A2@%Q$436MZGP,RV#P&243MIJ_D"9WIII)W39``PA. M<,U9-<-G+3V(K;6N!'PDO@YIEF1C<1)P>04P>!&`\SM15PD>!+9U'_>Y2T3HFE#&S618@(3A',R2&#P);&HVZ_]P6147B MJXJ"F$WFUUHB M7M(8*`6!<6Z%>25*>]DX+.U8T[IQ$O/?PKM^93_*CA7T&@#P"*QY,XI-D-G+ MZV'+C/Q'532W4)]R@1VU,(:;3BPU+0W;`I4@<`X8DMT-)+:,'QU?K/B$P#U@ MQA<'@#REA__#;A8?%Q:3FS3_[N69S;Z'W">'WKQB70^Y3PZ]/5TI4J#6(70HN M$IZ)KGG.JFX"\.-X?]*,L"ZD;X)&>9*^,])QG;?OFOT?]#3^Y!"!-6@V"G4/ MZ&MHR`[H8;-'#"<;1Z=_B$E[G1J.;I(L!"5EX\N\ MJ-_LODJ*B&4+D-D:NDV``A"$%.Q\*3#2#K8H%%`*K5]F(,V_+34L#F`US!#] M1D`)")Q0[HT+4XU@BU#AR,_"AF$X$9C]GE-N&B7]R@`:0;""*4G:5'/18HM6 MV9;[GI)9F,1JRT!5%0`C\"FZHI>'%5M(RK;4;W>DZGB(ULL\;[.=$>4Z#8)R M$#@F774$?0U@>_AF&\M7,&9I$J9LR_)8S6:I:7?@-1"<#!"X$EW1+T:,[>T< MP1+%+)J*4I;TO"B(U`30;"$XP9!NR^FZSH=L[\$=5XQ?1(T9(LYHJET7.CD" M_Z\KEKE@[3W;XY!?6I'X+@F?D]1\-=^N#L`1.'8=LLS%B^W!'\$L=$5&!":A ME?RR:W:Z38`"?O3)6X`9VQL_V](O!7\@+R239K-5U@7("%RWKFCF@L7V1D\_ M_Y.SD"!0%@+_[4["2'IKR=XK/DZ[U&WV`D:JPV@SPP^`\A#X?ZU$FW5";N^Q M(4NOA2V2?S_E%]&?54+)VGDE&+8ZY\'ZC8`2$/A];1+*[S*F&K'W\I&E;D'S MB)"XN`'=<XQUT#%.5V'N<"<,ZXVQ]`64A<#2[[S\VM&3O M72FG76IUDNYJZV+X@>#D&($SV\K6I1-R>T]@V5^CZOLC6033:>MNB.;*Q*T+ MD!&X.&W2IUZ/)(JP]R"7U6UK*]R&G<$LLX,P$'7XC7K/JFH!X"-P@NZ@'YBH MP]ZS7BYG@BORK+LY7:\$(!'X07V-_3<-8'OI:VE4-3(:#G1>+8")P!.ZL\$M M5@&V%[\>R&PE\L)O+QW+W/(`#:\WTR*[$O#8'O_JIPQG.WQ0%@*GI/N>8D-+ MV!X9NQZ-2`3[ENO7:!)F8\(>N!YF#"9L8-@_S)_R$J9$'N)NT@PH`H$3T\P0 M-,>'[M$QKJQ-`L#-8T`)T2;-@"(0."7-B#;'A^X=,BZ""YBZ*)W#C%3G^31F M>*,^0$?@+[1!+1>8_`DR#ZG$6'ADC31,E^G8%BFT=!QX.M6#DQ,$'AO#!&3: MN`2$>HPO;!*XL%2-L*V0QJ.LE00X"!PJ^HH7Q9UP0`F2!1UZ2(5XE4?UQ41V MG@0[.99P9Y1#B?K.?^!7P?+KK8_>2;(?JJH$ M)Z<])ZX>@HMR'\J*@\`N-XC<#(AZ2ESOS6H,>+(AZE)X1\9AVO1Y08I#3JG@ MU&G@DU860S49V^1Q83A)5ZBK_D8882ZZS2(@L5/+6YE@4*C%;65OR^TD1Z!# M3>/(ZM=#Y8X3\YDN$RQ;G6)I8$5@]'JT-?HN#&\(G.37T]7Y!<@2,WENTI#W M#DS.-Q?5>M#Y[M M$+,%QTE6-+--T@,9)\RFS\IOX50T>_&*`@*/!\1="1$C<9.)S(R,2T!#P_0V MB\GK_R&\>VO"L@#"XXEN/SJX4-P\$:?+QV5SC?EM0I4O[Z+B`,7CZ6E75N1H MW"3Q,ALH-TE*Z"6(-,ZI?)BLE00`'D\G^PT2#A`W^;)TF7BB(7LX\'$^?&7;7/@>`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`0J>4"((`^; M8@!IL=;&@\PB8Y(F<1+2>9-WNHXBU%C;N'4`H4TAQ.?KPTPUN[]"U>Q1R!E2-F]>^5BMU8.("%(-BL9*'QZ.!CD=Q!]K&.+ M9RQ(?%51=O>PSE'1W*#\1K[7?Y(O:#H-0"?&L*WL)P%Y??O?Z=98T+PH\D:G(9N<6!D'Q'1-(>5%A M$2C=GI-D^>VG_+ZBT20L2&L*>&#"J!@0UPQ.,3R-U9D.%3#!.;%CU`NAY=.[-;O3.[ M\+/6>ZY*PW;WW**P&,@2T^:T4LK6P^6DE$3QI0?)[+L/,^VR(Z@( M\A?!8)`,_O'?7K(%9CM+D3]^]?_/N.P"3,(U0\O2G[WYZN#KYY^_`O_WK M?_]O?_R[DQ/P"28P"PH8@<<]N`B*X"$+PE_RFA^\?_/^S3\!\L,/)U_2EY,? MWKW_1_#UW3_^^/X??_SAXW^!_WW[^?^`R_L'<`*^??OV)L(M%+2%-V&Z!2/']_2OV+2'/V84_Z; M-`P*VE5*N8"0@OSKI"8[(;\ZP1WVX?V;USSZ#OP0V@`OQ8['?P M3]_E:+N+B>#T=\\9W`Q+$6?96\+_-H%/9+#(%SZ2+[S_`_G"WU>_O@D>8?P= M()0_W5T+%?K8::MB>HNEM"7G+I+V]H$^2-ML,Q/GH)@]Y9,4&]A M7.3U;^B4=?+N?>6-_[[Z]5_6Q3/,[F`(T4OP&,,<0^:\S#*8%*>/.9G#BOJK M5%??SPCD*+_*;_J0=L$V>8_Y(0Z+"Y1!$*$\C-.\Q#]NT@RD M5+NL:>6-.^!K`:K&N@&:['G9"[B!V,ZB\S0O\O-@AW`<@?Z&`Z$,[@(4G281 ME?@TSV&17S0#H>&")[=LW3]/[XL^B.L6`6T2.^U#HRM0-;L"01(!9K*L:7!H MVROW/A-6^KY_5J!8CD_J28K*)IM*M+C<1"1"'8:GE3KPJ+!J86IY@=ECVH3? M;I6Q'D[)$3881^G`RYZ=W&;I#F;%_A9W?X&-^?+7$NVV>F&\!J]UF]'1IP^V MF@=0)H"Y0,/FE8O7'JP^\`Q'R@/X'682';]MUHP_H!S6T@B?[6C$*_\X9FBU M<:L<5XL0#O9T48S%.PW#K`SB7,=WRKCL`U2J`X?'BIHBL:;WRU&JQX2#FNZ` MV$,6EB,MDR*O1*LE@]$-"AY1C`H$1P#!Z9@^/0XY7S4HR!'$#NG4\CRGISGFYW,,EI"OT.QF3CD2;%[I^##)*3 M"Q'VJ"0XU8G_IC9L'X]3>X*#[0&QZPUH-PFJ-EE>%AQ:!76S?GG(63#"&<*, M`/'07L[:4FMYYJDM^VLQPKZ0F$PJ,YD5LYF3OM'X-3',`Y71=J.#$WN&-*80,8MUJ$ND[V.X(@4-K5>^7#4,?;3IC8$[&)E%OUK8,V[$.3U,]^T!M M\=/45*<%7[,"HP:W#]X)(^L9C'6R5^QTWPJ/`[-PI5[E? M+-IM&B,BG(8'EC&YVA@8UD"0^R>S?TWME1M5#X<@>:\<"YL.,LFQ*!%=95&A M]GKN4,;FP/E)M>!=78M\Q<"U!U^K_WKFWM3CPSLSW<&QA[.?16$F`\5YZNTPGM]LCM)_/[4O*Y7"KRW^*!8,=(&M*ZQZT MPP#@LLF2T;<-5OWR(0)Z1]!5%PFI$*Q;$\0FDM7"UU('E/Y'7Y"M6;E$`RH6 M0](@?R9[@_@_Y"+;2Q#3W<+B/,BR/4J>?@[B4K9,U^2W'[AJZL5!"S.PC6+R M0XL5G!:@9@:4VZ6E3%*/5(\(R0_PP.KV(OYD=?JCM0*!I>': MO[.KU2J]A!>I3YN*6"U64O>P7N(X7=>,U&[=JUNW5)16M&K!+J_$"B10,!PN M;K!KF9+HOKJ!'=DL8$/+H%V^DHM&L%YH)M$7W#%*#Z'#[*!8C89&?(D:R@0J MKD/E+NPJ#HPN_<(DM2#CRFG,',$=V>#W(,FG#SZ^L(X9\FPG`]>;"Y3C;@[B M3UE:[JZ3,"ZCZGX+/5I=PFB]([7W49IH3,43&G645AS9`P-71FDC@+:R`DT[ MH-T0:%I:5<7V5E[,Y7/V1)6%?89Q1`O5XO8$ZP/[V4['NCV3_QQ@ M-*`@SN_+W2Y&L)GI)18MX;%NL#+Y^RAL:%>@IFZ5F'5I;"9:L#@S[&P-N,UJ MFDA_CAM!(?:)!>$`VYK5O3=06D+?V#7-P-%>GNX>GNN].^6>G=.UH$)2^KB( MEBTZVZ73VIWSK@0I7EQ*UVXR-G]*C#(MC$J*?A&E#&RMU,:I0F916--*$A]V MS'9I+;PHY=HR$>W2K9Q]6"X*SYR.5GY&0.^F$/R`W,-A635U^9%V,1-]T4A2 MRVQUY:U7R:I>MEZ17@3OP5KT!H3`B7-:6]-,W0@'] M.BHICU%=&4:K)*_&PGQ@\N`TL!I+$D/PY%QPKR"[_LF2/H/K*OT: M9T?J(OP^["X9"[]CE.Y1+T>,HN"_XWP;_]B`%N!%/"XP+Y1_`#G<,Q-^(-]8 MA5@5]UA:]"PANF73E<-_P'IUL&__4=([^`*34F.Z$C$X>T*4DUSX,FA%Z8/1 M:@M?!VJT)&R:D-/\4:U/QIC=FX$<1*)'2&4(+%>T5NGN/3T6C)W M-S^]*&R[&\6/# M<)0*OH8U:OQKHL>%"23%.?XOTL/^@=@AZ%L22]".73PC\P/F.D+[L;\LAH88 MU<.X\_?/P7>F2OV+M'O1I/?-$R/3!9O5/) MI@\JFJKZP2"UBUN3`S(/W">L9G1*MF)5"E;@.L]+N%0U$=WKD4;RY[3\Y&E9 M/*<9^AO^Q0_O5N_>T?^!G!3ESE=@%V3@A;0$_L>[-^_>O7=O'1)D#=R0E,/* M[A-$::)E##RIDV>$>M(./124)E4)4^>%.O0%'@"]&O65<=.#W6E9Y`7^@:2; M?OC#ZMT__?/J]Q]^H'\B__SP^]7O/_ZA:@D$K,XKAC7' ML9(8G)S-NO$IM.CCNB:G%T`8`VAQN+3*D9JX![X.D/I&H(\BB^4PZ@\\PR?$,>YV$Z1;>I#DI0;/> M/`2O,KLP;L-P`TY/@0UH\XINQ'? MT3G&[!Y8X3@<#QQ#&@]BFU45BP`E,*K?B&J)?0$W*)1N9^@P.ZB=J*$17SJ0 M,8'F2;#OVVBM&'_GMC[B"+W:2D2,RFW=B66UL%O<4==R^'J.9F;C,KO>%,*Y M9:?C3HLB0X]E00Y&/Z1D^S5-"MQM6)2GZP0#&>9FF?AQ'_`@:S^R9W0R_(>B M4U7;H-TX>$A!MWE0M^]RPVNQ'F)[9?D1;2%,,1KU=L-TBW%S'S.)>%WT]I@% MK$YO:@JTD1T2)4FC`7/W9)=:5R-NZYKF5_TU3UT(RBZ`JO%GSZ2N`I31S"\I M38>73&6F===9SF;=E!1:]$%'R-G.!V@Q>/4JJLZX]#&F/R@.\'6V/POP((3P M_AG"@I9%1.3PJ?IM:/TFW.%.K9T8@ROPN`<5.Z#\H&Z@>L'4KW>C38=4"%.C M\=2!;+A[?:5`?/?QPSL*0_*;O]R'SS`J8[C>]"M8T]Z58="0WQH`3?7BU@D5 M*\D$\L7D=5$W6;THQ6M5F!2T#NH":M[!'1:+ODZ!6:LT8:M`^QMWUC0*F;4I M38"EQ>5_5[[ZNC^MZ*(TO#&-V%_&FV@H-,&T-L&F;'OUYJ(M*]1,MOFAK=6U MN#&"N?7V2/AZ4(!3QSIUF/TIQBG#9\VTJFIR!IV:G#Z"4W_@M(M#+AEZ79"I M.$1TIL??/-V2=%-._VD:A1DTY2H@,]%6%INUVZ$9GW9+WLP0=I7_FV7E#8/4 M*=IC@C(.,A`U"WA6/Z#5#\0Q!:U^\">$-;9P030[TKQ=!+9\=9`1@:VZ$8>! MK8:&,A,>*L'#[/:K_)(V@7MAE?599:J[16H6_?<`*8"1VPF\Z#&K3'=!GL2 M=I]^"[*H+3G9.V#!89Z76_:[288UY4->&-FDGM(UN.HC@'Z%L[CF4Z#UK:,Q MO^E0TS'%N7#FQ"SA$Y']#M*Z=N0HT";-ME3JLWWU1T/[,VO1I:$9ZBY;$%7D MH&D,M%H#9_N&P,?UT6P=D2HZ@FZ)'WK":R4;M"O)8KJ`$&4E-5@M)N"U=&D#TO&0ZRSYJ+9QH:O0J!#V)D-4B>O M9CA"IG-+#L,W3^G+VP@B-JW@'_JS"?[57V[@4Q!?)@4IT!J5=UMKZ8N6<\/ M5:R6=[L[Q"AG+!&#<]0(YZIAW'@S5^E<`U7\77)M2/ESWU"0S#9C]^Z> MH2"Q;7+'T`,4FHR=Z:7"Z9GN\9B\C-$3PM^_QN:RSJA(5VG62,QV@17^VZ`- MZ^@TT8_SB14O(,P@S1@LP0;_U+JES9KPQET:#V@?K2-'TX$;9:(,R*M<[.@W MX'TASI,[Z2;GL M%^Z6ZL"5Q&Y1L].^E-ZC)9;&F'#%J'4'Q.(B'4>T^\]!]@LLKLHDTEBE"QCL M+]-%DG/K=$((&"6@I!ZA2-[_W$I=H_.=+$6:'_\=P0QWP?/^!K[@GI3'?+H- MN%R.R#63S9X-@S=AG=F`258@VJ/E`(R?84#N%9)U>\[+J1_5Z;7C#IJ:>DI* M0[4`ZE\D9S*,0J2:CZ$#P%XGN[+(J0&]5TZ_4BYW8!S40>8<&<,*4!;PWJ,9 M66-(6N'T:@ZP?/T?6#.;H&!\4MNCZ,0M<'K]#U802Z M/GB.K@_FZ!H<%!?KBH%$]Q5*\.]0$#>[,^R`DW+H&D:U&V#KZ1UF@WT:UDS#2_B!<\<8+%H/[5HUTE>9"6+?NO? ML=)<0QIIE<6=W+1]^YG>&YS]-+;1:K-M,JQ9D7&I"_%.[A3-FV\+]`WC^M$# MKS"3%7!>8583<+R'<(J]5I;ML7S*IS^UV/W85>"UTMQ>6(&`S'*,=]&G0S4- M=%[UW!NE"0BU=D^D"'2WC:)O5TI.YQLK:KCQ.RS>&=(,2KFW'DV4J7:-/+$9 M-E<.U/276(N$Q_ZKAA+YAZ.B5?O(SX%^!>@C(2X?-C'112*L36-0PH=[8E`/ M.S8K$[??@*=E5/+#Z]\2*U`Q.JA(K-"$KT9<,;`R.RM6B"=O/7[N'F!ZP\/7 M'M8?&U=0NPVR=4;S%A$UA5N844&U(2=NP#'T))HI(8AYR=DVQETY:AFMY*[6,6WGS#1)N]ZD!+V=E`QP*;$R[Z>C MZSPOS::BFL/]--3(KC,%,6*OIA^5_)6M($KF[[33A9!RRAG"CT,#6)=%7@0) M>2W8Q`HZ;.Y-H:N%CCVT.+PR"BU-*LM(#[3^FL<`P)0V(D27@Q,Y+(=&2RPV M[R%4AVRC=7('PS++L)R8X$N:9/4_SX(06: MUNB3.>WV/+SQ/!=PA&=TYD7-<9G6C-*1&!_]E*]'Y.9$V1*V*(#8E-+/N(>"_/D"9N@E*-`+/)S;.FD$\<>I49: MK_^-4>KA&9*'_$JL0+H!R8"*3*^2QZQWF#"-7#__I^T^ MND7)S7S'JP)WC14D8EQA.^`<0 M@(*T^P;@0#^'!YH@@Z`D#^H5:?W.-R2MIAFEQZR']\`P%%/R$C:F_H8*O#B@ M$`1;>O\TQVL%+`/[6HH%3#.P#9(]"%YQ-^/6R2J!R>`XT%-"O1/B:>+--?=AYTP+DMP) M;WT\VC.NOK5+[(DGM6Y"`](J9SR76\;:\F8J>6VB6X2)/J#E@)@O:W1>9AEY MN)7D[4W21@-\3O-&0WK(WNADT*BXV+:/GZDCX0#)*T9D:VK>;UPSN12P. MPGNA],/NHX,17W;W=,>"CSYU!L+%*\RW&0E%BOTM'H("3^.D\OZ./@FK.#VB MWX3#=Y:5VLF2W#4SH-ST`=>&7^ZT[,S$$]2L&5:5;H&^;C9G;5.8BA]!-L&H MS4MB`JG.]N0U(44&7XO;P?4P'9U$@!RTM;.]^G4Q.R8W3;E!:_/LY30#2/)7 MP0SQZ(&A$<&4J7\M;G\,K:.3D:$Q)$I3]X[M3$LWJ9UYLS%A@$EM2Q,!TNH) M_UV)Q[@12?UH@HC#Q;E^@>P#!^$I93MHDM:DM&,V(Q0@-@(UE;!\D%^&HX$S M_&H06=R,+K,$%64&L7%>H5?RD_JA!QF3_6UCF0;<4=Z:F,XG-;D7)C%2#V(6 MZ6:#0NBE=:CQQ>U4:X)K0HX*#T6:$>J]VOFK&.SFIV22ANE6:U'3,B\G-_T(3A<.<^4-*PT?FW^"-K<7UC:/DOZ8F2DD^\8V M#H\>I/UDFZYSOH\LE.Q3 MEN:CC*MB],>P:DV,C(HR>6E-2G4Z"<$5>!)KXH7Q=("F;3@#*+-Z^+?/ZZ9! MNVW0-$[-N-V\]!"(FUO<%CKJ!N;YCZ#=75'K"^Z]P=P6-'"L>0'SL>=A=(26 M>`\]=NN>05.K/IC;;*N6J0<]4W=[Y6`&Y:A&@5(CFX9J`L2^$9JCT)Z!Z>]N MN]_55N?2_=C'T)>W$ZOZE/U7P*./\,GY?N%=`X0;)2_W:&[$21ALWRX02\X? MU:UI?=J(\UT#K8VXA96P>*=#80B]RQQ:5N!B(^XJS>Z#&!KLOO4X'&ZY]667 M[;-=D><@R(U)'R:B<2IL]%1PLYLVB"/Q%IH$1!87,RC?I7D0TW<=K^EU>)0\ MD<>$4FRM20FC-;M,FR8W:?)T@UY@Q%0@-:'8M1O98F>6YNTOAN;I%6X]437+ MGDXE+V]7+8-VTZ!I>P5(ZX`VWSS">OC"4I,8J5*`R/<_E2@B+W_:[ZE!MW7H M#/=6/Z?=<&NSV8W&@SV+6JE1^Q8M9G_V+MH:&>U?-(Q>[F'(U*K,LB%9@3]G MJ"A@`M8;4H6A`&=I^HOL@4POMC4X+&IO;0B`:-6^0@BC_`IK2YRBY/*=W-#T M6W%A<08Z#I@>Y0:$G4TLCE3`"P@G6 MB+*E.5I'JE[+$DT-<2X%'W0*N'\HA(9VF" MQRX_5Z:-!?0NCLL-RBVRU8JP+J_E='_%4/1'1N@^J)%B9>`LF0HHUE&.HZD@ M0P8PYQAV8:Y-KNV-AOHT<2@P)C`3K0`-GUEQ$CM8^A58R&<4RWVHNL?+J`+S!.:V?/(:!<<$]LF*S..(8M56X:]L/0ZP5$2 MS(O;8$\R.>IP5,1@/0P52MZ'4$T(*LK5PF&GYOZON?P[1ND^SI2#IA]?ZB!F MEEV3FS1(\NHKFOLE`RRN=DJ&I)?MD5#Z&M/>[8X(QT*P+Z(8B-GP47U"N2FB MXG*)D@$=5$"I?88+:]@L+X0DCN9/4[(+5H ME85)FQF#4),LK?MUKX8"E[1>+BB(S)O%9#99W^KT^I8\7D?D)NEC;J:!3*>8 M#`91S)-==I$1#*UTY19@<]9(GH@(%_!1MK;MDCF8-3I2\KXX>3JA""<$2^V9 MD-U.*;H:]2%1\X$#(V"<355;]_=5S<>LX_-&#)C=BB'%GCQ3@):*[9DD3_3< MP6D2T;(993)XH,>\"?O'4?6U&TC`'2KMKC>@86:G2^@=^(;?Z2'5\3I^29.3 M,,B?Z[TRK%SH]NC,6%ARYU9'8=)BTA$E<+TYSV"$BJL@)#>-]EFFL[N,6+XQ'6"*A;60'2#BN90OY$-?B9KS`M$1+;3Q7;8"F M$5"WXB>252.K@V*]876+X#M($E98N*D8EC7D!8JEFFKCN&GE:)"L'F$=+.L. MK\5GK^,@S]>;*H^USN[0TW-Q^0JS$.7P-D,A;/Z85W_-WTM`/;(]^T]FC]2; M>Y*0M$,P7F=;TPQ0ZA6H6P.TN19-WA!Y$$Q/`@#WFO7TT;>XNHW^6N8%?>WM M(3V-(EJ7,XAO`Q1=)]7>6R4L6Z'+EKGF;=E?[X[0EUOX'MH@IQ0/K0#2##G, M6#6T:@R"M>5T$3R#XHWI(HDZ5A?!8]'+K8:G0=?FXS"/5`)2-E=TCTQ"Z^#9 M%UY>_AF41V8AA(@FCUR_YC*?S%9K!HNPP3_.(@6&331O8(:#0Y9^8K(<:@Q_ M@=+2WVI>!VA7Z\,CB?%4^5,&IDX=;I+K=VX2$Q3KY4[!]SF$6+T"@H^_\\%J M-#'(6Y$1`-VS+#D3_)I@T]=J?G.R5:R<]]DNQ1S4I6 MX!4SW<3U8!UB,G*R,YAZP^8XF9_!7TN8A/OUYI:)*`6E;@M>)(B&==//V-?L MY*]U`QZ@TVP4M;+SJB%TB]'Z\NU=4,`+F(<9VBE>7S1JQ0NLBG74QFMSQYJT M`5J-^(E9Q:CJX%9K2"<A*P=:])>(U\@-#!.<">I()C@,VMOQ4MSN82TSI2']GM.2%D M^#.-8KS,4@:!GDH[PU8=D9/Z,,GI4-`C;&LZ!^2G88%>B,WH%=$P;M!5\01S MS65U%6AK@#8'VNT!=O:Q:A'437I7HF,D#@1%`B:!P#*N;_2K?XQJU']\MWM@ M5HS?J,J+>`UT#AB3P2Y`A<6SZ8.BGI+@Z`F2B?AL?R"I5K"G.`:,*D5:A\V^ ME(JK5`M\R_Z)]P7ZB[,PD56U/@/.]AWKJSX%Z+<:PVM]#;#/+12VL>C_O@BR M0I5IM]YJ53,J85N`,/J&$'D9Z#&*2SEZT)W"@YFD_7#(T2#O!ZLV*I1P0 M=PEC6>]S/"[[$UWX7B?L$LJG+,VE=X^6^-K1N>WA/EO.<;/O@>NDNA4%Z"== M'J^QTX,##HLR^G`69T&[F]M7*8W.D\N/[9"X/D`H.X`WIC&_+D6*--:_(%G= MC^PML9JVW#Z1.(ON0U'+4NJ9G1*91;UJ4#=I!NC-.SP_-&EVK'-.Q[72''R/ M$I#3YCTX23+>EHUNQ&H8\O%$6U=IMH&H*+%>Y`7:UQUB#\\WWGG!V$OCVT<7 MB>GTYW)Q6>OK[`GLP_762Z5\\:SCPK:-S>D/]M9R3:WW-1M;00JY,I__$4:7-'Q@`MNN>B[/X_FE]PH3;O4'#.G%/[-,[/V\9BY M)A^YH^-FQIEGKV?13N\[U>/9`)K?WHT]ZE+&?D1>M=;"N6,U%.3X?*MI3P^Z MUY-'A7M]K-QK1=AQKZO:OQZVB,@;7TTM43=.5GT$#^"1PYV:I7:4/)DHEW_N>.%Q<+QK=M0!L>6AZ8?(_R]MMKE(1,SH M2H['K[?R^(X\N+8$1^>K]?O6SC:?R_2WW?V_J1G>W^B6H`NO.LJ\[?G/ZR1, MM_"^"`JJS.EC7F1!**O8)>2P[I_$LG.G$2DE:$C!UYK8@]>9%$/0!Z16_]L# MT!K[-VP2R1,.&+!UX-A!#2$)CW40R>3OPZBA!36Q$DAV0G<3)6H2]\!70J<>A4^*RMVZU!,%N?:%M;>S5$&@>T=5`U#QY2P#Y0/>54?\+-T>UE M^^@&EK_`+0K`/P3;W;^`F_UV]YQN`W"?A@@6>[`I):_D3,:%5D&?Q70G9:V" M0R6@:O0S&*99A%>[08Y=&_X+14*15N5;4=4>('X'!"TDT=)!*442UC)(JN>E M8X+@HQL*?1EN4(!(3%>@%JN,0):?U2$2M2Q_] M%0=UCET>'Z*1\?J0<"3H\+B/2#21UH])C&!FLV[Y#CM)Q!(Z6+;66WH2FY%R M.:A5+M.!+^9]H&8&TZ)W:29F:G3>K&1A^X'=O95HX(JO0JX)*@>)'99PNI%7 MT!BD=I?,Z<@L3N-4><&;!!BLN3A.88K=CB%S%UOH=5BM"#B@+:D.N; MC2'>[!G159I!])2[? MLA+V.&BD_H^Y">GV[3"#@]U;@>3\YFWU+@%9L#`GSVA=FHRY]&2=LD4Y.<(6 M)#`M\VJJ%UA6 M9*2D8+"X&(&%UNJZ1V=_D=&3DUM0P,*7M;2.J.(`9;*,FK=B5%(^$%7)@X%+ M]F<$-RBA;Z1^*E%$3E?/T*^TY!N>%ZJW4IPN(B=!P>H*<<@/<*M!L1.PY[$N M@XQ41T0AV39#<4F.-JJ3*-HM6/=R^KIQ9ZHJ3G++XW`H&85LQYZQ M>Y)9&:]D8^'8LEFY1O>&8PC'ODF-PJ(WQC;>R/PSKI%&Y;$E#6C$Q*<;5I5/ M()5/HQ2O"+.660E2EK9B$W.]CM`SC/0(\ST-V+T+P&J(K3?GZ7:;)JQ";*LP MC&1:G=2:Y><%Q^K,/4#8O\A3E;5;;P!KK"X?W2Y^Y7;Z7:@#@JH#T@T(F>:L MCC)(#^TX?9C1ZR&W]V+C)&OOONDX@ZG;BV`$TE(Y6V+J!S9C&[0>[XS6W`#Y M+"AJ(]ZK`&FV+AB.FYBG0V@ZIIYMR/M>:P98N+L5]+5.QU M$AP]0OM+K;ZDW,J*$G@Q/:`X@U$G=HYHF=E%_B&_;H!,_;/ MJ()--<;HQ5D M+ZF%;86J0QOTIN!3@OZVV&IQAYGJ3)'&5O-$'=G0M35UN0@>K*W\.71CYD_Z?G2,,SF"L$.G%C']XP76_2I`V<]!7"Y9:,Q8DN,):$;W M]9ABO;JU>JMBZ+)"O90$$*$`D0I0L3ROU[OX&'"9L"?"=1*17MJ07GHAC/PK MDH@].?F]:A_U**+/:=YCV:=V#5W'A%W2>>76\K:6OFMWY]5"/UI])MP;K^FJ M=S^9N$27&\`.^H:40Q%.&77//+'W-D#$7ITF!U8SN".WKO&_V-%54C@E#.*P MC.FZ$,_ZP6X7[VOR".5AG!+8LC9I\4SRQRTLGM,HC=.GO>N2*;;\9V>'VJ[S M/(*50"/Y*3;';5T6=`=##*N?4XPN%*-B?X=U7"+Z-_GZ\43\1GVZ0)1_F'A` M2X(5J&4`!R$`D>)(@_I)W7P@..)`W-QX9PN^QUKND;K$.Y3_S11[`%FV_Z'GQ@Q,V^*Q4WJ&''_E]!7) M#F/WZ.P?(NW)R9T5I=O3A`!\)20>G'(>[%KNH)VX7SV:.H6W#P[B)]$M'I`O MP19>I-L`R:JU+_,Y_Z;&<;TVYM"&XD9-RSC(-53R24"^";ZRKWI@+$M"<+[7 MU77Q9_6U,SR-D.";'K3^#,E]38GM">A=O&XV*/?`.TL5'6`GR;\R4@\@*^WZ M@2?`5/T^X4S>ES3Y&7\`,H#F0A3(B.V>?A-)/'#B'KQ00N;%<@\`H.[RSMD; MC?ZVYR]JKZ4(][IDUKU#3\H^*%H3F">QWE"W]EV`N$_M#[\R1G,>72GC(A^C M&+WX8VKD()@$V$7\:RQH0AYR(E^13P02!KN3@4QR09V$AIA%LYY,"LHAZ$P, MFOUOL9S&=A>G>PCO8?:"0C@<)^/I[*4UG=%<1OOOY/F]+VGQG["X:^XPTIBG MRH9(G(ZE[]LO_F&I7SE;J;X+J@\+[]&N0//U*LQ:==>:^,-@#PMP^/2JBL>K MK[OWO5;!RQ5!L8_T)6C*EN$I`V0=TH:%JEV6#2+J`-`]:R MO`"3I5,ABW5+VNJ6C:!;@JI;3O2[Q4U=JBG6(RY&-=UT+'J2(BAHSOX33)^R M8/>,PB!6)+( MT#2[X$\1S6$4]OP">17Q/$U(`1^8A`@J\W.7KZMJ$#'8LS(CE+JLA#M6CLSUDM^3C72_[F05IIFHQ6_7Q_M#G'/3S4 MEO&H/AW'S\\H0=MRJT1HC\XZ1OMR M]D>_^KMB_6@'I_/(:A.K@RCHHU4"`8MX#5[U\-JELX_7GIPL0"CB\BB%@,T-#*Z;>!EFQ?\B")`]">J;L;-_^BRI@-6C$01;&0$,^V\`* MRE(:T&8G-^NZ?_4@,)Y/56\B:&-\\KF1<>!T8X/*S=DA8J?D=:#LE"16%)L[&HQV-WQT-.'> MMF4\H&8"C`LP-J>QTI'JI%67WKI:UK;QM,VIL[5G:$L6;Q%FZ0YBIW-?/OX5 MAL5#NLY.7P(4DX3K59JM\1\#DH>]@4&NO&EJWI;]NX@C].6N*U9M@*H1\)"" M-<9IW0[`#8&F)4";\B#47$3U(@5I6_6-H>I6KW2.Q3IWZW,:T#VU;O5%XC&M M^6WAXBO)HVS<@X!Y(?6U[-R;P'L"[B?9^LRA>QTN*`[2]:@L'Z7KR\@=IJO# M.>>QME+4GW%8EI8O..;$[:09&2=L`;L@A"O`1:<^A-ES=;Z]LXR#B.Z>9I3` M>4I)A6_82+_`;_]!8*)8^0[36BZD,"PO=\N3D*T`)@2,TKV9+22YOP_`5N44`.^>^WNV?L4^[3$$%MXS=HP*X/,-&,.[U>\;)K M,14WJ-A]\@FS*/D/P7;W+P[5U/(2[H?3FM%/JET^\[;L[P&,T)>;[JHV6H$L:%H!=3/MO[I?E"ZD M]ZJG^(F)YE;S_F-QSF7]IX'<4\M6[_"-:+\,5T5]NX-VOX M"9B?9.=SK_[)AQ\P";PORDBQ)2$@MKS&%TC,P8MBBQ("2ND^:C<3_0/(;8BM MMU9?J-/MKF+_X)V5S=O= MEBUL$-D#]B6!M<-R$C<:A61D3.[+2MQ(2J`,U6:X\:/0R_)Z."TTP>%*66Q" M`*H),\]=N@_B8D^>"[^%&7DC(G@:*ITB([8[^X@DYF[>,#I`",&!TMGTHROW MX8^DBG!6:;$+]NQP(ZE35#Q#$&S3$B]],AA"6IF(_B$M,0H19B?OT)+2106Y MHK:!HM>G[4Q@BXR8M1E,:B&=.4S#/"98:I.O)>]?HZ0JT5[@T69%UT5&J^:S M:[\:>G#/KC8Y^18/8$Q5I7]G9CU)G:*E3L+4V2VICI:YVAP@:U:L:ST=@S8S MG2FS,`P+M$$A_<)ZD^7R\Y=B6^3D"8&*P;4M3U(#3]91 MI89[&[8Q(/9F8`WKZ$[$VJ8QP68OX`N,TQT9BJLR(6E9D:4.4=JUST%9^R!H M$8&*RIDE:@E<_85>^-EE*;T,A)(7\LZ=\*TP.^8W;W];,S0QI#OFI<+SE">& M2Y+Y66\>T!;F=S"'6/SGVXQ4?=]6WSJE"Y];MAX2F9QY.Y8?)C;7DWNSF#9! MG#5M!-2M@*J9&E.`-02JEIR9]'PJXYFVH"I7:^!Z;8P;P7_-ZG[85/KOV#=< M^@/?AMN:1QEKS]VGK2<9\P1O5-74.BSFU\D76-P',D+S!Y3 MA8>:27VA:H"L\G$OY*1%E^[(WW&VYIBFF';'.4VW:XOWDSHWPO.KLB@S6!6Z MK*3,+TI9Y73M%NS?8-+6C;L3U*T5D*\`8P9UY=*:'6#^%:#O8+K?33(<2^[Z MT)B!M+@'"PL24:XWYQF,4+$NB[P(6C.];"=6R6I_/U:M#7](G;*06)9:=!3!IQ#H6C33D:S8TS.#`O2*.$2`R];\6@#4!6!MNHKD%=24&&5/PDI]" M9IJ[*KX):(AW`4-Z?@6\7P$",_=6:H[JOKV.A;0/EGL/<3=%_XE7C:-LMLWN MD;5VM#*T4\8+"+.O!CI"/7/3_+W/ILG#5M\H19CUP1P?GE$VWAI;W!X98ULG M0UNDK%Z;HKERYI;X!Y\MD4.LOB$*X.J#'5YA)!7/HPVQS>Z1)7:T,C1%QNNU M+8Y0S]P8_\EG8^1AJV^-(LQ:?$"]?M%]O;DOTO"7YS2.\#KX\M>25'5XS*G@ M$GO4Y+?_L+JF7MPCZS4?V=AJ?'PT,Q"VW7'`GSPOE<*#INOH&"+0B%]11X+0QZ4 MS^_N?U*_32CG<_`VBEP/_B1?35^!B'*`.W`/?O+""B8KY(]5:&&,?TY%&V#V MK.4TPD$ACI*"^#9`T75R'NQ0$<1*:U'P6;<6E1[1\3,0(04WIR6REK4#;:"[@!H7(AW)[>@CB`SHU?&PF MF/JY!6DVB2=VD#H:D)C/$W&IH86@SNYNW1=!5JC@KB7Y61"3%]46E?8RB9:7 MU6ZF381B/JTFA[!%RWL.\`BV3C+)#(^GM6]W`_)R9D=I5MVS9V?P"27$U0$; MV-:S1`U=*F'!]R@!.:7_G7.CG%-LJ_8IPCIGGG*@6YX7K_.\A-%%F6%!V&W0 MGX.XA/1OZQV]-7CY"K,0Y7#HVO6$MMS,JH;Z#DZZ@#4"6"O5A6!`VZD226J?6Y<@RR!Z?2\;!VLHE* M[E=FWW&SO=(#-Y9;ID!;2G5)ZJX9R^+I!*AP8R;ZH8E3L`8P%DM<)]C@P M+YA)K#/R7W*]\&S_@`50E"+7;\(Z\`RTXQY&8YOR-6\]-ZPS4+.#LST@#7A0 M<7Q&/94:V;0R4W3V+6X<-'VQ/B*=LEBX?A.>65]'NQ'6QX#J03'P^=5,#VJN M=/3TQR1YR)J9I`BO]DSR"RSH3=8L?4$1C,[V/^'P[SII+A&>A@5Z0>1J*RM7 M6>+?57_$`:-&;#;7!ZR;\VP]P]5[@$5U>;IJ&CSNP?>D=8"2W[4>N#Y\804. MWP"'CRA#1#L>8;&>.G1%T#3AWB7,:S)]A[&$O=@\;O+7,F?/%CZD=^2N2HAB MB'5B^X=DR_0AU=1/P[DL\SD'AUL6Z37^"$GS&?"0@N9#M+!#M6E/-[7Q'[L. M"H?^U#]=)X/NR1,_Y*`;BY34Z:VZD50`B4G_X=^2GVF*J61^':1>^K(E[94_ MY[.TL=KS8WT+)">8FLQSFUV'YE&"7PB!X!&&)Y:,:9#IM+!L5D)(*=A3E*\ MN32CVPSN`A1=ON[((P1&1M1G]<"$.&VT#*CB`A6;;^:C5*J6'S(*-D5%<)?F MJ/#2D(9!IS8C&>)<&M'AC@C=$DNS@=C6R+3T&O3`X#0U%YKA]W53OR.Q5NON M$%VIDAW]H96I;Q8ZLA=:ZI)%I8^6:H)LM?V:P]JE57_&8,A0$.>G271?[G:Q MJ14/-^"!U0HTT[32AIO.,S6_;S:IJ2,+/,,RRUAY!;+$\]$096!4&YX:BXUOPP-1$NFG:&H/G@1^<2A#J>(6GH253QU\KDR)1_Q6#`ZX%M\?IH+?=J-I,K^F]L.Q^V%"O%:Z5D0XP8TJ%>[0D-2JU5IXGM`7@T_+HJ3(&IZ@9Z,*B8Y\M#,Y'C4# M0`48C^44X&*G_X[NU-^BI_VD#U1,GSM)VRJ+GKUWSOT_(C./;9H[5OK6*@>RP2_V,1^ M=!/ZHA.YOPN!\;W360B@W^!,OLP,[IF?N$))D(0++@2,/^"+WS#O&4/_T7S@ MV!<"TWOJT!5'X#Y&FHRF&YED+Q87`ED:0ACE5[C7Z-UHW*/K3:ODO"S^5_/: M#_LU].'/YC(>0)A`S45KPK2>#G!IL).T(@8!4*T5>:^&:<5J+I%0GSQH4Q6< M@O*"4U:C?EUHJM%MPM=[6T$VPV";V MUII*D_IM@L8>*;\7*^T)2I):9Z1^W\$@0[%:#M;8NM@4++#-@.EZFKN`C]+\ MEH3)DXFMTD!_1B,,_LUD*C7H%!:G0>+1@2HUI/3F)1Y/]M/`3`K#26B8RUFB M=U@'868W9;;@X_1BI@K1)"*:>#JCR,`E2M,JD67SZ8-=(U1U=$0Z:0CH'3Q\ M,"PW?\&IIB/30WV<:?Y)PLP21DA/GN3T:X:00H=_\D")FV-),BZ67#RZI.*B MR41_-R/&]P[MF5VK9S:_P8SB,IE$9Z5%-QL8XH7?Y6M(*[+<8?^^3H@B>`5( M_D.V5E^"F+@VB6(0!U)R>;)G/H5R$\C!.\S)C MNW"T>@I1%25XEMS2*,Z]#9I@DWMWPAB8-B^VL4+@Y*5;[/LDYL51.KBFUI>5 M/W%=%7*G3RQC&K?W.K7%):6AW&-<@`7^[I@$"!:3,4&!7<9ZHY=@&2"VGS09 MDI@+0"@133HV9&YO39J(G6XZQ[H>X&L!SO!`_.+!RPEBP'`9!P5:+(9$>)&( M-B@DI[%9>0'R6%8:HQ#!G/0N[5Q94*39@/VP2%G#'.3%]]2QAB\,SX&D-3A]O!B.C M`[-P]_I*P?/NXX=W%#KD-W^Y2,.2!+_D?@E&-'F-IHGT)>L\`UYK$#+1ARLI M4+&Q.U.4$;0XO7ANSWB\:D2-'"Q3YY7#\,U3^O(V@HCY+?Q#WUWA7S62M`1X M$!22DI-;0Y9":B&8.@BBU`[AH]/U-6+T^WUID)!'L!3`8"1.P%!))P0`^;L? M(][NQZ%1YCMQJ9$]Q9^+R">OXF#HL?0!&JMCVY>/J_54_QT0`K>C.]B7[>&5 M=.32EGM;/X=^$10J$^[1.K'EOKQ"HZYV6C`E(*1^V/=@;P\9NJ2KET;$%0YD M@_@_89!=X=\,I8BDU$Y0PS#%"://,7D5G$AD9H[^E.5;F^'&7[$H*JN M;R-$K]^7=1M7*(;9.?[H4YK)G4:/TH'+Z,LJC16![XO7W_(J[\#1N!VK`?[LCW*DHY<.#8XW*6_ M)[>9\W59Y$60$&GD@8*4T474(-=$%$*TZD*L`&,$+4X??(3.&`V$%]H#9/,V MTK?6IG"6)OC'D)TJHUO$>_;_.CNRYDTYN'%DK"U_MO=;Y\1`IY$5.T&P!U^K M_WJUFSMVK/F[-%,&VAZVZ56_WH,:ITED])*%01O6T6RBW_!+1/VG8.@NLFS4%*FG1OC\;X[!OB2'"Z?/&B?AS@#K[`I#1[@XGC]>"- M"UX?K==CFI<@*CZ_GHY1*]5ZR4(BO]USQYI04[]B(<69Q6.;X3.,RABN-Y=9 MEF;G*98I9(7MDN@V0VG&$MFGT5_+O&`E>'4.;`"'=>=#:`3#C>=Q#B"RRPB:9;N,YNTIS< M-J.+)]')*R-NNT?\M'42@G:](?=1`.,%ZPP0;H)5MDYV?U9KQ-AU#ON-&3B+ M'KD("KK.N0]A$F`;.'U%LL6#@-Z^#Q7(S>.,_1E\)00^N#=9AW-^2]W;-B=O M)L-/2;Z#(=H@&%VDVP`ETIE9R.-@VA7++X+-"K2HP5=&[P.*5&/!SX!:`V$? M3;(W]Z-"\9MR"9_%56[?Q,19I!=!FO`^TN,$T"[8$(VD[@TN? M$3\\*WZX5J11ST&[!4?96QW=!+E;RKH"!^;613(O[OV,',7A+*?A$#K!Z$$H MG42,BM$E(H+'C!SF\^1,EJ@=,$!_JCI8] M1W@6Q*1\]?TSA,4-^0RY#2S/QHE9K#LZB?1]G%6D@-*"FMB;#)UJ'/KN2F\0 MW.)(F:B3,7F!)6&J3H0F;W)UZO'00=38;-VX*<\@9:+B]VKJTTV7"*<_'S,E M>B-H,@_ZE"7YC)*E3(['(E*M9(GA;I\+57`6[KH$W0+$F3 MD]JT`MJ">W>M#SW)^EH+=S8KR#[F\-<22W#Y`G6KQHI8'%2*%4K/%U"M20&C M]2IKJ!H&OD"JSABX@Y%6;D;,XQQ(TNP+CR2_DBRJL5"!R7WBKRN0*,LB)W>- M(6$NI0C^RUBZ"`&J8^PWCQD09('H5:*1(?9/JIT-%+`RYM,B?[P M<$@S'!N+]T5NU\H#32T:^_<_6O)Q]SQNUQX=1.)ZDKOV,-R-$[)D/R41S/Z< MH0)FPD$4$=K->PU)VA].2@,8D0?C*N_A3KI*T;T31OC/04:JY>27KSO$:IH_ MP*UHE`7$=D=:)'%_M&LZ<"`$F'*A7%%4E:.BWYDJ^AW<81GHHJMXAN"%EI3& M\Y5`I3>.,2S%4`?'&@"R6.E7EN17L[BN^"M+Y0]7_?4B=Z\[%HKROQ,R]`I/ M^)#>XI%[#G+8*NYP1SZJ%Z=_=;\@X/N26Q8*.G*"FZS?P#DK<^R"3R9<\U'KN)(10S8!73\'29B6+S!+-QN,VGP7A/`1 MKWM0_ARF<;E]1,&6+H#DRU'C9NPBSES+/O::%M:TA7O2PAEKX;QJX:MBB3M9 M1<7V^-R:`J8JH+JN0*4MJ-7U94$_$L$=FYL$7V<;6#+OKV9QO9$E\_3\9I87 MGEUW'!2[6A.\^$R'G3#23^,XI84GUCNR`%"FC"4\]H\V2>3GSOU@VI.&&#!J M#WR7]EAPAW[D`X%U8#IAE/V"_XW_A7]XQ"L2JN3_!5!+`P04````"``<@&U% M7!S@S('@M,C`Q-#`Y,S!?<')E+GAM;%54"0`#"!QE M5`@<951U>`L``00E#@``!#D!``#M?5MSX[;6Y?M4S7_HR??<:4N6V^[4R7SE M:Q_/N"V7[21S:FJ*15.0A!.*5'AQ6YF:_SX;I"13$JXD*&PQ>3GITPU`6'MM M@,#"QL8__O-M%GYX)4E*X^CG'WH_'OWP@41!/*+1Y.'*S_SGQ`]^3U?U/_1^[/UX^H']H?_Q/G[] MV#_J#3[\[Z/!3[W!3_TO_^?#_WWX]O\^7#\]?_CXX?OW[S^.H(6L:.''()Y] M^/B1_4Y(H]]?_)1\@(Y%Z<\_3+-L_M.G3ZS\VTL2_A@GDT_]HZ/C3ZN"/Y0E M?WI+Z4;I[\>KLKU/_^O;W5,P)3/_(XW2S(^"]UJL&5Z]WI7Q=J/[`0G]+$[F4Q^*,28^L5*?Y`U]@GXV[.DP MFY+DD02$OOHO(4F->K=;V5:/+O,D8;#3E&0U^K15W4*O'I)X3I)LP8CX(Z=S M1HI1O_@-V+)774-9M-!Y$"0Y&=U1_X6&-*.&OL2K;J%7=[$?I0_^@OFG47\V M*UKHR5,6![]?P&0SNHQG"(3YIMU9RQY0Q9Z M"M!G-&,MIS"6+F.8%J,)?"Y-'4[:C@V^\Y>4_)%#^]>O[$?,F-ZI;,5R41J' M=,06#Q=^R+[`3U-B.F](6K%BM=G,3Q;#\1.=1'1,`Q^F\2"(\X*>!_AA1M#J MOX8V-6MZ;VB>S;^\9@U;0'+CT^17/\S)-^*G>4**<5.CX])V6EC/U.BBJ(E6 MUC9U^\=MI*5U3HT^RIJQN^:I:T#KEMM=P-3HFK@1RVNA&GWC56]M751G3I0V MU.;W\\%G8W%*,IB'0SL?TZTF6U[AU;"V3G,6>GWO9_"5&(XO\I1&)&5+M3L* M,\H(]L)7)/-IF#Z3MRPWM+M)LWM;!RQ_N(6%P+KEME8"=;HN;ZCEGM9Q&JWV M6EC#U#&NL(U65C&U>\AOI:5U3)U>2MMIMY\]6QWMM=W3.H-)ISG+W^RG#/ZW M&+3#\5VSC9'T>["](ZG9.T8GE=6Z=WW/KM]*O.2)$UT]KZ MN]9:1-Y2VWTUFR]53;7=VSJ>H-=@RWN%.IZAU5Z[VG`#LQNTVH)NW,1?%$VU M]7V%W0CSU&D6WVN(:X=)/IS=A_-W.0J'26LO[8FL[X3WN M?5O8]+:WAVR^:ZST;9Z0%/ZJF`OOH"L;G8212J(1&:VZR5IL'#=01#?`+X=Q ML/%C(8NKB!.52=C?>+(?.'])641)MFHH]%](6#3O:=?U!B>?WXVDV]FE88I( MCY0$/T[BUT\C0C^Q_K,_%$`^'O66<1[_`7^U[LVV?L7IO:PX=/ATH\-57L^3 MS<[[2;!J'OZX0^IFI,JRQ*=Y(0E^#*8T7/O#.(EGM2R[[$VL"RQ/H8OQG/TM M^W+$"*X$/A\]1'S52*XBF<^C01D58L`S,^NF>):?I>@W6[SV3E&S`[' M*>%C16YA>2,:6K(JX,MGKMDS'6=J/'Q:!P=`ZS,TJZ"1%0&87Q#2MD6#F+IW M#'RJ3A!3=0X`1@S$3>A/!%QME/$&GX\.D2P."#Y;GQ&SM0+^0!(:PV)L=`4[ M0<4(VR@+P'N'R)X$#)_%TP-@\8:F@1_^B_C)#?R-ZH.W51K`]P^922XB*997%&`/#I%' M,1;!)OT(/8>78(+$#V^C$7G[GV0A)7&K+"#'N&/79)$+1D`C9K%E&`1\XA=C;FA(DDO`,8D3^:#<*`FHG4JAS88D!XJ`0,QZ MS7/BL^NC3XO92QP*J-LH`T@Q*C)*TC@@!'1AUF&67X-X-HNCXI3S:0K62H=Y MQF[*,H#R;Z*D(MCD(#4;760"MIM(.6"D3]O'U^U?IQXOOSTNM(F*6KO]EVO^5?>]M]N"?9*CI3?)ZG7]GK?3$?2H+#QZU?8_$, M%U#_=]&!HZB\UW!T8(0(THJY&"MK(P_'U;X\LHXO M-^6%#,R2-HY@4)>7LC3&5*.&O>.!L[&GV_&+:L>UQFBSEKUCI\?N%HD5C'D+ MYNG`W"!-Y^=@AECVXI',XX1=]M(8^Z(JWO&IJU&]W26SKZM&;>_8Z6&NENGY MXTX77`?&EBP#I8.A);OF;+)^-6K'&QRY&H1:_=09CV8->0.G<=WU6>*/UQK@ M.S!T=_*SNO@4;O5!YU,HJ.*='#D[S=CND]874%0'@*`XJ)`;6O#EDX/JP*@1 MIPYV,7S>\TK=7]`;H!`ZM8TK&$F[ MF/#<7[?`Z67HI^DR'8K@;KNR#DPJJ)A^ITK!*1<(GNON#=:C%6#":_#BPMX) MBG6EG"?!&I(/!L\M>0MC]DYR6UY>_$ZO7#8M^57?I)LJ#1I$C!)?N@ZM3W3E`<>HCI%'Q?M;%9NJ+O MWAT>"5B%!NRDIJ%C&+;DG:`0($Q=I`Y*2SD`W#O+*D)F%=W-O8NA$54DK>^Y MS0]7US'TL5E*(.#>'9:Q_M=O[-"7K$P5C=[C'Z51U:K*GMO45W4=01.8K1P$ M[MV@--!P?$73>9SZX=W41#FH^6Y9''8D9/1<,Y>9`7$&E-%[48]MZFW M:L\?S0#;RH7@WIV^P08LH7Z8/N7S>4C)>D:5>(NPCN:'CE<"@CM#L/21K@'$U3RWR<",I0,E%EO9 M%MR/6NY5%]/+29[;Y&#&_(I!V$JLX)[8U2O7BGG8,ZG MW,JE%`UUEE/:'`'9!ZRG M+6]=Z0MHFQ4\MQFI-&F3RV8<1`*>#U`HV[U'J$4UOX[G-DU54[8EH`3!*0U*):@DC`\P%J548CFN/UIRB4C%K\"M`(N#77 MIMPOL.-H\DR2&;O4JK7-Y5?P3E'H&(8K,#$4`<'FHI7SP;LU0VEQ+*SCG:*0 M,\QHEJ,1,'V`@M4[SBB[A/]2/8I7A;U3%'I'76XW8`A(/4"QJIH_1NNCZYVB M$#QJ[X6+_@OX.T`!:_>14JW;)*)*WBD*I<-(SE*@$7!]@*K6PZJ_!6)5)!FG MM'>*(BA(09@P((0+1T#O`>I8E>33RO#1K:+>*0KMJA:Q7"P"5@]0M?K-3]BS M*2SVX)%.IIDBR[I.->\4A795BVTE+L$UG`.4K\Y'(UK">/#IZ#9:YO>5J97\ M&MX9"@&K%M\R2`*J#U#!.@^"?)87J7K*Q,OQ#"!,29325W(;!?&,W,4I"V$= MCI_]-[E@;=*2=X9"^ZKG&C6@"ESF`(.V'DGFP^)V=.TG$<_&@*J)$HUT3:8;"\*IZ9RC4 MOMIQ,4),`O;-I;\M]ATD%9K-_&0Q'#_1241A6F41EV4<03$H0LJR*JW^ZR)G MRFYO=&[0"BMY@V-W6_M5*AI@L.C70B_5E[B:-T`QP!3F%FWY%;BZD#_EEY0, MQ]=I1F@6%247\>%OC^8-N4-4!S'U/*/6ECMIVY!NJYZ=O;R MHO55U:F[9([!E(SRD'UTDB1.+F-PD("1R=;O#PF-D_+=^?/1O_,TT\Y5WJ19 M,`?Z(7LJ3@K9&'D'\D;>^#0I3J*^$9^EDRUA.ANOZ^Z\)[C5&;&R:M[99U=# M=MVMBT4U)V=Q3YNR<#GU\-1MPCM#<=JM)((_%(U0=F#4;:?[<#?@VGZ:^,S> MT\3O\S77?,JGBG7K>XA>AU,;=W-`F0/MRFC:?/[5V7C"^Z#Q%V%Q0G-S;X4BU/W0WU=M]`_H+O#>1&+Q]7?!+%GE&/`?X` MU`3I5MA7KJ*N"/0CH*7AH]'YC!T-ER]QF2ZHM)OROJ#8IM0AOQ%D2R<#".;@ MRD?+\:YE/Z]?HUDV;7>VQJ))V`3`1+%F,F)%:W&D@-R!W<_N!7F'2R+K+V1_ MJ:$?V!Y^`@N;#4!5(U[O"(7LH")#->KT<'9G3U)]`]NE[&#G)>S>$8+/'>M; MC1&V6PW@H/BLR8RM&D\B5!WXO_$!"`0O38KY,VM9?]6,J]?]^$;W(^%'Q-248#P.;@2[>/!SI[ M`W=?K9HO=/9P1"#JFU#SIN]T]@9( M4D-(F>+3*X+3A:CRID]U]I"]G:P_5K#64!2"RR$))&#"?M*0)UY^;."M,8,H%$;[(5"L*_M`')@ MEE[U1#GV;],T-QOW90VP#(J[W0W'?!5,9U[KW$&IE\Y-5@TLA.+*=T.Z=Q"U M]3;GWD7+KR2>)/Y\2H,G,F$&NHW&,91P>S2W[,LCF;,PNVBB(U(*JGB](P0Q M)=N]JUCY8K'\1\.C"I,6O5X/QV9+2I+RM,$<7=DXH?78(QL(3@KX)0"L$Y7I2:4 M;)(I!(/G?$"7N1*!\!Q@NPC`=+JT%%I^EZ#=;G="Y<]?4O)'#B:Z?F5?7O@] MU>D M2*)/S('C:%;.EQ;)5426Y'RG!+.GN[+ETUT:DS:O.!C#Z0EM\QE;C,J2 M?(^*8N5+57>;4;6 M37C*J9M;WCLYQK'^4I/&9UN"2L#R806W+M\*4D[=&^4`/XK`.`DY?#8Y*`0L M[DN@JJ$5WTF"&?4K`WJGF]_Z$[$I1@'#AR5RM?V43:_O]`3!E%/^\-;%*?`( M8RD,142,GT[!4.P_;#I\]4>!E`%'F*L MH&'PD")^I`P4NLH3=CA7Y!IT&O!.WFW0[/F*"5>`DAZ7" M/21Q0,@HO0%#,G#LNF!Q47,5>20-KE;4]09NH^SL^(0F3($[-%'LD";67\9Y M="'`8[#UJF^31?M[A-`]RUYQ%8XKC?+0JPT=1K'U4IF4LV0W`8@G MWL."?O84D,B'KXBN;E8M[PWYFE_FQ>"VT78E'62!E.R1C?*`?PW6]^3-GB M#V\.+DL1*.YO&VV_L7?AIS2`/>(5#?-,>K5,41/LY#0PU"+_6D@M!:Q@D,Q^ M(W0R!6#GT!E_0NYS]@U;IIFJW,'2=Y5Z#8)=W0>DVO&@)@9H[?XJCF?/'*HI M;;Q[UNNC??A,D99+ISK`0Q$SK*:`/P[U,>*18%J^'25 MUB[>])U*H4++[Q*TV^TNB"'7(9U0<$OV\1\FA:?>Q,G:D, M(@:X[CBM";@+EW:VP'$LH!1+=9L`HZ'03@U95GRKM4!W06>Y)$E6G#IF)"W> M.F+I1Y7*JJ06F`:%J&I&I2!\106S"Y>"OL4167SSD]])=I-'(XT[!=P*8!`4 M-^)M\"Y#V(5+0I4OZOJ/_Z0D`4M/%W?DE82*-81>`V`P%!F?FBX@3-!VX9(1 M5S/91:Z_A-!I!\R'(E^4"=D*=]&'W87+2VN$M]$\S]+"5#WEQT12"TR#(DM[ M#3X5CB'"VHE;3#R4_5I^T%_;!I<`V(8?;&#MQ#TG'LKC6GYPO+8-+MVP#3_8 MP.KXII3MQ29G[;5^]N(]D[Y?/A4CBP&QU318&45HI[T%:A,[=.+6UAKM;91F M25Z.S=7?E6_$\HRD=0;7L&FO-T"FIS;Q%H$G6K%1IVZ+\30D@\MB&M7!:"@D M6#OD&TAQ7#MTZ2+9MA"E[S>*FF`J'"IMBRZC90);-\HP>$MI+TZ<@NRBCJ@. MF`>'GMNBARC`V[I>EL69'V(-@G*8.KB56*B34^<;G=*MBDN/Z[?1EY8?#:-' M$N0)N^<*!>[C*%G]7Q:(EVH'3#7]#3`4KLVTD$S%EL>.(?"$7AW`J>SAM3[ M6;AK/="HLP8SLI'L:^-WP/PX=L)[_9S9LYS;(#A1,KD42^@I$OI+W MS>,E[(TFXH<_5!4!-(YML7TF-UW&Q!SVP^#VOD4>9E.2@+4(`&5O7SF\(K3= ME7N270)K`%EC[[3P#GUK.5V,RSXQFV/5MD615X!0+I_/*/&-*2# MJ@L;V&6*M;18+&X'A,#FVB0P6 MV6`+IW)5?8KY2#J3::;BP>*UO-[`%M<'F[E_8*/I`%?!LW3MR?E1>(%SM8DK MI!.'._VKI>DNXS1++_TY!>/0/\GH(2%SGXY6M"S[N3X@U9`!&K8,G`_:T@BJ MQC<1"7;J02=1W!BR8FNUA"#`CT=#:#EIR"FFQ$PR1C:I%&+!LQ%O+5O(J5/1 M16CY78)VNXUW)[KQ\=+;B_*K`%"G`D7M(:4'K`L;TF\^K*&I'Z9/^7P>LI3? MRX^)+/)75`?,XEY]4-+&7ZDJ0+6V#=W[^O0AB>L8W4TK+;O6>P)S)SZ,8:J3JG%K\&V`6%RJ%-(=\#I.@L+=7=LWZ3)Q%E M;U^!@6[H&_N3.I^6N!)8!T4<3$/N50`MK=Z;T"_8<$-K<<)*+]3C6%X!D*)( M8E*32AUPW3DU*O:E_R3AZ!?8PB5+2?>.^*G&:%97!FNA"`QI.*IU@=HZ.7+N M%@6T:1R.BFC;U?^YGL1SEE)'O0_%(O>[KT]MUP"PHM"(>60I: M^5#PA#HU$/0KR)0G.[N%P1`H1!\%4P+Q7@"G"[DKU@;1V9SO%@9#H%!J:HS5 M+0Q=B)?26=9+HZ;5U3V`BHKP+1KYI.LC^TN$4CE,>M?NLK9_U'XQHJI_ MA'MON[H*QF5HX8E M'U1F:+#1O-?OH9!T='U#(/%8LX2E0*P1&=.(LE:^YG3$7FA`-S^M;%9K?EI7 M!JL=2O"-Q']T<78I%"L@9)3>@"'9IUDRKL`V9!(="+"./3JX#3&4G^$;@`.TYA`7_%GAV*BW7W$K2$ M;FD]L!$*>5Y!(I]Y#60(I'G!N1J_\^=)XD>3POE_H]FT2(W%'KUEK\?'P_$X M)5F1GO*V5/I&'-XMM@XV1"'8&WF'=?Q-)7Q$]X.^D@@L&;*`P=&,1I19D3T' MI)Y%%#6]/HZ[K+7F$2ULG;G5O#?Q"\=-UGH>80"QJ8Z^.3T\._>/:HAQO9#K MG7AD')=.:WF"$E=W5/&U?4J9ZTY^CYU3&@R"0J:K1;003V--6W`Q=/\$W\=1 MO(ER:2"-3:.R+A@+EX:GM7G4A&7M(-!*V!`%#J@)M-\-S'&*W"8`PS7O8V@#R3-5HF:2]M)CYUX M%<`L*&3#1FX@@R9@'$,(;XNOZ/9QW'"NQ:H)1`&[^C(B(A%@Y<7J3?]623`% M"K'0RAC>P"2@5U\G1$3O/A)=P;@1-XQ0&J=PK8];T!#(5" MKS/BM99KE$@%+K'7^%?!>NTWV&M,&=97^,A-R'W.KIH,QY?Q;!9'!:)TF&=I MYAI-`8J"!@YP!5/($5"OP5^/KS1KT&P:Q.M<#&'L&? M6IH80^!CC>_^NWE[T_FCFY5>O%]\,7I<4[,%;U`GQYS>(YK;OV[RD":W+G06 MA[8SS"RY,&THBI@%*>2C"%[_&E6#JX+ MT;4\A,HH6W$E,`P*:49.G#[9550HG_!4>/B=ZCU/W?I@`O>//=8=SC60=B$H M=_60]`V-F&,7(67O@.6IF)5UO1.W:DT-3D61%5I(6\MCYW3%^@U60B2$>8_$ MN=X%>75EL)=3!<>:9^A"M13)R*_W@+]@GG+WN4_3+#W7ND4AJ>?U>&UOF7:-I[I<%%:&;*#;+ M2DM*EU52<'AVQRD)?IS$KY]&A):>"7_8=DCX*^^.3/SP.LIHMA!L@3FE`"RF M7:^4DDTRA6#P[')UF2L1"'>QVT4`IM,]J]#RNP3M=AOEIG37[93[4$D5`(II MZVDPIO20=6&KN01Y$4>`)KU4KANYY;U^W_V64DD7?ZDH`=29FY]+C$]^Z"?4 M@.6M"F`5]_O#9C1S$2&XXVF5YX#<$`.^!17!2NZWA@OD5P"X'._7*$-FZ](B!ZE)L M#((XC[)T"78EQ&Q832G':K0!DYW36W)-',(0I+5[DUC6916$VDNRW3I@'*?W MX2RLQD2@.O.$ZEWL1RL/=RC+7Y$7LX`V?@4@Y[0%,;YJ)$T9?J<*=`U%V(K, M<%+M78#H+Z.Z]S$IA`(R-/3VOE`.[)3>?NQ4YA-:7J6W'PO%/#1!8,SUEIZG ME-SEM0"N^^VAX9C2AM4%R;UJ$UMO,Z/D.[\SI&<>%?9CC3G=>Q^/X_XE5\S9W7P/V1O9(,C9W7 M0+BV[]3.:^!T32^TO&KG-1"NV1WOO/Y)D@`\#[X1P32*PWBR^)K$W[/II3^G M\"63OU"J51G`.UVS\\G@3(D&:+JP_5HG!&!I6+/%93R;QQ'\WU3W\1%>/3`/ MMM6^EH*-#.!@8.#TKK;-&T89E*Z#(\=(T#GZ_35,6 M))$VM]L">^(_HQ<[3`'/C+/08?.A\].\\S9BVF3['YR,80@6\=)TUX*4.M<8(IHBXVR8`>G:F-#W@5X M;&6MQQ"KU6Y.O/X)INPOYO1KX;.5L=YQ].Q[!-LW/\N3XAK1(YG[B^(Q=_@G MV"V"S0Y9-C5#: M2C6/SC-6EY(?_8QLGAHC%7C)O@14T>LGR\W1AT;7KS;LN[2(^L_ZR6LE8NCPQ?6Z=574"=BOU'# MP/B@A6B!U7-5F^8O2!D6CI6>!QE]93.#7MR_88,`"T4HE0URI)$(M>SRE[E; M\!F3F%*+JDWRA2#_`CY'EE_#\NY^,EJ:I1$"4K]7)XL]L_Q;0@$ES MJ>U(_`UW2^:R=%MC7H;597Z2.57^FUKI:[$COHW*,,&OB?Q5ZQ9^S>N?8I*% MD#FQT&"=2Q,F8T`PVRRQ(]OIM3I.BA?6@;'&Z5/XVL(5)YT,V>6J:K^D5I`XYN^/E M["FFN$9DSBPPEZ4+6N5R]CHZ;/==?L78QK=U]]WY+>`#4V0E,O<5F,O6S;1N M^&]EC/]&6.PJ&9V_DL2?D(T0U_U,RK(>`'F8(D&1^;J1$6U=PCL802(UVO*V M-0[L]0)H/,P#'3MCP;8AK:4Y=Z]L-#7=RCK.!X-11X!&3.'"V,9##5O:NE6) M(5*]]3V]HX53HWX!S8=YQHA#QE&;UM9UTP/XJ'1HB_'WX:8=(]JZ/=N-379% MB7`T`C1[X/7/_CX9M6-$6W=_>2,`5Q1QST48<9EK3",L>+.@=WQTXFP64?BU MSHI>%"5L_3?`4(C2_6W2)QC==J'_56*#CX]0Y`ZTS-YN-"H7=_?#A8^/G&[S MA);?)6BWVV[#A1TO'>\D(<;V&@=#HW@UHM7A;]M<78A"/@^+QLF(;Y3E6]X2 MW]-KP#ON.=U0V*:>[U@FMD#QTA:.;;'TG*;XQRLPZCH%X-Z"A)4]`2:=1G#N MQZN=&!7%:V:BFT*6(ZLU''POOPN6=QK2V:X[[]&$EI+]'_39KFLY5P M-B5N>7!'(FFN]:$F.X#>L0G#G>Q]&OT&52PDWE3P-S"P.XPU!\+3&M MLH2E``RG4\#*"HK%2+48@,>A@>YC+;(+W%)<`0K6E8N(G4&"0A7<)45.7K7W MED[6+2?++V+3;Z,`P--7POJM>+I=5`%`HE"Q>*;GS*X*');.@G$O^UW'[?:= MQG7O=3:W92Y+Q[5._?)Z-@_C!2%/)'FE`>&;!E8_KY753R'V5O^=24/W)QF-)AJG5Z(JP%7?_;G4(WDE44[2&Q@7U\!5`BYSF:=9/",) MRQ'"'GF\@[7PZ#Q-29;J'T;5:1A,@D.\DU*F.ENJC]S2@1*"``V@K)@[WX>Q M'RI$'6$=L`T.H<\"PP+?D4.W=-R$P"W*<55%J3XX$M4!V^`0_N3D"1B7H[)T MG-.$<8$V]`NL--A*'#`K1/O=DH`-A6"G,#Y'&!)A07FT'`Z,(1A>$77T(!"1VG&FB#VJH+0TNF+>U[O278;!6"6 M._D+81OEP`8H0N[:8)D#M+4;:'L7LB[CV8QF98AJ-+J,(R8HD"B@)'4?LBWK MW#H*5T/C,FH'&#YV-?:8AVUT3R5H\2L`!!221`V[\X>@#&9G5*E'IN@K5*AU M&<".0EZ0,2-8/FU"Z(QZ5.!21X6^EP+\*/2&+4(DK%7[C4`#LL/;-QK163Y3 M,K=1#FR`0I38H87/'J?OEK0A!/SY;WK\5P=WR" M1($PXT_M!55\"'0E@;Y\D=",IM/+.,QG+]2_]*.`).?,ZQ6:L[(B($>B.O`Y MX0C0FI@ZHR8])/&<@%F>\I=_DR![CH?)^:M/0S;9W<3)$/[19W/@'?%3Y;T* MT[;`EBANX)G/]36A6M*E#LQMU!Z*(]:GI"!:\JFH'6X&L+7Q=5C.I MXD!YHQ2`0J&/U>:#=]C,08@AI8[H$L]W]KPU^?X_6-.*=0"O+`!$H7_9I%", M$\-3F0(B?X453)R_DB0>CVE`TKD?D)=RD1,L77)6()%S;-B,=X)#X;9)?RT3 M=.G%R&$V)4GUS$"^'.05!^.BT%3-5WQB--UYTG`;HW+AQJ\`9D$AOHHITZ.X MBL;6RWTMS/`/"85-:A9'OT04IHF4/2@S24@15"J?U-4U`3P*'59>JU@5F MZS6Z%EB](_GO9$9]%A2QF,VG`/@IAIE*FUSM!L`4*!170XX-\0FH/L#`KH<\ M"::P7'DWU?5;$.;L!5(6/@,=G+W_DTJR,6W+._Z,0JRM(=G4@RKPFT.4^DP, MH-9LS%L#@Z*0@VMZ@@6WJMI!X%A[%0-%*PH&Z!F*D*_T]UF9RHRC`PR&S6N>1`U/`X@&&JNU\'>\T;A2(*X%Y M4*@YYA]]%28!Y1B$N\=XX8?E6S(/)&$YA?R)\"TL;F&`B$*#59'`&:,2/`+* M,-QN7&\\6-I\&BV3,V0T(&6Z!1%[JGH`'*=JIB92#YJ`T[U*:*)A2(*,CFE0 M]'PXOB)C/P\S.9^R.@`8A3A69U`J80EXQ*"279%7$L9SYHHW><06#B+V=DL" M.!0J6`W.1&`$3&%0ONYSMB0;CI_IC*2/8&@PTO0A87=(9TL,Y[,XC[('?R&X M?E&K'3`,"AVL!LOUH`I\`$-,VC*@]OW;/XSN2?;DAR2]B9-+/YTN4RD-DW*I M`&82^4&=MKSC4YPRE]H7ZL,5^,-!OE:X>;*;WN19GI!EF/WJS84@NDP#\.*U/D'F.`4>8JRB8?B*B+$_D2".1O^"A58M%WFO#D;#J:TU=(YMA`*WL/"" M&B:W>)[2I+Y7K&N#R0Y0N3,&*/")@PR.$X.^B?,DF]9VBO?J8+0#E`'-$0K< MPE@-1)"^XRE_2BW6TLYS=FSW2"<%K:"*=W)TYFJX;?5)F5B64QRZ MCT+OD9N7/YC$>+KPJN`V.O7[@H(:WDD/A8PCIDN/W@TXG7@^@.I6KJ`Z8 M!<7^2LJ:-M%53%UXEV\+HC(/!+<\F`/%+DG!EQ;)541N,\#:(YB.J)\LF,@\ M'!?O;&C,U]PZ8!84&EJ=&5L"J`NOZU6`L<>PAN-*D@3UY*VL#(9"L;M1,"F@ M7Q->%Y+9WCX,E9/XN@S`1A'NH$L0G]XM."B?W?L%]J?);PG-5% MXZ[%D0Q3%Y[<&[Z2Y#P,XR*TM7R^2CG\A'6\$QS9E9H-1P6\+CQHMWX6HGQ4 MDCWG%$=$?>E66@]LBD)6-EY?"_^2?X]UFD`ID,<*W`I MHZ*/LSY"6ZDRG/K$0Q('A(R*-PP8.)8B<#AFU\_BJ#"&Q!V4=6'?@E'_TO($ M37"V4FFX#2$+_30=CI=?MV'R2"?3[/J-)`%-R4-"&?+E/Z;+?TUEC^?6:@_L MB?'@0\M9&@"VE;7#KOZRZNSUVYPF!0//9";28+B%`1W&0PXIG2HTMM)NM,/5 MR?'!S>!&T&QEQ'"[L&/+DV*:D2W>UH4`^<'.M-LH M;"6>J/#GX%FD*(U#.O)7[VH62F`I*$[C$!"EY4[528B5K$,Z\58Z];WCLYYS M<5(9=K51$+J,8V;4MZ]"CZS`ZLPS1^THS\=G..9/#G-U-.<"3F>>1K*C.Q^? MX5B]JHDST9T+5)UY3*FRHE/JSSMEP18HCH\D1`GVFGPDG7EBZ9'`-XL&Q5H( M,++GQM/'IU_4CYW)ZH&-4*C2QFQKH.K,XTSUSI*.SU"<$!HSRT'1F4>4SDRZ&T]I#WP[WW5JA!#N%P1XXCI#-=]A;&#`\9F0Q>F!3CE1$"FP4 M!G/@TLNVB)+$`W!PV(K=FI?A!9F?9&[)+0(<*FE25`<)U;)@$EQZF!ZU?!BV MXKG0,,N/:/G5#W-2_%L92!KMP4FQ26CZ0]ZF1^,-&.3`""J'0C&L.!%OQ9B,RIA'% M,`,41G,82 MJ_KI]":,OZ>.@]+6_3"+1=NI!M3UG:NEAB%H@R-#%G'0M-$L+7RANDV`99# MH:&8,5W'6[8Q_QW>5IPH#HY02"1FW/'Y%X#K3,1;T\/2P1$N:4,Y_8LP=":2 M#?;RQ=LD2?Q*8AS0DOMH=#Z+DXS^6?Q?B5M* M:H%]4$23M<<]W]>4)K$4<.C>9?9U[CS`D<]WWXYD8IWN!#Q^A6TI,^4P*A,\ M@C'!?-GB(?3+^WC%0Z02I])K`,R&0L7=MU.96*=QN.67TJDB,F%N7-.M1$^\ M@J7`+%+)3MZG2;`-.A4(7W_@$SLD]W`CG!G`E["_6* ME/^M&'`9/:2QX=-O!,R'0G1N?QMG:A-;09XH78K=7X-!3&"^?@FE"235E<%< M*,1L4X*UW82+MW&XIY7U35L.\I"0N4]'ZEV8JBH8"X5>W99S\-`VCN5$[1KO MZ0V*R)$XXX8-N M'`:+VE_.@W++^.`O%$&;RKHPO%"<3[3E(URX@J"^`]2)N8"3'/I/_1<:FJ]A M=JN#R5`TD<$=S43B&88+1'6^C5Y*V&>]J^`-@=A3G$U;B76MA%[C<`898PV9B=2\^ M^".G[%&`2OS`>332B=#0;P3,A^)9$[69>5O[+H*A41R$M.]]-NPD<$CS"&NLR[5U7$Q; MRS7#'_`&QRB.6JPLUVIA%[C<`49HM_O.Y.`8A8!NDWKU5U1B"L$=Z`,4UY>K MT4K0'CN77*7:8_"+(#[U&E_5`A@.A<2^!Q\R,8C`D_8<>=WF''1%7G07\YN5 MP$`H='97L\Z[#01.+3)H!$Z*0 MR(#B[2KM(WNO M`);FTGC%C9)@"!1BK#YIHKA$#BP!OXV#FO>>&OS>S_*$#,<7>0HC(&4WANXH MS'8C%L?L("OX\IX!>WHG#FF@F]!@`BBFV+B@3!LL0`HZ7Q%SH<>#<^38JU]S?8IL,D4WS)78RS=4=8[IDP M9GW1&6FR:M[@I.=JK/'ZI3/$I/4`$(I5H-KH_+&E`6YO0^H?GU@77_R4%.;\ M_U!+`P04````"``<@&U%`!%!B30-```ZE0``$0`<`&-P>'@M,C`Q-#`Y,S`N M>'-D550)``,('&54"!QE5'5X"P`!!"4.```$.0$``.U=6V_CN!5^7V#_@^H" MQ?;!<3S)[&[2R2XRN4Q39))@XKT`1;&@)=HF1B(]))7$*/K?>TA)MF21U,7> MK(KJQ9#%O?C2Q1Z3Y@+PNC98'QP./`P]5E`Z/QL\-/D>OC] MP/OQAZ^_>O>GX=#[@"GF2.+`FZZ\2R31A"/_L\CTO?'!^.`[3QV\&=ZQI^&; MP_&Q]\_#X]/Q\>F;DW]Y_W[X^!_OZG'B#;WGY^>#`"Q(;>'`9Y$W'*IZA+_` M$?(DXG,L[U"$Q1+Y^&RPD')Y.AHI/1^'2#*^7"`>(:4Z4A4=GAPI\"&.,)77 MC$>7>(;B4)X-OL0H)#."@X$'WE)QZB]?7FI;U"H%Z>>C`\;G('(X'OWZ\?91 M(\YLAX1^+DB_3'F8R1^-5/$4"9R)J])`KA7RPF]'2>%:-'38_?46#.>-$H
FFIH;X`$[,.%!C$\8N_,,NK$H,"H4]8 M2+-*4F;PAB+B"[..+E(JXZ**(+Y9`0H,XD"`7"VQ,%*C2PR^"+GDEDJ@Q%!+ M@)<<^ZH/L%Y?)R/$?A-/.\=HI1!-P/=D_ZOSBR7A,Y8^A=.J.O[5`&>@+JG#G[Z M=%/1/VC_+ID?J][FG`975!*YN@&[(*%J&W@$FL@IL4:080CPC%"BL8X/Q]!+ M9NKY0S#E);:\G+%WHVT+7W^U;3X6.+BG/^AC8%&`-:VKNHY4/Q5QZVXJ::KI MH]"/0VNEJ=JH0$C.9'NF+A@5+"2!NG#?HU!U?H\+C*5(:+(7NSEZ`\0\0B/B ME*2\'2\UY"66>H+:$?2`H)^7"RP)8*M@JRCKINZH/G7>-P7#?^VIK$WENH7% M_>R6"4.XE23/W]8/1F72TS9[ MZIS4W2$9Q\+0K$0,-V[)7#-!^LH=$JX"?M.322)\$,FP`3\26PI@C)K M'H+YY=I>3Y:3K,MM#'N9Y9Y*)Y77B/"?41CCCQBIMM4]5\*3,]*TY6[F'2S3]A'Y,G-`VS4"J==7(Q/MSF0NM[.0,]"]4L7.B,FSP78KUL M-IQW,S$V,Y&:\!(;/1E.,AXX6V(N5RJE!*/T4G4C"1W&$CT4L-IPD+AC+O]WVZWO];U4N6^Y=UK$)4B>8^@H@L6+3$5N=L/ MEC(W&]^6UAC*BJ?->'D[/3%.8CY@-N=HN2#^(YZK4;1T=\@IX2:IM)+?V/)2 M8_WMH0;YLB@B4B_(8/)TP?3*&=/-XMTEX":JM&+/F=*3K(*QGJ>*?,M4X"\Q M>'SUM%F?E\ZZ&2DMS3?Z7F*@9V$/6:\VV:]Z6;`WI05]_2R8]TUVU-_&VP?+ MDUQ:II&&F^%2HJ`)PTD-/;\M$IYY.ET";O9*605+\K.GJET6=.+(A=8BR))U MR)GIJ6F;&BV18RIUTU/*1YC2I#U#[?.E>8XR[:9E;SE%A+WEW(9#N'V)/4.HE8H,DEX":JE!:QI1%[JG:E:ES)U;B" MK%*ZI((L;]S3U9JNPORBAIR;NE(:I8JZ?G;1-&]?'K@:C%C'EMREE3XP=WR-Q=BS MNF7<_%6_XO)_S9GZ49NP?L(S3^]N>JHVCCP;"!(MU>NKR;D%Q[.S@=HK=ICM M!OL;.'WP$H69B*K!L<^J)GN[G=**,Q/I7IGNW5?!B,Y50;"-,O`#;[1'QX"1 MIHX52>RF6R&:-G4+5'#878\@`)IZM!4S^_4KB;?\GJKP+[_GJCX%;C$N/6K< MS]FV.7&R%?0M\[4IAXKZ-\STANK4#0^>!'!IO6;@-CXV`Q$IM<"A'GK MYYK59PJJWK=U:W3NW6RI6%=J5!SA4(KLS'!CJI'_CGV478`,:NGQ<&.B%1#3 M_M1UD.3ULC\[8S'M>5T+3%YQ_6]7CDK;8]>!LE;21[M"*&^=70?#1BLY'&X, MM$*QO1]W'0R9CCK8N?[MK;IK`[K M1'6;XV]WAE&S\\Q!D'NIWKWY>5U(>2M7&R,M$#JWP*]SI60ZZJ!%P+HW::_5 M(-M:N_)DWE^^&1)&[UJ#<>_,WW[DU;;L%*7?QM"`2@]^J67@^Y#YGP=>,A5- M-N@_E=GY&XDCM9H:>&@JU&<[Y-E@AD+]*0OUO8E3F!\2%DRT']S0[/XH_Z#$<0A_A^9GPE MMFO^U8=;Z>^E_B8#T8#.:7`>P55'!ZMG^2;$:5^)P@`>\( MG9O\35S8@[N!/%V`)O?C*;XI.EX#K,U-1GTD%I<`[`G@/.$;6.UP_4&(BX7Z M5$[1S8C!:(;X:D_$)K+39%-\$,13(NO370-[NY#N$K654.OUP@(6Z-JT>'7G MJGK@/+1Z?.6?6NTZ80:L+L8*#^1VC3,;.(M#MVC*N)Y=KA^"^XBC*>9;PT7` M(D3HZ_KCP&:]!@G\42_J=,\;![;*B+*\=-W-D+*"M;A9EN]03#G!N1VZ"`E5 MGXR9<()"6,9A*K#8PU"=Y#IEY4CMY^*A6KFJ5"EK%X,G@O'(.P0S,Q4(NF/8Q+OU>JV4#ULHN M^Q&6T;CT%)Y^CNY^J0[%N0\+[RZF1'9P8H_-TLF!KA5\2Z-\P@(C[B_.:9"; M[9RK&)IKN5^(7.C%XW5,U<>?)^Q^-H/UHYX0W5!]SS!XS;!I.F[NRT-;1XC) M?"%QQ5%,"9?L\;8@__G)JB]L67,9K,M?* M[U<;$9BE:0Z>$0_2*_:#[K1OZ(-V4O^[1!*O-P_H<,?\^[MNS_W^C(7B4%D3 MG9E&6'#9QF#]W4:(,Y4!><(/881T=SRI@=%V':4J MG7%E&Y"M-WJ&T>X./_\#HNZ2I:+@#](_,)[J*;#;#:V%S`O&&R`.%'&0?=N20MN)Q> M/+,N^K"%RK928BL4RM4G&$1AIJ9F!&AS=UTYL$S.OG*^PP++EO;,+CJ51"!4 MUWW')/%Q,OOL1`JG&J1U,>OKFVA:0SU$,D-Q*#ODF1N@Q:O1>D!Z_?6XO-?+F.-79J\Y8(OG']$+B>)H M$Z_W]`[+1Q1B<V!MI199 MZY=`NY,DJ8>R,M\(S01K2!;A>W[+A(`6U`F!#N=!N MW9G;0E;AQX0]Q##,PCP]34VKVQR?E'K=2^T57'*!;/%\BJ29,BY,_PQR2 MQ;"\9S.8]28O.TR3G)*?YF,B?3EW)M`:(U:>OQLEKV;H1O@O4$L!`AX#%``` M``@`'(!M1?":QS2,E0``U64*`!$`&````````0```*2!`````&-P>'@M,C`Q M-#`Y,S`N>&UL550%``,('&54=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M'(!M1:.^G='@M,C`Q-#`Y M,S!?8V%L+GAM;%54!0`#"!QE5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`!R`;45V4W#/!#$``'/[`@`5`!@```````$```"D@6"A``!C<'AX+3(P,30P M.3,P7V1E9BYX;6Q55`4``P@<951U>`L``00E#@``!#D!``!02P$"'@,4```` M"``<@&U%LL>"8@!)``">)P0`%0`8```````!````I(&ST@``8W!X>"TR,#$T M,#DS,%]L86(N>&UL550%``,('&54=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`'(!M15P'@M,C`Q M-#`Y,S!?<')E+GAM;%54!0`#"!QE5'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`!R`;44`$4&)-`T``#J5```1`!@```````$```"D@=A4`0!C<'AX+3(P M,30P.3,P+GAS9%54!0`#"!QE5'5X"P`!!"4.```$.0$``%!+!08`````!@`& +`!H"``!78@$````` ` end XML 41 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 42 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Liquidity
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Nature of Operations [Text Block]

1.

Nature of Business and Liquidity

Celator Pharmaceuticals, Inc. (the “Company”), with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the Company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes.

The Company has incurred recurring losses and negative cash flows from operations since inception. As of September 30, 2014, the Company had an accumulated deficit of $147.0 million. The Company expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. At September 30, 2014, the Company had cash and cash equivalents of $20.2 million. On October 28, 2014, the Company completed a public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock. The Company received approximately $13.5 million in net proceeds from the public offering (See Note 13). Management believes that the cash and cash equivalents at September 30, 2014 cash available to the Company through the Hercules Technology Growth Capital Inc. (“Hercules”) term loan and the funds received from the October 28, 2014 public offering will be sufficient to meet estimated working capital requirements and fund planned operations into the second half of 2016.

The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. Substantial additional financing will be needed by the Company to fund its operations and to commercialize its product candidates. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Preferred Stock, Shares Authorized 20,000,000 20,000,000

peferred stock, par valur (in dollars per share) $ 0.001 $ 0.001

Common stock, authorized shares 200,000,000 200,000,000

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, issued shares 26,078,532 26,035,596

Common stock, outstanding shares 26,078,532 26,035,596

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 44 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Geographic Segment Information
9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

11.

Geographic Segment Information

The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.

Total Assets

September 30, 2014

December 31, 2013

United States

$

22,226,025

$

26,190,516

Canada

266,844

284,563

Germany

895,598

997,671

Total Assets

$

23,388,467

$

27,472,750

Net Loss

Three months ended

Nine months

September 30,

September 30,

2014

2013

2014

2013

United States

(5,046,236)

(3,274,731)

(12,977,790)

(15,649,089)

Canada

(433,581)

(402,681)

(1,570,722)

(1,753,248)

Total Net Loss

$

(5,479,817)

$

(3,677,412)

$

(14,548,512)

$

(17,402,337)

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
9 Months Ended

Sep. 30, 2014

Nov. 11, 2014

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q3

Entity Registrant Name Celator Pharmaceuticals Inc

Entity Central Index Key 0001327467

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol CPXX

Entity Common Stock, Shares Outstanding 33,681,355

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 46 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
9 Months Ended

Sep. 30, 2014

Commitments And Contingencies Disclosure [Abstract]

Commitments And Contingencies Disclosure [Text Block]

12.

Commitments and Contingencies

In September 2014, the Company entered into a lease agreement for a laboratory space in Vancouver, British Columbia, which expires in September 2015. The remaining minimum lease payments as of September 30, 2014 were $35,090.

In March 2013, the Company entered into an office lease agreement for office space in Ewing, New Jersey, which commenced in June 2013 with a term of sixty months. The remaining minimum lease payments as of September 30, 2014 were $530,232. Under the Ewing, New Jersey lease agreement, the Company will be obligated to maintain a letter of credit from a bank with respect to its security deposit obligations in the amount of $200,000 during the first year of the Agreement, which amount will be reduced by $40,000 per year on each of December 1, 2014, 2015, and 2016 and by $60,000 on December 1, 2017.

In February 2013, the Company renewed its office lease agreements for office space in Vancouver, British Columbia, effective April 1, 2013, which expires in June 2016. The remaining minimum lease payments as of September 30, 2014 were $111,638.

The Company has a worldwide exclusive license agreement with Princeton University dated June 2007 that provides the Company with exclusive rights to some aspects of its nanoparticle polymer technology arising from research sponsored by the Company at Princeton University between 2003 and 2007. These inventions are generally characterized as particulate constructs for release of active agents for medical application. Of the products currently in the Company’s pipeline, only the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation is subject to this agreement. The Company is obligated to pay a royalty on net sales to Princeton University of a low single-digit percentage if any invention is sold by the Company or a company to which the product covered by the invention was licensed by the Company, which was generated under the exclusive licensing agreement. No royalty or other product/sub-license-related payments have been made to date. The Company is obligated to provide Princeton University a percentage within the range of 45% to 55% of proceeds obtained from a sub-license of the intellectual property to a third party in cases where the Company has not conducted any research or development activities and is solely licensing out the original intellectual property jointly developed by the Company and Princeton University. The Company may terminate the agreement at any time by giving 90 days written notice to Princeton University. Princeton may terminate the agreement if the Company should breach or fail to perform under the agreement, with written notice of default provided by Princeton University to the Company and only if the Company fails to cure the default within 60 days. The Company is obligated under the agreement to provide an annual progress report to Princeton University on any developments of the licensed technology as well as prosecution of the patents covering the technology and the use of commercially reasonable efforts to develop licensed products.

The Company has a collaborative research agreement dated May 2001 with the British Columbia Cancer Agency (“BCCA”) whereby in consideration for the license and conditional assignment of all Company-sponsored intellectual property to the Company by BCCA, the Company will pay to BCCA a royalty in the low single digits on net sales of royalty-bearing products in territories so long as a valid claim exists for inventions made between June 2000 and June 2005 under the agreement. All obligations relating to the conduct of the research and assignment of intellectual property have been completed. No payments of royalties have been made to date. Either party may terminate the agreement if the other party commits a material breach or default and such breach or default is not reasonably cured within 45 days.

In consideration of funding by the Leukemia & Lymphoma Society ® (“LLS”) and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company may be required to pay LLS a cash multiple on the LLS funding, (LLS funding is the $5 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of the Phase 2 study). Subject to exclusions under the agreement, the Company is obligated to pay LLS an amount equal to 50% of the cash payments the Company receives from out-licenses and transfers of rights to the product or other liquidity event, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding the Company receives from LLS. The total amount payable by the Company to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties (not to exceed 5% of net sales) but will not exceed the maximum amount referred to in the preceding sentence.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Loss (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Expenses

Research and development $ 3,334,789 $ 2,325,891 $ 9,238,756 $ 5,995,866

Leukemia & Lymphoma Society funding (135,747) (135,746) (907,240) (425,339)

General and administrative 1,874,412 1,434,436 5,491,779 3,922,084

(Gain) loss on disposal of property and equipment 0 (12,059) 0 126,633

Amortization and depreciation 48,521 51,239 144,609 148,291

Operating loss (5,121,975) (3,663,761) (13,967,904) (9,767,535)

Other income (expenses)

Foreign exchange loss (1,408) (16,745) (27,721) (21,229)

Interest and miscellaneous income 2,887 3,094 7,144 6,560

Non-cash derivative instrument charge 0 0 0 (7,473,108)

Interest expense (359,321) 0 (560,031) (147,025)

Net loss $ (5,479,817) $ (3,677,412) $ (14,548,512) $ (17,402,337)

Net loss per share

Basic and diluted (in dollars per share) $ (0.21) $ (0.14) $ (0.56) $ (0.84)

Weighted average of common shares outstanding

Basic and diluted (in shares) 26,078,532 26,026,793 26,065,006 20,641,876

X

- Definition

The amount of non-cash derivative charges recognized during the period.

+ References

No definition available.

+ Details

Name: cpxx_NoncashDerivativeInstrumentCharge

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of funding recorded as an offset to costs incurred from arrangement with other organizations.

+ References

No definition available.

+ Details

Name: cpxx_ResearchAndDevelopmentArrangementWithOtherFundingToOffsetCostsIncurred

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: cpxx_WeightedAverageNumberOfCommonSharesOutstandingAbstract

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).

+ References

No definition available.

+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 48 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and Equipment
9 Months Ended

Sep. 30, 2014

Property Plant And Equipment [Abstract]

Property Plant And Equipment Disclosure [Text Block]

6.

Property and Equipment

Property and equipment as of September 30, 2014 and December 31, 2013 including assets held under capital lease, consists of the following:

September 30, 2014

December 31, 2013

Computer and equipment

$

141,998

$

136,498

Furniture and office equipment

96,457

96,457

Laboratory equipment

1,769,589

1,760,633

Capital lease equipment

155,523

155,523

Leaseholds

37,789

37,789

2,201,356

2,186,900

Less: Accumulated depreciation

(1,192,930)

(1,048,321)

$

1,008,426

$

1,138,579



Three months ended

Nine months ended

September 30,

September 30,

2014

2013

2014

2013

Depreciation and amortization

$

48,521

$

51,239

$

144,609

$

148,291

In February 2012, the Company closed a laboratory in Canada and consigned certain property and equipment for sale with net book value of $507,622. At September 30, 2014 and December 31, 2013, the net book value of the remaining consigned equipment was $74,086 and consisted solely of scientific equipment, which is presented as assets held for sale on the consolidated balance sheet.

During nine months ended September 30, 2013 assets held for sale with a net book value of $177,428 were sold for proceeds of $51,776 resulting in a loss on disposal of $125,422. There were no disposals during the nine months ended September 30, 2014.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Current Assets
9 Months Ended

Sep. 30, 2014

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets [Text Block]

5.

Other Current Assets

Other current assets as of September 30, 2014 and December 31, 2013 consist of the following:

September 30, 2014

December 31, 2013

Clinical trial materials

$

541,468

$

468,389

X

- Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for other current assets.

+ References

No definition available.

+ Details

Name: us-gaap_OtherCurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Receivables (Tables)
9 Months Ended

Sep. 30, 2014

Other Receivables, Net, Current [Abstract]

Schedule Of Other Receivables [Table Text Block]

Other receivables as of September 30, 2014 and December 31, 2013, consists of the following:

September 30, 2014

December 31, 2013

Receivables related to the sale of New Jersey net operating losses

$

-

$

1,412,302

Other receivables

6,335

5,011

$

6,335

$

1,417,313

X

- Definition

Represents the other receivables.

+ References

No definition available.

+ Details

Name: cpxx_ScheduleOfOtherReceivablesTableTextBlock

Namespace Prefix: cpxx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherReceivablesNetCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
9 Months Ended

Sep. 30, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

13.

Subsequent Events

Public Offering of Common Stock and Warrants to Purchase Common Stock

On October 28, 2014, the Company completed a public offering of 7,602,823 shares of common stock and warrants to purchase up to 760,282 shares of its common stock, including the exercise in full of the underwriters’ overallotment option to purchase up to an additional 991,673 shares of common stock. The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock at a price of $1.95 per unit. The Company received approximately $13.5 million in net proceeds from the public offering after payment of fees, expenses and underwriting expenses. The shares of common stock and the warrants were immediately separable and were issued separately. The warrants have an exercise price of $3.58 per share and have a term of five years. In addition, the Company issued to the underwriters, underwriter warrants to purchase 114,042 shares of common stock at an exercise price of $3.58 per share.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Loans Payable
9 Months Ended

Sep. 30, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

9.

Loans Payable

On May 9, 2014, the Company entered into a term loan agreement for $15 million with Hercules Technology Growth Capital, Inc. (“Hercules”). The first $10 million of the term loan was funded at closing, and is repayable in installments over forty-two months including an initial interest-only period of twelve months after closing. The remaining $5 million of the term loan can be drawn down at the Company’s option at any time between December 15, 2014 and March 31, 2015. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015, contingent upon achieving full enrollment of the CPX-351 Phase 3 study by December 31, 2014. The funds will be used to provide general working capital.

On October 24, 2014, the Company achieved full enrollment of the CPX-351 Phase 3 study resulting in the interest only period extendable to December 1, 2015 and the term loan maturity date of December 1, 2017 extendable to June 1, 2018. As a result, the outstanding term loan balance has been classified as non-current at September 30, 2014.

Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase 158,006 shares of the Company’s common stock at an exercise price of $2.67 per share with a term of five years. The fair value of the warrants of $320,752 and financing costs of $357,253 incurred in connection with the term loan were recorded as debt issuance costs and will be amortized as interest expense using the effective interest method over the term of the loan. Amortization of debt issuance costs was $57,670 and $88,176 for the three and nine months ended September 30, 2014 respectively and the remaining unamortized debt issuance costs of $589,828 are included in other non-current assets.

In addition, the Company will pay an end of term charge of $592,500 on the earliest to occur of (i) the term loan maturity date, (ii) the date that the Company prepays the outstanding loan, or (iii) the date that the loan become due and payable. The end of term charge will be accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company accrued $50,396 and $77,056 of this fee during the three and nine months ended September 30, 2014 respectively.



Long-term debt as of September 30, 2014 consists of the following:

Loan payable

$

10,000,000

End of term fee

77,056

Long-term debt

$

10,077,056

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Assets
9 Months Ended

Sep. 30, 2014

Other Assets, Noncurrent Disclosure [Abstract]

Other Assets Disclosure [Text Block]

7.

Other Assets

Other assets as of September 30, 2014 and December 31, 2013 consist of the following:

September 30, 2014

December 31, 2013

Deferred financing costs (see Note 9)

$

589,828

$

-

Other non-current assets

22,352

5,745

$

612,180

$

5,745

X

- Definition

The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.

+ References

No definition available.

+ Details

Name: us-gaap_OtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherAssetsNoncurrentDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Liabilities
9 Months Ended

Sep. 30, 2014

Payables And Accruals [Abstract]

Accounts Payable And Accrued Liabilities Disclosure [Text Block]

8.

Accrued Liabilities

Accrued liabilities as of September 30, 2014 and December 31, 2013 consist of the following:

September 30, 2014

December 31, 2013

Accrued bonuses

$

748,444

$

624,472

Accrued salaries and vacation

213,775

143,484

Accrued professional fees

60,000

30,911

Accrued clinical trial expenses

494,651

636,497

Accrued drug manufacturing expenses

145,565

-

Interest payable

83,339

-

Accrued trade payables other

276,688

195,445

$

2,022,462

$

1,630,809

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Based Compensation
9 Months Ended

Sep. 30, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

10.

Stock-Based Compensation

The following table summarizes the activity of the Company’s stock option plans for the nine months ended September 30, 2014:

Number of options

Exercise price

December 31, 2013

2,578,252

$

2.98

Granted

499,100

3.13

Exercised

(42,936)

2.34

Cancelled

(14,603)

3.17

September 30, 2014

3,019,813

$

3.01

Exercisable at September 30, 2014

1,193,556

$

2.75

The following table provides information regarding stock options activity during the periods:

Three months ended

Nine months ended

September 30,

September 30,

2014

2013

2014

2013

Stock compensation expense recognized

$

354,204

$

235,289

$

996,801

$

322,069

Weighted average grant-date fair value of stock options issued (per share)

$

2.22

$

2.11

$

2.68

$

2.14

Grant-date fair value of stock options issued

$

45,732

$

59,080

$

1,337,588

$

3,314,341

Volatility

112.0

%

117.0

%

114.4

%

118.3

%

Risk-free interest rate

1.9

%

1.6

%

2.0

%

1.9

%

Dividend yield

0

%

0

%

0

%

0

%

Expected life in years

6.0

6.0

6.2

6.2

Intrinsic value of stock options exercised

$

-

$

-

$

38,892

$

-

The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.

The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At September 30, 2014, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $3,988,729 and 2.9 years, respectively.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements (Details Textual) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Non-cash derivative instrument charge $ 0 $ 0 $ 0 $ 7,473,108

Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Non-cash derivative instrument charge $ 7,473,108

X

- Definition

The amount of non-cash derivative charges recognized during the period.

+ References

No definition available.

+ Details

Name: cpxx_NoncashDerivativeInstrumentCharge

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

The net loss per share for the nine months ended September 30, 2013 has been corrected for an immaterial error in the calculation of average weighted shares outstanding. The revision is as follows:

As Reported

As Revised

Net loss

$

(17,402,337)

$

(17,402,337)

Net loss per share

$

(0.87)

$

(0.84)

Weighted average shares outstanding

19,977,071

20,641,876

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22644-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22663-107794

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22658-107794

+ Details

Name: us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Assets (Tables)
9 Months Ended

Sep. 30, 2014

Other Assets, Noncurrent Disclosure [Abstract]

Schedule of Other Assets, Noncurrent [Table Text Block]

Other assets as of September 30, 2014 and December 31, 2013 consist of the following:

September 30, 2014

December 31, 2013

Deferred financing costs (see Note 9)

$

589,828

$

-

Other non-current assets

22,352

5,745

$

612,180

$

5,745

X

- Details

Name: us-gaap_OtherAssetsNoncurrentDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Details Textual) (USD $)
9 Months Ended 1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Oct. 28, 2014

Subsequent Event [Member]

Oct. 28, 2014

Subsequent Event [Member]

Warrant [Member]

Oct. 28, 2014

Subsequent Event [Member]

Under Writer [Member]

Warrant [Member]

Oct. 28, 2014

Subsequent Event [Member]

Over-Allotment Option [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues 7,602,823 760,282 114,042 991,673

Proceeds From Issuance Of Common Stock $ 104,387 $ 32,499,986 $ 13,500,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 3.58 $ 3.58

Warrants Expiration Tem 5 years

Warrants To Purchase Common Stock Ratio consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock

Share Price $ 1.95

X

- Definition

Represents the value of Warrants Expiration Tem.

+ References

No definition available.

+ Details

Name: cpxx_WarrantsExpirationTem

Namespace Prefix: cpxx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the ratio of warrants to purchase of common stock.

+ References

No definition available.

+ Details

Name: cpxx_WarrantsToPurchaseCommonStockRatio

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Liabilities (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Accrued Liabilities [Line Items]

Accrued bonuses $ 748,444 $ 624,472

Accrued salaries and vacation 213,775 143,484

Accrued professional fees 60,000 30,911

Accrued clinical trial expenses 494,651 636,497

Accrued drug manufacturing expenses 145,565 0

Interest payable 83,339 0

Accrued trade payables other 276,688 195,445

Accrued liabilities $ 2,022,462 $ 1,630,809

X

- Definition

Accrued Clinical Trial Expenses

+ References

No definition available.

+ Details

Name: cpxx_AccruedClinicalTrialExpenses

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accrued Drug Development Costs

+ References

No definition available.

+ Details

Name: cpxx_AccruedDrugDevelopmentCosts

Namespace Prefix: cpxx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: cpxx_AccruedLiabilitiesLineItems

Namespace Prefix: cpxx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedBonusesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedSalariesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations, including trade payables, incurred through that date and due within one year (or in the operating cycle if longer) arising from transactions not otherwise specified in the taxonomy.

+ References

No definition available.

+ Details

Name: us-gaap_OtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 61 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statement of Stockholders' Equity (USD $)

Total

Common Stock [Member]

Warrants [Member]

Additional Paid-In Capital [Member]

Accumulated Other Comprehensive Loss [Member]

Accumulated Deficit [Member]

Balance at Dec. 31, 2013 $ 23,464,487 $ 26,036 $ 1,083,193 $ 155,953,894 $ (1,133,266) $ (132,465,370)

Balance (in shares) at Dec. 31, 2013 26,035,596

Issued for cash on exercise of stock options 100,639 43 0 100,596 0 0

Issued for cash on exercise of stock options (in shares) 42,936 42,936

Stock based compensation 996,801 0 0 996,801 0 0

Warrants issued 320,752 0 0 320,752 0 0

Net loss for the period (14,548,512) 0 0 0 0 (14,548,512)

Balance at Sep. 30, 2014 $ 10,334,167 $ 26,079 $ 1,083,193 $ 157,372,043 $ (1,133,266) $ (147,013,882)

Balance (in shares) at Sep. 30, 2014 26,078,532

X

- Definition

Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 62 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Receivables
9 Months Ended

Sep. 30, 2014

Other Receivables, Net, Current [Abstract]

Other Receivable [Text Block]

4.

Other Receivables

Other receivables as of September 30, 2014 and December 31, 2013, consists of the following:

September 30, 2014

December 31, 2013

Receivables related to the sale of New Jersey net operating losses

$

-

$

1,412,302

Other receivables

6,335

5,011

$

6,335

$

1,417,313

X

- Definition

The entire disclosure for other receivable.

+ References

No definition available.

+ Details

Name: cpxx_OtherReceivableTextBlock

Namespace Prefix: cpxx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherReceivablesNetCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 63 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Liabilities (Tables)
9 Months Ended

Sep. 30, 2014

Payables And Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities as of September 30, 2014 and December 31, 2013 consist of the following:

September 30, 2014

December 31, 2013

Accrued bonuses

$

748,444

$

624,472

Accrued salaries and vacation

213,775

143,484

Accrued professional fees

60,000

30,911

Accrued clinical trial expenses

494,651

636,497

Accrued drug manufacturing expenses

145,565

-

Interest payable

83,339

-

Accrued trade payables other

276,688

195,445

$

2,022,462

$

1,630,809

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 98 180 1 false 39 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.celatorpharma.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.celatorpharma.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 103 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.celatorpharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 104 - Statement - Consolidated Statements of Loss Sheet http://www.celatorpharma.com/role/ConsolidatedStatementsOfLoss Consolidated Statements of Loss false false R5.htm 105 - Statement - Consolidated Statement of Stockholders' Equity Sheet http://www.celatorpharma.com/role/ConsolidatedStatementOfStockholdersEquity Consolidated Statement of Stockholders' Equity false false R6.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.celatorpharma.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R7.htm 107 - Disclosure - Nature of Business and Liquidity Sheet http://www.celatorpharma.com/role/NatureOfBusinessAndLiquidity Nature of Business and Liquidity false false R8.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.celatorpharma.com/role/FairValueMeasurements Fair Value Measurements false false R10.htm 110 - Disclosure - Other Receivables Sheet http://www.celatorpharma.com/role/OtherReceivables Other Receivables false false R11.htm 111 - Disclosure - Other Current Assets Sheet http://www.celatorpharma.com/role/OtherCurrentAssets Other Current Assets false false R12.htm 112 - Disclosure - Property and Equipment Sheet http://www.celatorpharma.com/role/PropertyAndEquipment Property and Equipment false false R13.htm 113 - Disclosure - Other Assets Sheet http://www.celatorpharma.com/role/OtherAssets Other Assets false false R14.htm 114 - Disclosure - Accrued Liabilities Sheet http://www.celatorpharma.com/role/AccruedLiabilities Accrued Liabilities false false R15.htm 115 - Disclosure - Loans Payable Sheet http://www.celatorpharma.com/role/LoansPayable Loans Payable false false R16.htm 116 - Disclosure - Stock Based Compensation Sheet http://www.celatorpharma.com/role/StockBasedCompensation Stock Based Compensation false false R17.htm 117 - Disclosure - Geographic Segment Information Sheet http://www.celatorpharma.com/role/GeographicSegmentInformation Geographic Segment Information false false R18.htm 118 - Disclosure - Commitments and Contingencies Sheet http://www.celatorpharma.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R19.htm 119 - Disclosure - Subsequent Events Sheet http://www.celatorpharma.com/role/SubsequentEvents Subsequent Events false false R20.htm 120 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R21.htm 121 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R22.htm 122 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.celatorpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) false false R23.htm 123 - Disclosure - Other Receivables (Tables) Sheet http://www.celatorpharma.com/role/OtherReceivablesTables Other Receivables (Tables) false false R24.htm 124 - Disclosure - Other Current Assets (Tables) Sheet http://www.celatorpharma.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) false false R25.htm 125 - Disclosure - Property and Equipment (Tables) Sheet http://www.celatorpharma.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) false false R26.htm 126 - Disclosure - Other Assets (Tables) Sheet http://www.celatorpharma.com/role/OtherAssetsTables Other Assets (Tables) false false R27.htm 127 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.celatorpharma.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) false false R28.htm 128 - Disclosure - Loans Payable (Tables) Sheet http://www.celatorpharma.com/role/LoansPayableTables Loans Payable (Tables) false false R29.htm 129 - Disclosure - Stock Based Compensation (Tables) Sheet http://www.celatorpharma.com/role/StockBasedCompensationTables Stock Based Compensation (Tables) false false R30.htm 130 - Disclosure - Geographic Segment Information (Tables) Sheet http://www.celatorpharma.com/role/GeographicSegmentInformationTables Geographic Segment Information (Tables) false false R31.htm 131 - Disclosure - Nature of Business and Liquidity (Details Textual) Sheet http://www.celatorpharma.com/role/NatureOfBusinessAndLiquidityDetailsTextual Nature of Business and Liquidity (Details Textual) false false R32.htm 132 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R33.htm 133 - Disclosure - Fair Value Measurements (Details) Sheet http://www.celatorpharma.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) false false R34.htm 134 - Disclosure - Fair Value Measurements (Details Textual) Sheet http://www.celatorpharma.com/role/FairValueMeasurementsDetailsTextual Fair Value Measurements (Details Textual) false false R35.htm 135 - Disclosure - Other Receivables (Details) Sheet http://www.celatorpharma.com/role/OtherReceivablesDetails Other Receivables (Details) false false R36.htm 136 - Disclosure - Other Current Assets (Details) Sheet http://www.celatorpharma.com/role/OtherCurrentAssetsDetails Other Current Assets (Details) false false R37.htm 137 - Disclosure - Property and Equipment (Details) Sheet http://www.celatorpharma.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) false false R38.htm 138 - Disclosure - Property and Equipment (Details 1) Sheet http://www.celatorpharma.com/role/PropertyAndEquipmentDetails1 Property and Equipment (Details 1) false false R39.htm 139 - Disclosure - Property and Equipment (Details Textual) Sheet http://www.celatorpharma.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) false false R40.htm 140 - Disclosure - Other Assets (Details) Sheet http://www.celatorpharma.com/role/OtherAssetsDetails Other Assets (Details) false false R41.htm 141 - Disclosure - Accrued Liabilities (Details) Sheet http://www.celatorpharma.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) false false R42.htm 142 - Disclosure - Loans Payable (Details) Sheet http://www.celatorpharma.com/role/LoansPayableDetails Loans Payable (Details) false false R43.htm 143 - Disclosure - Loans Payable (Details Textual) Sheet http://www.celatorpharma.com/role/LoansPayableDetailsTextual Loans Payable (Details Textual) false false R44.htm 144 - Disclosure - Stock Based Compensation (Details) Sheet http://www.celatorpharma.com/role/StockBasedCompensationDetails Stock Based Compensation (Details) false false R45.htm 145 - Disclosure - Stock Based Compensation (Details 1) Sheet http://www.celatorpharma.com/role/StockBasedCompensationDetails1 Stock Based Compensation (Details 1) false false R46.htm 146 - Disclosure - Stock Based Compensation (Details Textual) Sheet http://www.celatorpharma.com/role/StockBasedCompensationDetailsTextual Stock Based Compensation (Details Textual) false false R47.htm 147 - Disclosure - Geographic Segment Information (Details) Sheet http://www.celatorpharma.com/role/GeographicSegmentInformationDetails Geographic Segment Information (Details) false false R48.htm 148 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.celatorpharma.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R49.htm 149 - Disclosure - Subsequent Events (Details Textual) Sheet http://www.celatorpharma.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) false false All Reports Book All Reports Element cpxx_DevelopmentFunding had a mix of decimals attribute values: -6 -5. Element cpxx_RoyaltyRatePercentage had a mix of decimals attribute values: 1 2. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 0. 'Monetary' elements on report '148 - Disclosure - Commitments and Contingencies (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 103 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 104 - Statement - Consolidated Statements of Loss Process Flow-Through: 106 - Statement - Consolidated Statements of Cash Flows cpxx-20140930.xml cpxx-20140930.xsd cpxx-20140930_cal.xml cpxx-20140930_def.xml cpxx-20140930_lab.xml cpxx-20140930_pre.xml true true XML 65 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and Equipment (Details 1) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Depreciation and amortization $ 48,521 $ 51,239 $ 144,609 $ 148,291

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 66 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Basis of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.

Use of Estimates, Policy [Policy Text Block]

Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, among other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.

Earnings Per Share, Policy [Policy Text Block]

Loss per share: The net loss per share for the nine months ended September 30, 2013 has been corrected for an immaterial error in the calculation of average weighted shares outstanding. The revision is as follows:

As Reported

As Revised

Net loss

$

(17,402,337)

$

(17,402,337)

Net loss per share

$

(0.87)

$

(0.84)

Weighted average shares outstanding

19,977,071

20,641,876

The above correction has no impact on any other prior year financial statement amounts or disclosures.

New Accounting Pronouncements, Policy [Policy Text Block]

New Accounting Pronouncement : In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation , which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification (ASC) Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification. The amendments in this Update remove the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASC Topic 915 is removed effective for annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of its June 30, 2014 financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40). The ASU provides U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Stock Based Compensation (Details Textual) (Non vested Awards [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Non vested Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 3,988,729
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 10 months 24 days

Fair Value Measurements (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Assets:
Total		$ 22,601,202
Fair Value, Inputs, Level 1 [Member]
Assets:
Total		22,601,202
Fair Value, Inputs, Level 2 [Member]
Assets:
Total		0
Fair Value, Inputs, Level 3 [Member]
Assets:
Total		0
Certificates of Deposit [Member]
Assets:
Certificates of Deposit		15,003,472
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Certificates of Deposit		15,003,472
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Certificates of Deposit		0
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets:
Certificates of Deposit		0
Money Market Funds [Member]
Assets:
Money Market Fund	17,727,260	7,597,730
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Money Market Fund	17,727,260	7,597,730
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Money Market Fund	0	0
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets:
Money Market Fund	$ 0	$ 0

Loans Payable (Details) (USD $)	Sep. 30, 2014
Schedule Of Loan payable [Line Items]
Loan payable	$ 10,000,000
End of term fee	77,056
Long-term debt	$ 10,077,056

Property and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,201,356	$ 2,186,900
Less: Accumulated depreciation	(1,192,930)	(1,048,321)
Property and equipment, net	1,008,426	1,138,579
Computer and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	141,998	136,498
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	96,457	96,457
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,769,589	1,760,633
Capital lease equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	155,523	155,523
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 37,789	$ 37,789

Geographic Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
Geographic Segment Information (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$ 23,388,467		$ 23,388,467		$ 27,472,750
Total Net Loss	(5,479,817)	(3,677,412)	(14,548,512)	(17,402,337)
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	22,226,025		22,226,025		26,190,516
Total Net Loss	(5,046,236)	(3,274,731)	(12,977,790)	(15,649,089)
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	266,844		266,844		284,563
Total Net Loss	(433,581)	(402,681)	(1,570,722)	(1,753,248)
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$ 895,598		$ 895,598		$ 997,671

Loans Payable (Details Textual) (USD $)	0 Months Ended	3 Months Ended	9 Months Ended
Loans Payable (Details Textual) (USD $)	May 09, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Schedule Of Loan payable [Line Items]
Amortization Of Financing Costs And Discounts			$ 165,232	$ 74,751
Adjustments to Additional Paid in Capital, Warrant Issued			320,752
Deferred Finance Costs, Noncurrent, Net		589,828	589,828		0
Line of Credit Facility, Frequency of Payments	any time between December 15, 2014 and March 31, 2015
Warrants Maturity Term	5 years
End of Loan Term, Fees		50,396	77,056
Warrant [Member]
Schedule Of Loan payable [Line Items]
Amortization Of Financing Costs And Discounts		57,670	88,176
Adjustments to Additional Paid in Capital, Warrant Issued			0
Term Loan [Member]
Schedule Of Loan payable [Line Items]
Debt Issuance Cost			357,253
End of Term Fee [Member]
Schedule Of Loan payable [Line Items]
Debt Issuance Cost			592,500
Hercules Technology Growth Capital [Member]
Schedule Of Loan payable [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	10,000,000
Line of Credit Facility, Maximum Borrowing Capacity	15,000,000
Line of Credit Facility, Remaining Borrowing Capacity	5,000,000
Long-term Debt, Maturities, Repayment Terms	repayable in installments over forty-two months including an initial interest-only period of twelve months after closing
Line of Credit Facility, Interest Rate Description	Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the US prime rate with interest only period extendable to December 1, 2015,
Hercules Technology Growth Capital [Member] \| Warrant [Member]
Schedule Of Loan payable [Line Items]
Stock Issued During Period, Shares, New Issues			158,006
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.67	$ 2.67
Adjustments to Additional Paid in Capital, Warrant Issued			$ 320,752

Stock Based Compensation (Details) (USD $)	9 Months Ended
Stock Based Compensation (Details) (USD $)	Sep. 30, 2014
Schedule Of Share Based Compensation Stock Options Activity [Line Items]
Number of options, Beginning balance	2,578,252
Number of options, Granted	499,100
Number of options, Exercised	(42,936)
Number of options, Cancelled	(14,603)
Number of options, Ending balance	3,019,813
Number of options, Exercisable	1,193,556
Exercise price, Beginning balance	$ 2.98
Exercise price, Granted	$ 3.13
Exercise pice, Exercised	$ 2.34
Exercise price, Cancelled	$ 3.17
Exercise price, Ending balance	$ 3.01
Exercise price, Exercisable	$ 2.75

Other Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Schedule Of Other Assets Noncurrent [Line Items]
Deferred financing costs (see Note 9)	$ 589,828	$ 0
Other non-current assets	22,352	5,745
Assets, Noncurrent	$ 612,180	$ 5,745

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 20,180,490	$ 23,589,516
Restricted cash	285,801	287,657
Other receivables	6,335	1,417,313
Prepaid expenses and deposits	679,681	491,465
Assets held for sale	74,086	74,086
Other current assets	541,468	468,389
Total current assets	21,767,861	26,328,426
Property and equipment, net	1,008,426	1,138,579
Other assets	612,180	5,745
Total assets	23,388,467	27,472,750
Current liabilities:
Accounts payable	183,174	1,193,148
Accrued liabilities	2,022,462	1,630,809
Current portion of deferred revenue	542,986	542,986
Total current liabilities	2,748,622	3,366,943
Long-term debt	10,077,056	0
Deferred revenue	180,996	588,236
Deferred rent	47,626	53,084
Total liabilities	13,054,300	4,008,263
Stockholders' equity
Preferred stock Authorized 20,000,000 shares, par value $0.001	0	0
Common stock Authorized 200,000,000 shares, par value $0.001 Issued and outstanding 26,078,532 and 26,035,596 shares as of September 30, 2014 and December 31, 2013, respectively	26,079	26,036
Warrants	1,083,193	1,083,193
Additional paid-in capital	157,372,043	155,953,894
Accumulated other comprehensive loss	(1,133,266)	(1,133,266)
Accumulated deficit	(147,013,882)	(132,465,370)
Total stockholders' equity	10,334,167	23,464,487
Total liabilities and stockholders' equity	$ 23,388,467	$ 27,472,750

Stock Based Compensation (Details 1) (USD $)	3 Months Ended		9 Months Ended
Stock Based Compensation (Details 1) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense recognized	$ 354,204	$ 235,289	$ 996,801	$ 322,069
Weighted average grant-date fair value of stock options issued (per share)	$ 2.22	$ 2.11	$ 2.68	$ 2.14
Grant-date fair value of stock options issued	45,732	59,080	1,337,588	3,314,341
Volatility	112.00%	117.00%	114.40%	118.30%
Risk-free interest rate	1.90%	1.60%	2.00%	1.90%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life in years	6 years	6 years	6 years 2 months 12 days	6 years 2 months 12 days
Intrinsic value of stock options exercised	$ 0	$ 0	$ 38,892	$ 0

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2014	Sep. 30, 2013
Operating activities
Net loss	$ (14,548,512)	$ (17,402,337)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation	144,609	148,291
Non-cash stock-based compensation expense	996,801	322,069
Loss on disposal of property and equipment	0	126,633
Non-cash derivative instrument charge	0	7,473,108
Non-cash financing costs	165,232	74,751
Changes in operating assets and liabilities
Other receivables	1,407,230	1,990,932
Prepaid expenses and deposits	(189,470)	(134,177)
Restricted cash	(38)	(250,037)
Other current assets	(73,079)	(530,391)
Other assets	(16,568)	0
Accounts payable	(1,007,161)	(22,332)
Accrued liabilities	400,843	208,124
Deferred rent	(5,458)	23,148
Deferred revenue	(407,240)	(425,339)
Cash used in operating activities	(13,132,811)	(8,397,557)
Investing activities
Purchase of property and equipment	(14,456)	(82,009)
Proceeds on disposals of property and equipment	0	51,776
Cash used in investing activities	(14,456)	(30,233)
Financing activities
Proceeds from issuance of common stock and on options exercised	104,387	32,499,986
Payment of share issuance costs	0	(3,079,611)
Proceeds from loans payable	9,827,216	0
Payment of debt issuance costs	(184,469)	0
Repayments of loans payable	0	(3,000,000)
Cash provided by financing activities	9,747,134	26,420,375
Effect of foreign exchange rate changes	(8,893)	877
Net change in cash	(3,409,026)	17,993,462
Cash and cash equivalents, beginning of period	23,589,516	9,648,008
Cash and cash equivalents, end of period	20,180,490	27,641,470
Supplemental disclosure of cash flow information
Interest paid	$ 311,458	$ 79,388

Other Receivables (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Other Receivables [Line Items]
Receivables related to the sale of New Jersey net operating losses	$ 0	$ 1,412,302
Other receivables	6,335	5,011
Other receivables, net	$ 6,335	$ 1,417,313

Other Current Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Other Current Assets [Line Items]
Clinical trial materials	$ 541,468	$ 468,389

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred Stock, Shares Authorized	20,000,000	20,000,000
peferred stock, par valur (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, issued shares	26,078,532	26,035,596
Common stock, outstanding shares	26,078,532	26,035,596

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2014	Nov. 11, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Entity Registrant Name	Celator Pharmaceuticals Inc
Entity Central Index Key	0001327467
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CPXX
Entity Common Stock, Shares Outstanding		33,681,355

Consolidated Statements of Loss (USD $)	3 Months Ended		9 Months Ended
Consolidated Statements of Loss (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Expenses
Research and development	$ 3,334,789	$ 2,325,891	$ 9,238,756	$ 5,995,866
Leukemia & Lymphoma Society funding	(135,747)	(135,746)	(907,240)	(425,339)
General and administrative	1,874,412	1,434,436	5,491,779	3,922,084
(Gain) loss on disposal of property and equipment	0	(12,059)	0	126,633
Amortization and depreciation	48,521	51,239	144,609	148,291
Operating loss	(5,121,975)	(3,663,761)	(13,967,904)	(9,767,535)
Other income (expenses)
Foreign exchange loss	(1,408)	(16,745)	(27,721)	(21,229)
Interest and miscellaneous income	2,887	3,094	7,144	6,560
Non-cash derivative instrument charge	0	0	0	(7,473,108)
Interest expense	(359,321)	0	(560,031)	(147,025)
Net loss	$ (5,479,817)	$ (3,677,412)	$ (14,548,512)	$ (17,402,337)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.21)	$ (0.14)	$ (0.56)	$ (0.84)
Weighted average of common shares outstanding
Basic and diluted (in shares)	26,078,532	26,026,793	26,065,006	20,641,876

Fair Value Measurements (Details Textual) (USD $)	3 Months Ended		9 Months Ended
Fair Value Measurements (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-cash derivative instrument charge	$ 0	$ 0	$ 0	$ 7,473,108
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-cash derivative instrument charge				$ 7,473,108

Subsequent Events (Details Textual) (USD $)	9 Months Ended		1 Months Ended
Subsequent Events (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Oct. 28, 2014 Subsequent Event [Member]	Oct. 28, 2014 Subsequent Event [Member] Warrant [Member]	Oct. 28, 2014 Subsequent Event [Member] Under Writer [Member] Warrant [Member]	Oct. 28, 2014 Subsequent Event [Member] Over-Allotment Option [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues			7,602,823	760,282	114,042	991,673
Proceeds From Issuance Of Common Stock	$ 104,387	$ 32,499,986	$ 13,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 3.58	$ 3.58
Warrants Expiration Tem				5 years
Warrants To Purchase Common Stock Ratio				consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock
Share Price			$ 1.95

Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities [Line Items]
Accrued bonuses	$ 748,444	$ 624,472
Accrued salaries and vacation	213,775	143,484
Accrued professional fees	60,000	30,911
Accrued clinical trial expenses	494,651	636,497
Accrued drug manufacturing expenses	145,565	0
Interest payable	83,339	0
Accrued trade payables other	276,688	195,445
Accrued liabilities	$ 2,022,462	$ 1,630,809

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013	$ 23,464,487	$ 26,036	$ 1,083,193	$ 155,953,894	$ (1,133,266)	$ (132,465,370)
Balance (in shares) at Dec. 31, 2013		26,035,596
Issued for cash on exercise of stock options	100,639	43	0	100,596	0	0
Issued for cash on exercise of stock options (in shares)	42,936	42,936
Stock based compensation	996,801	0	0	996,801	0	0
Warrants issued	320,752	0	0	320,752	0	0
Net loss for the period	(14,548,512)	0	0	0	0	(14,548,512)
Balance at Sep. 30, 2014	$ 10,334,167	$ 26,079	$ 1,083,193	$ 157,372,043	$ (1,133,266)	$ (147,013,882)
Balance (in shares) at Sep. 30, 2014		26,078,532

Property and Equipment (Details 1) (USD $)	3 Months Ended		9 Months Ended
Property and Equipment (Details 1) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Depreciation and amortization	$ 48,521	$ 51,239	$ 144,609	$ 148,291